

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number  
WO 03/020953 A2

- (51) International Patent Classification<sup>7</sup>: C12Q (74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US02/27728
- (22) International Filing Date: 29 August 2002 (29.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/316,259 31 August 2001 (31.08.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/316,259 (CIP)  
Filed on 31 August 2001 (31.08.2001)
- (71) Applicant (for all designated States except US): DI-ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SUN, Yongming [CN/US]; 551 Shoal Drive, Redwood City, CA 94065 (US). LIU, Chenghua [CN/US]; 1125 Ranchero Way #14, San Jose, CA 95117 (US). GHOSH, Malavika, G. [IN/US]; 1733 Via Lugano, San Jose, CA 95120 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic colon cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon, identifying colon tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered colon tissue for treatment and research.

WO 03/020953 A2

286

**COMPOSITIONS AND METHODS  
RELATING TO COLON SPECIFIC GENES AND PROTEINS**

**INTRODUCTION**

5           This application claims the benefit of priority from U.S. Provisional Application No. 60/316,259, filed August.31, 2001, which is herein incorporated by reference in its entirety.

**FIELD OF THE INVENTION**

10           The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic colorectal cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of  
15 the invention and methods for the use of these compositions. This invention relates to newly developed assays for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancers, particularly colorectal cancer, and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered  
20 colorectal tissue for treatment and research.

**BACKGROUND OF THE INVENTION**

          Colorectal cancer is the second most common cause of cancer death in the United States and the third most prevalent cancer in both men and women. M. L. Davila & A. D.  
25 Davila, *Screening for Colon and Rectal Cancer*, in Colon and Rectal Cancer 47 (Peter S. Edelstein ed., 2000). Approximately 100,000 patients every year suffer from colon cancer and approximately half that number die of the disease. Hannah-Ngoc Ha & Bard C. Cosman, *Treatment of Colon Cancer*, in Colon and Rectal Cancer 157 (Peter S. Edelstein ed., 2000). Nearly all cases of colorectal cancer arise from adenomatous polyps, some of  
30 which mature into large polyps, undergo abnormal growth and development, and ultimately progress into cancer. Davila & Davila, *supra* at 55-56. This progression would appear to take at least 10 years in most patients, rendering it a readily treatable form of

cancer if diagnosed early, when the cancer is localized. *Id.* at 56; Walter J. Burdette, Cancer: Etiology, Diagnosis, and Treatment 125 (1998).

Although our understanding of the etiology of colon cancer is undergoing continual refinement, extensive research in this area points to a combination of factors, including age, hereditary and nonhereditary conditions, and environmental/dietary factors. Age is a key risk factor in the development of colorectal cancer, Davila & Davila, *supra* at 48, with men and women over 40 years of age become increasingly susceptible to that cancer, Burdette, *supra* at 126. Incidence rates increase considerably in each subsequent decade of life. Davila et al., *supra* at 48. A number of hereditary and nonhereditary conditions have also been linked to a heightened risk of developing colorectal cancer, including familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (Lynch syndrome or HNPCC), a personal and/or family history of colorectal cancer or adenomatous polyps, inflammatory bowel disease, diabetes mellitus, and obesity. *Id.* at 47; Henry T. Lynch & Jane F. Lynch, *Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndromes)*, in Colon and Rectal Cancer 67-68 (Peter S. Edelstein ed., 2000). In the case of FAP, the tumor suppressor gene APC (adenomatous polyposis coli), located at 5q21, has been either mutationally inactivated or deleted. Alberts et al., Molecular Biology of the Cell 1288 (3d ed. 1994). The APC protein plays a role in a number of functions, including cell adhesion, apoptosis, and repression of the *c-myc* oncogene. N. R. Hall & R. D. Madoff, *Genetics and the Polyp-Cancer Sequence*, Colon and Rectal Cancer 8 (Peter S. Edelstein, ed., 2000). Of those patients with colorectal cancer who have normal APC genes, over 65% have such mutations in the cancer cells but not in other tissues. Alberts et al., *supra* at 1288. In the case of HNPCC, patients manifest abnormalities in the tumor suppressor gene HNPCC, but only about 15% of tumors contain the mutated gene. *Id.* A host of other genes have also been implicated in colorectal cancer, including the *K-ras*, *N-ras*, *H-ras* and *c-myc* oncogenes, and the tumor suppressor genes *DCC* (deleted in colon carcinoma) and *p53*. Hall & Madoff, *supra* at 8-9; Alberts et al., *supra* at 1288.

Environmental/dietary factors associated with an increased risk of colorectal cancer include a high fat diet, intake of high dietary red meat, and sedentary lifestyle. Davila & Davila, *supra* at 47; Reddy, B. S., *Prev. Med.* 16(4): 460-7 (1987). Conversely, environmental/dietary factors associated with a reduced risk of colorectal cancer include a diet high in fiber, folic acid, calcium, and hormone-replacement therapy in post-

menopausal women. Davila & Davila, *supra* at 50-55. The effect of antioxidants in reducing the risk of colon cancer is unclear. *Id.* at 53.

Because colon cancer is highly treatable when detected at an early, localized stage, screening should be a part of routine care for all adults starting at age 50, especially those with first-degree relatives with colorectal cancer. One major advantage of colorectal cancer screening over its counterparts in other types of cancer is its ability to not only detect precancerous lesions, but to remove them as well. Davila & Davila, *supra* at 56. The key colorectal cancer screening tests in use today are fecal occult blood test, sigmoidoscopy, colonoscopy, double-contrast barium enema, and the carcinoembryonic antigen (CEA) test. *Id.*; Burdette, *supra* at 125.

The fecal occult blood test (FOBT) screens for colorectal cancer by detecting the amount of blood in the stool, the premise being that neoplastic tissue, particularly malignant tissue, bleeds more than typical mucosa, with the amount of bleeding increasing with polyp size and cancer stage. Davila & Davila, *supra* at 56-57. While effective at detecting early stage tumors, FOBT is unable to detect adenomatous polyps (premalignant lesions), and, depending on the contents of the fecal sample, is subject to rendering false positives. *Id.* at 56-59. Sigmoidoscopy and colonoscopy, by contrast, allow direct visualization of the bowel, and enable one to detect, biopsy, and remove adenomatous polyps. *Id.* at 59-60, 61. Despite the advantages of these procedures, there are accompanying downsides: sigmoidoscopy, by definition, is limited to the sigmoid colon and below, colonoscopy is a relatively expensive procedure, and both share the risk of possible bowel perforation and hemorrhaging. *Id.* at 59-60. Double-contrast barium enema (DCBE) enables detection of lesions better than FOBT, and almost as well as colonoscopy, but it may be limited in evaluating the winding rectosigmoid region. *Id.* at 60. The CEA blood test, which involves screening the blood for carcinoembryonic antigen, shares the downside of FOBT, in that it is of limited utility in detecting colorectal cancer at an early stage. Burdette, *supra* at 125.

Once colon cancer has been diagnosed, treatment decisions are typically made in reference to the stage of cancer progression. A number of techniques are employed to stage the cancer (some of which are also used to screen for colon cancer), including pathologic examination of resected colon, sigmoidoscopy, colonoscopy, and various imaging techniques. AJCC Cancer Staging Handbook 84 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998); Montgomery, R. C. and Ridge, J.A., *Semin. Surg. Oncol.* 15(3): 143-150



(1998). Moreover, chest films, liver functionality tests, and liver scans are employed to determine the extent of metastasis. Fleming et al. eds., *supra* at 84. While computerized tomography and magnetic resonance imaging are useful in staging colorectal cancer in its later stages, both have unacceptably low staging accuracy for identifying early stages of the disease, due to the difficulty that both methods have in (1) revealing the depth of bowel wall tumor infiltration and (2) diagnosing malignant adenopathy. Thoeni, R. F., *Radiol. Clin. N. Am.* 35(2): 457-85 (1997). Rather, techniques such as transrectal ultrasound (TRUS) are preferred in this context, although this technique is inaccurate with respect to detecting small lymph nodes that may contain metastases. David Blumberg & Frank G. Opelka, *Neoadjuvant and Adjuvant Therapy for Adenocarcinoma of the Rectum, in Colon and Rectal Cancer* 316 (Peter S. Edelstein ed., 2000).

Several classification systems have been devised to stage the extent of colorectal cancer, including the Dukes' system and the more detailed International Union against Cancer-American Joint Committee on Cancer TNM staging system, which is considered by many in the field to be a more useful staging system. Burdette, *supra* at 126-27. The TNM system, which is used for either clinical or pathological staging, is divided into four stages, each of which evaluates the extent of cancer growth with respect to primary tumor (T), regional lymph nodes (N), and distant metastasis (M). Fleming et al. eds., *supra* at 84-85. The system focuses on the extent of tumor invasion into the intestinal wall, invasion of adjacent structures, the number of regional lymph nodes that have been affected, and whether distant metastasis has occurred. *Id.* at 81.

Stage 0 is characterized by *in situ* carcinoma (Tis), in which the cancer cells are located inside the glandular basement membrane (intraepithelial) or lamina propria (intramucosal). *Id.* at 84-85; Burdette, *supra* at 127. In this stage, the cancer has not spread to the regional lymph nodes (N0), and there is no distant metastasis (M0). Fleming et al. eds., *supra* at 85; Burdette, *supra* at 127. In stage I, there is still no spread of the cancer to the regional lymph nodes and no distant metastasis, but the tumor has invaded the submucosa (T1) or has progressed further to invade the muscularis propria (T2). Fleming et al. eds., *supra* at 84-85; Burdette, *supra* at 127. Stage II also involves no spread of the cancer to the regional lymph nodes and no distant metastasis, but the tumor has invaded the subserosa, or the nonperitonealized pericolic or perirectal tissues (T3), or has progressed to invade other organs or structures, and/or has perforated the visceral peritoneum (T4). *Id.* Stage 3 is characterized by any of the T substages, no distant

metastasis, and either metastasis in 1 to 3 regional lymph nodes (N1) or metastasis in four or more regional lymph nodes (N2). Fleming et al. eds., *supra* at 85; Burdette, *supra* at 127. Lastly, stage 4 involves any of the T or N substages, as well as distant metastasis. *Id.*

5       Currently, pathological staging of colon cancer is preferable over clinical staging as pathological staging provides a more accurate prognosis. Pathological staging typically involves examination of the resected colon section, along with surgical examination of the abdominal cavity. Fleming et al. eds., *supra* at 84. Clinical staging would be a preferred method of staging were it at least as accurate as pathological staging, as it does not  
10       depend on the invasive procedures of its counterpart.

Turning to the treatment of colorectal cancer, surgical resection results in a cure for roughly 50% of patients. Burdette, *supra* at 125. Irradiation is used both preoperatively and postoperatively in treating colorectal cancer. *Id.* at 125, 132-33. Chemotherapeutic agents, particularly 5-fluorouracil, are also powerful weapons in treating colorectal cancer.  
15       *Id.* at 125, 133. Other agents include irinotecan and floxuridine, cisplatin, levamisole, methotrexate, interferon- $\alpha$ , and leucovorin. *Id.* at 133. Nonetheless, thirty to forty percent of patients will develop a recurrence of colon cancer following surgical resection. Wayne De Vos, *Follow-up After Treatment of Colon Cancer, Colon and Rectal Cancer* 225 (Peter S. Edelstein ed., 2000), which in many patients is the ultimate cause of death.

20       Accordingly, colon cancer patients must be closely monitored to determine response to therapy and to detect persistent or recurrent disease and metastasis. From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of colorectal cancer are of critical importance to the outcome of the patient. Moreover, current procedures, while helpful in  
25       each of these analyses, are limited by their specificity, sensitivity, invasiveness, and/or their cost. As such, highly specific and sensitive procedures that would operate by way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.

Accordingly, there is a great need for more sensitive and accurate methods for  
30       predicting whether a person is likely to develop colorectal cancer, for diagnosing colorectal cancer, for monitoring the progression of the disease, for staging the colorectal cancer, for determining whether the colorectal cancer has metastasized, and for imaging the colorectal cancer. There is also a need for better treatment of colorectal cancer.

## SUMMARY OF THE INVENTION

The present invention solves many needs in the art by providing nucleic acid molecules, polypeptides and antibodies thereto, variants and derivatives of the nucleic acids and polypeptides, agonists and antagonists that may be used to identify, diagnose, monitor, stage, image and treat colon cancer and non-cancerous disease states in colon; identify and monitor colon tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered colon tissue for treatment and research.

One aspect of the present invention relates to nucleic acid molecules that are specific to colon cells, colon tissue and/or the colon organ. These colon specific nucleic acids (CSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the CSNA is genomic DNA, then the CSNA is a colon specific gene (CSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to colon. More preferred is a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 101-190. In another preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-100. For the sequences listed herein, DEX0234\_1 corresponds to SEQ ID NO: 1, DEX0234\_101 corresponds to SEQ ID NO: 101, etc.

This aspect of the present invention also relates to nucleic acid molecules that selectively hybridize or exhibit substantial sequence similarity to nucleic acid molecules encoding a Colon Specific Protein (CSP), or that selectively hybridize or exhibit substantial sequence similarity to a CSNA. In one embodiment of the present invention the nucleic acid molecule comprises an allelic variant of a nucleic acid molecule encoding a CSP, or an allelic variant of a CSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid sequence that encodes a CSP or a part of a nucleic acid sequence of a CSNA.

In addition, this aspect of the present invention relates to a nucleic acid molecule further comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a CSNA or the the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of a CSP.

Another aspect of the present invention relates to vectors and/or host cells comprising a nucleic acid molecule of this invention. In a preferred embodiment, the nucleic acid molecule of the vector and/or host cell encodes all or a fragment of a CSP. In another preferred embodiment, the nucleic acid molecule of the vector and/or host cell comprises all or a part of a CSNA. Vectors and host cells of the present invention are useful in the recombinant production of polypeptides, particularly CSPs of the present invention.

Another aspect of the present invention relates to polypeptides encoded by a nucleic acid molecule of this invention. The polypeptide may comprise either a fragment or a full-length protein. In a preferred embodiment, the polypeptide is a CSP. However, this aspect of the present invention also relates to mutant proteins (muteins) of CSPs, fusion proteins of which a portion is a CSP, and proteins and polypeptides encoded by allelic variants of a CSNA as provided herein.

Another aspect of the present invention relates to antibodies and other binders that specifically binds to a polypeptide of the instant invention. Accordingly antibodies or binders of the present specifically bind to CSPs, muteins, fusion proteins, and/or homologous proteins or a polypeptides encoded by allelic variants of an CSNA as provided herein.

Another aspect of the present invention relates to agonists and antagonists of the nucleic acid molecules and polypeptides of this invention. The agonists and antagonists of the instant invention may be used to treat colon cancer and non-cancerous disease states in colon and to produce engineered colon tissue.

Another aspect of the present invention relates to methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. Such methods are useful in identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon. Such methods are also useful in identifying and/or monitoring colon tissue. In addition, measurement of levels of the nucleic acid molecules of this invention may be useful for diagnostics as part of panel in combination with other markers.

Another aspect of the present invention relates to use of the nucleic acid molecules of this invention in gene therapy, for producing transgenic animals and cells, and for producing engineered colon tissue for treatment and research.

Another aspect of the present invention relates to methods for detecting polypeptides this invention, preferably using antibodies thereto. Such methods are useful to identify, diagnose, monitor, stage, image and treat colon cancer and non-cancerous disease states in colon. In addition, measurement of levels of the polypeptides of this invention may be useful to identify, diagnose, monitor, stage, image colon cancer in combination with other colon cancer markers. The polypeptides of the present invention can also be used to identify and/or monitor colon tissue, and to produce engineered colon tissue.

Yet another aspect of the present invention relates to a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences. In addition, the computer records regarding the nucleic acid and/or amino acid sequences and/or measurements of their levels may be used alone or in combination with other markers to diagnose colon related diseases.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A

Compendium of Methods from Current Protocols in Molecular Biology – 4<sup>th</sup> Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999).

5           Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in  
10 the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of  
15 nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at  
20 least 10 bases in length, unless otherwise specified. The term includes single and double stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.

The nucleic acid molecules may be modified chemically or biochemically or may  
25 contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*,  
30 phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially

duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A "gene" is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term "exon" refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript. The term "intron" refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be "spliced out" during processing of the transcript.

A nucleic acid molecule or polypeptide is "derived" from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An "isolated" or "substantially pure" nucleic acid or polynucleotide (e.g., an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, e.g., ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous

systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

5           A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus  
10       to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded  
15       by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a  
20       reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

          The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded  
25       deoxyribonucleotides, but it can refer as well to single-or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes  
30       or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.



Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

The term "naturally-occurring nucleotide" referred to herein includes naturally-occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g., LaPlanche et al. Nucl. Acids Res.* 14:9081-9093 (1986); *Stein et al. Nucl. Acids Res.* 16:3209-3221 (1988); *Zon et al. Anti-Cancer Drug Design* 6:539-568 (1991); *Zon et al., in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach*, pp. 87-108, Oxford University Press (1991); *Uhlmann and Peyman Chemical Reviews* 90:543 (1990), and United States Patent No. 5,151,510, the disclosure of which is hereby incorporated by reference in its entirety.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given

sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally-  
5 occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum  
10 correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence  
15 identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98  
20 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998)). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the  
25 scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1.

A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense  
30 therapy, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology" interchangeably. In this

application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term “substantial similarity” or “substantial sequence similarity,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists between a first and second nucleic acid sequence when the first nucleic acid sequence or fragment thereof hybridizes to an antisense strand of the second nucleic acid, under selective hybridization conditions. Typically, selective hybridization will occur between the first nucleic acid sequence and an antisense strand of the second nucleic acid sequence when there is at least about 55% sequence identity between the first and second nucleic acid sequences— preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% — over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. “Stringent hybridization conditions” and “stringent wash conditions” in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, “stringent hybridization” is performed at about 25°C below the thermal melting point ( $T_m$ ) for the specific DNA hybrid under a particular set of conditions. “Stringent washing” is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular set of conditions. The  $T_m$  is the

temperature at which 50% of the target sequence hybridizes to a perfectly matched probe.

See Sambrook (1989), *supra*, p. 9.51.

The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) -$$

5  $0.63 (\% \text{ formamide}) - (600/l)$  where  $l$  is the length of the hybrid in base pairs.

The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) +$$

$$11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:

10  $T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) +$

$$11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of  
 15 sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other  
 20 higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC  
 25 at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for  
 30 hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing

the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (*e.g.* 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These  
5 agents are well-known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook  
10 (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in  
15 the particular hybridization assay indicates detection of a specific hybridization.

As defined herein, nucleic acids that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid is created synthetically or recombinantly using a high codon degeneracy as permitted by the  
20 redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N}),$$
 wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For  
25 hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art.  
30 *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term “digestion” or “digestion of DNA” refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their

reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are  
5 digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars  
10 of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques  
15 for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize  
20 detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-  
25 derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with  
30 the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies. In another aspect, the invention is directed to single exon probes based on the CSNAs disclosed herein.

In one embodiment, the term "microarray" refers to a "nucleic acid microarray" having a substrate-bound plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). Additionally, these nucleic acid microarrays include substrate-bound plurality of nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000). Examples of nucleic acid microarrays may be found in U.S. Patent Nos. 6,391,623, 6,383,754, 6,383,749, 6,380,377, 6,379,897, 6,376,191, 6,372,431, 6,351,712, 6,344,316, 6,316,193, 6,312,906, 6,309,828, 6,309,824, 6,306,643, 6,300,063, 6,287,850, 6,284,497, 6,284,465, 6,280,954, 6,262,216, 6,251,601, 6,245,518, 6,263,287, 6,251,601, 6,238,866, 6,228,575, 6,214,587, 6,203,989, 6,171,797, 6,103,474, 6,083,726, 6,054,274, 6,040,138, 6,083,726, 6,004,755, 6,001,309, 5,958,342, 5,952,180, 5,936,731, 5,843,655, 5,814,454, 5,837,196, 5,436,327, 5,412,087, 5,405,783, the disclosures of which are incorporated herein by reference in their entireties.

In an alternative embodiment, a "microarray" may also refer to a "peptide microarray" or "protein microarray" having a substrate-bound collection of plurality of polypeptides, the binding to each of the plurality of bound polypeptides being separately detectable. Alternatively, the peptide microarray may have a plurality of binders, including but not limited to monoclonal antibodies, polyclonal antibodies, phage display binders, yeast 2 hybrid binders, aptamers, which can specifically detect the binding of the polypeptides of this invention. The array may be based on autoantibody detection to the polypeptides of this invention, see Robinson *et al.*, *Nature Medicine* 8(3):295-301 (2002). Examples of peptide arrays may be found in WO 02/31463, WO 02/25288, WO 01/94946, WO 01/88162, WO 01/68671, WO 01/57259, WO 00/61806, WO 00/54046, WO 00/47774, WO 99/40434, WO 99/39210, WO 97/42507 and U.S. Patent Nos. 6,268,210, 5,766,960, 5,143,854, the disclosures of which are incorporated herein by reference in their entireties.

In addition, determination of the levels of the CSNA or CSP may be made in a multiplex manner using techniques described in WO 02/29109, WO 02/24959, WO 01/83502, WO01/73113, WO 01/59432, WO 01/57269, WO 99/67641, the disclosures of which are incorporated herein by reference in their entireties.

5       The term “mutant”, “mutated”, or “mutation” when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci  
10       within a nucleic acid sequence. In a preferred embodiment of the present invention, the nucleic acid sequence is the wild type nucleic acid sequence encoding a CSP or is a CSNA. The nucleic acid sequence may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

      The term “error-prone PCR” refers to a process for performing PCR under  
15       conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-33 (1992).

      The term “oligonucleotide-directed mutagenesis” refers to a process which enables  
20       the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

      The term “assembly PCR” refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the  
25       products of another reaction.

      The term “sexual PCR mutagenesis” or “DNA shuffling” refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of  
30       the crossover by primer extension in an error-prone PCR reaction. *See, e.g.*, Stemmer, *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes (“Family shuffling”).



The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term "cassette mutagenesis" refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. See, e.g., Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. See, e.g., Delegrave *et al.*, *Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993).

"Operatively linked" expression control sequences refers to a linkage in which the expression control sequence is either contiguous with the gene of interest to control the gene of interest, or acts in *trans* or at a distance to control the gene of interest.

The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature

of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors").

In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refers to that portion of a transcript-derived nucleic acid that can be translated in its

entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence is meant to be inclusive of all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally-occurring proteins and polypeptides, as well as polypeptide fragments and polypeptide mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a CSP encoded by a nucleic acid molecule of the instant invention, or is a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be determined by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well-

known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

The term "fragment" when used herein with respect to polypeptides of the present invention refers to a polypeptide that has an amino-terminal and/or  
5 carboxy-terminal deletion compared to a full-length CSP. In a preferred embodiment, the fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring polypeptide. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least  
10 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" when used herein with respect to polypeptides of the present invention refers to a polypeptide which is substantially similar in primary structural sequence to a CSP but which include, *e.g.*, *in vivo* or *in vitro* chemical and biochemical  
15 modifications that are not found in the CSP. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation,  
20 formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.  
25 Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as <sup>125</sup>I, <sup>32</sup>P, <sup>35</sup>S, <sup>14</sup>C and <sup>3</sup>H, ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores,  
30 chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation.

Methods for labeling polypeptides are well-known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*.

The term “fusion protein” refers to polypeptides of the present invention coupled to a heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence that encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term “analog” refers to both polypeptide analogs and non-peptide analogs. The term “polypeptide analog” as used herein refers to a polypeptide that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

The term “non-peptide analog” refers to a compound with properties that are analogous to those of a reference polypeptide. A non-peptide compound may also be termed a “peptide mimetic” or a “peptidomimetic.” Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH=CH--(*cis* and *trans*), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>--, and --CH<sub>2</sub>SO--, by methods well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of

the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992)). For example, one may add  
5 internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

The term "mutant" or "mutein" when referring to a polypeptide of the present invention relates to an amino acid sequence containing substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a CSP. A  
10 mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or  
15 different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to a CSP. In an even more preferred embodiment, a mutein exhibits  
20 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming  
25 protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred  
30 embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a

replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H.

- 5 Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991).

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed., Sinauer Associates (1991). Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino  
10 acids, unnatural amino acids such as  $\alpha$ -,  $\alpha$ -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include:  
4-hydroxyproline,  $\gamma$ -carboxyglutamate,  $\epsilon$ -N,N,N-trimethyllysine,  $\epsilon$ -N-acetyllysine,  
O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine,  
15 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

By "homology" or "homologous" when referring to a polypeptide of the present  
20 invention it is meant polypeptides from different organisms with a similar sequence to the encoded amino acid sequence of a CSP and a similar biological activity or function. Although two polypeptides are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the polypeptides. Instead, the term "homologous" is defined to mean that the two polypeptides have similar amino acid  
25 sequences and similar biological activities or functions. In a preferred embodiment, a homologous polypeptide is one that exhibits 50% sequence similarity to CSP, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous polypeptides that exhibit 80%, 85% or 90% sequence similarity to a CSP. In a yet more preferred embodiment, a homologous polypeptide exhibits 95%, 97%, 98%  
30 or 99% sequence similarity.

When "sequence similarity" is used in reference to polypeptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity"

comprises conservative or moderately conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. *See, e.g., Pearson, Methods Mol. Biol.* 24: 307-31 (1994).

For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992). A “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as “Gap” and “Bestfit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. *See, e.g., GCG Version 6.1.* Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program



BLAST, especially blastp or tblastn. *See, e.g., Altschul et al., J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al., Nucleic Acids Res.* 25:3389-402 (1997). Preferred parameters for blastp are:

	Expectation value:	10 (default)
5	Filter:	seg (default)
	Cost to open a gap:	11 (default)
	Cost to extend a gap:	1 (default)
	Max. alignments:	100 (default)
	Word size:	11 (default)
10	No. of descriptions:	100 (default)
	Penalty Matrix:	BLOSUM62

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences.

Algorithms other than blastp for database searching using amino acid sequences are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. A Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains;

a F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consists of the VH and CH1 domains; a Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

5 By "bind specifically" and "specific binding" as used herein it is meant the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

10 A single-chain antibody (scFv) is an antibody in which VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston *et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but  
15 using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it an  
20 immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one or  
25 more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional"  
30 antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a

cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

5       A “neutralizing antibody” or “an inhibitory antibody” is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An “activating antibody” is an antibody that increases the activity of a polypeptide.

10       The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than 1  $\mu$ M, preferably less than 100 nM and most preferably  
15       less than 10 nM.

      The term “patient” includes human and veterinary subjects.

      Throughout this specification and claims, the word “comprise,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

20       The term “colon specific” refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the colon as compared to other tissues in the body. In a preferred embodiment, a “colon specific” nucleic acid molecule or polypeptide is detected at a level that is 2-fold higher than any other tissue in the body. In a more preferred embodiment, the “colon specific” nucleic acid molecule or polypeptide is detected at a  
25       level that is 5-fold higher than any other tissue in the body, more preferably at least 10-fold, 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot  
30       analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

*Nucleic Acid Molecules*

5 One aspect of the invention provides isolated nucleic acid molecules that are specific to the colon or to colon cells or tissue or that are derived from such nucleic acid molecules. These isolated colon specific nucleic acids (CSNAs) may comprise cDNA genomic DNA, RNA, or a combination thereof, a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. A CSNA may be derived  
10 from an animal. In a preferred embodiment, the CSNA is derived from a human or other mammal. In a more preferred embodiment, the CSNA is derived from a human or other primate. In an even more preferred embodiment, the CSNA is derived from a human.

In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to colon, a colon-specific polypeptide (CSP). In a more preferred embodiment,  
15 the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 101-190. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-100. Nucleotide sequences of the instantly-described nucleic acid molecules were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic  
20 polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham Biosciences, Sunnyvale, CA, USA).

Nucleic acid molecules of the present invention may also comprise sequences that selectively hybridizes to a nucleic acid molecule encoding a CSNA or a complement or  
25 antisense thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may or may not encode a CSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes a CSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule that encodes a polypeptide  
30 comprising an amino acid sequence of SEQ ID NO: 101-190. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1-100 or the antisense sequence thereof. Preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a

CSP under low stringency conditions. More preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a CSP under moderate stringency conditions. Most preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense  
5 sequence of a nucleic acid molecule encoding a CSP under high stringency conditions. In a preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 101-190. In a more preferred embodiment, the nucleic acid molecule hybridizes under  
10 low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1-100.

Nucleic acid molecules of the present invention may also comprise nucleic acid sequences that exhibit substantial sequence similarity to a nucleic acid encoding a CSP or  
15 a complement of the encoding nucleic acid molecule. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule encoding human CSP. More preferred is a nucleic acid molecule exhibiting substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 101-190. By substantial sequence similarity it is  
20 meant a nucleic acid molecule having at least 60% sequence identity with a nucleic acid molecule encoding a CSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 101-190, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule  
25 encoding a CSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. Most preferred in this embodiment is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a CSP.

The nucleic acid molecules of the present invention are also inclusive of those  
30 exhibiting substantial sequence similarity to a CSNA or its complement. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 1-100. By substantial sequence similarity it is meant a nucleic acid molecule that has at

least 60% sequence identity with a CSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1-100, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. More preferred is a nucleic acid molecule that has at least 90% sequence identity with a CSNA, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. Most preferred is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a CSNA.

Nucleic acid molecules that exhibit substantial sequence similarity are inclusive of sequences that exhibits sequence identity over their entire length to a CSNA or to a nucleic acid molecule encoding a CSP, as well as sequences that are similar over only a part of its length. In this case, the part is at least 50 nucleotides of the CSNA or the nucleic acid molecule encoding a CSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 101-190 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1-100. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule from a human, when the CSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a CSNA. In a preferred embodiment, the substantially similar nucleic acid molecule is an CSNA.

The nucleic acid molecules of the present invention are also inclusive of allelic variants of a CSNA or a nucleic acid encoding a CSP. For example, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes and the sequence determined from one individual of a species may differ from other allelic forms present within the population. More than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001) – Variants with small deletions and insertions of more than a single nucleotide are also found in the general population, and often do not alter the function of the protein. In addition, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes a CSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes a CSP comprising an amino acid sequence of SEQ ID NO: 101-190. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is a CSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1-100. Also preferred is that the allelic variant is a naturally-occurring allelic variant in the species of interest, particularly human.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences comprising a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a CSP. In a preferred embodiment, the part encodes a CSP. In one embodiment, the nucleic acid molecule comprises a part of a CSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to a CSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that is an allelic variant of a CSNA. In yet another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that encodes a CSP. A part comprises at least 10 nucleotides, more preferably at least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences that encode fusion proteins, homologous proteins, polypeptide fragments, muteins and polypeptide analogs, as described *infra*.

5 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences containing modifications of the native nucleic acid molecule. Examples of such modifications include, but are not limited to, nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is  
10 used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent,  
15 the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

Accordingly, in one embodiment, a nucleic acid molecule may include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a  
20 subsequent reaction, such as biotin or various haptens. The labeled nucleic acid molecules are particularly useful as hybridization probes.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $\alpha$ - $^{32}\text{P}$ -dATP,  $\alpha$ - $^{32}\text{P}$ -dCTP,  $\alpha$ - $^{32}\text{P}$ -dGTP,  $\alpha$ - $^{32}\text{P}$ -dTTP,  $\alpha$ - $^{32}\text{P}$ -3'dATP,  $\alpha$ - $^{32}\text{P}$ -ATP,  $\alpha$ - $^{32}\text{P}$ -CTP,  $\alpha$ - $^{32}\text{P}$ -GTP,  $\alpha$ - $^{32}\text{P}$ -UTP,  $\alpha$ - $^{35}\text{S}$ -dATP,  $\gamma$ - $^{35}\text{S}$ -GTP,  $\gamma$ - $^{33}\text{P}$ -dATP, and the like.

25 Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP,  
30 Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas



Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. *See Henegariu et al., Nature*

5 *Biotechnol.* 18: 345-348 (2000).

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules of the present invention can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and Peptide Nucleic Acids (PNA) to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994); Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994). Alternatively, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. See, e.g., Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); and United States Patent Nos. 5,846,726, 5,925,517, 5,925,517, 5,723,591 and 5,538,848, the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the present invention may also be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. See Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997). Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction, Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000).

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, United States Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361;

and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, United States Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred nucleic acid molecules, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, United States Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference in its entirety. Automated PNA synthesis is readily achievable on commercial synthesizers (*see, e.g.*, "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA). PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and

PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The  $T_m$  of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the  $T_m$  of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the  $T_m$  by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the  $T_m$  by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999).

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), and United States Patent Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acid molecules of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); and Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994). Triplex and quadruplex conformations, and

their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997).

5            *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably  
10    labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect and characterize gross alterations in the gene of a CSNA, such as deletions, insertions, translocations, and duplications of the CSNA genomic locus  
15    through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.*, Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999). The isolated nucleic acid molecules of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated  
20    nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include a nucleic acid molecule of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

The isolated nucleic acid molecules of the present invention can be also be used as  
25    probes to detect, characterize, and quantify CSNA in, and isolate CSNA from, transcript-derived nucleic acid samples. In one embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>-selected RNA samples. In another embodiment, the isolated nucleic acid molecules of the present invention can be  
30    used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.*, Schwarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000). In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization

probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to CSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000).

In another embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify and/or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In this embodiment, it is preferred that the probe or primer be derived from a nucleic acid molecule encoding a CSP. More preferably, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 101-190. Also preferred are probes or primers derived from a CSNA. More preferred are probes or primers derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-100.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et*

- al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to  
5 Genetic Engineering, Vol. 67, Humana Press (1996); and McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995). Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; and Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995).  
10 PCR and hybridization methods may be used to identify and/or isolate nucleic acid molecules of the present invention including allelic variants, homologous nucleic acid molecules and fragments. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules of the present invention that encode homologous proteins, analogs, fusion protein or muteins of the invention. Nucleic acid  
15 primers as described herein can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

These nucleic acid primers can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

- 20 Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 (2001); international patent publications WO 97/19193 and WO 00/15779, and United States Patent Nos. 5,854,033 and 5,714,320, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with  
25 other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

- Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization  
30 probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or

positively-charged derivatized nylon. The nucleic acid molecule of the present invention can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without  
5 limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like  
10 and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some  
15 combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate  
20 bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that comprise one or more of the nucleic acid molecules of the present invention.

In yet another embodiment, the invention is directed to single exon probes based  
25 on the CSNAs disclosed herein.

#### *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention provides vectors that comprise one or more  
30 of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acid molecules of the present invention in host cells (cloning vectors), for shuttling the nucleic acid



molecules of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acid molecules of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acid molecules of the present invention *in vitro* or within a host cell, and for  
5 expressing polypeptides encoded by the nucleic acid molecules of the present invention, alone or as fusion proteins with heterologous polypeptides (expression vectors). Vectors are by now well-known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential  
10 Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); Sambrook (2001), *supra*; Ausubel (1999), *supra*. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof are well within  
15 the skill in the art. Thus, only basic features need be described here.

Nucleic acid sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and  
20 translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in  
25 expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred  
30 embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*,

including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989,  $\lambda$ GT10 and  $\lambda$ GT11, and other phages, *e.g.*, M13 and filamentous single stranded phage DNA. Where *E. coli* is used as host, 5 selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or 10 plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for 15 protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEplac series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are 20 based on yeast linear plasmids, denoted YLp, pGPD-2, 2 $\mu$  plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific 25 auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to 30 replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences

resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

The host cells may also be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include, include but are not limited to, resistance to neomycin (G418), blasticidin, hygromycin and zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the nucleic acid molecules of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC system, the major operator and promoter regions of phage lambda, the control regions of *fd* coat protein, and the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast  $\alpha$ -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include, but are not limited to, those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 and the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic

enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the CSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit  $\beta$ -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the *Tn10* tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone

receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one embodiment of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization.

- 5 Such tags include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal
- 10 of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverley, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega,
- 15 Madison, WI, USA). As another useful alternative, the polypeptides of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the
- 20 Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope, detectable by anti-HA antibody.

- 25 For secretion of expressed polypeptides, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

- 30 Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such

as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

- Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the  $\alpha$ -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.
- A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See* Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. *See* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999).
- A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see*,

*e.g.* Cormack *et al.*, *Gene* 173: 33–38 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.*, Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in United States Patent Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. *See also* Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the polypeptides of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The *bsd* gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus.



The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA) allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid molecules of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed polypeptide in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide CSPs with such post-translational modifications.

In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid molecules of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid molecules of this invention.

The recombinant nucleic acid molecules and more particularly, the expression vectors of this invention may be used to express the polypeptides of this invention as

recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid molecules according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

5            Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

10           Transformation and other methods of introducing nucleic acids into a host cell (e.g., conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*).

15           Bacterial, yeast, plant or mammalian cells are transformed or transfected with an expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the  
20           polypeptide will be constitutive or inducible. One having ordinary skill in the art will be able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

                 A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and  
25           prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*,  
30           *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda* — e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA) — *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include

BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from colon are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human colon cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*.

Methods for introducing the vectors and nucleic acid molecules of the present invention into the host cells are well-known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, e.g., with  $\text{CaCl}_2$ , or a solution of  $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Rb}^+$  or  $\text{K}^+$ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent to take up exogenous DNA by electroporation by various pre-pulse treatments; vectors are

introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided by BioRad (Richmond, CA, USA).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action  
5 of hydrolytic enzymes such as a snail-gut extract, usually denoted Glusulase or Zymolyase, or an enzyme from *Arthrobacter luteus* to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and  $\text{Ca}^{2+}$ . Subsequently, the cells are resuspended in a solution of sorbitol, mixed  
10 with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate to permeabilize the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased  
15 frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension  
20 pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

25 Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with  $\text{CaPO}_4$  or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for  $\text{CaPO}_4$  transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated  
30 transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis,

IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA).

Protocols for electroporating mammalian cells can be found in, for example, ; Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000). Other transfection techniques

- 5 include transfection by particle bombardment and microinjection. *See, e.g.,* Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

- 10 Purification of recombinantly expressed proteins is now well within the skill in the art and thus need not be detailed here. *See, e.g.,* Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale,  
15 Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001).

- Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means  
20 appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

- Polypeptides, including Fragments Muteins, Homologous Proteins, Allelic Variants,  
25 Analogs and Derivatives

- Another aspect of the invention relates to polypeptides encoded by the nucleic acid molecules described herein. In a preferred embodiment, the polypeptide is a colon specific polypeptide (CSP). In an even more preferred embodiment, the polypeptide comprises an amino acid sequence of SEQ ID NO:59-82 or is derived from a polypeptide  
30 having the amino acid sequence of SEQ ID NO: 101-190. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings

of the specification and using methods well-known to those having ordinary skill in the art.

Polypeptides of the present invention may also comprise a part or fragment of a CSP. In a preferred embodiment, the fragment is derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 101-190. Polypeptides of the present invention comprising a part or fragment of an entire CSP may or may not be CSPs. For example, a full-length polypeptide may be colon-specific, while a fragment thereof may be found in other tissues as well as in colon. A polypeptide that is nevertheless useful, especially for immunizing animals to prepare anti-CSP antibodies. In a preferred embodiment, the part or fragment is a CSP. Methods of determining whether a polypeptide of the present invention is a CSP are described *infra*.

Polypeptides of the present invention comprising fragments of at least 6 contiguous amino acids are also useful in mapping B cell and T cell epitopes of the reference protein. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of a polypeptide of the present invention have utility in such a study.

Polypeptides of the present invention comprising fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize polypeptides of the present invention. *See, e.g., Lerner, Nature* 299: 592-596 (1982); Shinnick *et al., Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al., Science* 219: 660-6 (1983). As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic and are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the polypeptides of the present invention have utility as immunogens.

Polypeptides comprising fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire polypeptide, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein;

this competitive inhibition permits identification and separation of molecules that bind specifically to the polypeptide of interest. See United States Patent Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The polypeptide of the present invention thus preferably is at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the polypeptide of the present invention is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger polypeptides having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments by truncating the nucleic acid molecule, *e.g.*, a CSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally-occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment, preferably a fragment of a CSP, may be produced by chemical or enzymatic cleavage of a CSP polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule of the present invention encoding a fragment, preferably of a CSP, in a host cell.

Polypeptides of the present invention are also inclusive of mutants, fusion proteins, homologous proteins and allelic variants.

A mutant protein, or mutein, may have the same or different properties compared to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native polypeptide. Small deletions and insertions can often be found that do not alter the function of a protein. Muteins may or may not be colon-specific. Preferably, the mutein is colon-specific. More preferably the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 101-190. Accordingly, in a preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more

preferably at least 80% sequence identity to a CSP comprising an amino acid sequence of SEQ ID NO: 101-190. In a yet more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a CSP comprising an amino acid  
5 sequence of SEQ ID NO: 101-190.

A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to  
10 another amino acid residue using synthetic or semi-synthetic chemical techniques. In a preferred embodiment, a mutein is produced from a host cell comprising a mutated nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid molecule of the invention and then expressing it recombinantly. These  
15 mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is colon-specific, as described below. Multiple random mutations can be introduced into the gene by methods well-  
20 known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook  
25 (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), as well as United States Patent No. 5,223,408, which is herein incorporated by reference in its entirety.

The invention also contemplates polypeptides that are homologous to a polypeptide of the invention. In a preferred embodiment, the polypeptide is homologous to a CSP. In an even more preferred embodiment, the polypeptide is homologous to a  
30 CSP selected from the group having an amino acid sequence of SEQ ID NO: 101-190. By homologous polypeptide it is meant one that exhibits significant sequence identity to a CSP, preferably a CSP having an amino acid sequence of SEQ ID NO: 101-190. By significant sequence identity it is meant that the homologous polypeptide exhibits at least



50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a CSP comprising an amino acid sequence of SEQ ID NO: 101-190. More preferred are homologous polypeptides exhibiting at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to a CSP comprising an amino acid sequence of SEQ ID NO: 101-190. Most preferably, the homologous polypeptide exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to a CSP comprising an amino acid sequence of SEQ ID NO: 101-190. In a preferred embodiment, the amino acid substitutions of the homologous polypeptide are conservative amino acid substitutions as discussed above.

Homologous polypeptides of the present invention also comprise polypeptide encoded by a nucleic acid molecule that selectively hybridizes to a CSNA or an antisense sequence thereof. In this embodiment, it is preferred that the homologous polypeptide be encoded by a nucleic acid molecule that hybridizes to a CSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. More preferred is a homologous polypeptide encoded by a nucleic acid sequence which hybridizes to a CSNA selected from the group consisting of SEQ ID NO: 1-100 or a homologous polypeptide encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes a CSP, preferably an CSP of SEQ ID NO: 59-82 under low stringency, moderate stringency or high stringency conditions, as defined herein.

Homologous polypeptides of the present invention may be naturally-occurring and derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, or baboon, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 101-190. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the CSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, e.g., dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule

encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. The homologous polypeptide may also be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. Alternatively, the  
5 homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of a CSP. In a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a CSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an  
10 antibody. It is, therefore, another aspect of the present invention to provide isolated polypeptide not only identical in sequence to those described with particularity herein, but also to provide isolated polypeptide ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using  
15 immunoassays well-known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, polypeptides of the present invention are also inclusive of those encoded by an allelic variant of a nucleic acid  
20 molecule encoding a CSP. In this embodiment, it is preferred that the polypeptide be encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 101-190. More preferred is that the polypeptide be encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-100.

Polypeptides of the present invention are also inclusive of derivative polypeptides encoded by a nucleic acid molecule according to the instant invention. In this  
25 embodiment, it is preferred that the polypeptide be a CSP. Also preferred are derivative polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NO: 101-190 and which has been acetylated, carboxylated, phosphorylated,  
30 glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents,

enzymes, and antigens that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common  
 5 modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.),  
 10 Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there  
 15 are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting  
 20 sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

25 General examples of types of post-translational modifications include, but are not limited to: (Z)-dehydrobutyryne; 1-chondroitin sulfate-L-aspartic acid ester; 1'-glycosyl-L-tryptophan; 1'-phospho-L-histidine; 1-thioglycine; 2'-(S-L-cysteiny)-L-histidine; 2'-[3-carboxamido (trimethylammonio)propyl]-L-histidine; 2'-alpha-mannosyl-L-tryptophan; 2-methyl-L-glutamine; 2-oxobutanoic acid; 2-pyrrolidone carboxylic acid; 3'-(1'-L-histidyl)-  
 30 L-tyrosine; 3'-(8alpha-FAD)-L-histidine; 3'-(S-L-cysteiny)-L-tyrosine; 3', 3'', 5'-triiodo-L-tyrosine; 3'-4'-phospho-L-tyrosine; 3-hydroxy-L-proline; 3'-methyl-L-histidine; 3-methyl-L-lanthionine; 3'-phospho-L-histidine; 4'-(L-tryptophan)-L-tryptophyl quinone; 42 N-cysteinyl-glycosylphosphatidylinositol ethanolamine; 43 -(T-L-histidyl)-L-tyrosine; 4-

- hydroxy-L-arginine; 4-hydroxy-L-lysine; 4-hydroxy-L-proline; 5'-(N6-L-lysine)-L-topaquinone; 5-hydroxy-L-lysine; 5-methyl-L-arginine; alpha-l-microglobulin-Ig alpha complex chromophore; bis-L-cysteinyl bis-L-histidino diron disulfide; bis-L--cysteinyl-L-N3'-histidino-L-serinyl tetrairon' tetrasulfide; chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-alanine; D-allo-isoleucine; D-asparagine; 5 dehydroalanine; dehydrotyrosine; dermatan 4-sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-glucuronyl-N-glycine; dipyrrolylmethanemethyl-L-cysteine; D-leucine; D-methionine; D-phenylalanine; D-serine; D-tryptophan; glycine amide; glycine oxazolecarboxylic acid; glycine thiazolecarboxylic acid; heme P450-bis-L-10 cysteine-L-tyrosine; heme-bis-L-cysteine; hemediol-L-aspartyl ester-L-glutamyl ester; hemediol-L-aspartyl ester-L-glutamyl ester-L-methionine sulfonium; heme-L-cysteine; heme-L-histidine; heparan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; heme P450-bis-L-cysteine-L-lysine; hexakis-L-cysteinyl hexairon hexasulfide; keratan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-threonine; L-15 oxoalanine- lactic acid; L phenyllactic acid; l'-(8alpha-FAD)-L-histidine; L-2'.4'.5'-topaquinone; L-3',4'-dihydroxyphenylalanine; L-3'.4'.5'-trihydroxyphenylalanine; L-4'-bromophenylalanine; L-6'-bromotryptophan; L-alanine amide; L-alanyl imidazolinone glycine; L-allysine; L-arginine amide; L-asparagine amide; L-aspartic 4-phosphoric anhydride; L-aspartic acid 1-amide; L-beta-methylthioaspartic acid; L-bromohistidine; L-20 citrulline; L-cysteine amide; L-cysteine glutathione disulfide; L-cysteine methyl disulfide; L-cysteine methyl ester; L-cysteine oxazolecarboxylic acid; L-cysteine oxazolinecarboxylic acid; L-cysteine persulfide; L-cysteine sulfenic acid; L-cysteine sulfinic acid; L-cysteine thiazolecarboxylic acid; L-cysteinyl homocitryl molybdenum-heptairon-nonasulfide; L-cysteinyl imidazolinone glycine; L-cysteinyl molybdopterin; L-25 cysteinyl molybdopterin guanine dinucleotide; L-cystine; L-erythro-beta-hydroxyasparagine; L-erythro-beta-hydroxyaspartic acid; L-gamma-carboxyglutamic acid; L-glutamic acid 1-amide; L-glutamic acid 5-methyl ester; L-glutamine amide; L-glutamyl 5-glycerolphosphorylethanolamine; L-histidine amide; L-isoglutamyl-polyglutamic acid; L-isoglutamyl-polyglycine; L-isoleucine amide; L-lanthionine; L-leucine amide; L-lysine 30 amide; L-lysine thiazolecarboxylic acid; L-lysinoalanine; L-methionine amide; L-methionine sulfone; L-phenylalanine thiazolecarboxylic acid; L-phenylalanine amide; L-proline amide; L-selenocysteine; L-selenocysteinyl molybdopterin guanine dinucleotide; L-serine amide; L-serine thiazolecarboxylic acid; L-seryl imidazolinone glycine; L-T-

bromophenylalanine; L-T-bromophenylalanine; L-threonine amide; L-thyroxine; L-tryptophan amide; L-tryptophyl quinone; L-tyrosine amide; L-valine amide; meso-lanthionine; N-(L-glutamyl)-L-tyrosine; N-(L-isoaspartyl)-glycine; N-(L-isoaspartyl)-L-cysteine; N,N,N-trimethyl-L-alanine; N,N-dimethyl-L-proline; N2-acetyl-L-lysine; N2-succinyl-L-tryptophan; N4-(ADP-ribosyl)-L-asparagine; N4-glycosyl-L-asparagine; N4-hydroxymethyl-L-asparagine; N4-methyl-L-asparagine; N5-methyl-L-glutamine; N6-1-carboxyethyl-L-lysine; N6-(4-amino hydroxybutyl)-L-lysine; N6-(L-isoglutamyl)-L-lysine; N6-(phospho-5'-adenosine)-L-lysine; N6-(phospho-5'-guanosine)-L-lysine; N6,N6,N6-trimethyl-L-lysine; N6,N6-dimethyl-L-lysine; N6-acetyl-L-lysine; N6-biotinyl-L-lysine; N6-carboxy-L-lysine; N6-formyl-L-lysine; N6-glycyl-L-lysine; N6-lipoyl-L-lysine; N6-methyl-L-lysine; N6-methyl-N6-poly(N-methyl-propylamine)-L-lysine; N6-mureinyl-L-lysine; N6-myristoyl-L-lysine; N6-palmitoyl-L-lysine; N6-pyridoxal phosphate-L-lysine; N6-pyruvic acid 2-iminyl-L-lysine; N6-retinal-L-lysine; N-acetyl-glycine; N-acetyl-L-glutariaine; N-acetyl-L-alanine; N-acetyl-L-aspartic acid; N-acetyl-L-cysteine; N-acetyl-L-glutamic acid; N-acetyl-L-isoleucine; N-acetyl-L-methionine; N-acetyl-L-proline; N-acetyl-L-serine; N-acetyl-L-threonine; N-acetyl-L-tyrosine; N-acetyl-L-valine; N-alanyl-glycosylphosphatidylinositoethanolamine; N-asparaginyl-glycosylphosphatidylinositoethanolamine; N-aspartyl-glycosylphosphatidylinositoethanolamine; N-formylglycine; N-formyl-L-methionine; N-glycyl-glycosylphosphatidylinositoethanolamine; N-L-glutamyl-poly-L-glutamic acid; N-methylglycine; N-methyl-L-alanine; N-methyl-L-methionine; N-methyl-L-phenylalanine; N-myristoyl-glycine; N-palmitoyl-L-cysteine; N-pyruvic acid 2-iminyl-L-cysteine; N-pyruvic acid 2-iminyl-L-valine; N-seryl-glycosylphosphatidylinositoethanolamine; N-seryl-glycosylsphingolipidinositoethanolamine; O-(ADP-ribosyl)-L-serine; O-(phospho-5'-adenosine)-L-threonine; O-(phospho-5'-DNA)-L-serine; O-(phospho-5'-DNA)-L-threonine; O-(phospho-5'rRNA)-L-serine; O-(phosphoribosyl dephospho-coenzyme A)-L-serine; O-(sn-1-glycerophosphoryl)-L-serine; O4'-(8alpha-FAD)-L-tyrosine; O4'-(phospho-5'-adenosine)-L-tyrosine; O4'-(phospho-5'-DNA)-L-tyrosine; O4'-(phospho-5'-RNA)-L-tyrosine; O4'-(phospho-5'-uridine)-L-tyrosine; O4-glycosyl-L-hydroxyproline; O4'-glycosyl-L-tyrosine; O4'-sulfo-L-tyrosine; O5-glycosyl-L-hydroxylysine; O-glycosyl-L-serine; O-glycosyl-L-threonine; omega-N-(ADP-ribosyl)-L-arginine; omega-N,omega-N'-dimethyl-L-arginine; omega-N-methyl-L-arginine; omega-N,omega-N'-dimethyl-L-arginine; omega-N-phospho-L-arginine; O-octanoyl-L-serine. ; O-palmitoyl-L-serine; O-

palmitoyl-L-threonine; O-phospho-L-serine; O-phospho-L-threonine; O-phosphopantetheine-L-serine; phycoerythrobilin-bis-L-cysteine; phycourobilin-bis-L-cysteine; pyrroloquinoline quinone; pyruvic acid; S hydroxycinnamyl-L-cysteine; S-(2-aminovinyl) methyl-D-cysteine; S-(2-aminovinyl)-D-cysteine; S-(6-FW-L-cysteine; S-(8 $\alpha$ -FAD)-L-cysteine; S-(ADP-ribosyl)-L-cysteine; S-(L-isoglutamyl)-L-cysteine; S-12-hydroxyfarnesyl-L-cysteine; S-acetyl-L-cysteine; S-diacylglycerol-L-cysteine; S-diphytanylglycerol diether-L-cysteine; S-farnesyl-L-cysteine; S-geranylgeranyl-L-cysteine; S-glycosyl-L-cysteine; S-glycyl-L-cysteine; S-methyl-L-cysteine; S-nitrosyl-L-cysteine; S-palmitoyl-L-cysteine; S-phospho-L-cysteine; S-phycobiliviolin-L-cysteine; S-phycocyanobilin-L-cysteine; S-phycoerythrobilin-L-cysteine; S-phytochromobilin-L-cysteine; S-selenyl-L-cysteine; S-sulfo-L-cysteine; tetrakis-L-cysteiny diiron disulfide; tetrakis-L-cysteiny iron; tetrakis-L-cysteiny tetrairon tetrasulfide; trans-2,3-cis 4-dihydroxy-L-proline; tris-L-cysteiny triiron tetrasulfide; tris-L-cysteiny triiron trisulfide; tris-L-cysteiny-L-aspartato tetrairon tetrasulfide; tris-L-cysteiny-L-cysteine persulfido-bis-L-glutamato-L-histidino tetrairon disulfide trioxide; tris-L-cysteiny-L-N<sup>3</sup>'-histidino tetrairon tetrasulfide; tris-L-cysteiny-L-N<sup>1</sup>'-histidino tetrairon tetrasulfide; and tris-L-cysteiny-L-seriny tetrairon tetrasulfide.

Additional examples of PTMs may be found in web sites such as the Delta Mass database based on Krishna, R. G. and F. Wold (1998). Posttranslational Modifications. Proteins - Analysis and Design. R. H. Angeletti. San Diego, Academic Press. 1: 121-206. ; Methods in Enzymology, 193, J.A. McClosky (ed) (1990), pages 647-660; Methods in Protein Sequence Analysis edited by Kazutomo Imahori and Fumio Sakiyama, Plenum Press, (1993) "Post-translational modifications of proteins" R.G. Krishna and F. Wold pages 167-172; "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335 (2001) "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta et al. Nucleic Acids Research, 27: 370-372 (1999); and "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239 (1999) see also, WO 02/21139A2.

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from

normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on  
5 different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be  
10 critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is  
15 prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signalling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).  
20

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to  
25 the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is  
30 cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein

interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, Ann. N.Y. Acad. Sci. 936: 580-593 (2001).

- 5           Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for  
10 different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the  
15 particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.
- 20           In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP  
25 kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-  
30 translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-



translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website [www.expasy.org](http://www.expasy.org). The nucleic acid molecule may also be introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), e.g., offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa

Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

- 10 The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS,
- 15 Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMFA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB,
- 20 SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

- Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to polypeptides of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

- Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-CSP antibodies.

Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999). PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

Polypeptides of the present invention are also inclusive of analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, this polypeptide is a CSP. In a more preferred embodiment, this polypeptide is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 101-190. Also preferred is an analog polypeptide comprising one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally-occurring polypeptide. In one embodiment, the analog is structurally similar to a CSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another embodiment, the analog comprises substitution of one or more amino acids of a CSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Koe et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A

Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993).

- 5 Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl--(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and tBOC derivatives of
- 10 dabcyl-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyl chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyl quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS--Fmoc-L-glutamic
- 15 acid or the corresponding tBOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated Fmoc synthesis of peptides using (Fmoc)--TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

- Other useful amino acid analogues that can be incorporated during chemical
- 20 synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

- A large number of other Fmoc-protected non-natural amino acid analogues
- 25 capable of incorporation during chemical synthesis are available commercially, including, e.g., Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-
- 30 5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-

amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

#### *Fusion Proteins*

Another aspect of the present invention relates to the fusion of a polypeptide of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide of the present invention is a CSP. In a more preferred embodiment, the polypeptide of the present invention that is fused to a heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 101-190, or is a mutein,

homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the fusion protein is encoded by a nucleic acid molecule comprising all or part of the nucleic acid sequence of SEQ ID NO: 1-100, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-100.

The fusion proteins of the present invention will include at least one fragment of a polypeptide of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the polypeptide of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of a polypeptide of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and preferably at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g., Ausubel, Chapter 16, (1992), supra.* Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins into the periplasmic space or extracellular milieu for prokaryotic hosts or into the culture medium for eukaryotic cells through incorporation of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be

purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful fusion proteins of the present invention include those that permit use of the polypeptide of the present invention as bait in a yeast two-hybrid system. See Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); ; Colas *et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; Norman, T. *et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, Fabbriozio *et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; Xu *et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; Yang, *et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; Kolonin *et al.*, (1998) Targeting cyclin-dependent kinases in Drosophila with peptide aptamers. *Proc Natl Acad Sci U S A* 95, 14266-14271; Cohen *et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; Uetz, P.; Giot, L.; al, e.; Fields, S.; Rothberg, J. M. (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; Ito, *et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl Acad Sci U S A* 98, 4569-4574. Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded polypeptide on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

- 5           The polypeptides of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

- Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST,  
10 immunoglobulins,  $\beta$ -galactosidase, biotin *trpE*, protein A,  $\beta$ -lactamase,  $\alpha$ -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), *lacZ*, green fluorescent protein (GFP), yeast  $\alpha$  mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of  
15 IgG. *See, e.g.*, Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (*e.g.*, a  
20 Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the CSP.

- As further described below, the polypeptides of the present invention can readily  
25 be used as specific immunogens to raise antibodies that specifically recognize polypeptides of the present invention including CSPs and their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly CSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning  
30 cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of CSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of CSPs.



One may determine whether polypeptides of the present invention including CSPs, muteins, homologous proteins or allelic variants or fusion proteins of the present invention are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the polypeptide at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides or fusion proteins of the present invention is well-known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated polypeptides or fusion proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated polypeptide or fusion protein of the present invention are used as therapeutic agents, such as in vaccines and replacement therapy, the isolated polypeptides of the present invention are also useful at lower purity. For example, partially purified polypeptides of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In a preferred embodiment, the purified and substantially purified polypeptides of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides or fusion proteins of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

For example, the polypeptides or fusion proteins of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the polypeptides or fusion proteins of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized polypeptide or fusion protein of the present invention.

As another example, the polypeptides or fusion proteins of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides and fusion proteins of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biologic interaction there between. The polypeptides or fusion proteins of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biological interaction there between.

#### Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention. In a preferred embodiment, the antibodies are specific for a polypeptide that is a CSP, or a fragment, mutein, derivative, analog or fusion protein

thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 101-190, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a CSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or vis versa. In addition, alternative splice forms of a CSP may be indicative of cancer. Differential degradation of the C or N-terminus of a CSP may also be a marker or target for anticancer therapy. For example, an CSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-CSP polypeptides by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the polypeptide of the present invention in samples derived from human colon.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$  M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the polypeptides of the present invention will

typically have resulted from fortuitous immunization, such as autoimmune immunization, with the polypeptide of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

5 Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies  
10 therefrom upon specific immunization are described, *inter alia*, in United States Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced  
15 using techniques developed for production of murine antibodies.

15 Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

20 IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention are also usefully obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster), lagomorphs, (typically rabbits), and also larger mammals, such as sheep, goats, cows, and horses; or egg laying birds or reptiles such as chickens or alligators. In such cases, as with the transgenic human-antibody-  
25 producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the polypeptide of the present invention. One form of avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000.

30 As discussed above, virtually all fragments of 8 or more contiguous amino acids of a polypeptide of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide of the present invention to other moieties. For example, polypeptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical  
5 definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in  
10 Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996). Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and  
15 Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the polypeptides of the present invention and  
20 monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the polypeptides of the present invention. Antibodies from avian species may have particular advantage in detection of the polypeptides of the present invention, in human serum or tissues (Vikinge *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998). Following immunization, the antibodies of the present invention can be obtained using any  
25 art-accepted technique. Such techniques are well-known in the art and are described in detail in references such as Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); and Kenney,  
30 Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997).

Briefly, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two

methods of production are not mutually exclusive: genes encoding antibodies specific for the polypeptides of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the polypeptides of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in United States Patent No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant antibody production of whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.*, Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. *See, e.g.*, Barbas (2001), *supra*; Kay, *supra*; and Abelson, *supra*.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell. Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention. For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.*, Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20

(1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); and Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998).

Antibodies, including antibody fragments and derivatives, of the present invention  
5 can also be produced in insect cells. *See, e.g.*, Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992).

Antibodies and fragments and derivatives thereof of the present invention can also  
10 be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995).

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol. Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); and Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995).

20 Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells. Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998) review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies. Antibodies of the present invention can also be prepared by cell  
25 free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999).

The invention further provides antibody fragments that bind specifically to one or  
30 more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecule of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid

molecules of the present invention. Among such useful fragments are Fab, Fab', Fv, F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

The present invention also relates to antibody derivatives that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus are more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g., Morrison et al., Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al., Nature* 309(5966): 364-7 (1984); Takeda *et al., Nature* 314(6010): 452-4 (1985); and United States Patent No. 5,807,715 the disclosure of which is incorporated herein by reference in its entirety. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al., Nature* 332(6162): 323-7 (1988); Co *et al., Nature* 351(6326): 501-2 (1991); and United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties. Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. Accordingly, the present invention includes any recombinant vector containing the coding sequences, or part



thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either  
5 with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

- 10 The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively  
15 inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. The choice of label depends, in part, upon the desired use.

- For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that  
20 catalyzes production and local deposition of a detectable product. Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase,  $\beta$ -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG);  
25 o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN);  
5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BlueGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS);  
30 phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), horseradish

peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. *See, e.g., Thorpe et al., Methods Enzymol.* 133: 331-53 (1986); Kricka *et al., J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al., J. Biolumin. Chemilumin.* 10(6): 353-9 (1995). Kits for such enhanced chemiluminescent detection (ECL) are available commercially. The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, *e.g.,* for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores. There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention. For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention. For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for western blotting applications, they can usefully be labeled with radioisotopes, such as  $^{33}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ , and  $^{125}\text{I}$ . As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be  $^{228}\text{Th}$ ,  $^{227}\text{Ac}$ ,  $^{225}\text{Ac}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the polypeptides of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. *See* Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998).

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, attached to a substrate. Substrates can be porous or nonporous, planar or nonplanar. For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography. For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the polypeptides of the present invention. As

another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to  
5 provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the polypeptides of the present invention, to one or more of  
10 the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

In sum, one of skill in the art, provided with the teachings of this invention, has  
15 available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

## 20 Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid  
25 molecule encoding a CSP. In a preferred embodiment, the CSP comprises an amino acid sequence selected from SEQ ID NO: 101-190, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a CSNA of the invention, preferably a CSNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-100, or a part,  
30 substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human CSG. The

transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, 2d ed., Cold Spring Harbor Press (1999); Jackson et al., Mouse Genetics and Transgenics: A Practical Approach, Oxford University Press (2000); and Pinkert, Transgenic Animal Technology: A Laboratory Handbook, Academic Press (1999).*

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology 11: 1263-1270 (1993); Wright et al., Biotechnology 9: 830-834 (1991); and United States Patent No. 4,873,191, herein incorporated by reference in its entirety); retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985); gene targeting in embryonic stem cells (*see, e.g., Thompson et al., Cell 56: 313-321 (1989); electroporation of cells or embryos (*see, e.g., Lo, 1983, Mol. Cell. Biol. 3: 1803-1814 (1983); introduction using a gene gun (*see, e.g., Ulmer et al., Science 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g., Lavitrano et al., Cell 57: 717-723 (1989).******

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810-813 (1997).*

The present invention provides for transgenic animals that carry the transgene (*i.e., a nucleic acid molecule of the invention*) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e., mosaic animals or chimeric animals.*

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, *e.g., head-to-head tandems or head-to-tail tandems.* The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g., the teaching of Lasko et al. et al., Proc. Natl. Acad. Sci. USA 89: 6232- 6236 (1992).*

The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106

(1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g.,* Smithies *et al.*, *Nature* 317: 230-234 (1985); Thomas *et al.*, *Cell* 51: 503-512 (1987); Thompson *et al.*, *Cell* 5: 313-321 (1989).

5           In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another  
10           embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted  
15           gene. *See, e.g.,* Thomas, *supra* and Thompson, *supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

          In further embodiments of the invention, cells that are genetically engineered to  
20           express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient in vivo. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells  
25           are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures,  
30           including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

          The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve

expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, United States Patent Nos. 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### Computer Readable Means

A further aspect of the invention is a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 101-190 and SEQ ID NO: 1-100 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and



“amino acid sequences of the invention” mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and  
5 mass spectrographic data.

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the  
10 invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic  
15 acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence  
20 comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character  
25 sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and  
30 sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a

computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence  
5 comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the  
10 steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence. In addition, the invention includes a method of using patterns of expression associated with either the nucleic acids or proteins in a computer-based method to  
15 diagnose disease.

#### Diagnostic Methods for Colon Cancer

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by  
20 comparing expression of a CSNA or a CSP in a human patient that has or may have colon cancer, or who is at risk of developing colon cancer, with the expression of a CSNA or a CSP in a normal human control. For purposes of the present invention, "expression of a CSNA" or "CSNA expression" means the quantity of CSG mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any  
25 method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of a CSP" or "CSP expression" means the amount of CSP that can be measured by any method known in the art or the level of translation of a CSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing colon cancer in a patient,  
30 in particular squamous cell carcinoma, by analyzing for changes in levels of CSNA or CSP in cells, tissues, organs or bodily fluids compared with levels of CSNA or CSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a CSNA or CSP in

the patient versus the normal human control is associated with the presence of colon cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing colon cancer in a patient by analyzing changes in the structure of the mRNA of an CSG compared to the mRNA from a normal control.

- 5 These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing colon cancer in a patient by analyzing changes in a CSP compared to a CSP from a normal patient. These changes include, *e.g.*, alterations, including post translational modifications such as glycosylation and/or
- 10 phosphorylation of the CSP or changes in the subcellular CSP localization.

- For purposes of the present invention, diagnosing means that CSNA or CSP levels are used to determine the presence or absence of disease in a patient. As will be understood by those of skill in the art, measurement of other diagnostic parameters may be required for definitive diagnosis or determination of the appropriate treatment for the disease. The
- 15 determination may be made by a clinician, a doctor, a testing laboratory, or a patient using an over the counter test. The patient may have symptoms of disease or may be asymptomatic. In addition, the CSNA or CSP levels of the present invention may be used as screening marker to determine whether further tests or biopsies are warranted. In addition, the CSNA or CSP levels may be used to determine the vulnerability or
- 20 susceptibility to disease.

- In a preferred embodiment, the expression of a CSNA is measured by determining the amount of a mRNA that encodes an amino acid sequence selected from SEQ ID NO: 101-190, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the CSNA expression that is measured is the level of expression of a CSNA
- 25 mRNA selected from SEQ ID NO: 1-100, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acid molecules. CSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ*
- 30 hybridization. *See, e.g.*, Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. CSNA transcription may be measured by any method known in the art including using a reporter gene hooked up to the promoter of a CSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*,

aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, CSNA expression may be compared to a known control, such as normal colon nucleic acid, to detect a change in expression.

5 In another preferred embodiment, the expression of a CSP is measured by determining the level of a CSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 101-190, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a  
10 diagnostic assay in accordance with the invention for diagnosing over- or underexpression of a CSNA or CSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of colon cancer. The expression level of a CSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the CSP expression level may be determined by radioimmunoassays,  
15 competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g., Harlow (1999), supra; Ausubel (1992), supra; and Ausubel (1999), supra.* Alterations in the CSP structure may be determined by any method known  
20 in the art, including, *e.g.,* using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein.  
*Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An  
25 antibody specific to a CSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-CSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the CSP will bind to the anti-CSP antibody.  
30 The sample is removed, the solid support is washed to remove unbound material, and an anti-CSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the CSP to the labeled antibody will occur. After binding, the unbound

labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an CSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are  
5 obtained by reference to a standard curve.

Other methods to measure CSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-CSP antibody is attached to a solid support and an allocated amount of a labeled CSP and a sample of interest are incubated with the solid support. The amount of labeled CSP detected which is attached to the solid  
10 support can be correlated to the quantity of a CSP in the sample.

Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size  
15 using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance  
20 of a given protein and the identity of the proteins in the sample.

Expression levels of a CSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase  
25 PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

30 Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more CSNAs of interest. In this approach, all or a portion of one or more CSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*,

total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. As used herein "blood" includes whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of CSNA or CSP includes, without limitation, colon tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, colon cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary colon cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and colon. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration. See Scott, *supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in CSNAs or CSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples are disclosed in Franklin, *supra*.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a CSNA or CSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other CSNA or CSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular CSNA or CSP is measured. In a more preferred

embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

#### *Diagnosing*

5 In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more CSNA and/or CSP in a sample from a patient suspected of having colon cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of a CSNA and/or CSP and then ascertaining whether the patient has colon  
10 cancer from the expression level of the CSNA or CSP. In general, if high expression relative to a control of a CSNA or CSP is indicative of colon cancer, a diagnostic assay is considered positive if the level of expression of the CSNA or CSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human  
15 control. In contrast, if low expression relative to a control of a CSNA or CSP is indicative of colon cancer, a diagnostic assay is considered positive if the level of expression of the CSNA or CSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a  
20 different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether colon cancer has metastasized in a patient. One may identify whether the colon cancer has metastasized by measuring the expression levels and/or structural alterations of one or more CSNAs and/or CSPs in a variety of tissues. The presence of a CSNA or CSP in a certain tissue at  
25 levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of a CSNA or CSP is associated with colon cancer. Similarly, the presence of a CSNA or CSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a CSNA or CSP is associated with colon cancer. Further, the  
30 presence of a structurally altered CSNA or CSP that is associated with colon cancer is also indicative of metastasis.

In general, if high expression relative to a control of n CSNA or CSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of

the CSNA or CSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a CSNA or CSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the CSNA or CSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

#### *Staging*

10 The invention also provides a method of staging colon cancer in a human patient. The method comprises identifying a human patient having colon cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more CSNAs or CSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and the  
15 expression levels of one or more CSNAs or CSPs is determined for each stage to obtain a standard expression level for each CSNA and CSP. Then, the CSNA or CSP expression levels of the CSNA or CSP are determined in a biological sample from a patient whose stage of cancer is not known. The CSNA or CSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the  
20 CSNAs and CSPs from the patient to the standard expression levels, one may determinethe stage of the tumor. The same procedure may be followed using structural alterations of a CSNA or CSP to determine the stage of a colon cancer.

#### *Monitoring*

Further provided is a method of monitoring colon cancer in a human patient. One  
25 may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the colon cancer. The monitoring may determine if  
30 there has been a reoccurrence and, if so, determine its nature. The method comprises identifying a human patient that one wants to monitor for colon cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of



one or more CSNAs or CSPs, and comparing the CSNA or CSP levels over time to those CSNA or CSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a CSNA or CSP that are associated with colon cancer.

- 5           If increased expression of a CSNA or CSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of a CSNA or CSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased  
10 expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of a CSNA or CSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of a CSNA or CSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous,  
15 respectively. In a preferred embodiment, the levels of CSNAs or CSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a patient for onset of colon cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

- The methods described herein can further be utilized as prognostic assays to  
20 identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a CSNA and/or CSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more CSNAs and/or CSPs are detected. The presence of higher (or lower) CSNA or CSP levels as compared to normal human controls is diagnostic for the human patient being at  
25 risk for developing cancer, particularly colon cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more CSNAs and/or CSPs of the invention can also be monitored by analyzing levels of expression of the CSNAs and/or CSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of  
30 the physiological response of the human patient or cells, as the case may be, to the agent being tested.

*Detection of Genetic Lesions or Mutations*

The methods of the present invention can also be used to detect genetic lesions or mutations in a CSG, thereby determining if a human with the genetic lesion is susceptible to developing colon cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing colon cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the CSGs of this invention, a chromosomal rearrangement of a CSG, an aberrant modification of a CSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a CSG. Methods to detect such lesions in the CSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

#### Methods of Detecting Noncancerous Colon Diseases

The present invention also provides methods for determining the expression levels and/or structural alterations of one or more CSNAs and/or CSPs in a sample from a patient suspected of having or known to have a noncancerous colon disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of a CSNA and/or CSP, comparing the expression level or structural alteration of the CSNA or CSP to a normal colon control, and then ascertaining whether the patient has a noncancerous colon disease. In general, if high expression relative to a control of a CSNA or CSP is indicative of a particular noncancerous colon disease, a diagnostic assay is considered positive if the level of expression of the CSNA or CSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a CSNA or CSP is indicative of a noncancerous colon disease, a diagnostic assay is considered positive if the level of expression of the CSNA or CSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a CSNA and/or CSP is associated with a particular noncancerous colon disease by obtaining colon tissue from a patient having a noncancerous colon disease of interest and determining which CSNAs

and/or CSPs are expressed in the tissue at either a higher or a lower level than in normal colon tissue. In another embodiment, one may determine whether a CSNA or CSP exhibits structural alterations in a particular noncancerous colon disease state by obtaining colon tissue from a patient having a noncancerous colon disease of interest and  
5 determining the structural alterations in one or more CSNAs and/or CSPs relative to normal colon tissue.

#### Methods for Identifying Colon Tissue

In another aspect, the invention provides methods for identifying colon tissue.  
10 These methods are particularly useful in, *e.g.*, forensic science, colon cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is colon tissue or has colon tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising colon tissue or having colon tissue-  
15 like characteristics, determining whether the sample expresses one or more CSNAs and/or CSPs, and, if the sample expresses one or more CSNAs and/or CSPs, concluding that the sample comprises colon tissue. In a preferred embodiment, the CSNA encodes a polypeptide having an amino acid sequence selected from SEQ ID NO: 101-190, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the CSNA  
20 has a nucleotide sequence selected from SEQ ID NO: 1-100, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a CSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining  
25 whether a CSP is expressed. Determining whether a sample expresses a CSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the CSP has an amino acid sequence selected from SEQ ID NO: 101-190, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two CSNAs and/or CSPs is  
30 determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five CSNAs and/or CSPs are determined.

In one embodiment, the method can be used to determine whether an unknown tissue is colon tissue. This is particularly useful in forensic science, in which small,

damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into colon tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new colon tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

10 Methods for Producing and Modifying Colon Tissue

In another aspect, the invention provides methods for producing engineered colon tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing a CSNA or a CSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of colon tissue cells. In a preferred embodiment, the cells are pluripotent. As is well-known in the art, normal colon tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered colon tissue or cells comprises one of these cell types. In another embodiment, the engineered colon tissue or cells comprises more than one colon cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the colon cell tissue. Methods for manipulating culture conditions are well-known in the art.

Nucleic acid molecules encoding one or more CSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode CSPs having amino acid sequences selected from SEQ ID NO: 101-190, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1-100, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, a CSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

Artificial colon tissue may be used to treat patients who have lost some or all of their colon function.

#### Pharmaceutical Compositions

5           In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, fusion proteins, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, or inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a CSNA or part thereof. In a more preferred embodiment, the CSNA has a nucleotide  
10       sequence selected from the group consisting of SEQ ID NO: 1-100, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises a CSP or fragment thereof. In a more preferred embodiment, the pharmaceutical composition comprises a CSP having an amino acid sequence that is  
15       selected from the group consisting of SEQ ID NO: 101-190, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the pharmaceutical composition comprises an anti-CSP antibody, preferably an antibody that specifically binds to a CSP having an amino acid that is selected from the group consisting of SEQ ID  
20       NO: 101-190, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable  
25       carrier or excipient.

Pharmaceutical formulation is a well-established art that is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.),  
30       Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. (2000) and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions

utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

5           Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

          Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other  
10   plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

15           Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

          Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl  
20   methylcellulose, sucrose, starch and ethylcellulose.

          Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

          Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

25           Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

30           Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally,

stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings  
5 for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral)  
administration are prepared in water or other aqueous vehicles and can contain various  
suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin,  
carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations  
10 can also include solutions, emulsions, syrups and elixirs containing, together with the  
active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated  
for parenteral administration. Formulations for parenteral administration can be in the  
form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

15 For intravenous injection, water soluble versions of the compounds of the present  
invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically  
acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline,  
0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include  
carriers, excipients or stabilizers including, without limitation, calcium, human serum  
20 albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form  
of the compounds of the present invention, can be dissolved and administered in a  
pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution.  
Alternatively, a suitable insoluble form of the compound can be prepared and  
25 administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base,  
such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil,  
triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as  
vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate,  
30 isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene  
glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the  
viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.

Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically. For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.



Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

5 The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

10 After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

15 A "therapeutically effective dose" refers to that amount of active ingredient, for example CSP polypeptide, fusion protein, or fragments thereof, antibodies specific for CSP, agonists, antagonists or inhibitors of CSP, which ameliorates the signs or symptoms of the disease or prevent progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

20 The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

25 For example, the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population) can be determined in one or more cell culture or animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

30 The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED<sub>50</sub> with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known

in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

## Therapeutic Methods

The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of colon function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

*Gene Therapy and Vaccines*

The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for the purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further described in United States Patent Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. See, e.g., Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid molecule of the present invention is administered. The nucleic acid molecule can be delivered in a vector that drives expression of a CSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a CSP are administered, for example, to complement a deficiency in the native CSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. See, e.g., Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid molecule encodes a CSP having the amino acid sequence of SEQ ID NO: 101-190, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express a CSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in CSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a CSP having the amino acid sequence of SEQ ID NO: 101-190, or a fragment, fusion protein, allelic variant or homolog thereof.

*Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of a CSG antisense nucleic acid, are administered to downregulate transcription and/or translation of

a CSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a CSG. For example,

5 oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to CSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995).

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the CSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); and McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000). Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a CSP, preferably a CSP comprising an amino acid sequence of SEQ ID NO: 101-190, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-100, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### 25 *Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a CSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant CSP defect.

30 Protein compositions are administered, for example, to complement a deficiency in native CSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to CSP. The immune response can be used to modulate activity of CSP or, depending on the immunogen, to immunize against

aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate CSP.

In a preferred embodiment, the polypeptide administered is a CSP comprising an amino acid sequence of SEQ ID NO: 101-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-100, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

*Antibody, Agonist and Antagonist Administration*

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well-known, antibody compositions are administered, for example, to antagonize activity of CSP, or to target therapeutic agents to sites of CSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a CSP comprising an amino acid sequence of SEQ ID NO: 101-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antibody specifically binds to a CSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-100, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to a CSP or have a modulatory effect on the expression or activity of a CSP. Modulators which decrease the expression or activity of CSP (antagonists) are believed to be useful in treating colon cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a CSP can also be designed, synthesized and tested for use in the imaging and treatment of colon cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the CSPs identified herein. Molecules identified in the library as being capable of binding to a CSP are key candidates for further evaluation for use in the treatment of colon cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of a CSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of CSP is administered.

Antagonists of CSP can be produced using methods generally known in the art. In particular, purified CSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a CSP.

- 5           In other embodiments a pharmaceutical composition comprising an agonist of a CSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

- In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a CSP comprising an amino acid sequence of SEQ  
10 ID NO: 101-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a CSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-100, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

15

#### *Targeting Colon Tissue*

- The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the colon or to specific cells in the colon. In a preferred embodiment, an anti-CSP antibody is  
20 linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if colon tissue needs to be selectively destroyed. This would be useful for targeting and killing colon cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting colon cell function.

- 25           In another embodiment, an anti-CSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring colon function, identifying colon cancer tumors, and identifying noncancerous colon diseases.

**EXAMPLES****Example 1: Gene Expression analysis**

Identification of CSGs was carried out by a systematic analysis of gene expression data in the LIFESEQ® Gold database available from Incyte Genomics Inc, Palo Alto, CA, using the data mining software package CLASP™.

The CLASP target gene identification process is focused on, but not limited to, the following 5 CLASP profiles: tissue specific expression, cancer specific expression, differentially expressed in cancer, maximum tissue differential expression.

(1) For these profiles: cDNA libraries were divided into 48 unique tissue organs. The genes were grouped into gene bins, each bin is a sequence based cluster grouped together with a common contig. The expression levels for each gene bin were calculated in each organ. Differential expression significance was calculated with rigorous statistical significant test considering the influence of sequence random fluctuations and sampling size of cDNA libraries from concept published by Audic S and Claverie JM (Genome Res 1997 7(10): 986-995: The significance of digital gene expression profiles).

(2) Highly expressed organ specific genes were selected based on the percentage abundance level in the targeted organ versus all the other organs (organ-specificity).

(3) The expression levels of each highly expressed organ-specific gene in the tumor tissue libraries were compared with normal tissue libraries and tissue libraries associated with tumor or disease (cancer-specificity) and analyzed for statistical significance.

(4) Target genes exhibiting each CLASP profile criteria were selected  
CLASP 1 tissue specific expression profile: In order to meet the organ-specificity criteria, the expression level of the component clones which the gene is composed of must exhibit 3 or more occurrences regardless the total number of genes isolated for the target organ. The percentage abundance level in each organ was calculated to identify the organ with the highest expression percentage level.

CLASP 2 cancer specific expression profile: In order to fulfill the cancer specific criteria, genes must exhibit 0 expression in normal and libraries associated with tumor and

disease but not tumor per se. If the gene then exhibited organ-specificity, the gene was selected as a CLASP target for this profile.

CLASP 3 maximum tissue differential expression profile: CLASP targets were selected based on ratio of expression in tumor libraries compared to expression in normal libraries (including normal libraries associated with tumor or disease) for each organ regardless of whether the gene exhibited organ-specificity. This profile was divided into 2 sub-profiles, since the ratio of expression cannot be obtained if no expression is present in normal libraries (including normal libraries associated with tumor or disease). In this case, the maximum expression percentage of the gene, as calculated by the occurrence of the gene divided by the occurrence of all genes in the target organ, was used. CLASP selects the top 50 targets for each sub-profile.

CLASP 4 maximum tissue differential expression profile with negligible expression in normal tissues: CLASP targets were selected based on ratio of expression in tumor libraries compared to expression in normal libraries (including normal libraries associated with tumor or disease) for each organ regardless of whether the gene exhibited organ-specificity.

CLASP 5 differentially expressed in cancer profile: Expression levels in tumor libraries in each organ and normal libraries (including normal libraries associated with cancer or disease) for all organs were obtained and statistically analyzed. If the gene exhibited 90% of confidence that it is over-expressed in tumor libraries in the target organ than normal libraries for all organs, it was selected as a CLASP target for this profile. Accordingly, CLASP allows the identification of highly expressed organ and cancer specific genes based on the gene expression levels in each tissue organ. CLASP scores for a portion of the CSG of this invention are listed below.

The CLASP scores for SEQ ID NO: 1-100 are listed below:

SEQ ID	Organ	Abundance - Percentage	Organ	Abundance - Percentage	Organ	Abundance - Percentage	Organ	Abundance - Percentage
NO: 1	INS	3 - .0028						
NO: 2	INS	3 - .0028	FTS	2 - .0003				
NO: 3	INS	3 - .0028	SKN	2 - .003	EYE	1 - .0062		
NO: 4	INS	3 - .0028	UTR	1 - .0004	OVR	1 - .0007		
NO: 5	INS	3 - .0028	INL	1 - .0004	LNG	1 - .0003	TST	1 - .0011
NO: 6	INS	3 - .0028	BRN	1 - .0001	THR	1 - .002		
NO: 7	INS	3 - .0028						
NO: 8	INS	2 - .0257						



8								
NO: 9	INL	5 - .002	INS	3 - .0028	THY	1 - .0019		
NO: 10	INS	5 - .0047	INL	1 - .0004				
NO: 11	INL	5 - .002	TNS	3 - .0049	UNC	1 - .0011		
NO: 12	INL	4 - .0016						
NO: 13	INL	3 - .0012						
NO: 14	INL	4 - .0016						
NO: 15	INS	5 - .0047	INL	5 - .002	PAN	1 - .0008		
NO: 16	INS	5 - .0047	INL	5 - .002				
NO: 17	INL	3 - .0012						
NO: 18	INL	3 - .0012						
NO: 19	INL	3 - .0012						
NO: 20	INL	3 - .0012	PRO	1 - .0003				
NO: 21	INL	3 - .0012						
NO: 22	INL	2 - .0043						
NO: 23	INS	3 - .0028						
NO: 24	INL	8 - .0032						
NO: 25	INL	8 - .0032						
NO: 26	INL	8 - .0032						
NO: 27	INL	8 - .0032						
NO: 28	INL	3 - .0012						
NO: 29	INL	2 - .0047						
NO: 30	INL	9 - .0036	INS	1 - .0009	GEM	2 - .0042		
NO: 31	INL	9 - .0036	INS	1 - .0009				
NO: 32	INL	2 - .0059						
NO: 33	INL	3 - .0012						
NO: 34	INS	3 - .0028	MSL	1 - .002	BLV	1 - .0006		
NO: 35	INS	3 - .0028						
NO: 36	INS	2 - .0162						
NO: 37	INS	4 - .0038						
NO: 38	INL	3 - .0012						
NO: 39	INS	2 - .0353						
NO: 40	INS	2 - .0019						
NO:	INS	2 - .0019						

41								
NO:	INS	2 - .0019						
42								
NO:	INL	2 - .0052	MAM	1 - .0007				
43								
NO:	INL	3 - .0012	STO	1 - .0021				
44								
NO:	INL	3 - .0012						
45								
NO:	INL	3 - .0012	ADR	1 - .0013				
46								
NO:	INS	3 - .0028	NRV	1 - .0008				
47								
NO:	INS	2 - .0019						
48								
NO:	INS	3 - .0028						
49								
NO:	INS	3 - .0028	BON	1 - .002	LMN	1 - .0017		
50								
NO:	INS	3 - .0028						
51								
NO:	INS	4 - .0038	INL	2 - .0008				
52								
NO:	INL	3 - .0012	KID	2 - .0012				
53								
NO:	INL	3 - .0012						
54								
NO:	INL	4 - .0016						
55								
NO:	INS	5 - .0047	CON	1 - .0007				
56								
NO:	INL	3 - .0012						
57								
NO:	INS	2 - .0019	INL	1 - .0006	LIV	2 - .0038	BLO	1 - .004
58								
NO:	INL	3 - .0012						
59								
NO:	INL	3 - .0012	INS	2 - .0019				
60								
NO:	INL	3 - .0012	PNS	1 - .0022				
61								
NO:	INL	3 - .0012						
62								
NO:	INL	3 - .0012						
63								
NO:	INS	3 - .0028						
64								
NO:	INL	3 - .0012						
65								
NO:	INS	3 - .0028						
66								
NO:	INL	3 - .0012						
67								
NO:	INS	3 - .0028						
68								
NO:	INS	3 - .0028						
69								
NO:	INS	2 - .0019	INL	1 - .0006				
70								
NO:	INS	3 - .0028						
71								
NO:	INS	2 - .0019						
72								
NO:	INL	17 - .0067	ESO	1 - .0039				
73								
NO:	INL	17 -						

74		.0067					
NO: 75	INS	3 - .0028					
NO: 76	INS	3 - .0028	INL	3 - .0012	PIT	1 - .0029	
NO: 77	INS	2 - .0019					
NO: 78	INS	2 - .0019					
NO: 79	INS	2 - .0019					
NO: 80	INS	2 - .0019					
NO: 81	INS	2 - .0353					
NO: 82	INS	2 - .0353					
NO: 83	INS	2 - .0353					
NO: 84	INS	2 - .0353					
NO: 85	INS	2 - .0162					
NO: 86	INS	2 - .0162					
NO: 87	INS	3 - .0028					
NO: 88	INS	3 - .0028					
NO: 89	INS	3 - .0028					
NO: 90	INS	2 - .0162					
NO: 91	INL	6 - .0024	INS	1 - .0009	PTH	1 - .004	
NO: 92	INT	2 - .03	NOS	1 - .0287			
NO: 93	INT	2 - .03					
NO: 94	INS	17 - .0161	INL	1 - .0004			
NO: 95	INS	17 - .0161	INL	1 - .0004			
NO: 96	INS	4 - .0038	INL	1 - .0004			
NO: 97	INS	3 - .0028					
NO: 98	INS	3 - .0028					
NO: 99	INS	4 - .0038	INL	2 - .0008			
NO: 100	INS	4 - .0038	INL	2 - .0008			

- 5   INS   Intestine, Small  
      INT   Intestine  
      INL   Intestine, Large  
      CON   Connective Tissue  
      MSL   Muscles  
      NRV   Nervous Tissue  
 10   SKN   Skin  
      NOS   Nose  
      UNC   Mixed Tissues  
      EYE   Eye

OVR Ovary  
 UTR Uterus  
 FTS Fetus  
 KID Kidney

- 5 There are 2 values for each organ in the format 9 - 0.9999. The first represent the number of occurrences of the gene in the given organ. The 2nd number represents the percentage of the expression of the gene in the given organ.

Based on sequence alignment with the human genome, the following chromosomal locations were assigned.

Nucleotide Name	Chromosomal Location	ORF location	Amino acid Name
DEX0234 1	3p26.3c	304-125	DEX0234 101
DEX0234 2	5p15.33e	717-523	DEX0234 102
DEX0234 3	6p25.3b	136-285	DEX0234 103
DEX0234 4	6p25.3b		
DEX0234 5	2p25.3g	123-1	DEX0234 104
DEX0234 6	1p36.33b	620-775	DEX0234 105
DEX0234 7	1p36.33b	160-23	DEX0234 106
DEX0234 8	19p13.3j	471-316	DEX0234 107
DEX0234 9	12p13.33d	1-2787	DEX0234 108
DEX0234 10	17p13.3g	58-1113	DEX0234 109
DEX0234 11	2p25.3g	165-2312	DEX0234 110
DEX0234 12	6p25.3b	131-328	DEX0234 111
DEX0234 13	19p13.3j	66-1	DEX0234 112
DEX0234 14	13p13e	19-84	DEX0234 113
DEX0234 15	11p15.5d	157-32	DEX0234 114
DEX0234 16	11p15.5d	32-160	DEX0234 115
DEX0234 17	5p15.33e		
DEX0234 18	4p16.3d	31-117	DEX0234 116
DEX0234 19	8p23.3b	349-56	DEX0234 117
DEX0234 20	19p13.3j	462-872	DEX0234 118
DEX0234 21	19p13.3j	231-386	DEX0234 119
DEX0234 22	16p13.3f	907-638	DEX0234 120
DEX0234 23	12p13.33d	713-904	DEX0234 121
DEX0234 24	2p25.3g	102-1	DEX0234 122
DEX0234 25	2p25.3g	596-1051	DEX0234 123
DEX0234 26	2p25.3g	465-644	DEX0234 124
DEX0234 27	2p25.3g	865-614	DEX0234 125
DEX0234 28	10p15.3d	288-184	DEX0234 126
DEX0234 29			
DEX0234 30	19p13.3j	1117-3705	DEX0234 127
DEX0234 31	19p13.3j	120-683	DEX0234 128
DEX0234 32	15p13e	48-13	DEX0234 129
DEX0234 33	16p13.3f	1938-1609	DEX0234 130
DEX0234 34	9p24.3b	533-916	DEX0234 131
DEX0234 35	2p25.3g	573-809	DEX0234 132
DEX0234 36	8p23.3b	279-109	DEX0234 133
DEX0234 37	20p13f	351-190	DEX0234 134
DEX0234 38	11p15.5d	186-43	DEX0234 135
DEX0234 39	9p24.3b	1-489	DEX0234 136
DEX0234 40	7p22.3d	546-686	DEX0234 137
DEX0234 41	7p22.3d	321-178	DEX0234 138
DEX0234 42	7p22.3d	40-246	DEX0234 139
DEX0234 43	13p13e	39-1	DEX0234 140

DEX0234 44	3p26.3c	326-3	DEX0234 141
DEX0234 45	3p26.3c	304-188	DEX0234 142
DEX0234 46	10p15.3d	343-119	DEX0234 143
DEX0234 47	5p15.33e	2153-1794	DEX0234 144
DEX0234 48	11p15.5d	68-1	DEX0234 145
DEX0234 49	1p36.33b	39-140	DEX0234 146
DEX0234 50	2p25.3g	810-1202	DEX0234 147
DEX0234 51	12p13.33d	375-220	DEX0234 148
DEX0234 52	7p22.3d		
DEX0234 53	13p13e	733-605	DEX0234 149
DEX0234 54	2p25.3g	529-395	DEX0234 150
DEX0234 55	3p26.3c	204-1	DEX0234 151
DEX0234 56	6p25.3b	275-3	DEX0234 152
DEX0234 57	3p26.3c		
DEX0234 58	16p13.3f	107-577	DEX0234 153
DEX0234 59	15p13e	320-388	DEX0234 154
DEX0234 60	1p36.33b		
DEX0234 61	17p13.3g	288-148	DEX0234 155
DEX0234 62	17p13.3g	698-543	DEX0234 156
DEX0234 63	15p13e	1574-1356	DEX0234 157
DEX0234 64	4p16.3d	16-114	DEX0234 158
DEX0234 65	20p13f	334-275	DEX0234 159
DEX0234 66	19p13.3j		
DEX0234 67	17p13.3g	137-1	DEX0234 160
DEX0234 68	8p23.3b	140-1	DEX0234 161
DEX0234 69	17p13.3g	459-872	DEX0234 162
DEX0234 70	2p25.3g	1596-1390	DEX0234 163
DEX0234 71	11p15.5d	52-2	DEX0234 164
DEX0234 72	3p26.3c	466-2820	DEX0234 165
DEX0234 73	17p13.3g	884-1174	DEX0234 166
DEX0234 74	17p13.3g	940-293	DEX0234 167
DEX0234 75	17p13.3g	257-460	DEX0234 168
DEX0234 76	15p13e	2214-1906	DEX0234 169
DEX0234 77	6p25.3b	461-577	DEX0234 170
DEX0234 78	1p36.33b	157-2	DEX0234 171
DEX0234 79	7p22.3d	134-1	DEX0234 172
DEX0234 80	15p13e		
DEX0234 81	7p22.3d	448-549	DEX0234 173
DEX0234 82	9p24.3b	12-101	DEX0234 174
DEX0234 83	3p26.3c	9-71	DEX0234 175
DEX0234 84	5p15.33e	158-394	DEX0234 176
DEX0234 85	10p15.3d	9-122	DEX0234 177
DEX0234 86	20p13f	293-358	DEX0234 178
DEX0234 87	5p15.33e	246-416	DEX0234 179
DEX0234 88	2p25.3g		
DEX0234 89	7p22.3d		
DEX0234 90	Xp22.33f	228-299	DEX0234 180
DEX0234 91	2p25.3g	590-312	DEX0234 181
DEX0234 92	16p13.3f	56-139	DEX0234 182
DEX0234 93	16p13.3f	90-590	DEX0234 183
DEX0234 94	17p13.3g	222-464	DEX0234 184
DEX0234 95	17p13.3g	105-584	DEX0234 185
DEX0234 96	12p13.33d	1-2787	DEX0234 186
DEX0234 97	2p25.3g	688-398	DEX0234 187
DEX0234 98	10p15.3d	376-233	DEX0234 188
DEX0234 99	4p16.3d	317-2251	DEX0234 189
DEX0234 100	4p16.3d	252-106	DEX0234 190

**Example 2A: Custom Microarray Experiment—Colon Cancer**

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature  
5 Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was  
10 hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was polyA+ RNA isolated from cancer tissue from a single individual and the reference sample was a pool of polyA+ RNA isolated from  
15 normal tissues of the same organ as the cancerous tissue (*i.e.* normal colon tissue in experiments with colon cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition  
20 and Analysis Software (Axon). Two different chip designs were evaluated with overlapping sets of a total of 38 samples, comparing the expression patterns of colon cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 7 normal colon tissues were analyzed. For Chip1 all 38 samples (23 Ascending colon carcinomas and 15 Rectosigmoidal carcinomas including: 5 stage 1 cancers, 15 stage 2 cancers, 15 stage 3  
25 and 2 stage 4 cancers) were analyzed and for Chip2 a subset of 27 of these samples (14 Ascending colon carcinomas and 13 Rectosigmoidal carcinomas including: 3 stage 1 cancers, 9 stage 2 cancers, 13 stage 3 and 2 stage 4 cancers) were assessed.

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression  
30 analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated

negative control + 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection limits were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has minimum thresholding criteria that employ user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background + 2SD)-(% pixels saturated)], and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors and saturated features were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up- and down- regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene is up- or down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. The results for the statistically significant upregulated and downregulated genes are shown in Table 1 and Table 2. The first three columns of each table contain information about the sequence itself (Oligo ID, Parent ID, and Patent#), the next 3 columns show the results obtained. '%valid' indicates the percentage of unique experiments total (n=38 for Chip1, n=27 for Chip2) in which a valid expression value was obtained, '%up' indicates the percentage of experiments in which up-regulation of at least 2-fold was observed, and '%down' indicates the percentage of the experiments in which down-regulation of at least 2-fold was observed. The last column in each table describes the location of the microarray probe (oligo) relative to the parent sequence.

Table 1. Colon Microarray expression data.

Patent	ParentID	OligoID	%valid n=38	%down n=38	%valid down n=38	Oligo Start Pos in Par Seq	Oligo Stop Pos in Par Seq
DEX0234_11	11855	26273	94.7	68.4	72.2	158	217
DEX0234_11	11855	26272	92.1	60.5	65.7	209	268
DEX0234_15	11865	23559	13.2	2.6	20	201	260

123

Patent	ParentID	OligoID	%valid n=38	%down n=38	%valid down n=38	Oligo Start Pos in Par Seq	Oligo Stop Pos in Par Seq
DEX0234_16	11865	23558	86.8	86.8	100	611	670
DEX0234_27, DEX0234_24	11897	38407	100	68.4	68.4	1092	1151
DEX0234_27	11897	38408	100	63.2	63.2	1051	1110
DEX0234_52	11696	27384	94.7	63.2	66.7	968	1027
DEX0234_52	11696	27383	100	63.2	63.2	1028	1087
DEX0234_60	11848	34228	65.8	55.3	84	1642	1701
DEX0234_60	11848	34229	52.6	28.9	55	1245	1304

Table 2. Colon Microarray Tissue Descriptions.

Experiment Name	Renamed	Tissue ID	Region affected	Stage	Grade	TNM
CNA1C038NMP		BS993038A		1	1	T1N0M0
CNA1C089NMP		S9914089A		1	1 or 2	T1N0M0
CNA1C108NMP		9706C108RA		1	2	T2N0M0
CNA1C281NMP		S992281A		1	1	T2N0M0
CNA1C795NMP		S9915795A		1	1 or 2	T1N0M0
CNA2C012NMP		9608B012		2	2-3	T4N0M0
CNA2C062NMP		S993062C		2	1 or 2	T3N0M0
CNA2C074NMP		9709C074RA		2	2-3	T3N0M0
CNA2C382NMP		4005382A3		2	2	T2N0M0
CNA2C56CNMP		1056C		2	2	T3N0M0
CNA2C677NMP		4005677A1		2	3	T3N0M0
CNA2C695NMP		4004695A9		2	2	T3N0M0
CNA2C821NMP		S9914821A		2	2	T3N0M0
CNA3C003NMP		96108003		3	3	T3M1M0
CNA3C004NMP		9707C004GB		3	2	T3N1M0
CNA3C032NMP		S9921032A		3	2	T3N1M0
CNA3C068NMP		9706C068RA		3	2 or 3	T3N1M0
CNA3C401NMP		S9819401A		3	2	T2N1M0
CNA3C720NMP		S993720A		3	3	T1N2M0
CNA3C806NMP	CNA4C806NMP	S9915806A		4	2	T3N1M1
CNA3C810NMP		BS986810A		3	2	T41N1M0
CNA4C005NMP		9706C005RA		4	3	T3N2M1
CNA4C006NMP		9609B006		4	2 or 3	T3N2M1
CNR2C020NMP		9408C020R		2	2	T3N0M0
CNR2C024NMP		9704C024RA		2	2	T3N0M0
CNR2C036ANMP		9705C036A		2	2	T3N0M0
CNR2C086NMP		9707C086B		2	2	T3N0M0
CNR2C162NMP		9406C162R		2	2	T4N0M0
CNR2C196NMP		S9820196A		2	2	T3N0M0
CNR2C404NMP		S9819404A		2	2	T4N0M0
CNR3C006BNMP		9702B006B		3	2	T3N1M0
CNR3C014NMP		9707C014RA		3	2	T3N2M0
CNR3C022NMP		9611B022F		3	2	T3N1M0
CNR3C036NMP		9706C036RA		3	2	T3N2M0
CNR3C053NMP		9409C053R		3	2	T3N1M0
CNR3C091NMP	CNR4C091NMP	9703C091R		4	3	T3N1M1
CNR3C457NMP		4004457A3		3	3	T3N1M0
CNR3CC98NMP		1194C98		3	2	T3N1M0



**Example 2B :Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the CSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to normal thymus (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the CSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values are compared to normal thymus (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, the CSNAs that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples. Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared.

- 5 This comparison provides an indication of specificity for the cancer stage (*e.g.* higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1-100 being a diagnostic marker for cancer.

10 **Example 3: Protein Expression**

The CSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the CSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the CSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of CSNA, and six histidines, flanking the

- 15 COOH-terminus of the coding sequence of CSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

- 20 Large-scale purification of CSP is achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that are separated from total cell lysate were incubated with a nickel chelating resin. The column is packed and washed with five column volumes of wash buffer. CSP is eluted stepwise with various concentration imidazole buffers.

25 **Example 4: Fusion Proteins**

The human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the

- 30

present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if  
5 the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e. g.*, WO 96/34891.

#### **Example 5: Production of an Antibody from a Polypeptide**

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such  
10 cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any  
15 suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

20 The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody  
25 which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic  
30 antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

For the polypeptides of the invention, the following attributes were found, epitopes, post translational modifications, signal peptides and transmembrane domains. Specifically, the Jameson-Wolf methods were used to predict epitopes were predicted. (Jameson and Wolf, CABIOS, 4(1), 181-186, 1988). Examples of post-translational

5 modifications (PTMs) and other motifs of the CSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. The PTMs and other motifs were predicted by using the ProSite Dictionary of Proteins Sites and Patterns (Bairoch et al., Nucleic Acids Res. 25(1):217-221 (1997)), the following motifs, including PTMs, were predicted for the

10 CSPs of the invention. The signal peptides were detected by using the SignalP 2.0, see "Machine learning approaches to the prediction of signal peptides and other protein sorting signals" Henrik Nielsen, Søren Brunak, and Gunnar von Heijne, Protein Engineering 12, 3-9 (1999). Prediction of transmembrane helices in proteins was performed by the application TMHMM 2.0, "currently the best performing transmembrane

15 prediction program", according to authors (A. Krogh, B. Larsson, G. von Heijne, and E. L. Sonnhammer. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. Journal of Molecular Biology, 305(3):567-580, January 2001). S. Moller, M.D.R. Croning, R. Apweiler "Evaluation of methods for the prediction of membrane spanning regions" Bioinformatics, 17(7):646-653, July 2001. E.

20 L.L. Sonnhammer, G. von Heijne, and A. Krogh. A hidden Markov model for predicting transmembrane helices in protein sequences in J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen, editors, Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology, pages 175-182, Menlo Park, CA, 1998. AAAI Press. Using the PSORT II program, the following cellular localizations

25 and the k nearest neighbors classifier values were determined (Paul Horton and Kenta Nakai, Better Prediction of Protein Cellular Localization Sites with the k Nearest Neighbors Classifier, Intelligent Systems for Molecular Biology 5 147-152 (1997). In the table below are the following: PTM and other motifs (type, amino acid residue locations); Amino acid location and antigenic index (location, AI score, length); TM (number of

30 membrane domain, topology in orientation and position).

128

name	DEX0234 .aa.ai	DEX0 234.a a.pst	DEX0234.aa.ptm	DEX0234 .aa.sp	DEX0234. aa.tmhm
DEX0234_101		nuc	Ck2_Phospho_Site 27-30;32-35; Cytochrome_C 36-41; Pkc_Phospho_Site 27-29;	28 0.945 0.628	
DEX0234_102		cyt	Asn_Glycosylation 36-39; Pkc_Phospho_Site 16-18;		
DEX0234_103		nuc			
DEX0234_104		nuc			
DEX0234_105		pla			
DEX0234_106		pla	Myristyl 18-23;31-36;		1 i12-34o
DEX0234_107		cyt	Myristyl 14-19;38-43; Pkc_Phospho_Site 20-22;30-32;		
DEX0234_108	53-65 1.23 13  744-755 1.19 12 864-880 1.11 17 564-581 1.06 18 588-604 1.06 17 435-460 1.03 26 697-709 1.02 13 271-281 1.02 11	cyt	Amidation 699-702; Asn_Glycosylation 83-86;120- 123;161-164;198-201;239-242;276- 279;373-376;902-905; Atp_Gtp_A 527-534; Camp_Phospho_Site 701- 704;876-879; Ck2_Phospho_Site 11-14;70-73;91-94;169-172;247- 250;286-289;376-379;525-528;609- 612;791-794;809-812;842-845; Myristyl 127-132;205-210;282- 287;456-461;471-476;625-630;749- 754;786-791;866-871; Pkc_Phospho_Site 84-86;130- 132;162-164;208-210;240-242;414- 416;540-542;681-683;754-756;770- 772;791-793;835-837;844-846;848- 850; Transferrin_1 146-154;224- 232;		
DEX0234_109	335-344 1.06 10  267-277 1.05 11	ves	Asn_Glycosylation 228-231; Camp_Phospho_Site 125-128; Ck2_Phospho_Site 60-63; Leucine_Zipper 205-226; Myristyl 66-71;112-117;163-168;346-351; Pkc_Phospho_Site 109-111;124- 126;169-171;		

DEX0234_110	424-434 1.22 11	pla	Amidation 373-376; Asn_Glycosylation 103-106;157- 160;174-177;264-267;452-455;498- 501;539-542;551-554;594-597; Ck2_Phospho_Site 40-43;64-67;85- 88;265-268;287-290;339-342;403- 406;481-484;507-510; Myristyl 144- 149;354-359;383-388;419-424;511- 516;544-549; Pkc_Phospho_Site 54- 56;87-89;108-110;180-182;224- 226;355-357;386-388;474-476;507- 509;515-517;541-543;599-601;608- 610;712-714; Tnfr_Ngfr_1 489-522; Tyr_Phospho_Site 139-147;292- 298; Zinc_Protease 402-411;	17 0.956 0.866	1 o673-695i
	85-94 1.14 10 495-536 1.07 42 354-364 1.06 11 548-566 1.06 19 382-392 1.05 11 18-36 1.03 19				
DEX0234_111		nuc	Amidation 11-14; Ck2_Phospho_Site 49-52; Pkc_Phospho_Site 11-13;		
DEX0234_112		cyt	Myristyl 12-17;		
DEX0234_113		cyt	Tyr_Phospho_Site 12-19;		
DEX0234_114	8-28 1.00 21	nuc	Asn_Glycosylation 35-38; Ck2_Phospho_Site 10-13;12-15; Myristyl 28-33; Pkc_Phospho_Site 7-9;12-14;		
DEX0234_115		nuc	Myristyl 27-32;		
DEX0234_116		cyt	Ck2_Phospho_Site 19-22;		
DEX0234_117		pla	Asn_Glycosylation 61-64; Myristyl 7- 12; Pkc_Phospho_Site 40-42;		2 i13- 35o64-86i
DEX0234_118	18-35 1.17 18	exc	Camp_Phospho_Site 20-23; Ck2_Phospho_Site 64-67; Myristyl 4-9;37-42; Pkc_Phospho_Site 27- 29;		
DEX0234_119		cyt	Myristyl 43-48;		
DEX0234_120		exc	Ck2_Phospho_Site 62-65; Pkc_Phospho_Site 83-85;	15 0.953 0.880	
DEX0234_121		nuc	Camp_Phospho_Site 45-48; Myristyl 47-52; Pkc_Phospho_Site 55-57;		
DEX0234_122		nuc	Asn_Glycosylation 30-33;		
DEX0234_123	117-137 1.10 21	nuc	Ck2_Phospho_Site 14-17;36-39; Myristyl 46-51;113-118; Pkc_Phospho_Site 11-13;94- 96;100-102;132-134;		
DEX0234_124		pla	Myristyl 20-25; Pkc_Phospho_Site 36-38; Prokar_Lipoprotein 15-25;	23 0.996 0.908	

130

DEX0234_125		exc	Ck2_Phospho_Site 76-79; Myristyl 40-45; Pkc_Phospho_Site 18-20;76-78;	
DEX0234_126		nuc		
DEX0234_127	445-476 1.29 32	pla	Amidation 682-685; Asn_Glycosylation 199-202;530-533;617-620;830-833; Atp_Gtp_A 464-471; Camp_Phospho_Site 613-616; Ck2_Phospho_Site 45-48;80-83;101-104;116-119;150-153;302-305;327-330;336-339;376-379;395-398;433-436;632-635;765-768;772-775;824-827;842-845; Glycosaminoglycan 747-750; Myristyl 217-222;238-243;390-395;431-436;464-469;585-590; Pkc_Phospho_Site 185-187;213-215;225-227;302-304;409-411;445-447;473-475;501-503;611-613;673-675;682-684;857-859; Tyr_Phospho_Site 684-691;685-691; Zinc_Finger_C2h2 437-457;465-485;493-513;521-541;549-569;577-597;605-625;633-653;661-681;	1 o803-825i
	765-800 1.28 36 251-263 1.27 13 76-86 1.24 11 482-508 1.17 27 648-666 1.16 19 510-582 1.13 73 584-642 1.12 59 39-74 1.03 36			
DEX0234_128	76-86 1.24 11  39-74 1.03 36	nuc	Ck2_Phospho_Site 45-48;80-83;101-104;116-119;150-153; Pkc_Phospho_Site 185-187;	
DEX0234_129			Tyr_Phospho_Site 3-11;	
DEX0234_130	4-22 1.10 19	nuc	Asn_Glycosylation 4-7; Ck2_Phospho_Site 13-16;34-37; Myristyl 29-34;84-89; Pkc_Phospho_Site 70-72;79-81;	
DEX0234_131		ves	Myristyl 44-49;57-62;61-66;90-95;	2 o74-96i103-125o
DEX0234_132	33-50 1.01 18	nuc	Camp_Phospho_Site 58-61; Pkc_Phospho_Site 56-58;	

131

DEX0234_133		mit	Myristyl 27-32;36-41;40-45; Pkc_Phospho_Site 48-50;		1 o22-44i
DEX0234_134		cyt	Myristyl 9-14;13-18; Pkc_Phospho_Site 14-16;		
DEX0234_135		cyt	Myristyl 21-26;		
DEX0234_136	51-76 1.06 26	ves	Amidation 64-67; Myristyl 38-43;74- 79;135-140; Pkc_Phospho_Site 8- 10;52-54;154-156;		
DEX0234_137	19-35 1.16 17	exc	Asn_Glycosylation 43-46; Myristyl 26-31;	15 0.992 0.951	
DEX0234_138	18-36 1.08 19	cyt	Asn_Glycosylation 29-32;		
DEX0234_139	21-51 1.16 31	nuc	Ck2_Phospho_Site 28-31;42-45; Myristyl 13-18;38-43;50-55; Pkc_Phospho_Site 35-37;41-43;42- 44;		
DEX0234_141	49-68 1.17 20	nuc	Asn_Glycosylation 65-68; Ck2_Phospho_Site 56-59; Pkc_Phospho_Site 25-27;30-32;56- 58;84-86;		
DEX0234_142		cyt	Pkc_Phospho_Site 7-9;		
DEX0234_143	41-61 1.16 21	cyt	Ck2_Phospho_Site 68-71; Myristyl 42-47;46-51;55-60;59-64;63-68;64- 69;		
DEX0234_144		pla	Ck2_Phospho_Site 45-48; Myristyl 5-10; Pkc_Phospho_Site 54-56;82- 84;91-93;	52 0.996 0.764	1 i13-35o
DEX0234_145		nuc	Ck2_Phospho_Site 13-16; Myristyl 4-9; Pkc_Phospho_Site 8-10;20-22;		
DEX0234_146		cyt	Ck2_Phospho_Site 8-11; Pkc_Phospho_Site 28-30;		
DEX0234_147	96-106 1.34 11	nuc	Ck2_Phospho_Site 77-80; Myristyl 26-31; Pkc_Phospho_Site 11-13;		
DEX0234_148	16-26 1.04 11	nuc	Ck2_Phospho_Site 2-5; Pkc_Phospho_Site 2-4;34-36;		
DEX0234_149	26-40 1.16 15	nuc			
DEX0234_150		cyt	Pkc_Phospho_Site 2-4;		
DEX0234_151	34-58 1.14 25	exc	Ck2_Phospho_Site 42-45;50-53; Pkc_Phospho_Site 42-44;	38 0.962 0.620	
DEX0234_152	13-24 1.19 12	nuc	Asn_Glycosylation 22-25; Ck2_Phospho_Site 10-13;33-36; Pkc_Phospho_Site 6-8; Tyr_Phospho_Site 76-83;		
DEX0234_153	96-136 1.03 41	mit	Amidation 111-114; Ck2_Phospho_Site 41-44; Glycosaminoglycan 56-59;60-63; Myristyl 17-22;19-24;21-26;36- 41;39-44;57-62;59-64;61-66;91- 96;117-122;118-123;122-127;130- 135;145-150; Pkc_Phospho_Site 25- 27; Prokar_Lipoprotein 14-24;	24 0.924 0.693	
DEX0234_154		cyt	Ck2_Phospho_Site 17-20;		



132

DEX0234_155		cyt	Asn_Glycosylation 13-16; Ck2_Phospho_Site 15-18;		
DEX0234_156		cyt	Pkc_Phospho_Site 35-37;		
DEX0234_157		nuc	Asn_Glycosylation 25-28; Ck2_Phospho_Site 66-69; Pkc_Phospho_Site 11-13;45-47; Prokar_Lipoprotein 49-59;		
DEX0234_158		cyt			
DEX0234_160	9-18 1.05 10	nuc	Ck2_Phospho_Site 37-40; Prokar_Lipoprotein 17-27;		
DEX0234_161		nuc	Ck2_Phospho_Site 8-11; Pkc_Phospho_Site 21-23;		
DEX0234_162		nuc	Amidation 15-18; Asn_Glycosylation 73-76; Camp_Phospho_Site 61-64; Myristyl 30-35;92-97;123-128; Pkc_Phospho_Site 64-66;		
DEX0234_163		cyt	Amidation 62-65; Myristyl 13-18;		
DEX0234_164			Asn_Glycosylation 2-5; Pkc_Phospho_Site 5-7;		
DEX0234_165	241-251 1.20 11  164-181 1.17 18 341-354 1.16 14 202-231 1.13 30 720-735 1.10 16 679-702 1.09 24 447-459 1.02 13	nuc	Asn_Glycosylation 465-468; Camp_Phospho_Site 227-230; Ck2_Phospho_Site 3-6;31-34;38- 41;132-135;137-140;239-242;484- 487;635-638;691-694;726-729; Myristyl 46-51;97-102;167-172;183- 188;225-230;229-234;449-454; Pkc_Phospho_Site 141-143;171- 173;226-228;333-335;407-409;429- 431;501-503;508-510;654-656; Zinc_Finger_C2h2 16-37;		
DEX0234_166	58-75 1.22 18	cyt	Ck2_Phospho_Site 21-24; Myristyl 58-63; Pkc_Phospho_Site 26-28;		
DEX0234_167	115-131 1.14 17  54-80 1.09 27	nuc	Amidation 206-209; Ck2_Phospho_Site 26-29; Myristyl 16-21;20-25;47-52;105-110;130- 135;155-160;158-163; Pkc_Phospho_Site 17-19;64- 66;114-116;124-126;125-127;162- 164;		1 092-114i

133

DEX0234_168		nuc	Myristyl 8-13; Pkc_Phospho_Site 2-4;13-15;54-56;		
DEX0234_169		nuc	Amidation 90-93; Myristyl 40-45;75-80;78-83;		
DEX0234_170	11-28 1.08 18	nuc	Amidation 19-22; Asn_Glycosylation 17-20; Ck2_Phospho_Site 6-9; Pkc_Phospho_Site 19-21;		
DEX0234_171		nuc	Asn_Glycosylation 22-25;		
DEX0234_172		exc	Myristyl 21-26; Pkc_Phospho_Site 9-11;31-33;	25 0.986 0.919	1 113-350
DEX0234_173		cyt	Pkc_Phospho_Site 28-30;		
DEX0234_174	13-25 1.18 13	cyt	Pkc_Phospho_Site 17-19;		
DEX0234_175		exc			
DEX0234_176		nuc	Camp_Phospho_Site 30-33;		
DEX0234_177	22-34 1.03 13	cyt	Pkc_Phospho_Site 2-4;		
DEX0234_178		nuc			
DEX0234_179		cyt	Myristyl 34-39; Pkc_Phospho_Site 30-32;		
DEX0234_180		cyt	Pkc_Phospho_Site 19-21;		
DEX0234_181		nuc	Ck2_Phospho_Site 33-36; Myristyl 46-51; Pkc_Phospho_Site 49-51;63-65;89-91;		
DEX0234_182		nuc			
DEX0234_183	104-113 1.01 10	pla	Ck2_Phospho_Site 87-90;141-144; Myristyl 115-120; Pkc_Phospho_Site 9-11;66-68;87-89;104-106; Tyr_Phospho_Site 89-96;		1 031-531
DEX0234_184	29-70 1.04 42	exc	Asn_Glycosylation 62-65; Ck2_Phospho_Site 47-50; Myristyl 39-44;43-48;57-62;	21 0.945 0.793	
DEX0234_185	103-112 1.36 10  14-30 1.20 17	nuc	Asn_Glycosylation 62-65;106-109; Camp_Phospho_Site 55-58;104-107; Ck2_Phospho_Site 41-44;50-53; Pkc_Phospho_Site 25-27;41-43;54-56;118-120;		
DEX0234_186	53-65 1.23 13	cyt	Amidation 699-702; Asn_Glycosylation 83-86;120-123;161-164;198-201;239-242;276-279;373-376;902-905; Atp_Gtp_A 527-534; Camp_Phospho_Site 701-704;876-879; Ck2_Phospho_Site 11-14;70-73;91-94;169-172;247-250;286-289;376-379;525-528;609-612;791-794;809-812;842-845; Myristyl 127-132;205-210;282-287;456-461;471-476;625-630;749-754;786-791;866-871; Pkc_Phospho_Site 84-86;130-132;162-164;208-210;240-242;414-416;540-542;681-683;754-756;770-		



135

	1.05 17				
DEX0234_190		cyt			

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

5 RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1-100.

Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at  
10 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The  
15 intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected  
20 individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1  
25 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and  
30 variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region

hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

- 5           Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then
- 10           incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three
- 15           times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

- The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on
- 20           the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

**Example 8: Formulating a Polypeptide**

- The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the
- 25           individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

- As a general proposition, the total pharmaceutically effective amount of secreted
- 30           polypeptide administered parenterally per dose will be in the range of about 1 , µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most

preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution  
5 may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an  
10 oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

15 The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-  
20 556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et  
25 al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected  
30 proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable

carrier, i. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e. g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation

for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

- 5           The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or
- 10   sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

**Example 9: Method of Treating Decreased Levels of the Polypeptide**

- It will be appreciated that conditions caused by a decrease in the standard or
- 15   normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the
- 20   activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

25

**Example 10: Method of Treating Increased Levels of the Polypeptide**

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

- 30           For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the



treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

**Example 11: Method of Treatment Using Gene Therapy**

5 One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, 10 closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days.

15 After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using 20 glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and 25 the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

30 The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now

produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

#### **Example 12: Method of Treatment Using Gene Therapy-In Vivo**

Another aspect of the present invention is using in vivo gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO 90/11092, WO 98/11779; U. S. Patent No. 5,693,622; 5,705,151; 5,580,859; Tabata H. et al. (1997) *Cardiovasc. Res.* 35 (3): 470-479, Chao J et al. (1997) *Pharmacol. Res.* 35 (6): 517-522, Wolff J. A. (1997) *Neuromuscul. Disord.* 7 (5): 314-318, Schwartz B. et al. (1996) *Gene Ther.* 3 (5): 405-411, and Tsurumi Y. et al. (1996) *Circulation* 94 (12): 3281-3290.

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, colon, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et al. (1995) Ann. NY Acad. Sci. 772: 126-139 and Abdallah B. et al. (1995) Biol. Cell 85 (1): 1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, colon, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05  $\mu\text{g/kg}$  body weight to about 50 mg/kg body

weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined  
5 by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to colons or bronchial tissues, throat or mucous membranes of the nose. In addition, naked  
10 polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
15 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the  
20 anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e. g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual  
25 quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection  
30 may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (I. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver et al., *Biotechnology (NY)* 11: 1263-1270 (1993); Wright et al., *Biotechnology (NY)* 9: 830-834 (1991); and Hoppe et al., U. S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., *Science* 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., *Cell* 57: 717-723 (1989). For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115: 171-229 (1989).

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., *Nature* 380: 64-66 (1996); Wilmut et al., *Nature* 385: 810813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992)). The regulatory sequences required for

such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some  
5 nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265: 103-106 (1994)). The regulatory sequences required for such a  
10 cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished  
15 by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR).  
20 Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding  
25 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to  
30 both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### **Example 14: Knock-Out Animals**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., *Nature* 317: 230-234 (1985); Thomas & Capecchi, *Cell* 51: 503-512 (1987); Thompson et al., *Cell* 5: 313-321 (1989)). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (I. e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence

associated with the polypeptides of the invention, e. g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

5           The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

10           Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent No. 5,399,349; and Mulligan & Wilson, U. S. Patent No. 5,460,959 each of which is incorporated by reference  
15       herein in its entirety).

          When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of  
20       components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

          Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with  
25       aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

          While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and  
30       not by way of limitation. The present invention is limited only by the claims that follow.



**What is Claimed is:**

1. An isolated nucleic acid molecule comprising:
  - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 109, 119, 120, 122, 123, 124, 125, 153, 166, 167, 182, 183, 184, 185, 189 or 190;
  - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 10, 20, 21, 24, 25, 26, 27, 58, 73, 74, 92, 93, 94, 95, 99 or 100;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
  - (d) a nucleic acid molecule having at least 90% sequence identity to the nucleic acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid molecule is a human nucleic acid molecule.
6. A method for determining the presence of a colon specific nucleic acid (CSNA) in a sample, comprising the steps of:
  - (a) contacting the sample with the nucleic acid molecule of SEQ ID NO: 9, 10, 11, 20, 21, 24, 25, 26, 27, 30, 31, 58, 72, 73, 74, 92, 93, 94, 95, 96, 99 or 100 under conditions in which the nucleic acid molecule will selectively hybridize to a colon specific nucleic acid; and
  - (b) detecting hybridization of the nucleic acid molecule to a CSNA in the sample, wherein the detection of the hybridization indicates the presence of a CSNA in the sample.

7. A vector comprising the nucleic acid molecule of claim 1.
8. A host cell comprising the vector according to claim 7.
- 5 9. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of:
- (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and
- 10 (b) incubating the host cell under conditions in which the polypeptide is produced.
10. A polypeptide encoded by the nucleic acid molecule according to claim 1.
11. An isolated polypeptide selected from the group consisting of:
- (a) a polypeptide comprising an amino acid sequence with at least 60% sequence identity to of SEQ ID NO: 109, 119, 120, 122, 123, 124, 125, 153, 166, 167, 182, 183, 184, 185, 189 or 190 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 90% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 10, 20, 21, 24, 25, 26, 27, 58, 73, 74, 92, 93, 94, 95, 99 or 100.
12. An antibody or fragment thereof that specifically binds to
- (a) a polypeptide comprising an amino acid sequence with at least 60% sequence identity to of SEQ ID NO: 108, 109, 110, 119, 120, 122, 123, 124, 125, 127, 128, 153, 165, 166, 167, 182, 183, 184, 185, 186, 189 or 190; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 90% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 9, 10, 11, 20, 21, 24, 25, 26, 27, 30, 31, 58, 72, 73, 74, 92, 93, 94, 95, 96, 99 or 100.

150

13. A method for determining the presence of a colon specific protein in a sample, comprising the steps of:

- 5 (a) contacting the sample with a suitable reagent under conditions in which the reagent will selectively interact with the colon specific protein comprising an amino acid sequence with at least 60% sequence identity to of SEQ ID NO: 108, 109, 110, 119, 120, 122, 123, 124, 125, 127, 128, 153, 165, 166, 167, 182, 183, 184, 185, 186, 189 or 190; and
- (b) detecting the interaction of the reagent with a colon specific protein in the sample, wherein the detection of binding indicates the presence of a colon specific protein in the sample.

10

14. A method for diagnosing or monitoring the presence and metastases of colon cancer in a patient, comprising the steps of:

- (a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of claim 11 in a sample of a patient; and
- 15 (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the colon specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of colon cancer.

20

15. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 11 in a sample of a patient.

25

16. A method of treating a patient with colon cancer, comprising the step of administering a composition according to claim 11 or 12 to a patient in need thereof, wherein said administration induces an immune response against the colon cancer cell expressing the nucleic acid molecule or polypeptide.

30

17. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 11.

## 1

## SEQUENCE LISTING

<110> diaDexus, Inc.  
Sun, Yongming  
Liu, Chenghua  
Ghosh, Malavika

<120> Compositions and Methods Relating to Colon Specific Genes and  
Proteins

<130> DEX-0342

<150> US 60/316,259

<151> 2001-08-31

<160> 190

<170> PatentIn version 3.1

<210> 1  
<211> 461  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (288)..(288)  
<223> n=a, c, g or t

<220>  
<221> misc\_feature  
<222> (290)..(290)  
<223> n=a, c, g or t

<220>  
<221> misc\_feature  
<222> (393)..(393)  
<223> n=a, c, g or t

<400> 1  
agcaatatac taagggttac cttgccctca gtgggccag agtagatgac acgatgtggg 60  
ataagaagtg gcccatgcac agaaggagag actccttttg tctggagaca ctatggcgag 120  
tttcttagac aagggtggtat ccgagatgag tttgcaaacg tgtgcacgat ttgatcatgc 180  
agatgtggca ggaagagcat tccagatagg aggaatcacg tgaggatgag tatgggtggca 240  
ggaaagggag aaccatatat atataagaga ggaaaggaag tgttaganan ggtgttgcac 300  
gcatgaaagg gaagaggagg aagaaatgaa gttggcaaga caaatctgaa cctgatctgg 360  
gagaatcttg actatctcat gattttttgag agntgggtgca caaaacatct gtcttgttta 420  
cttgctggaa tgttgtggcc tgtctgggtt gctttttaga c 461

<210> 2

<211> 943  
 <212> DNA  
 <213> Homo sapien

<400> 2  
 ggatgggccc cagttccagc cttggctttg cgtcctgacc agtgtgtctg tgggcaagtc 60  
 acctgacatt tcttgtcttc aagtctcatt tgtgaagtga agaggggtgac gaaccacaca 120  
 gataacaaga ggttcttttt agtgtaaga gttatgtaac taatagccat ccctctttga 180  
 ttcttcttgc actacttgca gggtagcagt gagaaaacta agaagaaatt ttgagttaga 240  
 agttgagtga attcttgttc ctttcatggc taaaatatgt gaccaccagc ccactgaatg 300  
 aaatggagcg tgtttgaatt tgcctcactg tggtcactct ggaagcaggc tcagcttacc 360  
 agggccattt ctctgatgta cctttggaat tcttccaaaa tgtataggga gaattagaaa 420  
 aaccagaggc attctgagtg aggaaataag cagatgactc agcaaatcac caatctactt 480  
 catctccttg aatagcaaat agttgaattt catgaagaaa ctttaatttt ttctgattat 540  
 gaaagtcata tacaattgtt ttaaccaagt gtgcacagaa tgatcacact tatagaaaat 600  
 gtctgttttg ttcataagtg aattaaaaag gtcaggaaag atatattcca tattatgaac 660  
 atttttttta gaaaatgaaa tgggcatgat gattagaaaa atgttgtaag tgctcattgt 720  
 aggacagtca gataatatat aaagatgcaa aaaataaaaa ataaaaatca ccataaatcc 780  
 tatgccttaa taacaatcac agtttgattt tggcataatt tccctcaagt cagttttcct 840  
 ctgcttagaa aaaggggttg ggaaaataga tactgtctac tcaattgtgt gtcttttatt 900  
 tttaaactta tgtcttaagc actttacact ggattagaat ccc 943

<210> 3  
 <211> 537  
 <212> DNA  
 <213> Homo sapien

<400> 3  
 gctcgagggtg aacgtcatta aattaaaagc tagaaattat taagctaagt gagaaaggca 60  
 tgccaagtaa gtataaatcc ggagttgtcc aacttgagct gaagtgtctat tagatctacc 120  
 aagtcataag actgaatggt cactgcaacc atctatccta taatggatgc aatatgtttt 180  
 agggcaagag aaaatgcaaa agacaaaagt aggctgaatg aacagttggc ccagatccct 240  
 atatcactga tgccctcttc tcagcttata catacagtct cctaggctct tccaaccagc 300  
 tgatacctta gtaacaagc caggcctaata gcaagggcac tttggctagg tatattggca 360  
 caatatgtca accactcaga tgtgggacct caaatataat ccatgagggt aaacctactc 420  
 tgataagtag aatacataga ttcacgcca tccatagaaa ggggttcagaa aacaggagct 480  
 ggccctgtgc ttttacagag ctttatcctt ccataaggg caggaccaga tattatc 537

<210> 4  
 <211> 513  
 <212> DNA  
 <213> Homo sapien  
  
 <220>  
 <221> misc\_feature  
 <222> (129)..(319)  
 <223> n=a, c, g or t

<400> 4  
 ggggtagtaa atgcatagta aaatacatag ttgtttgctt ttaaccacgc tgggagtgca 60  
 gtaggattgt ttacagcagc aatcccacaa acatgtaagt aatgcattgt gctacaatat 120  
 tattacggnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300  
 nnnnnnnnnn nnnnnnnnnc ccttatgcaa aacagtgcga gaagttatac actgcaataa 360  
 gacaagaaaa taattaaagg acatacagat cagaatggaa aaaatagaac agtccctacc 420  
 tacaacagac atgactttct acatagaaat ccaaataaat ctatttcaca aacctcctta 480  
 aattaagaag tgagtcatt aaggtcacag aat 513

<210> 5  
 <211> 255  
 <212> DNA  
 <213> Homo sapien

<400> 5  
 ttaatcaaat ttcaaaacca ggtttttag tagcatattc caaagcagtt 60  
 ggggttgctt gcgttgagcgt ttaattattaa gctatacttc cctttcaaata aaggtatttt 120  
 catcgtaag cctgtaaatt ctagtgtgtc attgtttaga tatttatagt cattttaata 180  
 tatctgttta cggccagctg caatggctaa cacctgtaaa ctgagcactt ttttgaggcc 240  
 aaggtggggc cgatt 255

<210> 6  
 <211> 777  
 <212> DNA  
 <213> Homo sapien

<400> 6  
 gctgttaaca tcaagagggtg gggatcatag gaggtccatc ataaagtttg tcctccaccg 60  
 tagaggggag gtgacgggat tagaaggcat tataacagtt cttcagggtga ggccttgga 120  
 gatgcagatg gaaaaacggg agctttcaga ggcggaagtt ttggaagtgc agttccagtt 180

```

gaaagttggg atagtcaggt ggtgacgctt ctcaggaggc cttctgtgcc ctttgtcttc 240
atgtgccttc tatgtgctct ctcctgcttag acaaatgaac attctgtggt acagttgcca 300
ccgataaaatc catctgtctg gctaaaatgg aattattttac cagccaattc ctggccagtg 360
gaggatctctg ccctcttgcc ttatggtttt gttgaggatc aaatgaggta attcatatga 420
agtgttttat agactacaaa gtaatatgca aacaaaaggt attaaacggg gctacctttt 480
tctctatgtt aagtagaacc catggaattt aacttacatt ttccttaata acttgggttc 540
attatgttgt atgtagctta ttaaaactggg ctttatttaa cactgtgatt tgggtttttg 600
gagtagagag tttactttta tgataaatga ccccaaactg ctataccttt caaatccttg 660
tgtcccattt ttattgttta aaaaaacaat ctcaccttgc cgttgcctgt cactcttttg 720
cttctgtgtg tcagttttga gctacatttt tccccctccg atttgttgct tctgac 777

```

```

<210> 7
<211> 234
<212> DNA
<213> Homo sapien

```

```

<400> 7
tgtttgtaaa ttgtttgtgt aattaaaaat taactttaaa aaacaaaatt ggaaaactat 60
agtacgatcc aattttggct aaaaatatag ctacagcaat atatataccg agaaaagcgg 120
ggaatacata ttgaattgtt gaaagtgtgt atctctgcat agggtagtga caggatggga 180
ttatgggagg attttgactt cctgtgacgg gtgttagggc ctgaatattt ctgt 234

```

```

<210> 8
<211> 1484
<212> DNA
<213> Homo sapien

```

```

<400> 8
acagtattct tggacaatta atgggaagtt tcagcaatca ggacaaaatc tgtttatccc 60
ccaaattact acaaagcata gcgggctcta tgtttgctct gttcgtaact cagccactgg 120
cgaggaaagc tccacatcgt tgacagtcaa agtctctgct tctacaagaa taggacttct 180
tcctctcctt aatccaacat agcagctgtg atgtcatttc tgtatttcag gaagactggc 240
agagacgtgg tctcccttct ttgctcaggc tggctctaaa ctcttggttt caagtgatcc 300
tcctgcctta gagtctcaaa ctgctgggat tacaggcctc tgccagcaca cctggcccc 360
caattcttca aaagctttca gagaaagcat tgtagaagac atgactttgt gactgtaagt 420
ttcatctgat cctacatcac taggaaggct cattcttaag aagtcatgca tggaaaaggg 480
gatgaagaca aatcagaaaa gggcaaaggg aagtcacagc aaaaaaggga cagtataatc 540

```

5

```

ctggaacctt attaaagtca cacaactgct gcttcaatta gagcaattcg tttggcaaac 600
atcgttctaa ccctatagac taggttttcc agagtttctg aagtatcttc taattgcaat 660
ggcaatctga cacatttttc tgaattgcag tctgaatcca gtgttcattg gtaccttttg 720
tatagtcacac acatcagcag ccacaaaggt tgtttatata taagttgcta tgatttctcc 780
agaagtttac ataagtcatt gagtttcagc ttgcaagggt taatctatcc atctgacaaa 840
aggctaatat ccaaactcta caagaaactt aaacaaattt acaagaaaaa aaaaaaaaaa 900
aaaatttggg ggggggttggg cccggaaaag gtttttaaaa cttcgggtggg gcgcgcgggg 960
gcgcacaaaag aagggctacg gtgaaccact gtgggccatt agcgtgtgtt ccctaaggag 1020
aagactccgg gcgcaagaga gccaaagggg cgtgggtctt ctctcccaa tataaaaaac 1080
caggccgggg gggtagccga gcgcggtttc tgagaacaac taccaaaagg ggggcttctt 1140
aggggcgcac actaaggggg tctctatctc acaagagggg gctctcaaga ggggagccgt 1200
ggaatatctt caataaattt aagccccggg ctctgtgtgg gcttactccc actatcacta 1260
gccagtcgga taaaacaaca gcaccgcgag caaacatcac actaagtact aggcacgcga 1320
tccacgacca cgcgaaatca taccaccgag gatctgtcaa ccaagcgagg agcagtagag 1380
agcacgacca aactgctagc accacaaccg catccagaag caaacgtaca gcggcaaaga 1440
gcagagcacc accaacagga ggtgcaaaga gagaagcaga ccaa 1484

```

```

<210> 9
<211> 5046
<212> DNA
<213> Homo sapien

```

```

<400> 9
atggcagaag gcaaggagaa gcaagtcaca tcttacatgg atggcagcag accttatgac 60
gtgagcatga cctacatcca caaagcagga gggcctgac agcaggaatt agtcatgctc 120
acctgcactg tgccccttga ctctgttgt catctgctc aggcccgaa gaattatcgc 180
aaatatttcc ggtcagaggc tgccttcacc ttggcagatt tcatctaca gagcatgac 240
cgagtaaata gttccagatt ggttcgagtc acccagggtg agaatgagga gaaactgaag 300
gagctagagc agtttagtat ctggaacttt ttttcctcct ttttaaaaga gaaattgaat 360
gacacctatg ttaacgtggg tctatacagc acaaaaacct gcctcaaagt tgagattata 420
gagaaggaca ccaagtacag tgtcattgtg atccggagggt cctgggatgt tatccgagta 480
aatagttcca gattgggtcg agtcaccag gtggagaatg aggagaaact gaaggagcta 540
gagcagttta gtatctggaa ctttttttcc tcctttttta aagagaaatt gaatgacacc 600
tatgttaacg tgggtctata cagcacaaaa acctgcctca aagttgagat tatagagaag 660

```



gacaccaagt acagtgtcat tgtgatccgg aggtcctggg atgttatccg agtaaatagt	720
tccagattgg ttcgagtcac ccagggtggag aatgaggaga aactgaagga gctagagcag	780
tttagtatct ggaacttttt ttctctcttt ttaaaagaga aattgaatga cacctatgtt	840
aacggcatat cgtggacaaa ggtggactac tttgataatg gcatcatttg taagctcatt	900
gagcataatc agcgagggtat cctggccatg ttggatgagg agtgccctgc gcctgggggtg	960
gtcagtgact ccacttttct agcaaagctg aaccagctct tctccaagca tggccactac	1020
gagagcaaaag tccccagaa tgcccagcgt cagtatgacc acaccatggg cctcagctgc	1080
ttccgcctct gccactatgc gggcaagggt acatacaacg tgaccagctt tattgacaag	1140
aataatgacc tactcttccg agacctgttg caggccatgt ggaaggccca gcacccctc	1200
cttcggctct tgtttctga gggcaatcct aagcaggcat ctctcaaacg ccccccgact	1260
gctggggccc agttcaagag ttctgtggcc atcctcatga agaactctga ttccaagagc	1320
cccaactaca tcagggtgcat aaagcccaat gagcatcagc agcgagggtca gttctcttca	1380
gacctggtgg caaccaggc tcggtacctg ggactgctgg agaacgtacg ggtgcgacgg	1440
gcaggctatg cccaccgcca gggttatggg cccttctctg aaagggtaccg attgctgagc	1500
cggagcacct ggctcactg gaatggggga gaccgggaag gtgttgagaa ggtcctgggg	1560
gagctgagca tgtctcggg ggagctggcc tttggcaaga caaagatctt cattagaagc	1620
cccaagactc ttttctacct cgaagaacag aggcgcctga gactccagca gctggccaca	1680
ctcatacaga agatttaccg aggtggcgc tgccgcaccc actaccaact gatgcgaaag	1740
agtcagatcc tcattctctc ttggtttcgg ggaaacatgg cccgaaagaa ttatcgaaa	1800
tatttccggt cagaggctgc cctcaccttg gcagatttca tctacaagag catggtacag	1860
aaattcctac tggggctgaa gaacaatttg ccatccacaa acgtcttaga caagacatgg	1920
ccagccgccc cctacaagtg cctcagcaca gcaaatcagg agctgcagca gctcttctac	1980
cagtggaagg caactcctgt ccctccttcc tcacagtgca agaggttccg ggatcagctg	2040
tccccgaagc aggtagagat cctgagggaa aagctctgtg ccagtgaact gttcaagggc	2100
aagaaggctt catatcccca gagtgtcccc attccattct gtggtgacta cattgggctg	2160
caagggaaacc ccaagctgca gaagctgaaa ggcggggagg aggggcctgt tctgatggca	2220
gaggccgtga agaagggtcaa tcgtggcaat ggcaagactt cttctcggat tctcctcctg	2280
accaagggcc atgtgattct cacagacacc aagaagtccc aggccaaaat tgtcattggg	2340
ctagacaatg tggtctgggt gtcagtcacc agcctcaagg atgggctctt tagcttgcat	2400
ctgagtgaga tgtcatcggt gggctccaag ggggacttcc tgctggtcag cgagcatgtg	2460
attgaactgc tgacaaaaat gtaccgggct gtgctggatg ccacgcagag gcagcttaca	2520

gtcacctga	ctgagaagtt	ctcagtgagg	ttcaaggaga	acagtgtggc	tgtcaaggtc	2580
gtccagggcc	ctgcaggtgg	tgacaacagc	aagctacgct	acaaaaaaaa	ggggagtcac	2640
tgcttgagg	tgactgtgca	gcagctcacg	gccggctatc	atgctggcca	gggagaactg	2700
attaacttct	cttcctgcct	gcagattaat	ctgctgtctg	agcacaagcc	acgtgcttct	2760
ggcacacct	gctttgagct	gagatagaac	ctggggaatc	atctgttttc	aggcgggtga	2820
ggggctagag	cctgccttgt	ttgggaggag	ggtggctctg	ttcagaatag	gggtagctca	2880
ggctctggcc	agccttctcc	cgcccccaac	agctcccccc	atccttgact	tctcagaatc	2940
aggccgagaa	gagcctatct	ggccgagagt	ggggtgggtg	cctgcgcctc	atcgcccccg	3000
ctctccatct	catctcctgc	tcccagggcc	caaattgtcg	tcactttccc	agtgaagtgt	3060
ctggtcattt	tcagaagcaa	tttcaggaga	acatgcagct	gccgctccct	atcctgcatt	3120
tcccttcaca	gggctgaagg	cactgtcagc	tccctgggct	gggggtgatg	ggagagggga	3180
agggtctagg	ccctcacccc	tgtcctcact	gtgcccatca	tgtagatgga	ctggagtcca	3240
aggaagggca	ggcactcccc	tcctccttta	ctcttctgtc	actctcttcc	tcctcttctt	3300
tcctgtctct	gcctctcttt	tctggagcct	aggagtgtgt	gttttcatcc	cctgaaacaa	3360
atagggactc	agtttcccca	cctgtgttac	agggttgga	ttggctccat	cactgtggga	3420
gaagctggag	ttctgctacc	agtccctccc	tccccagccc	tgctcttctt	ctcccagccc	3480
tctcccttca	gccagttcag	cgctctgaga	gtctgggttg	tttcagcctc	tgaggggcac	3540
aagccatcct	ggattccctt	aaccccatga	ggagccattc	tagcatctca	cagcttaaac	3600
cagctctagc	tcagtcctcc	tggttagtgc	catttttctt	cctcaggctc	tgagggcctc	3660
ttgttccttg	ctctgtgggg	ttttctccag	ttgtctcctg	gctgcaggac	atggcaggac	3720
atagaatgct	gtcatccttc	cactcttcat	tggcatctcc	accagtgctc	acatatgacc	3780
ctagccctgg	ctctcccttt	gccagtacct	cctctgggat	tttgcgagag	tccacaagtt	3840
gtgcatgtgg	tggatatatt	caggccatct	tgtgtgtaca	agcctagagg	gtctgcttcc	3900
acctctggcc	ctcagtgaat	tgctgactaa	cctgtctcaa	cacagcacia	ctgtacacac	3960
cttttcctgg	cctcatccct	aacccatcat	agcagcaaag	aggggaagtt	gcaggggagg	4020
agctgctaag	gaccttgga	tccaagtacc	ctgctcctct	aggccaggga	catcatctga	4080
gatgtggctc	aaataaagg	tgggtgttca	agaaaaaaca	cttggggact	ctatagctgc	4140
aacacccact	ttacatgtca	tttccatatg	attttagtag	aaaatgaagc	ccaggctgtc	4200
ctagccctcc	aatacctccc	tctctcatca	cctctccaac	atagcctagc	attagctctt	4260
tcaagtcttt	gctaatacca	gagatcaagg	ggtgatcaac	tctccctgcc	atccccctgt	4320

8

```

tccccgcacc ccccgccccg gctccccccac catccttgge tcctgccatc ctctttgaga 4380
tgctgcatca tcaaaggaca ttatttatgg tgtacctttg ctgaagccct gcttccctgg 4440
tgccagggct tgggagcagg gatgggtggg ttggtggggg agaggggtgg atgcagagat 4500
tggacccagg aggccttttag tcctcagctc ttggcttaac acctcctcct cttacacacc 4560
caactccctc cagcctgccc agcttgggcc ttcagctcca gattgggtgg gttaggagag 4620
gaggaggagg gagatggatg gaaccaatta ggaacagcac ctgggctcct cacaggaatg 4680
aaccagtcac gccatttgca tgtaaacagc ttcccacttc tctcctcatc ctaccaaatg 4740
ctcccaaccc tgggttctgg cccatgttct ttgccacac agccctgtaa ttagctgggt 4800
aatgagaagc ttttaatgag tcccattagc atctcgtgta ataaagaggc cttgagaccc 4860
agctgctgtc ctcactttgg gatgaacacg ggtccctgtg tagccagtga cttctgtcag 4920
tacagtctaa gttctcggat ggggtgggag acaaacattt caggacccca gcagcacttg 4980
agaggttcca tggtggtacc atgtttttga ctgtgataca agaaacttgg ctctggcttc 5040
cttggtt 5046

```

```

<210> 10
<211> 1493
<212> DNA
<213> Homo sapien

```

```

<400> 10
acacacgccc cagtcctcca gtccctccgtg cgcgtcgggc ccgagcccac agagtccatg 60
gaacccacgg agccgatgga acctacggag cccatggaac ctacggagcc catggaacct 120
acggagccca tggaacctac ggagcccatg gaaccggcgc ggagcgcgca ccgtgggggc 180
gaggcgctgc tgcgggagct ggaggtgctg gtgcaggacg tggtagggac gagctcctgg 240
tgggagcgcc acggcggtgga ctgcgccatc ctgcgcgtca gcctcttcgc cttgccggca 300
ggcttcctgt gcctgcgctg ggagaatgcc ctggctcttg catccggcat caccatcttg 360
ggtgtgtgcc actacacact cactgtcaag ggcagccacc tggccactca tggggccctc 420
accgagtcca aacgctggag caagatctgg ctgcttttct ttgtggaggt gtgcacagcc 480
ttcactgcag agcacgccac gcatgggcac gtcaagatgc accatgccta caccaacgtg 540
gtgggcctgg gggactccag cacgtggagg ctgccttgcc tcaaccgcta tgtctacatg 600
ttccttgctc ctttcctcct ccccatcgcc actccactgg tggctgtcga ggggctgagg 660
aagggtggag tcgggacagc cctgcggacg ctggccctga tttctctggg cctttattct 720
cactactggc tgctcctgaa cgtgtcaggc ttcaagaacc ccagctcagc cctgggctgc 780
atgttcctca ccagatccct gttggcccac cctacctcc acgtcaacat cttccagcac 840

```

9

```

atcggactgc ccatgttctc ccgggacaac aagccccgtc ggattcacat gatgagcctg 900
gggggtgctta acctggcccc gctgcccgtg ctggactggg cgttcggcca ctcgatcatc 960
agctgccatg tggaaacacca tctattcccc aggtctctctg ataacatgtg cctgaaggta 1020
gtcgaagggtt gggctggggg cgctggaata aagggaactgt tagaggatgg aaaggaagat 1080
tcttacggcc tgggggctgt gtcacacta taatcctggc acttgcgag gctgaggtgg 1140
gcagatcgct ttgagcccag gagtatgaga gcagctgggc aacatggtga aacccatct 1200
ctacaaaaaa ttcaaaaatt agcgggggtgt ggtggcacat gcttgtggtc caagctgttg 1260
gaagctgaag tgaggaccaa ctgagtctgc agaggttgag gctgcatgga accataatcg 1320
aggcactgca ctacagccgg gtgacagagt aggaccctgt ctcaacaaaa gaacacaaag 1380
gggcgaccgc caggaaacac cctgcagggg ccaagataag ggaccagaat tttagacaag 1440
ggcgccaatg ggagagcaaa agagagaaaag gcggagaaaa acaggggacg gaa 1493

```

```

<210> 11
<211> 3892
<212> DNA
<213> Homo sapien

```

```

<400> 11
tcgagcctgg cggtagaatc ttcccagtag gcggcgcggg agggaaaaga ggattgaggg 60
gctaggccgg gcggatcccg tctcccccg atgtgagcag ttttccgaaa ccccgtcagg 120
cgaaggctgc ccagagaggt ggagtcggta gcggggccgg gaacatgagg cagtctctcc 180
tattcctgac cagcgtggtt cctttcgtgc tggcgccggc acctccggat gacccgggct 240
tcggccccca ccagagactc gagaagcttg attctttgct ctgagactac gatattctct 300
ctttatctaa tatccagcag cattcggtta gaaaaagaga tctacagact tcaacacatg 360
tagaaacact actaactttt tcagctttga aaaggcattt taaattatac ctgacatcaa 420
gtactgaacg tttttcaca aatttcaagg tcgtggtggt ggatggtaaa aacgaaagcg 480
agtacactgt aaaatggcag gacttcttca ctggacacgt ggttggtgag cctgactcta 540
gggttctagc ccacataaga gatgatgatg ttataatcag aatcaacaca gatggggccg 600
aatataacat agagccactt tggagatttg ttaatgatac caaagacaaa agaattgttag 660
tttataaatc tgaagatata aagaatgttt cacgtttgca gtctccaaaa gtgtgtggtt 720
atttaaaagt ggataatgaa gagttgctcc caaaagggtt agtagacaga gaaccacctg 780
aagagcttgt tcacgagtg aaaagaagag ctgaccacga tcccatgaag aacacgtgta 840
aattattggt ggtagcagat catcgcttct acagatacat gggcagaggg gaagagagta 900
caactacaaa ttacttaata gagctaattg acagagttga tgacatctat cggaacactt 960

```

10

catgggataa tgcagggtttt aaaggctatg gaatacagat agagcagatt cgcatttctca	1020
agtctccaca agaggtaaaa cctggtgaaa agcactacaa catggcaaaa agttacccaa	1080
atgaagaaaa ggatgcttgg gatgtgaaga tgttgctaga gcaatttagc tttgatatag	1140
ctgaggaagc atctaaagtt tgcttggcac accttttcac ataccaagat tttgatatgg	1200
gaactcttgg attagcttat gttggctctc ccagagcaaa cagccatgga ggtgtttgtc	1260
caaaggctta ttatagccca gttgggaaga aaaatatcta tttgaatagt ggtttgacga	1320
gcacaaagaa ttatggtaaa accatcctta caaaggaagc tgacctggtt acaactcatg	1380
aattgggaca taattttgga gcagaacatg atccggatgg tctagcagaa tgtgccccga	1440
atgaggacca gggagggaaa tatgtcatgt atcccatagc tgtgagtggc gatcacgaga	1500
acaataagat gttttcaaac tgcagtaaac aatcaatcta taagaccatt gaaagtaagg	1560
cccaggagtg ttttcaagaa cgcagcaata aagtttgtgg gaactcgagg gtggatgaag	1620
gagaagagtg tgatcctggc atcatgtatc tgaacaacga cacctgctgc aacagcgact	1680
gcacgttgaa ggaagggtgc cagtgcagtg acaggaacag tccttgctgt aaaaactgtc	1740
agtttgagac tgcccagaag aagtgccagg aggcgattaa tgctacttgc aaaggcgtgt	1800
cctactgcac aggtaatagc agtgagtgcc cgctccagg aaatgctgaa gatgacactg	1860
tttgcttggga tcttggaag tgtaaggatg ggaaatgcat ccctttctgc gagagggaac	1920
agcagctgga gtccctgtgca tgtaatgaaa ctgacaactc ctgcaagggtg tgctgcaggg	1980
acctttctgg ccgctgtgtg ccctatgtcg atgctgaaca aaagaactta tttttgagga	2040
aaggaaagcc ctgtacagta ggattttgtg acatgaatgg caaatgtgag aaacgagtac	2100
aggatgtaat tgaacgattt tgggatttca ttgaccagct gagcatcaat acttttgga	2160
agtttttagc agacaacatc gttgggtctg tcctgggttt ctccttgata ttttgattc	2220
ctttcagcat tcttgtccat tgtgtgataa gaaattggat aaacagtatg aatctctgtc	2280
tctgtttcac cccagtaacg tcgaaatgct gagcagcatg gattctgcat cggttcgcat	2340
tatcaaaccc tttcctgcgc cccagactcc aggcgcctg cagcctgccc ctgtgatcct	2400
tcggcgccag cagctccaaa actggaccac cagagaatgg acaccatcca ggaagacccc	2460
agcacagact cacatatgga cgaggatggg tttgagaagg accccttccc agcaatagcg	2520
acagctgcca agtcatttga ggatctcacg gaccatccgg tcaccagaag tgaaaaggct	2580
gcctccttta aactgcagcg tcagaatcgt gttgacagca aagaaacaga gtgctaattt	2640
agttctcagc tcttctgact taagtgtgca aaatatTTTT atagatttga cctacaaatc	2700
aatcacagct tgtattttgt gaagactggg aagtgactta gcagatgctg gtcattgtgt	2760
tgaacttcct gcaggtaaac agttcttgtg tggtttggcc cttctccttt tgaaaaggta	2820

11

```

aggtgaaggt gaatctagct tattttgagg ctttcagggt ttagttttta aaatatcttt 2880
tgacctgtgg tgcaaaagca gaaaatacag ctggattggg ttatgaatat ttacgttttt 2940
gtaaattaat cttttatatt gataacagca ctgactaggg aaatgatcag ttttttttta 3000
tacactgtaa tgaaccgctg aatatgaggc atttggcatt tatttgtgat gacaactgga 3060
atagtttttt tttttttttt tttttttgcc ttcaactaaa aacaaaggag ataaatctag 3120
tatacattgt ctctaaattg tgggtctatt tctagtatt acccagagtt tttatgtagc 3180
agggaaaata tatatctaaa tttagaaatc atttgggtta atatggctct tcataattct 3240
aagactaatg ctctctagaa acctaaccac ctaccttaca gtgagggcta tacatggtag 3300
ccagttgaat ttatggaatc taccaactgt ttagggccct gatttgcctg gcagtttttc 3360
tgtattttat aagtatcttc atgtatccct gttactgata gggatacatg ctcttagaaa 3420
attcactatt ggctgggagt ggtggctcat gcctgtaatc ccagcacttg gagaggctga 3480
ggttgcgcca ctacactcca gcctgggtga cagagtgaga tcctgtctca aaaaaaaaaa 3540
aaatatcacc cttaaatcaa caaaaagacc tcatgctcat gcagtggaca tttcttgccc 3600
tgttttcctg tgggttttct tcagcatgat atgaagcaac tggtggcata gccagtggga 3660
taaataagaa atggaatcat ttggctgcct cgtcacttgt gctaattggc agttgtacac 3720
acatgacatg tggaagtga cgtgtagcagc ggtcactcat ttaacaatt gaactctgct 3780
gggttgggta tttaccttg tctagaaaag aaatatgata tattttctct aaataaattt 3840
attttcatca ttcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaatgagcgg cc 3892

```

```

<210> 12
<211> 482
<212> DNA
<213> Homo sapien

```

```

<400> 12
gatgaaaaga agaaagggga ggcagggttt cattgaaact gccagcctct aggtcagtgc 60
acatagatag ttactgcctc aggaggcaca attgctgggt gaatggtacc acagagattg 120
atthagagtc atggctagtg ggggtgttct acatgtcatg tctggaagaa aatcaggtgt 180
gtttttgaga cagtgtgttt tcatgtggag caaacaatca aaaccagtga gtgagagcaa 240
ccccagcatg accatgtttc ctcacctgtg ccacactctc tgtgaagagt tgtgtccaca 300
ctttagttta ttttaataatt tgatgtaatc tgtatgtatc cctcatttta ttcagaaaaa 360
aagctcagag aatttttata tcttaaggcc acagaattaa tgaatgacag gagagcctgg 420
attaatgaat gactagagag ttcaggtagt cctgacttta gtaatgtcta catttcatgg 480
tt 482

```

<210> 13  
 <211> 295  
 <212> DNA  
 <213> Homo sapien

<400> 13  
 ctcaaaaaca tttgggtatc cacagtttga cccaggaaag ttgactgggt agatataatg 60  
 gtccatatag aaaatttata gaagcagaat ctgtaaatta tgatgtgaaa aagtcagata 120  
 atttttattht aaatatagtg atcatgataa caataattca gttgaattaa aaattagaac 180  
 agattaactt gaattttgta tgttctataa aatataaata atggagttaa aatgtcatat 240  
 atgagtttgc tctggaaaac acattctcaa aataaataaa atctgatttt atttg 295

<210> 14  
 <211> 188  
 <212> DNA  
 <213> Homo sapien

<400> 14  
 gctcgagtac ggtgtggtat gaaatttcaa ttgttttcaa tgcataaaaa cagatattat 60  
 gatatagttc attatactat gtgattttgt tactttacaa tcctattata ctgtgtgatt 120  
 ttgttacctt aaaatcctta tgtttatggt aagaatgatt cattcttggg tgagcttggt 180  
 ggctcatg 188

<210> 15  
 <211> 304  
 <212> DNA  
 <213> Homo sapien

<400> 15  
 ctgctctcta ctgccctata aaatccctgt gtcaagggat gctctcagta tcatttgccc 60  
 ttgcacagaa tatccctggg gtttgagggt ctttgaatc tccctctttg tcatctcttt 120  
 cgctgccact tctggctgtg gtcactagct tggccatagc acctctcttc tccacttctg 180  
 atctgctgct tctaaccctc tatagattgc agctggcttt aaaatagatt gtaaagtgtg 240  
 aggcattagg ttctgagaca gcggcagaga gagccatgca aatgtttagg acaaccagc 300  
 cttt 304

<210> 16  
 <211> 212  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (157)..(157)

13

&lt;223&gt; n=a, c, g or t

<400> 16  
aaccacaatct ttcaaaacat gaaagggggt gatggagaaa accttagctt ggttgtctaa 60  
agacatgggt gcaaaactcta ggctagctct gccaatcact tactgtgcgg gtttgactca 120  
gtcccttccc ctactaggt ccagtttct ccattntaa aacaagcaat tgtgctacat 180  
tgatgggttta catcaataaa ggttgaaacg gc 212

<210> 17  
<211> 122  
<212> DNA  
<213> Homo sapien

<400> 17  
gtaaaactat taaaaaacat tagaaaaagt tatgtgcatt tttagatgat atattcaaac 60  
atatctaaag cgtaataaaa aatctaaaat ctctgcaaaa attaaatata gaatatagta 120  
ag 122

<210> 18  
<211> 220  
<212> DNA  
<213> Homo sapien

<400> 18  
gcgagggtgc atctaaaatg aagtagcttc atggaaaccc atttgctgat gagaaagcaa 60  
tttacaactt gttctattga acactcatat ttggagttca acacccatct ctattaattt 120  
cctttctcat atcctcaggg ataactttac agaacacctg aaatgttaac aatttgtaat 180  
tcaagaatga atgtatctgg gcactttttc aaatacagga 220

<210> 19  
<211> 442  
<212> DNA  
<213> Homo sapien

<400> 19  
attgagtact tgctatattg gggatagatc tgggaacaaa atgaaaccaa attatctaac 60  
cccttgagat tacaatatcc tgggggagag agacaataag ccagaaatat acggtgaaaa 120  
aaaatagaac agaagaagga gacaggtagt atggagtgga agagctgttg cacgtaagat 180  
gatcatagaa agcttcacca agcagggtggc atatggtcag aaacctgaaa gaggcaaaga 240  
aactggctat gcgtatatct aggggaagag ccttgagggc aaagagaagg caagtgcagt 300  
ggcctatgaa tgagcatgcg tggcagggtc cagtcacagc tagtggcatg gaaaaggcac 360  
ggagtagtag cagatggaac cagtgaata gcagcaggcc actgatgtag ggccataaag 420



14

accattcttag gcttgctgcg gt

442

<210> 20  
 <211> 872  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (188)..(247)  
 <223> n=a, c, g or t

<400> 20  
 ggaatcccg gggcgagcac aattttaaaa gaacagtaca ccagcgtaat agagtaatag 60  
 ttttttcatg ccttggtgcc agtctgttaa gtctgtctga ttgtactgtg cagaaatata 120  
 tgaattcctc ccagtaaaat gcaaaccaca accttggtta tgaaggtaaa gtttggggga 180  
 gagaactnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240  
 nnnnnnngtc ttgggtcagg atctgggaca cagtcagtac tgtgtgtttt gtgtttgtcc 300  
 ttcctcatgg taacctggat tccttgatct cccggtaggt ccactccttc atcacacctg 360  
 ggactactct catatttgtt ccttcctatc ctgagtccta gtgggttttc atttgacttc 420  
 caggttcagc tgcagaccca ccagggaag acccaccagg tatgtgtttg ggagtgaggga 480  
 tcacttggtc tggaccccag atcttttctt ctgcttgga aaggtttact agttcggctt 540  
 catccagggt tggttccagg ggaattgatg gctgctgac ctccacgttc tctttccag 600  
 cacaccttgc cctgcttctg ggccacgtct ctccagtga cctgcaggag acctctgtgg 660  
 atgcacgtg tctcctaaca ctgtctccag cccacactga gcttgtcttg cgtggaaatc 720  
 tttgtctctg ctgttgctt tgccctggag gtccttgccc cacacctct cacagctgcc 780  
 tctctgtcat ctttccaatg tctgtcctca gagagccctt cctggccact ccatctaaag 840  
 gagtcctggg ccagggtgtg tggcccacac ct 872

<210> 21  
 <211> 438  
 <212> DNA  
 <213> Homo sapien

<400> 21  
 aagaattcgg cagaggggt gaagaccac cagcacacct tgcctgctt ctgggccacg 60  
 tctctccagt gcacctgcag gagacctctg tggatgcacc gtgtctccta acactgtctc 120  
 cagccacac tgagcttgc ttgcgtgga atctttgtct ctgctgttgc ctttgcctgg 180  
 agcgtccttg cccacaccc tctcacagct gcctctctgt catctttcca atgtctgtcc 240  
 tcagagagcc cttcctggcc actccatcta aaggagtcct gggccagggt tgggtggcca 300

15

```

cacctgtaat ctcagaactt tgggagacgg aggtgggaag atcacttgag gccagggggt 360
caagaccaac ctgggcaaca tactgaaacc cccatgccta taacaataaa aaaaaaaaaa 420
aaaaaaaaat tggcggcc 438

```

```

<210> 22
<211> 1002
<212> DNA
<213> Homo sapien

```

```

<400> 22
gtggtgtgtg atttgtatgc ttgatttaca ttgctggatt tcctagtgc accttcttgg 60
ccctccgaaa ttctttgtca tgatagatta ttcttttaaa tgtgaccgca tttgataggc 120
taatatTTTA ctttggatct ttgcatgaag tactcagtgc aagttaactg ttaaagtTat 180
aaaaccataa gggaagcaca gggctgtgga ggttggggag ggtttttttt gaaggagtG 240
ggcatgtgag tagggatttg aagaatggta agactgagat caggggttag aaacttaagg 300
acctacaggg gccagagagg tcatatgaat gaatgccaca ggctcagtgg gagacatctg 360
agaggggtgg gaaccggggg gccccggggg aacacacacc ctgcctcaag ggggcagtgc 420
cactcaaccc cagccaatca ctgccatgtg ggaatatggc cctgggtgtt ccacacgggc 480
tgatcattaa gaaaatccag ctgtctgaat ttttatgtga aacttttcca atttaaaaaa 540
ttattgttaa ccaattaaaa tttttagaaa acaccttctt tgggtgactc agacgactgg 600
atttggcctg ttagtacact ggtctgtgtt tgctgattta gacctttaag attctgatgg 660
tgggtgttgt agagaagcag tatgttagtg ataaaaggac acacgagtga gtatcatatg 720
gactcaacat tgtgcctaact actttccatg cattctcttg tagaatcctc acaactgcct 780
taggtattat tccgctatcg catagatgag gaggcaggcc cagcaaatta gagtactag 840
cccagccagg gagagctgga tgcaggctgc atccaaggca gagagtgcag gccaagcaaa 900
ggctcattgc caggaagctg tgcacagtgt atttcagtct ggtgggagag caatgtggga 960
ggcacaggaa gggtaagtaa agatgtgggc tgggatggga gg 1002

```

```

<210> 23
<211> 906
<212> DNA
<213> Homo sapien

```

```

<400> 23
aatgtccttc cggtgagag tgaagagggc tttgggggga accacaacat cccaggcgac 60
agcttgagaa acatctctca ggcagagggt gcatcaggga catcccatct ggaactgaac 120
tagaaagggg ggctatttcc cagtgtgtct ctctctctt tctgctcccc ctgtccatgg 180

```

16

```

cagtagggct tgggcagtca gcctggacag ctcaaaacaa actactgggc acaacttctc 240
agaggcaagg aataataggg gtaatgagga ctggacatct ggtgactggg gactcttttg 300
cgatgtctgt gggaaagggg taggggtgaag atagaaacag gttagtatgt tcacaactag 360
ggctagaaaa aaaaaacaga tgagtaacca gtcacatcc tttttctgga aaaatcaggc 420
tccccctccc agttcaaaag acacatgccc tggtaacctt tgaagtttcc ctacctatgt 480
acaataagcc cttcataaca gtcagagaag atgggtggccc caactctggt ggaccccaga 540
actctgagag attccaggaa ttaggcaaag caggattagg tcaggaagca aggattgcct 600
ctccatgaaa cctacacaaa tctccatgcc atggaaaagt aattagtaag tagatgagct 660
catttatgaa gtcacctctc acggtgcctg atgcatatta agcacgtaat tgatgcctgc 720
tggtactata acgattatgt atttctgttg ctgccacact aaaatgaata acaacatact 780
tccccaccta aaacccaaaa gaagaaacca gtgggagggg tgtcttcagc cagcccacca 840
gcatagaaaa gggtcacctg ccagttaccc caactccag cggcccaatc ctaggtctct 900
ccatga 906

```

```

<210> 24
<211> 287
<212> DNA
<213> Homo sapien

```

```

<400> 24
gtccgcggac gcgttgggct ggactgagag taagaagagg agagttccag taagtttgac 60
tacagagcac tcattatcat tgtgattatt atgttcccgc atattttgtc gttcttagtt 120
aggcatactc ctttaacact attgtaataa aagcaaaatc tggaaatctt taagagtgtg 180
gcagttgctt ccaagggagg ctgaatttta ggaatgaagt tacatataac attgacatat 240
ctgggggaaa agactagaaa aatatagttt cattgctttt tgtgtgt 287

```

```

<210> 25
<211> 1378
<212> DNA
<213> Homo sapien

```

```

<400> 25
gcagagagaa gaaagcagac aggaaacgaa tcccttctc ctctcccctt taccctcttc 60
cttactctcc tagaccaagc tggtcacccg gctgggaatc aagattgtgt ggctgggaag 120
acaccagtct ctgtgctcgg gttcagccca gtcgggcaag aaagtctggg cagctggaga 180
aggctcgtcac agtctcccgt ggaatcttgt tgctgagag ccccataacg gaaagggcta 240
agacgactct tccacacaca ggtcgcagcc cctgcgcggg aggatcccca ggaagatgct 300
ggggacgctc tgagcatcgg cctttcttta ccccgactc cctggagctt ggtctcggga 360

```

```

tgccaacttg gggcacggag gcgacgggct gctccgaagc tggagggttt ctgcttgggt 420
cagagggatc acgacctcag cagagccagg agaggttggg tgacacccac tgcgtattgc 480
acttgactca aaactgccct cggcctgcgg aagaggcgag ggcaagaagc ctggtggcgg 540
gtcaaacctt caccctatta ttttctatca ttttttatgc ccatatattt gttaaagtga 600
tggttgctat acaccaacag cttattctac aagaagtgcc cccgaggagg attgggttaa 660
gctttgcaaa tttggcttcc caggtaatgc gcttcattat tctgctcccg acttaccac 720
cacaccagtg ggtacccgga gcagcaccca cttggcagaa ctgatgactg cttgggcccc 780
gcggagtgcg cattgcgcta acacgcgcac ggggaattgca cccttgccgg agcctccgca 840
ccgtgcccc ttcaaagagc tggcgacccc gctcacgtgt aagcaacctc ccactttgaa 900
actaattcgc acccgggtct ttacccccaa aggactttgc tgcggaagct gctctgacct 960
aagacgcggg agagaagtcc caaaggctac agccaggggc tgggggactc ctctgctcac 1020
cttagtcctt gatttcgaag gcccgaatta actatctgtt gtgtcagaat cggcgagtgc 1080
aaagtagctg cgcctcgctg acgcgctctc tcctgggtcc gggatatcca gggcatccgg 1140
agctggggag ggttgctgcg actaccaag gcacgcgcag atacggggca gggagaagg 1200
gctccgtgtt ccaaggatgg tcgtttacct ctcttgagat cagccctaatt cccttggtaa 1260
cttaagcgcc tctgaactcg gggagcgctt ggtggggcgc ctccctgcat ccaccctac 1320
cctggctcct tcccaggccc agcatcttcc ccaccattct cacccccacc acccccac 1378

```

```

<210> 26
<211> 834
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (817)..(817)
<223> n=a, c, g or t

```

```

<400> 26
aaacaatagt atccatcttc ccacaattac tattaagat tcttaaaatt tctggaata 60
ttgaaggaaa cgaattatgc tttaagattt taaacctacg gagtaagtta attctgtctt 120
tgccatttac tagctgtgta aacttggaag gatcagcttg agactctctg agcctcattt 180
ttttaatctg tcaaatgggt ctcaagaaca ttgtgtagga ttaaaatgaa atattaccct 240
gtaaatagtt tagaacagtt cttggaacat agtaaaaact cagaaagtgt tcagtaaaat 300
gttgagtata ttattgtgat gtgggaattg ctgatccagt tgactcaatt cacactgcaa 360
attactggat ttgaataagg agatgaagat tgagtcacat tgttctcttt gatccatttt 420

```

cttttagaca	acatcactca	aacaacccta	ttacttcagt	agcaatgaac	tgtctctgga	480
ttttattaag	catctcacta	gttccttttc	ttcagctgta	tggcaccctg	tcttcctgta	540
caccagagggc	tcctcagctg	ggtaagggtg	gccaacgtta	ccaggagtat	atgctgagag	600
gccatttcaa	agtctttcat	agaaggctgt	gcttgggcaa	gtagaacttt	tcatcataca	660
gtcccagaga	tgtgaagtta	tcaaggctag	agaaggaggaa	aagagactca	gagaaactgt	720
gttctctagt	ctttcattcg	ggaacaaatg	gtgtcgtacc	aaatggctga	aaagatccca	780
ggcttactct	gagaaacatc	tctctcttct	gaattanact	tgcacagtgg	ctac	834

<210> 27  
 <211> 1212  
 <212> DNA  
 <213> Homo sapien

<400> 27						
gcctccaagg	agcgggcggc	tgggagaggt	tgtgccaccc	gggaccaagc	catcggcgct	60
gcttcggact	cccggtaggg	ggagccgccg	cgggcgccag	gccggattgt	gttctggcct	120
cggggcggcc	ctgctgccag	cggccgggac	tctcagcaca	gagctcggga	ggactccacc	180
tgctctccag	ataaggcgcc	atgagcagag	aagggaacag	acggccaagc	tcctcctaa	240
ttccccgttg	ttgcagagca	aagaagatgg	gggagaacta	attatattct	ctaggtctaa	300
atattgttga	aaaatttgta	ggtgagatca	cctcctttgc	ccatatccat	atataatata	360
tccattacat	gtgtttgccc	atatatatac	gtatgccata	tgtaaatatg	tacgagtgtg	420
tatgtatgtg	tatagcagtg	gtttagaatt	agtctcagtt	ccacaaattt	tgagcccttt	480
taatatttta	ggtgacctaa	taccttctca	ctgtattttc	caagtcactt	atttccaaga	540
gttttaggtg	atcccagcat	aggagctgag	cataggagct	cagatgagac	ttgccagttt	600
tgctgcagta	atgtcagcaa	aagagtctct	ctctttctga	ctctatagac	ttaagtaagg	660
gtttacaggc	tttcatttta	aggtatgact	gatattttaga	gaacaagact	aaaccaaggt	720
caaggggaaa	acagttagac	tgtgaacctg	cagaccactc	cactgcaccc	agtgtggccg	780
tacacctgtg	ctgaacggcc	agagacttcc	tgggtcaatac	tcccacagat	aaaagactgc	840
aggatctgct	tatacacaaa	tccatctttc	gctgggaacc	cacaactcat	aacaactctc	900
ctaattgcaa	gtcatcaagg	cctcttgaaa	gagaatcata	aaaaacaaag	aatttcaaac	960
ttggaaggaa	acctaaagtt	tactggtgag	gagcttgaac	tgagtagaag	caaagaatca	1020
tactccagat	gagaaacgcc	ccatgcactg	agctgagact	ggaactctcc	tcttcttact	1080
ctcagtcag	taagtttgac	tacagagcac	tcattatcat	tgtgattatt	atgttcccgc	1140
atattttgtc	gttcttagtt	aggcatactc	ctttaacact	attgtaataa	aagcaaaatc	1200

tggaagatct tt 1212

<210> 28  
<211> 433  
<212> DNA  
<213> Homo sapien

<400> 28  
aaaaggcccc ctccggcctt caggggggtgg aaggggacctc ccccccccca cccaatccat 60  
gcaaattaaa ccagttgttc ccaagaagaa gggatcttgt cagactgact caagtatctg 120  
acctaacaga tgtagctttg gtagatatgg ctgcagcctg atgatgtctg gaatcatggt 180  
tatctaaaat gaattccctt tgttttgact cagctcaaca agcaaacttt tgattataat 240  
ttttggacag taaataatta ttttggttaa cttgaagatt ttcttcattc accctccttc 300  
attctgatgc acatattatg catcagagag ggcagtttca aataagccct cctaaaggct 360  
ctgaaatgag ttagaatagc acatttatta aatcaactta tagacaacac taacaactgc 420  
ctctacacaa aaa 433

<210> 29  
<211> 1359  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (729)..(864)  
<223> n=a, c, g or t

<220>  
<221> misc\_feature  
<222> (1030)..(1053)  
<223> n=a, c, g or t

<400> 29  
ttcaagtgat aacactaaag cattggggca aatttaaata tcaaaaaatg ttgtaattac 60  
aagtttcctc ttgtgcaccg agcttacaga ccgagacata aacagtaaga ctaatgtctc 120  
tggggagaaa aatatacaat tatcttctat attattggat aaataaatta ctgtatggta 180  
atttggttaa atattgtgtt gcattcactg tactgtgcta gttaaaacgg aaaaagtggg 240  
ttggtgcatt ttgaaatag aaagcattta aattttttta gcacataatt ttagagaaca 300  
acttagccct accctattta tgtaagaaaa ttgagacctg ttcaggcaga cctgctgcag 360  
gtgatatggt aacaaagtca gagttggcgt gtgcagcaca tttatttcac taaaattcat 420  
tttgtcatcc acatcatatc aatacaactc tttaatttta tgtaaaactat cttaaataca 480

20

```

aattctgaaa gagccacaat gcacaaaagt tcaaataatta ctttttctct actctctgct 540
aattttaact cgtaagtctg gaaaatacag tccttagttt acaaaaacaa .cttcagaatg 600
ttcctaccta caaaccaagg gtgaggggta cgttaagatc actgctcttt ctttcccaag 660
tgaagatgga aggaagctca cgtctattga gtgccccct tgacaagtca ctttgtgtat 720
atcaactttn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 840
nnnnnnnnnn nnnnnnnnnn nnnnttctaa tgacttttca ctacacagcc ctgtttgagt 900
tgagaacatc caggtgagtg actcagtcta aatgaaatct gctacagggg aaaaagggtc 960
caggtagttt acatgggtag ctatttgtag gatgtagaga ataacctaga gagatagggtg 1020
acttctcacn nnnnnnnnnn nnnnnnnnnn nnnagcatga agccctcttc tcaccaagga 1080
ggcctgtaga gatgatgtga tcctggcatg aactaggaat gctgttcaca atagagacag 1140
tgcttaagta gtcaataagt aaagtttaaa aagttagtaa aactgagtga agttgatgtt 1200
agtttccaaa tacagtgggt taaataggct tttgtgagtt ggcctgaaaa acagcattta 1260
tggcattgta tgggaagatt atttgagatt tctaaccagc tgtcttataa ataaaacaaa 1320
tgtctaacgt ttgaaacaaa attacagtac ttggaaaaa 1359

```

```

<210> 30
<211> 3705
<212> DNA
<213> Homo sapien

```

```

<400> 30
ccctatcgga aatttgtttt tagtggtgtt attatgtctt cttctctacc aagatgaaaa 60
tcaacagagt ggtgatttct gcagtttact tctggatcag gggttctact gcacagcttg 120
gcacatcata agtgccctgt aactaaggag actaaataat tttccctcca aaggggaaca 180
ccttgggtcg tgtaaggggt agtattaatc ttaatgccag gacaacagaa atgaaatgag 240
aaggacagaa atgaaggctt tatgtttgta tctgaaacag ctttatgaga ctagagtctt 300
ccaattgatt tagagcaaga aaggatttca aatcttagga ggggcttaat catctttctc 360
agtatgtcat caaaagattc tctcatggtg taactctagt taattgagct tattagaaac 420
agaaagcaac atgggtgttc tgaggttttt cttcatgagc aggaggtgtt caggtgaagg 480
tgggatctgg gtgtggcagt gagtatttaa ggtggcgagt gcacgatttc tttggaaacc 540
agagagtcaa ggagctatga aaatgacgtt gtgtcctgaa gcacagcaga aagagataca 600
gagaagcgtg aggtcttggg gaacagggaa gtctgggagc ccggtgtcct gttggggatg 660
ggttaggagg caccagcatc tgtgtagctg acagtggcag ggaagagaag agaggggtgt 720

```

21

cctctgagga ggatgaggag ggacaaggtc tggaaactgac cctgggtcat gaccttgagc	780
atttagtcct tgactcgcac cagcccgatg aggtcccagg acccagtgtc aatgcctgga	840
gctcctgcca gcagcatcag ggtcacacgg agaaatgcag actctagggc ccaccccaga	900
cttacttggg ttcaggcca catatctgac ttcagcaaac cctgcagggg ctgaggatgt	960
acactgccat ttgagacaca ttttcccaga aagagaggct ggtgggaaga ttccactgag	1020
gctgagagaa gccccccaca gctgatcttc tcctgtctcc atttggttga aatttcacat	1080
tttcttttct tttgaaaggg gaagctcaaa aggaacatga tgccctgggc tttacagaag	1140
aaacgagaaa tccacatggc caaggcccat cggagacgag ctgcgaggtc tgctctcccc	1200
atgagactca ccagctgcat cttccggagg ccggtgacaa ggatcaggtc tcatcctgac	1260
aaccagggtca gacgcagaaa aggggacgag cacctggaga agccgcagca actctgcgcc	1320
taccggagac tgcaggccct gcagccctgc agcagccaag gagaagggtc aagtccactg	1380
catttgagga gcgtcttaag tatccttgca ccggggacgg ccagtgaatc tctggacaga	1440
gctggtgctg agcgtgtgcg cagcccgtt gagcccaccc ctgggagggt tccagctgtg	1500
gcaggggggc caaccccagg aatgggttgt cagctccac cgccctctc tggccaattg	1560
gtgactcctg cagatatccg gagacaggcc aggagggtga agaaagccag ggagagactg	1620
gccaaggcct tgcaggcaga caggctggcc aggcgggcag aaatgctgac agggagacag	1680
actatcccta aatacaactg ccagacacag aacaaaactg ttgccgtcat gccagggtacc	1740
acgtcagtat cttcaaccaa gattggagct cttctggggg gctacagaag cccacggggg	1800
gctgtcctga gagcgctgcg ggataaagga ggagcgctcct gcttcccggc tgccctgttg	1860
ctgtcggagt cacaggatgg cggctgtcgt cctgccccca actgccgggc catgctctgg	1920
tttccttgga ttgctgtggg ttggtgtttg cttggagtag aggtggatgc tttgtgggtg	1980
actgtgtatg catggggacc tggtcgatcg caggcagcct ctacgcgaga aggcacacaca	2040
gagggcgagg agctgggtta tgagctcctg aaaagctggc taaagggtt ggtgaccttt	2100
gaggatgtgg ccgtggagtt cccccaggag gagtgggcat tgctggaccc tgcccaaagg	2160
acactgtaca gggacgtgat gctggagaac tgcaggaacc tggcctcact ggggaaccaa	2220
gttgataaac ctaggctgat ctcccagctg gagcaagaag ataaagtgt gacagaagag	2280
agaggaattc tctcaggtac ctgtccagat gtggagaatc catttaaacg caaagggtta	2340
actcctaagc tgcattgttt tcgaaaagaa caatctagaa atatgaaaat ggagaggaat	2400
catcttgagg caacactcaa cgaatgtaat cagtgtttta agtcttcag cacaaaatct	2460
tcccttacac ggcacaggaa gattcactact ggagaaagac cctatggctg cagtgaatgt	2520
gggaaatcct acagcagtag atcttacctt gctgttcata agagaatcca caatggggag	2580



```

aaaccctatg aatgcaatga ctgtgggaaa accttcagca gcagatctta ccttactgtt 2640
cataagagaa tccacaatgg ggagaaaccc tacgaatgca gtgactgtgg gaaaaccttc 2700
agcaattcct catacctcag accgcacttg agaattcaca ctggagaaaa accgtacaaa 2760
tgtaaccagt gttttcgtga gttccgcact cagtcaatct tcacaaggca caagagagtt 2820
catacggggg agggtcatta tgtatgtaat cagtgtggaa aggccttcgg cacgaggtca 2880
tctctttctt cgcactatag cattcataca ggggagtacc cttacgaatg ccacgattgt 2940
gggagaacct tcaggaggag gtcgaatctg acacagcaca taagaactca tactggagaa 3000
aaaccctaca catgtaatga gtgtgggaaa tcctttacca atagcttttc tcttacaatt 3060
cacaggagaa tacataatgg agagaaatcc tatgagtga gtgattgtgg aaaatccttt 3120
aatgttctct catccgttaa gaaacacatg agaactcaca ctggaaaaaa accctatgaa 3180
tgtaattatt gcgggaaatc cttcacaaaca tccactacct ccactacagc atctgctacc 3240
tccactacag catcatggat ccaccacagc aatcaccaca tccactacag catccactac 3300
agaatccact acagtgaact caacacagtg gcctccact cctgggggta tgcttcagga 3360
aatggaaggg tggaagaagg aggcagagat ccaagggtag tagccagcac tggaaatgat 3420
cctgaggcat cagataatga tgaagataat gatggtgatg ataagaatgg ccatgatggc 3480
gatgatagtg atggtaatga gggtgatgg gatgagatgg tgatgatgat gatgatactg 3540
acgatgatgg tgatgacggg gataatgatg atggtgatgc tgatgacagt gatggagatg 3600
gctaatttaa caaccccata ctgcggaact ctgggccaga gtttgaggga atgtgaagaa 3660
ttcagacgca actttcatgc agcctctgga aagctcccag gataa 3705

```

```

<210> 31
<211> 800
<212> DNA
<213> Homo sapien

```

```

<400> 31
aaagattctc tcatggtata cctctagtta attgagctta ttagaaacag aaagcaacat 60
gggtgtttctg aggtttttct tcatgagcag gaggtgttca ggggaagctc aaaagaaaca 120
tgatgccctg ggctttacag aagaaacgag aaatccacat ggccaaggcc catcggagac 180
gagctgcgag gtctgctctc cccatgagac tcaccagctg catcttccgg aggccggtga 240
caaggatcag gtctcatcct gacaaccagg tcagacgcag aaaaggggac gagcacctgg 300
agaagccgca gcaactctgc gcctaccgga gactgcaggc cctgcagccc tgcagcagcc 360
aaggagaagg ttcaagtcca ctgcatttgg agagcgtctt aagtatcctt gcaccgggga 420
cggccggtga atctctggac agagctggtg ctgagcgtgt gcgcagcccg cttgagccca 480

```

```

ccccctgggcg gtttccagct gtggcagggg ggccaacccc aggaatgggt tgtcagctcc 540
caccgcccct ctctggccaa ttggtgactc ctgcagatat ccggagacag gccaggaggg 600
tgaagaaagc cagggagaga ctggccaagg ccttgaggc agacaggctg gccaggcagg 660
cagaaatgct gacatgtaga tgaagcgag tcctgggctt tcggtccctt tcttttaatg 720
cccatcctca ttctactct gaattgtcac acttttcct tccccaccag ttctttaata 780
aaagtatttg aaaggcaaaa 800

```

```

<210> 32
<211> 74
<212> DNA
<213> Homo sapien

```

```

<400> 32
gtgggggttaa ttttaatatc tatattttcc aaaatgcagc tttctcatct ataattttaa 60
tattacttaa atgt 74

```

```

<210> 33
<211> 1943
<212> DNA
<213> Homo sapien

```

```

<400> 33
attgcaatgg gaatcttaaa ggaaaggctg agaggagcga ggtgaggctg ggtgggtgtg 60
ctgggtgggg tgaggctggt gttctcaggg ttgaacctca tgggtagat caatcagaac 120
ccaggaggtc tgaggactgt gggacctcca agcaactacc ctggactact cgtccatgat 180
tttcagatga gccacactct cttctgcagg aaggagacaa aaatttccga gatggcagag 240
aaaaatagtc accctgggtg gggagtggcc tgaggctgcc agagaaaatc taccaacaca 300
ctaatacttg tgtgacttta cataacatcg agaaagtat tttctcatat actcactggg 360
cggtccctac gcatgcctgt acaatctaac gcgtgttcag ctagggtctc tgtttgccct 420
gcgaaggctc caggggcagc tccttcctgt cctctgccat gtcctggtg tgcatccagg 480
cactcctggg cttgggcaac ttcactccaa tctctggtct ctgtgtcttc ctcttctgtc 540
tcttataagg gcactgtcat agggactcag tgaacctctc caaacaggat gatctcatgt 600
tgagatgcct aactgataat atctacaaag accccttttg caaagaagac ctcatcaca 660
ggctcagggg ttaggatgtg accatctctt cttggtgaag agtagtgagg gctaccattc 720
agccactac acccagcagt agccattcca tgccctgcag ctgcactgag atgacagaag 780
ttgtttagg aaattcttcc attttctctt cctggaaagc aaaactaatg caggaagacg 840
ggaggggaga gtaggatgt tgtgtggagt atgggttttg ctgctgcagt gcagatccag 900

```

24

```

aatagcacag gtctgaatga gagggaaatt aagtcttgct cattcactgc actccagggtg    960
tgctcgtgtgc agggctgagt ggtagtcccc tgtgccagag atccggaatc tcttgctggt    1020
tcctctgcca accataggct gctgtaccgc tctgcatggc tcacctccaa gtcctctttc    1080
tggccgaggg gagggctgtc cacgactaat ggtgaggttg gtgcacgttg tcatggctga    1140
gagcctcctc ctggtgctgt gtatcctaac tgcctgtact ctattggttg ttcaatgttt    1200
gggctgccac ccctggtata tccctccct tgaaggcatg acccagaagt tatacccgtc    1260
ttttctctct ccactcacac cctattggcc agtatttggg cctatgacca cagctagctg    1320
caaggagtc tgggaaatgt attctttatt ggagatggcc atttgctgg cagaaaattc    1380
taataatgga tattggggaa atggataact gggtagatgc taacattctc tgcaaaggag    1440
gggtctggct ttctgggacc acgctcagca tctcctggct cttccactga ccgggagatt    1500
gctggagaaa ggctgatggg tctttgcctg gaaaagccct agatcttatg gtggcctggt    1560
tccttgagga tagcagttat gggacattgc tggcttcact gcttggtttt acaccagctg    1620
atgccactgc cccagcatg acaagggttc agctttctgt cctttgagat gatagccac    1680
tctctgcccg tataggcgaa gagaaatgca ttgactatac actttgggtg taggtactgt    1740
agcaagcatt tctccatgaa ttattgctgt ttgagaagct gcaggaactc tctggcaaac    1800
tgccctctgc aaaataggat gtaaacaaac cccagagta gcctgctcaa ggcctttggg    1860
gacctggggg cagccccag catgacttgg ctctgggggtg gtatgttgcc cagcaggctg    1920
tgtgagggtta ccagccatag gaa                                     1943

```

```

<210> 34
<211> 1052
<212> DNA
<213> Homo sapien

```

```

<400> 34
tatcagctcg gaccttaatt cccacgatca cagattcaat gcaatcccta tcaaatttca    60
ttgacatttt tcaactgaaat aaatgaaata atcctaaaat tcgtatgagg gagtaacacc    120
tgctccacag tggcacaaaag cactgtcagg tgccacacac agcctgttgg gacatgtggg    180
ccacagtact tccccaccta aagtactgta gagggccagg agacatgagc cagggccatt    240
ttaactgtca gtaatggcca caaagacccc taaatagcct aagcaatctt aagcaaaaag    300
aacaagctg gagacaatac actacctaac ttcaaaatat actataaagc tataataatc    360
aaaacagcat ggtattggca taaaaacaaa cagaccaatg aaacagaata gagagcccgg    420
aagtgaatcc atgcatttat ggtcaactga tttttgacag aaatgccaaag aaacacaatg    480
tggaacgac agtctgttca ataaatgatg ttggggccag gtgcagtggc tcatgcttat    540

```

25

```

aatcctagca ctttgggatg cagaggtgga aggaccactt gaggcctccc tccaggtccc 600
ggaagagacc tcctccatga tcccttgtct aaggggaagg ttcctcagga ccttaccgtg 660
ggggctgaag gtggccaccc ctccaggaac ttatgcccca ggcgctgaat ttgggctgcc 720
taagtctgtg tgcgtgcgtc tgtgtttgtg tgcattgtct catgtctgtg tgtttgcatg 780
catgtctgtg tgtctgtgtg gtctatgtgt ctgtgtgtac acttctgtat gtctttctct 840
gtgcattttt gcatgtgtct ccatgtgtct ctgtgcatgt ctgtgtgtct atatgtctgt 900
gtctttgtat ctgtgaatct gtgtctgtgt gtctttgcgt gtctgggtgtg tgtctgtgtg 960
tgtgtgtcat gctgttgtgt gtctgtgtct ctgtgtgtct gtgtctgtgt atgtaatggg 1020
gcgtctctgt ggcaagaaga ggggtgtgtgt ga 1052

```

```

<210> 35
<211> 1451
<212> DNA
<213> Homo sapien

```

```

<400> 35
ctgtatgtaa tgttgcttcc tatctcctca ctggaatatg agcttcattg atgatgtctg 60
ttctccctag gtatctcgac taggggttcc tgagagaagg agccctgggg atgggtagaa 120
tgattcacag agacagacat ggcaaggaat gagtgtgttg atgggcagcc cggtcaccta 180
ggtatagacc ctttgaaacc ttgcacaacc attccttaga caatgtaggc caagggata 240
tggagggcat ttcaatcttt tctgtccaaa aagcaacccc caaattagtg gcatctaaac 300
agaagccttt atttttcact tgtgagtcag atgtgagtg ccctgctgat ccagctaggt 360
ttgcttctca tcaccgggta gctgggggta tagcaattcg gcttgcctag acagctgggc 420
ttcaagctgt gggccagcc ggtgtagatc ttcagatctg ctctaagtgt ctaattcttg 480
ggtgcaggat gaagtgatth agctacttgg tggagagcag aggaagatct catggcagtg 540
atggaggggc aggaaggcca ggccattgc acatgcataa ttacgtcata tctaccaaca 600
gcccatthgt gaaaacaaat cacatggcca agcctatagt cagagggaaa taaactgtct 660
tttttagagc aaactacaga ttacacagc aaaaggcatg gatacaggaa agagtgaagg 720
gttcaataat tcaactctacc aacagaagga tttcaaggct cagacaaaaa aacagatgcc 780
aaggacatgt acatcacaca gatataaac atgtaaaata ataaacttaa ctataatgaa 840
atgaagcaaa gggaaaactt gcgaagaggt gcctgaggag gtgaggagaa taggtcata 900
ttctttatgt aaaaagtgtc tgagctgaat ttgaattgaa tgaggacatt ctaacctcat 960
atgctatgtt ctacgaatct tgaaatactt gcaacgttgc tgatgcatgg tgctctctga 1020
ctctttatgc cttcaaacac actgctatct cttaaagtat tctgtcatca ttcaatccct 1080

```

26

```

atgtatccag ttaattggct aattaacttt atcttccaga tggcctccta caggaagtcc 1140
tccctagctt tttaaatcac tctaggtacc cccattctct atacacctct agcatcctgt 1200
aaatatccta ggaccctatt cgctaattat ctgtgtacat aatcaagacc gtgggtttat 1260
taatggcagg gatcagggtct taatcttctc tctattccta gggcttacag cagtagtgca 1320
cagtagacaa acaattattg gctgaataag taaatatctg aaaggctttc agcatgaact 1380
tatggaatca aaagaggcta aaggaaaatg tagaaggaga agtttacaag ttattttttg 1440
gtacagggtt t 1451

```

```

<210> 36
<211> 600
<212> DNA
<213> Homo sapien

```

```

<400> 36
gtccaccaag aagccaaatg acaacaggaa aggtgatggg aagatgaaaa caaaggaagg 60
tggacttttg ggtatatgtt atagccatgt atgtatgtct tcttttttct attttctctt 120
gttcttcatt ttaactgtcc tcagtctgcc ccacaccaac cctgtgtcac tcccagcaca 180
cataagacag agcagaagac cccatccttg agctgggtct ccctgggtat gggctgaggt 240
aacatcccac acaccaggac gatcttccct gcctcccatc ggtcacatta agacattttc 300
aaagtgtaat attataaatg gacctacctc taaatattga ctttacagtt attttatgag 360
gcactcaatt tatagctaag ggtttttcag tctagtgtca tgaaagagat aaaaggggtg 420
tcacagatta tttaagacat aaggctgggc agggatgagt cagagagtca ttctccatga 480
agtcaccctt ggccaacttt gaaaggaaga atgtttaact gcactttggg cgtaaatgac 540
aagcatctgg gaccctcccc ttccctgata cctgccagca ccaactcaatc ggccagatat 600

```

```

<210> 37
<211> 1595
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (484)..(547)
<223> n=a, c, g or t

```

```

<400> 37
tagagacaag gtctcactat gttgccagg ctggctcaaa ctctggggt cgagtgatgc 60
ccttaccttg gcctcccaaa gtgctgggat tacaggcata agccactgca tctggccaca 120
tcaacttata tataccttgt gttctaagaa gctagggcaa attataagaa tcattgtaca 180
cagtgttct cagccttggc tgccatttag aatcacttgg ggaacttcta aaactcctga 240

```

```

ttcctggacc tgacctttca gaccaattag aatctctgga ggtggaaccc aggcattcagt    300
atttttcaca gttccccaag tcattccact gaagccaggg tggggaacca tgacttgaca    360
aagtgtctcc taatccctga cccttgagca aaaggtgatt tacaacaggg atttcttaaa    420
ttttcatatg cataccagtc acctggagat cttgttaaaa tacagattct gattcagtaa    480
gttnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    540
nnnnnnngac gcaggggtggg gtaggggaca atagcaaggt tttaggtggg cccccaatac    600
aggctcttaa attgccttca tgaagagaag tgcccaaatt ccgggttagt tacaagact    660
ataactaaag gatgatgggt ttaaaataat agagatttgg aagagttggg gaattactat    720
tactgctttc tgctatagtt gacttgatac cttctttcta acctcatggc ataaatagac    780
acgccttata taggcaagac aattgtatat taactactgg gttgtgagtg catgcatgga    840
tgagtgtgag tgcattgtgt tgtttgaggg gatctcagtc ttccgtgtgt gtacaaccta    900
taaatgggac acgtggctag ggagaagtaa taggcagtgt agagccagtc tggcctgggt    960
ctcacccctga ctggcaaadc tttctcttc tgtgcttcag tttctgtatt aaaagaaagg   1020
tggggacagg ggaggcctaa ctacatgagc cccaagtgtt cagctttttt tcagcttgaa   1080
aatctatggt tgaaggtggg aatttgcaa tctatctctg tgtatttgg catcccagg   1140
gtacctctgt aagaaaacat ataaaatgta gaatttataa aaccaatcaa tgtagtagtg   1200
atttttctca tgccaaaaac ttagagggtg ttgtttgagt ggatgggtgt tgggaagatca   1260
agaaataaga gagccatttc gagttagtga tgaataataa atttgatcaa aaactccttg   1320
aaattagaat tctattctga ttgggggaaa tttttatttt acaaaattgt tttcacaact   1380
ttttggagcc caactatgtg agaatgggag actcatatat caatgggaag tgtacaaaaa   1440
gggggtaatt ggggttgcaa attcctcaaa ttaaggggtg gttaaaactt tgtgcgttac   1500
ttaatagggg aaaggttaata ccaggagttt cagggtaaac tggggggggg gagggagaat   1560
ggggcggcct ggggggaaaa gtggaaaaag gcgat                                1595

```

```

<210> 38
<211> 350
<212> DNA
<213> Homo sapien

```

```

<400> 38
acaaactgca cgcatttacc aaccagccct agaatccctg ccttagtaaa acattgtaac    60
tgaaaggagt gtcagaaccc tcaagtacat atttgaacat gggaaatggg tggtaaatat    120
tagcccaaag gcagaaagtc tattctggag gctattttgt gagtcaaaaa aggcaattgg    180
attcatcacc ccacctggcc ttggactcct atgatcattt cctectacta cctgttacc    240

```

ccgcctccag tcttcttcca gctcaaccta ctttatattt cataggggtg tattaccatc 300

ttcataagtt agaaaatfff catcatctca agatgttttt tacctagttg 350

<210> 39  
 <211> 863  
 <212> DNA  
 <213> Homo sapien

<400> 39  
 atggtgcgca gggttcttggg gacctccgg attcggcgcg cgtgcggccc gccgcgagtg 60  
 aggggttttcg tggttcacat cccgcggctc acgggggagt gggcagcgcc aggggcgccc 120  
 gccgctgtgg ccctcgtgct gatgctactg aggagccagc gtctagggca gcagccgctt 180  
 cctagaagac caggtaggaa aggccctcga aaagtccggg gcgcattcgg cacttgtttt 240  
 gtttgtaaccg ttgaacctgg acctcccttc acacagcccc tcaatcgtgg gaaactgagg 300  
 cgaacagagc ttctaaacct acctcagaag tcagagagtg gaggaccctg gagatacggg 360  
 gcacgcaggc agcgacttcc tgaaatgcta acaaggatcg taggatcagt tactgctgcg 420  
 aggagcaagc acttgcttct tgggggagtt ttgcagccaa cagggaatg ggctttcttt 480  
 gtgagttaga ggtagaggtc cggcggcctg agtgattgaa actgctcggg acaatgctcg 540  
 tatgttttagc aaacgacaga actgtagaac tgttctgag aaatcccaac tgatagtatt 600  
 ttagtcatct cagacgacag ttagcacagt taaaaatga ggcctacttc ttgaaaaaca 660  
 gaatccaagg tagttttgtc ctacattga caaatgttga cacagccagt gtaatttcct 720  
 ataaccagga aaactgaaag aatatatgta cagttaaaat atgtacaatg ctaattaaaa 780  
 cttgtgtaat aagtctaaaa gtaatttaat gaggcttcac ttttatgacc gtccttgtag 840  
 tatgcttcgc caggaatata tag 863

<210> 40  
 <211> 1063  
 <212> DNA  
 <213> Homo sapien

<400> 40  
 ggtatttgctc atttaggagg aaatccacca gactagtgtc gcaccgtatc tttcagttccc 60  
 ctctcccat cctcactggg gatgtcttag tttcaaaata ggtctcccca agaggtccat 120  
 ttattgagtt tgaatggcaa gtgcttttga aacaccctgc cttatcagca ctctataaaa 180  
 tgttctcggg tatagcatcc ttttgataat atagttaatt aacaactgat gttacagaga 240  
 ttttaattgt gagatcaaaa ttaagcaaag agcaatggaa tagaaagagc acatttgtag 300  
 ggcttaccat ctctgcacat gaaaccaagg ctcaaaatta ggattcaaag agaagtgtaa 360

29

```

ctgttatttc agaaggtgga ttcatacagc aatgagatc agtttcatca gcatgggtca 420
tgaatacaca ttcctagagt cccagatttc tatctagtga tacatactct atccttaaat 480
taaaaaaac aaaaatagat caaaatttta aaacctgggg tgagagaaga aagagactta 540
agagaatgag aatatgcctc tgtttccatt tactttccct ctgtctgtgt ctgtccaatc 600
ttccacccca agaacaccaa ggaaatcaat gttgtagacc cagattgaat ttaagatttt 660
tgaatggaag gaatgaaagc acttaggtgc attttctctt gttggaaact gattttaaaa 720
ctttttatta cttacgttta gggaaacatt tgggggtggg tgcagaaggg tataatatatt 780
atgttatttc tttgtttaca aattgaattt tagtgcatac ccctccttct tccaggaagg 840
attttaagct tctaaataat acaaatcaat tcagttcatt taaaaaatag tcctactcat 900
agcaaagtgt atccaacat aataaattga atatttggt attgacagtt gccctccttg 960
gcaaagcatg caatatgtgg tgtctcacca aggaagctca gtgatgatct acttcccgtg 1020
gtgaatgggc tttggaacga aatcaaagga tacattttag cag 1063

```

```

<210> 41
<211> 392
<212> DNA
<213> Homo sapien

```

```

<400> 41
gcacgaggca aaccagataa ggatacaaca aaaaaaaga aaactacagg ccaagatcat 60
tgatgaacat agatgcacaa atcctcaaca aaatactagc caactgaatt caacagcaca 120
tcaaaaagat cattcaccat gatcaagtgg gtttcacccc agggtgcaag gttgattcta 180
catatgcaaa ccaataagta ttgaaatgat cacatgattt ttgttctcag ttctattaat 240
gttcttgatt ctgttaatgt tctgttcaca ttgcagaaaa agcatttgac aaaataattt 300
cagtagctgc tgaaaaagca tttgataaaa ttcagcatat ctttatgata caaaaaacct 360
tcaataaact gggataaaa gaaacatacc aa 392

```

```

<210> 42
<211> 438
<212> DNA
<213> Homo sapien

```

```

<400> 42
gtccgtgtgt catggagcac ctggagtgtt ctgtctggaa tgctggctgg gagccttctc 60
ctggcatttg aacgaggggc agctgtgtcc tctgtttgcc gtgtaaagaa aagaggacag 120
agctcagagg agatgaaccc cagcagaaag ggggtgcttg ccagcaggag agaagataac 180
caagagggtc tgtgggtgtc tcttctgagc tacaccagtt tccaggttac ctgggacct 240
ggataactct cagatcagca acttgtcagt tgatttccaa gctgctgttg gctggactca 300

```



```

gactcagcag ggagcacctg ggcgagccct gtgctgcggg ctggactccg gcccatctcg    360
ctgattactc ttgcttttgc tccccagtgt gtectcaaga ggtcagagcc tgctttgttg    420
tttcttcatt accacggg                                     438

```

```

<210> 43
<211> 171
<212> DNA
<213> Homo sapien

```

```

<400> 43
tgttagagaa ctaaggaaac cgtcctctac ctgccacata agaataaagg aaacaatgga    60
acagtttccc tactttccct aattaacacg tattcccatt ttgaggcagt gagttgctgg    120
tacctgcttt ctctttcttt ctccaaatag tactttaaaa gtatcttatt c          171

```

```

<210> 44
<211> 869
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (847)..(847)
<223> n=a, c, g or t

```

```

<400> 44
atrtcacctt gttcaagcac agggatatta cactttccca aaattaaaaa aatgtatatt    60
tcgtttgatc tgatgcttgt ttggggtttt tgaaaatggg gttgcacctt gagaaattga    120
cagtatgtaa agttctgatc ctgggtgatt tctttatagc ttgacatgtg tctatgtaat    180
gtgtgtatgt ggacatgtat acattggaag gatTTTTGCC tgcattgctgc tttcatggtt    240
aaactctttt ttgagatttg cattgcatta aacaaaaatg ttggcattct gtcacataa    300
gcacatgaaa ataactctggg ctgcatcttt cttagagggg aatgtttttg attgttggag    360
tatttatatag cttgatgtgg tccagaagtg aagtaactct gtatcaatga gatagcattg    420
taatagcaag ccctttagta aaggtttagt gtaaatatct gactggtagg ggagctggtt    480
tctggaacag ttgtgcctct gtgagattac gaaaatggac gagaaagaaa gggctgaact    540
ctaattttcc tgaaattggg gcgtgggtgt ggagttgtag ccaatactgg gttgagatgt    600
gctgcaagga agcctggagc acaatagtcc ctgtccgggt ccccatgtt gggcactggg    660
aagcggagtg tgttttgcta aaaggaagaa agtaaagaga agaaatggct aaggcttgta    720
gtaaacgaac ttaccataa atatcaataa aatcctatct cccaggcata tgccttcgag    780
tgctttgatt gtgcatgtca gagcactgca aattttgacc cagtgggttaa gccctttcct    840

```

31

agtatntttc gtgtacagga ggcacagct

869

<210> 45  
 <211> 537  
 <212> DNA  
 <213> Homo sapien

<400> 45  
 aatgggccat tgctaattgtg atagtaaaat tgcaatatag cacagtaatt gtaaatttac 60  
 ctagaagttt ctaggatcat gtgggtacag tactactgca ttttttctta aatcctagtg 120  
 tgcataaatt cattaggttt gcttttctga ctttgatttt attggattgc taattttgaa 180  
 aatgggtatta atccacaagt atattatgat ataaatatgt tattactgtc actttcaccc 240  
 tgatttctgt ggatttcaga tgcttttttt ttttaagttt catagtgagg attagcagag 300  
 acatttaaga acatggcaga gatgtgtgaa tgagtaaact ctgtcttcag tagcccagca 360  
 ttctgtcagc actctccaat acccatcttt atatcctagc atgagaactc gtgtttgtgt 420  
 attctgtctgt ctttaagggg aaatgacaca tctctcagat aagttaccag ggcagtcttt 480  
 ttcatatggg gcattttcta tagcaataac ctgctaacac tctttcttta aaaataa 537

<210> 46  
 <211> 715  
 <212> DNA  
 <213> Homo sapien

<400> 46  
 gtgaccatct tgctctcccc tgaccccaga ggccctacga tctggcctca gcctcctttg 60  
 gatccttatt tctctctgca cctgcatccg aggcaggagc ctgttcccgg aacacccctc 120  
 actcagctgc ctctgcagtg ctgctgcaga cccgcctgc tggaacaccc tccccccac 180  
 cctcactgca ctccccccac ctcatccctg tttcacaccc tttccttagt gctagccct 240  
 cccagccttt ccctggaatt ccgctcctgg ctctgcccgc ctteagtgt tgcctctgggc 300  
 tgagctgggg atatgaaaca ccgtaataat gatgtgtgtg catttcttgc ttcccaacta 360  
 gcftgtatgt ttctgaagg caagaacttt gtcagggtca tctctgttcc tcacagcacc 420  
 ctcaacgtcg taggggctaa agacagggtt gtgaaataat ggtaacacaa ggtcaggcag 480  
 gtcaacagct tagtaatgtc agctcagcaa tttgatcctg cagtgggcat cacctgcgtc 540  
 agatgtggag cactgcgggg aagggtgctt atgttccaga ggcagcaagg gacatctgag 600  
 cccaggcctc agacttgccc attttgatag cacctatggg gggttacatc tcttgagctt 660  
 ggtaagagat ttctaaatat cggagaaaag catttagaaa ccatcctgag gttgg 715

<210> 47  
 <211> 2201

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 47

tagagtacta atatttcttt attgacatca aaaaggggtg ggaagaaaga attaaactct	60
tcttaatttt ttaatcctat acttaaagaa ttaaaggaat gagtttgacg ttccaagtta	120
atctgtgttt agtttgagtg tggtaacaaa ctgggatctg aagctgcac atttttaaac	180
cctcactgtc actttcttta gcatcacaga tgacacggtt ccctcgctca cgtcatgcaa	240
gttctcctcc tacccttttc cctctttctg tactaattg cactctctct catgatgcaa	300
ttcctgtggg ggactctgtg ttccagaaaa taaccattac tgtttacatt ttaaccatt	360
cttgatattt gtatgcattt ttcaaaagaa aaagtagcac tagttgtcat ctttaaggct	420
ggggatttga aagtttttgt tttaaaatat tttttgttcc ttttaacaaat ttcgactcag	480
cagtgaagac aactgcctgg gtctactttc acccctgtaa catattcctt gggtaatgta	540
ttgaaagtta acgtgaccca tccacattac ttccatttga aatacagagc agttcagccc	600
ttgggggtcac cttctccctc ttttcccccac tctgccctta ggcaactcca ccctgggtctc	660
tcccctgcct atgttcttgt tacctctctg cagccactcc aaaggcagcc tcagatcaga	720
attcctcata cctcccttgc tggatgaact aaaatatctc caaagtagca gcaaatatgg	780
ctgtaaaaaa gtccatgcaa aatgcagatg cccttcttgt tgctgtgatc ttctgaaaga	840
aatgggatca cggcctcctc tgggctctgt ttgttagccc tggaggggag ggggcaaaca	900
ccacagacat cttgctagct tctcccaaga gccaggaaca tgtcagctct cagcaactca	960
actcttcctt ttcagatata tctgggtctca gggccaggca tcacacgaat aaaaaataag	1020
tacagtagag taaaattttg gctaataatg actgttcctt actcagagtt ggtaggggtga	1080
ggatacaaaa agccatagaa aagtattgat actctataat aaattacaaa catatcattt	1140
aatgttattt ttaaaaatgg agaataaag cagtgaactt agcttaacag tgaaattaat	1200
gtgcttatct tgacttttgg aaggaaaatt tgaaaggaat ggtaagctg ccaccagta	1260
taaaatgggc agccataaga ggggctgaat gtagaccag acagaccacc tagccttctt	1320
tcccatatca cccctttttt agtgggtgaaa acaaaacacc aggtaccacaa gaaactgcc	1380
ttcctgttta atgtgcttgt gactttatga tccaagagtc acatatccag gaagaggtag	1440
ccaaaaatct agtgctgcag aactagtta tagcagaata aactccatgt atccaaaata	1500
aagcagcatc ttaagtcagc ctaagcacca gtgttgagaa actaggggtc cagagctgcc	1560
ctttctggga atcctacagg ccctgcgagc atgagacgga cgtgagcagt tgatacat	1620
gagcagtgat ttgaagcatt actttctggg ctttgttatg ggctattacg gtcaggtgaa	1680
aatcatgggc atatagtgtgta aaccacggcg aacactcatg aaacgtaaac acacagttgt	1740

```

tacgaaaagc acatttaaag tattattaga cgttaatttt ggactgggga ttctcagcga 1800
aacctgtttc caaaaggggg tgacctagca aggggtgccc acatggggta cccgggtacg 1860
ataggaaaacc tcacacgaac actgggacca ccgaaacgca ggcgacagga cggaagaagc 1920
gggggtacac gagacaaaga agaaacaccc ggaagagcga ggctacgaca acaggaagat 1980
ggccaacggt aagaaacgca ccaagaagta tcacagatag acaaaagaag atgaaagaaa 2040
gaataagaaa acgcgaaagc acaagtacaa cagtggcagg tccaaccaac aggtaacgaa 2100
aacaagagta gaaacgaatc cagcaaacaa caagcaagac cacgagcgat catacataag 2160
aggtcctcct cgcttgcttc gtttcccgct gtcgtagtgg g 2201

```

```

<210> 48
<211> 522
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (428)..(428)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (479)..(479)
<223> n=a, c, g or t

```

```

<220>
<221> misc_feature
<222> (506)..(506)
<223> n=a, c, g or t

```

```

<400> 48
cgtcgaccag attcttgtgt ttcacagaa gacttggttt ttgtactttt ccctatccct 60
ttaatcattt ggttatgatt tagttttttg gaatctttta ttttgaaatt tctttggaat 120
ttgttctttg gaaagttttc aaattatttt gaccaagatt gaatgtaata ccagtagttg 180
cttaactagt gcttgtttgt tttcttgttt ttgctaactc atcaagatac tctcttacct 240
gtgtctttta atactacagt taacacaaag tttatattta ttcatacaga tataaaatca 300
tgctcatgca ctttcttgtg tttggatttg tgaaaggaag tctttggttt tttttttttt 360
gagaacgccc aggtagaatg atttgtactt gttaaacgat gggatcaact aagacaggtc 420
agttttcnaa atgagtaatt gcctgtccag taccaaatga ccagtgaggt ttggagtcnc 480
aaagttttcc tgagccccct gcaagnccca aatagcagta gc 522

```

<210> 49  
 <211> 406  
 <212> DNA  
 <213> Homo sapien

<400> 49  
 gctcgaggaa ccactgcgct ggcaaggatg tatcattgat gcttaacttg cttatcattt 60  
 cccactgga ctgtaagatc tatgtgggca gggacaagat tgtgtctgtc ttaatagtgt 120  
 ctcctaagcc cctagaatag tggccagatt caataggcat ttgataaatg aatagaagaa 180  
 ttaataaaca agttaatgag tttcagttat gaaaatattt gagttttaat tttaaaccct 240  
 atgtaaagca tttattctat aaagtagagt tgcataataa tttcatgttt tctatattga 300  
 acttaatcat gtaccactta aactaaaata gtaaaacagt aaatattaat tataacttta 360  
 ttattttattc taaaaggatc aattctgtaa aacttaagtt ttcttt 406

<210> 50  
 <211> 2898  
 <212> DNA  
 <213> Homo sapien

<400> 50  
 atgggccaag gtaaccccta aggggttttc ttaggcttct tggagcttag atttgtatgt 60  
 atatcaaaat gtctttaaaa tgttaagttg ggcagaaggc agttgaagtg agctttcaag 120  
 gtatgggagg ttttctacat tttatactat ttcaatctat gcctttaaag ttgcttatga 180  
 ttttagctgt acactcattt ttttaaggga agaagtttcc ttggaccatt cgcctttctt 240  
 agatgtcttc actccctgtg atctcataaa actgcctatt tgacatctct atctagaaat 300  
 ctaattaaag ctcacactca gcataatcaa aactgaattc ttggtcttcc ctcccaaact 360  
 tgcttctcct tcagtcttct ccaactcagt aaatggcaat gccatacttc tggttgctca 420  
 ggccaaaaac cctgaagtca tccttgattc ttcttttagc acctatatcc aatccattag 480  
 caaatctggt agaccctacc ttcacaatat atctaaagct gaccacctct tttgacctct 540  
 actattaacg ccctattcca agccaccatc atctcttccc tggattgaag ctgtcatcta 600  
 caaaaattct tcttatatcc ttgcattcct acagtctgtt ccccataaag tagccagaat 660  
 gattattttt aaaacaagtc aactcatacc attcatctgc tcaaaacat tcattggctt 720  
 ctcatctcac tcagagcagt caaagtcctt aaaagttgca ggcctagact ccctgtccta 780  
 cctcaggtag caccatatcc cacctcctca tgcagctcca ggcaccttgg cctcagtgtc 840  
 cctcaaagca tcaagtatgc acttgccttg gacagtctgt acttggattt ccctctgcct 900  
 tgaatgttgt tctcccagaa aaatgcatag ttcactctta catccttaag gtgtcactcc 960  
 actgttacct gagcaggctg tccttgaata tatacatcag cattcccttt ccccccctgt 1020

ttatgtatgt ccatagcact caccacgac	tgactttact aagtatttat tcatttactg	1080
tttggtttcc cataccgaaa tataaacttt	ctaaggacag aaatttttgt gctttattgt	1140
tgaatctcca atttgtagaa aaatgcctac	cttatattaa aacttcagta aatgtttatt	1200
gaacattaaa agtattacta atagaacttt	ggtttttgaa agaaataata actttaatta	1260
taagacgtat atgatttttg cagttttact	tagtgtgaca ttgggtttat gagaatcgtg	1320
tacattcaag tccaggaata ataatggta	tccaaattgt ttgaaaggaa aataatccca	1380
gtggcaaaat gatggtagaa tttgggtaat	cttttttttt tttttatgaa aagagatttt	1440
attgaaggta aaacattaga ggttcattga	gaatctctaa atccatgttt tgacattgtc	1500
aagctcattg caacttcag attgagtaac	acttataaca catttccttt tcaaagtga	1560
agatttttaa aagagacttg tcacatattc	atttggctgg tttcaaagg tgagctgaat	1620
gctgggtaat ctctactagc tccttaata	ca gatttaaaat tctcagtgtt tcctagtgt	1680
ttctgcatac tttatgtgag ttgttatagc	tgtaacatta cactttattt gctgtttgtg	1740
tttcgtgact tttggtaatt ctggcattta	gaaacctttc actttgcttc aaaacgtagt	1800
tatatttttg agttttcatt tgatatataa	ttatttattt tgccctttta tttcccaaag	1860
acattgtaag ggttaattag atcattatat	tttattatta cagattaaag ttgggcagta	1920
atcttaatta tgatggaatt atcattatgc	taagtaatta actttaccta gtttgtttta	1980
caactagaac ctgccctaaa tgttgaatat	cttcctagca agaaacagtc tgtcatttta	2040
cttacacgat gtctaaccac accataactt	tacataaaact agtcgtttcg gtcaaataga	2100
aaaatgtgtg aatgccataa aaacaaaaat	tctcagttta atgatactgg gaaataggga	2160
agacagcaaa gtgagacttg ggctcaggat	ggttcaggaa aaaaaaaaaa aaaagacccc	2220
tgagtacat taatattcct cagaaattat	tatttcaaaa ggaaatattt ctgtattata	2280
aatttttcat gagcagccat tatgaaatct	cacaagaatc atagaattca ataaaaaagg	2340
tagaaagtaa ttttagatac ttaaacacta	taaattaaac ataaacattt ctaaaatcat	2400
aagcacataa atagaactta ccaggccaga	aacgcaaaag ctgaaggcaa ccatatctat	2460
cctgttcaaa aatgtgaaac ccaggatgat	ctctagaatg agatgcgcat gaatagagag	2520
gagagaaaaa caaaaaaaaaa aacacaaaca	accacaaaaa agaacaaaac aaacaccaa	2580
ccaagataac accggaacga taaacagcag	aaacagagaa aaaacataag accatataag	2640
ccgggaaact aaataaacac aaaaaacaga	aaagaagcta aaacaaggga aacaagccta	2700
agaaaaaagc gagaacagaa gtagaaaaca	ggaaaaaaag cggaaaaaa caagaaacaa	2760
caacgagata tagaaaacaa gcgaataaag	agaaaaaaac aggaaaaaga acaataaaaa	2820
aagaagaaaa aaaaaagcac aaaaaaaaaa	aaaaaaaaaag aaacaaagaa aaaaaagcag	2880

agaagtatat acaacgaa 2898

<210> 51  
<211> 678  
<212> DNA  
<213> Homo sapien

<400> 51  
gttggtggttt gtcagcagtt tacatattaa tattaacaaa agggaaaaga cttaaattatt 60  
gtttacagat tatcttattt tacaatgaga aaacctaaaa cattaattaa gaggtcagaa 120  
taaagtggct agatacatta aaatcagcat gtaaaactgt gatgaggaaa atggtgcatc 180  
ccagcttggc tgtgataaga tcttaatgac aggacactgt cagccaatgc ccagagacag 240  
cctgggcatg taagccccct gagaagctct caagggtttg aggagaatcc ataagcagtt 300  
aaattctgtc ctttgataac ccttcattag ccttcctagc agcagactgt ctagactgac 360  
ttctttgctg gacatgaacc aataagttaa cccagaaaaa tgtgcaaaca aaattcattc 420  
tccttgacta ctttcagttt ttctgtcttc ttctctctac aaattctggt ttttgcttc 480  
ttttcttgac cacagtctac tgattttttc ttccttgat gagtaaata gcatgcatat 540  
gacaaactaa agattatgct atatcaataa tcatttggaa aataatttta aaaagagatc 600  
acattgtaaa aatgaatcca tcaaaatcta aaacccccac ctggcatgaa tttcaataaa 660  
aggtcttttt aaaaaatg 678

<210> 52  
<211> 1107  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (764)..(833)  
<223> n=a, c, g or t

<400> 52  
aatatgaggt gggaaaaaga aatgaaagga gccacatgct ccttcctgcc actggtactt 60  
ttcatatgct tttcccactt ccttctctgt cccccaattt cacatcatta actcccact 120  
catcattatt cattgaccga gtcaaatccc tactatgtgc tcttgtagtc atactttcct 180  
caggtataat tttgcagttt gggggtggtt atgtaataaa tatttccac attggactat 240  
aagcctctat ggcagggact gtacctattt ctgctcacca tgatattccc aacgtgaccc 300  
tgcagtaggc tctccatcaa tatgtgttta attattgaat gaatgtactg agtttggtt 360  
tgttcaaagt catactgatt taaggacaat ccataatgaa atccatcact tacaacaatt 420

37

```

catgctaadc atatgattca cctgtgtaac tcattaaaag ttactactga atgtacaaaag 480
caggggaaaag aaaaacaaga aatagaaaaa aaggaagaag gctgaactaa agcactaatt 540
ttataggttt agttttgtca gaatttagga catttggaat cctaactta aaagggaatt 600
tatagatgtc tgttcatacc ttgtacagga attccttgta cagcatccct gtggaagggc 660
attttaaccc acattcaatt ccttcagtc taagaaccag ctccaaggca gcttgctctt 720
ctagctccgt agtagccacc ctgactacat gtttgaatca cctnnnnnnn nnnnnnnnnn 780
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnngaggca 840
ggcatcatag tgtttacagc tctccagatg attccatgtg cagccaggtg agctgctagt 900
tgggtattta aaaagccctt cttaggttaa tttcttaca agattagacc gtgtctttgt 960
atcctctgca ccaaacagaa gtatagtgg tcttaaactt ggtgaataaa tgtacatctg 1020
cttcttgtaa tttatgtgtc tggccttagt ccaacattct gaaatgacag attgcccact 1080
ccagtaccag cgacagactt tgcaaca 1107

```

<210> 53  
 <211> 816  
 <212> DNA  
 <213> Homo sapien

```

<400> 53
attctagtat aatacatcat tgaccaaadc tcttccttta gtttttctga ggtagtgcac 60
cccatataaa aagtctcttc aattagattt ggcttttagt tagaaagggg tttggtaagt 120
catgtcttcc atatgacatt tctactcatc cccacactgc cttccactta acctgtacag 180
acgagccctt acacatgcac atgtgtatac aactgtatat gcagcagcca gtgggctaac 240
aaatatcagc aaagaacttt tttaaaaaga atttgtaata atccgtgctg tctagaaatg 300
tgagttactt accttattag gaaaccggct tataatacta tatatgactc tgcctgcatt 360
ttatagttaa gaaatgtaca taaaaattgc tatattttca cagtttcatt ataatgtctg 420
tttagtaacc catgtccact gatactttaa atatgctaac tactgagcaa ttgcaataga 480
aatccagatt ttcataagaa aatgaaatag aaggatactg catcttttaa aaatagagtg 540
aagatatttt actgtattcg taacatatgt gatagtggaa aaagtatttt caaactcaca 600
aattttacag aggttgtaaa tagtttgatg aagtatgttg ggaaagagag cttctagttt 660
tcatcacaat aaaaagaaaa aacttggtca gatatgcctt gtatatctta cacacaatga 720
gtgaaattgc catgggaact ctgtccaact ttgtcagagc atgctcttcg tgttctgttc 780
aaaatagagt ggccacttgt catggtttag ccagga 816

```

<210> 54



<211> 640  
<212> DNA  
<213> Homo sapien

<400> 54  
ttatctgtat gtatatacat atatgtttgt atgtatacat acccacatta acattttatg 60  
accctgtaac atttgttttc tattctttta ggtgatgtga attgacctca gtgaagaaac 120  
atttcattta gtctaagcct tgcattcagg gtcttacaac agattttcttg tgcaagaatt 180  
attattagtt aaaatggaag gtgttagttt aacaaactga gagtcaaatt ttctaagttt 240  
ttaaatatgc attttaacat gcattatttt tggcatttaa tttaaaatag ttttgtttca 300  
tgtatacaac agctgttaca gatatatgcc agcaatattc atactttttt aacaagcttt 360  
tgttatatat tttctaactc ccataaaagt ctaatcatct atgaaaaaga tatttaggga 420  
gaaaataactt gttttctgta ataaaacaat taggttggtg ccatgtatgc caagttggat 480  
aaaagaatac aaagaaacag ctgaagggtt tgggagctcg ctctgacatt aattactaga 540  
aagcaaaacta aaatgcaaag tgaatagtta actcagagat tgattttgag aggggccac 600  
ctgtccctag gctaggtgca gtgcatatca cggctcactg 640

<210> 55  
<211> 404  
<212> DNA  
<213> Homo sapien

<400> 55  
cagagaaagc cacatgatta ttaatcgctg tataccatcc cgggtgttctt gtgtgctaac 60  
atgggaccag tcccgtaatg actgctgttt atattgtgtc ccactttcca gtaataaaaa 120  
taacactatg gtgaacatct ttttgtaccc tgtgggatga aagattctca gaagtagaac 180  
tgcagagcca aagaatatgt acatttttaa gattttgagt aaaagctaca aaactgcca 240  
cagagagtaa taatttgcac cccccagcc atgagatgcc agtttcttc accctcaact 300  
gccttgatg gccacgtag atgctaaaat ctaaacagcc caatcaagaa atacttatta 360  
acagagagat ttgaacataa ttgatttggt atggtaattt tttt 404

<210> 56  
<211> 1350  
<212> DNA  
<213> Homo sapien

<400> 56  
catccccctt cgtgtgttac aaagatataa gccctattct catggagctt actttgggag 60  
tggtgatact caacagactg taatttgaag tagaagcaat taactttgtc gataggttct 120  
tggagatata accttaaaca aaatgagtat attgcagcct ctttgtggtc atgcaatggt 180

39

```
ataagtgaaa ccatgttgaa agcagtggca ttatttgagg acctgctgtc tgcggtttca 240
cttaaagtta gttttaaaga atgtattgac cacattaagt gaggatctac tgtaatctag 300
ggatggcccc tggagaagga aggtagcatt taggttgaag tttgtgggga tggggatagg 360
taggatttgg aaagagagag gggcagagag tgcgcagggg agcacttagg atggaggaag 420
tgggaatatg cacagagatg aatgggtggg agcaatctgg tttgacttaa gatgttactt 480
acatacgtgt gtaaagtagt aggttaatgg gcttaacttg agaggatatt ttgggaccag 540
attataggca actaaagttt tttatatatt tagatagtaa gaaacctga aagtgttttg 600
agacagaatg ttgagaaaca tgatgaaaat tgtgatattg gcaattaatc tggcctttgt 660
gtagagattg attggagaac agacaccatt agcaacatgt tttagtagtt tgggtgctat 720
gccaaaaaca actggaacag taaatggaaa gagtgggacc aattcaaggt aaatggggtg 780
gccaaacatt ttgatgatta gagactatcc tgatttaggt ttgaagcatg gttattatta 840
gtgcccatTT ttgcttttaa aagttttctg ctttggacaa taaatcatat ggtgacccta 900
aagatagatt gctgtagcat tgatagcact tgctaattag attgaaagga gacagggatg 960
gtggtgtaag agagcagaat atacggtttt ttagaagtta ttatttcact gagttttcat 1020
atTTTgaaga attaaacata aaatttcctt acctaaattc tgtaatcaaa tcttgtatgt 1080
ttaaatttat ttgtgtgcac atgtgcacgc gcgtgtgtgt atgtgtgtgt ttaacgaaca 1140
catttgagtt cttggaatat tcagcaaaat gatagttgct ggctgggtgc agtggctcac 1200
accttgtaaa cttagcactt tgggaggctg aagcaggagg atcacttgaa gccaggagtt 1260
tgagaccagc ctgggctaca aaacgagacc ttgtctctac aaaaaaaaaa aaaaaaagtc 1320
gacgcggccg cgaatttagt agtagtaggc 1350
```

```
<210> 57
<211> 824
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (184)..(468)
<223> n=a, c, g or t
```

```
<400> 57
atcatctcag gtaccaaata gacagtatta tttaaaatcc ccctttgaca ttttatgtc 60
agtttttcag accatggaaa tctacaccta tgatgctctt ccaagatcac tgggcatttt 120
ttttagtatt agtaagtgc ttatttaatt tgcaattctc aattatttca tttatatgta 180
aacnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240
```

40

```

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    300
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn    420
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnntg tgagccacca    480
tgcccaacca taaacatttt ctttctttct taaaaagtta gttactcatg cttagtgtg    540
tctagcgata cttgggtttg gttgggtggg tggctttatt aactaatccc tcacagacct    600
caggggcttc agctattccc aaagaattag ttgtagtaa ttgttactct ttttttcaca    660
cattatttca gacagcaaataaacattgat tgtaagtct ctaaccacta acaagctagc    720
ttagggtatct caattcacct aactacagt acctgacatg ctagttaac tgaaaaaagt    780
agtatcaatc tgtaatcagc tcttttcccc caagatccta ccct                    824

```

<210> 58  
 <211> 832  
 <212> DNA  
 <213> Homo sapien

```

<400> 58
gagggttctcg gagagagagc tagtttcccg gttgcgctgg ccaaaggccg gcctgaactg    60
gatcctgcgg accgcttctc agcggcttca ccccccacacc actcgaatgc acagatcggg    120
acacctcagc tgggtgactt ccctcggtgc aatcggcctc gggagcggtg cggcgtgtac    180
cgagcggcgc ccctgggctc agcgcgctgc aggcgccccg ggcggatcct tcaccgaggc    240
aggactgggg ctggcgccag agccggtgcg gagcgggtgt gggttcaggcg ctggcgacag    300
tgctatggcc acggcagggg ccgcgtgcgt ctccagcggg gcgccttcgg accctattgg    360
cgccccgggac ttaagcgggg ccgcgctgc tggaccagga cgaactggag aaggagacgc    420
gggccgccac ggtgacctcg ggcgtagggc cggcgcgggc gggcacgctg gtggaagcgc    480
gggccgcggc aggggaggac atcggggcgc agagaaagtg ccgatggcct ggggcagcgg    540
tgcgaggggt ggaaaaacgc aggatattgc atcatagaga cgcggccacc ttcgcccctg    600
gagagcgcca gtctcaggag cgccgcaccg gtcacgggtg gaggtcagcc aggcctccgt    660
aagcgcggtc cccttcagg agtagccttc gcctgggctc ttgagtagat gccaagtaat    720
tccgcacgt ctctctagat atctgcgcta aaggccaccc ggtctcctta tcagaggggg    780
aaaactctcc tcgtgggtct tcatacctaa taaaagtcgg catcaaacca ct                    832

```

<210> 59  
 <211> 534  
 <212> DNA  
 <213> Homo sapien

41

<220>  
 <221> misc\_feature  
 <222> (143)..(169)  
 <223> n=a, c, g or t

<400> 59  
 gaaaatgagg ttacacagagt catttacttg tagttagtca tgatttctat tatattgaag 60  
 aaaaacatat ccattgttta gtttacctac tagagaaaat agagttatat ggcttcagtt 120  
 cgttaagtta ttacaaaac cannnnnnnnn nnnnnnnnnn nnnnnnnng caaatacaag 180  
 tcctggactg gtaggtatga acttaattgg agcaattttc tgtacagttt tccttgagtg 240  
 gaggtaacta agtagcttca gtataccttc agattgaatt ccagctcatt gtagcggag 300  
 aacatgggtca gctacagcta tgtttcgaga tcttggttat ttaaagaag tttccgctgc 360  
 agttgtaaca gatgtggaat tactctagtt agcaaccag gggggttaa tcgctaaccg 420  
 gtctctgtag ccttctggtt acggaaaatg gctttccatt ctggaacacc acagaatctt 480  
 tcttagagga atcctcttta aagtgcctaaa tcgtgatgcc tgtgtccctt tacc 534

<210> 60  
 <211> 1780  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (1036)..(1073)  
 <223> n=a, c, g or t

<400> 60  
 gaccgcttaa taaagatct tttttttttt ttttttttg ccattggtag agcaaattcc 60  
 agtgggtgga aatcaagaac tctaaagttc agtagagaca ggtgttttga atgtcaagga 120  
 aatcactgag gtagatttgg gattacaata agacagctgc cctgtgaggt cataagagct 180  
 tttgtgaggc ttactccagg ggttctcagt cttggcatta ctgacatttt gaattggatg 240  
 tgttcttctg cctgatgtgt gggttgtgta ctgtaggatg tttagctgca cccctgaccg 300  
 ctatgcataa atgccggtac tgtcccccga agttgtgaca accaatgtct ccagacattg 360  
 ccacatataa cctgggaaaa aaaattgccc caagttctga gccactgggt agaactaagg 420  
 gtagtttagg gacaatgtta atgaaagcct ctccaaagtc ccatagtctt ttaataaatt 480  
 aattctgcag aatttgctct ttaaaaacat atttttaag gcaagaccag cctattcata 540  
 aaaattgcag tggtttccac ataagaactt tggatattta aagaaaaatg taatttgaaa 600  
 tgaaaagccc ttataaatcc ctttatactc atcagtcatt ataacagtaa atgaaatgaa 660  
 gaaaagcat ttgatctcac tcttctgtgc tgatctcttt aactcctgaa tctcctcaat 720

```

ttgatgagcc cactatccaa tgagactgga tagttatcag cacaattgat tcatgggggtt 780
gagatgttta aatctccttc atatttaaaa tgatcgattt taaacttgat gatgttaatt 840
cttcttagtt cctggtaagc agctcatctt agtgctaagt acaagttcag atgttaaaaa 900
aatctttatc atttatggct aattttatcc ttgccaaat catatctatt ttcttcaaga 960
gagcaaaata catttcctga ttttaaagta ttctattttt aaatatatct tcacattcct 1020
gtagtaaaag actgcnnnnn nnnnnnnnnn nnnnnnnnnn nnnctgatgt 1080
agaaaaaatg aagaacatg acctgatttg aattttgagt ttggatgaat gatcgcgagc 1140
tgcatgcctg ctctatagaa gtcatgcacc tgataaagtg tcacgtattt gtgcttctta 1200
gtttattttac ccttgagtag ccacaggtag aaatgagggt gtcaaaccag gaatttagtt 1260
tctcaagtgg aaattgcatt gaaagataat cctcaatgta atctgcatgt tcttaccat 1320
ctggagttta gataatgcag acgagtcatt ttctgggtgt tctcttttca tgtgttttat 1380
ttcgtacctt tttgtttaca tggaactttc ttgaatgttt gctagatgat caactgtcac 1440
ctcttagtac aaagccatgc cagacactgc acctactctg cactctaattg agaacaatcc 1500
ggaaaggatg attttcaagg gagagtgaac tcttcctgga gatctgaggt tatgttacag 1560
tattgtggag ttttgttgct taaaattctc ctctgtcct cacaggcaat ttgctagag 1620
ttgcaatcct cacatttgag agaactgtca aaactctaag acataaagtt taaataactc 1680
attaataatt gcatgtgaat cccccagtaa tgtatgtaca tgagcatacc tttcaaagat 1740
gttcaatggt gctgtaata aaattttttt aaaaaaaaaa 1780

```

```

<210> 61
<211> 382
<212> DNA
<213> Homo sapien

```

```

<400> 61
tgatgtctta gaaacaagcc ttaaaagatc ttaatcttac tcttgctaaa ttagtataa 60
gtctaagcca gcctcagctc ttggcctgag attactagtc tccttgtttc tattctacat 120
gtattctcta cacagcagtg agggtaatca ttgcaagtaa aatattgtct tacttatttg 180
cttaaatctc tcccatagtt tccctttaca cttagagtaa aatccagacc ctttctcctg 240
atctgtaaga ttgtatgcag tctcttgctt ccttagttct tcacccatgt tacctactgg 300
tactctactt gtctcctgat ttagctacac cagcatcctt gataaattat tcaactgctt 360
atcccttctt atcattcagt gc 382

```

```

<210> 62
<211> 969

```

<212> DNA  
 <213> Homo sapien  
 <220>  
 <221> misc\_feature  
 <222> (949)..(949)  
 <223> n=a, c, g or t

```

<400> 62
cctttctcct gatctgtaag attgtatgca gtctcttgcc tccctagttc ttcacccatg      60
ttacctactg gtatcctact tgtctcctga tttagctaca ccagcatcct tgataaatta      120
ttcaaaaagc caagctcatt cctcatggcc ttttagaatt ggattataaa gaggggtgaac      180
tgcttatccc ttcttatcat tcagtgtctgc tcaaaagtta tcttctcagg gaagattttc      240
ctcaccattht tatctaaact atgggtctttc tctcccaaact cactgcctat cctgtatgct      300
gcttttaatt tcttcttagc atatatctga aattatatta tgtatttgct aatgggtcttt      360
tccctattag aatgtaagct ctatgagggc aaggactctt gtcttggtta ctgctgtatt      420
cttctagcat aaacacacac acccccttag aacaattctg gatacacaat agaaattcag      480
caaatgtttg ggtgaatgaa atggccctaa aatactattht taaaacttgt tttctttcca      540
ggttatattht tcttatttaa tgtgtgtaaa aatgtgggtg tatgaagtht tttggthttht      600
aaaccttcaa tagtgagtht ttgtgggcac attgtattca taagagctgt taattctagc      660
cataacttht aataaatgta ttggttgctt gtgtacatga ctatctgtaa gtaaaatgaa      720
ggctctcttag aagttaatac agtttaacct taaaatctgt tctaaaatta tttgacattht      780
ttctcactga ataagaatga gaaggaggaa gcatagtgtg gaaaagtagc gtgcagggtg      840
gagtgggtact ggattgtaat tatgtaagtht aaggaaataa catgctttgc ctattccttg      900
tcacccttht tttctgcctt atagacaagg gaaaaaaaag attgaatana agagthttht      960
ttttaaaaa

```

<210> 63  
 <211> 2081  
 <212> DNA  
 <213> Homo sapien

```

<400> 63
gggtgagcag ataggggaaa gaagagaaca cgaaaagaaa aatagaacat atctgacaga      60
ttgtaaacca agttaccagc attgtgtgga atcgtagttc caagtcatat aataccaaac      120
attcaagaaa actagtgtccc tgtaactggg gggaagcaga tttatatact ttttgaagaa      180
agtcacctta ttctgtgtat cagaaatctc tttcaaataa cctttcagaa ctatagagca      240
tcatacaaaag atgaccaagc atacaagaaa acaaggcaca gtgaggggaaa cacagcagga      300

```

44

tacagcagaa aatagctctt atatatattca gatgacattg ttattatatg tagattatag	360
aacagtttca ctttctatgt tttaagaaat aagcttgaaa atatcagtag gaaacaggaa	420
gttatatagg aattgacata gcagagttga atgaaatact tcaagatgtg aaaaaatacg	480
atgacaaaa ctaattaatg cagtaaacad ggtggaagta gattttccat aaccgcagag	540
agaatttgtg aaccaaagat agaagaaatt atctagaatt caatgcaaat attaaaaggc	600
agaaaatatc aagaaagggt taaagaaaag gaggatcatg tttagaagtt ctagcttatg	660
cttaattggc attgtagaag acggaaacag agaatcgggt agaggcaata tttgatgaga	720
taatgacaca attttctagg attgatgaaa gccaccatc cttagattta agaaattcaa	780
atcccatgca gagtaaatgt gtaaaaaaa aaaaaaaaa aaactctata tagacatagt	840
gaaactgtgc agaaaacaaa gacaagaaag acgtaaagaa actatcctca aaagagtgtc	900
atttccaaat aacaaatgaa atctggagtc aatgaaatga tatcctaagt gtgctgttta	960
ggaagggagt agaatgcaac ctagagttct ataccagag aaaatttcga cagggaaagc	1020
ataacacctg tatatcagtg ttacaatcaa accatctact gctttggaag atagggccaa	1080
gaccaagtca ggctgccatg gtaagcagtc ttcacgaat gaccagatga tctctacagt	1140
cttcatgtgg acgatgatct atgtctaatt tatcagtaaa tatcagcatc tagtaggggtg	1200
ctttcgataa atttggttga atgaaagaaa aaaggcaaat taaggatattt attcagtaaa	1260
caaaaagggg tagtgaagaa ccaagctcca ggacttttga agatagactt tcttgtctgt	1320
ggtgcactga gaatcagctc tatcttagta ttcatttacg tgtggagatc tagaacagag	1380
ttacattctt tctggtgaca agctgagact acctggctgc tcaatatcca gctcctggga	1440
gacaagggcc tcaaaactgt tgggattggg ggggtgggca ggtagggaat cttactacca	1500
tttgttagga tttttaccat caaacctagg agtagcttgg aactgggtaa gatcttagaa	1560
tttagagaag ccatagcctg aacaccacac acttctcact gaggaagata ggggtgataa	1620
gatcatggag gaactggaga ggaatatgaa gacagtgcct acaaccacca catacacagt	1680
aaacattctc tcttctcagt ggttgaagtt gttcttgatt acagctctct tatctgttct	1740
ccctttgatt tgctgactga tggatgcagt ccatttaaga aatgagcata gcatattgga	1800
aagagcacta gacttagatt ctagtcccag ttctgtcact taacagctat gtgttgaggt	1860
gaggtgaggg aagagtactt ggatctctgg atctctttta actttaatat tctcctctat	1920
aagggtagaa gatgaactag aggatcacia cagtaccatt tagttttccg ttcagtggca	1980
attttgacat acttttttga gcatacataa tctcagaatc ctatgcctca aaactttgat	2040
tcattggaca gatttcaaga aaaatataat ttaacaaatg t	2081

45

<210> 64  
<211> 148  
<212> DNA  
<213> Homo sapien

<400> 64  
caatggtaga atgggatgaa atgcagacag atggcaagat gttgtgaggt caaatggctg 60  
tggcacttag ttgctacaga aacaacagtt ataaaaatta tgattattac ctagattcctt 120  
ttgatgatga tgaccccaga cagagaac 148

<210> 65  
<211> 362  
<212> DNA  
<213> Homo sapien

<400> 65  
acaacattta ttaaggtctt gccaggcttc ctgctaccag caggatcag tcactgggct 60  
gtgctttttc cacacttcag taggttgggt tcatttcatt ttcattgacaa ccctatatgg 120  
gaaaatgttg tgaaaatgaa atgagcccag cccattgaac ctattacaat tcctcccttt 180  
ttgtggatga aggaactgag gccacaatg gttaagcaac ttgcctaggg cccacaact 240  
gatccttgga agatctgaag tcccagagct tctgctatct ggaccacact tcagcactgt 300  
ctattatttt atgctctcca gataccaggg acatttaaaa ttgttttcag cccaagcaag 360  
gg 362

<210> 66  
<211> 1446  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (218)..(345)  
<223> n=a, c, g or t

<220>  
<221> misc\_feature  
<222> (1073)..(1276)  
<223> n=a, c, g or t

<400> 66  
tatctgaatc catcccccta ctctcttctg ctatgtgccg ggcactctca caagtgtcag 60  
tggttgggca cagtcattca ccctttcacc tctagattcc tccttcattc ccatcactga 120  
cccatccttg ggtgggggtgc agtcaggaac atcctgtttg acccttgaga ttcaaagaca 180  
gatgactggg aatacagaac accatcccaa aggtatgnnn nnnnnnnnnn nnnnnnnnnn 240  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300



```

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnagggt tgtcctgagg 360
acaaaatgtg gagaactcag aacttggtgc ctggtgcata ttggatgctt aataaatgtg 420
gccattatta cctcctctct gagaaagtct ggctaataaa ccatgttgcc tttcaagata 480
gtttttttct accacgactt taaagactgt cttggaactt acaggcaaaa attgtaatat 540
ttgtgctcct tgaataatct cttgcctttt agagggtgtg gcatttagga ggcaattttt 600
tctaagactg gttgcgggca cctgaaagtg caagggtgga ggagaaggaa agaagcctca 660
gttaatgttt taaaatgatg tcctgccaca aacattgacc tctgttcata gcctaaggaa 720
ttctgcaccg ctgcaccctg cagacttgct agatcttctc tccagctcat attcctccct 780
ttttacactc agtcaccttg tccttgattc ttatctcca atacattata ttttcttggt 840
tagggccatt gtacttcctt ggaactcttg tgaaagatca gttgcctata cttaacgtgg 900
gtctattttc tgggatttgt attctggtcc attgacctat ttgtctttta ctaataccac 960
aacatcttga ttactgtaac ttacagtaa gtcttgaagt gggatattgt cattcctcaa 1020
acaatattcc acttcttcaa cagtgtgttg actattctag gtcttttgtc tcnnnnnnnn 1080
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1140
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1200
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1260
nnnnnnnnnn nnnnnntaaa attatctggc agaaactgga aaaaacttca cagtgtgaac 1320
ctttacacac tattttgtct tccaagtgga agaagcatac taacaatgcc accaatccac 1380
catctcagga aaaaaattaa taaactgtct tttctgtaat ccccttttca atgggggtga 1440
ggtggtt 1446

```

```

<210> 67
<211> 642
<212> DNA
<213> Homo sapien

```

```

<400> 67
cggacgcgtg ggataacatc caattctgag atgaaacagt ctaaaatagg agtaaagcat 60
gcactacttg tgaagtgtga aatggagact ctggactttg ggtatttttg taaaactttt 120
gatatttctg tatacattta aaaaatcaat tgccactaca gtgagttcct taagaataat 180
ctagttatat tttttgaaat cacatataat tagactttat aatatatata ctttttcata 240
tataattaga tctttctttg taatttcata tgtagttcct cataggggtct cagatacaat 300
ggtttttata attgacatat tgaaaaagta tatgaacata atgaaacacc tcattttatt 360
gataattcac taacgtttta tattcatata ttaggaaagt gaacttagca agcttttttg 420

```

```

aatttaagga tcacatttag acatctcatg ggctgatgaa cacagctggt atctttgtgg 480
agctttctaa tttaaaaaat gctttgtaga ccccatgtgc tttaaaccat acaacatgcc 540
cgtgaagctg atctgggtggg tatgtttatt cttgggttttc agtagggaaa tagcagttca 600
gagagaggaa gctctctgtc ccagcaccga gactcactcc ta 642

```

```

<210> 68
<211> 325
<212> DNA
<213> Homo sapien

```

```

<400> 68
agactgtaga gagggagggt ggcaagggtc ggtgacacta gacagggtgca gtaggtctgg 60
accatgggtg gccttgcgct acacattaca gagctcaggc tttttttctc cagggtgagag 120
ggctgggtgcc actgagggcat caagcagagg tttgagatct ccttgggtgac agtgtagagc 180
agacaggtag atttgggaat ttaagcttag actcacgttg gagactgaga tagctcatct 240
gagaggcact cagggcctaa tctcaggcag taattttagg gatgtagggg aagagatgga 300
ttctgcacat acttgggagg cttgt 325

```

```

<210> 69
<211> 1117
<212> DNA
<213> Homo sapien

```

```

<400> 69
ttacaacccc acgatcactc agtcccaggg tgactccatg tctgagagga gaatgccct 60
gttgtgaggg ggtgacatga tgttgtagat cattactgag gggaggtagg gagatcagg 120
ggcacagggt gggcaacagg aaggcagtga caggcagaaa tacattctga gctcatccct 180
tctgttttct tgtggcagga attttgagtc tagaggaggc aagcgggaag atgtacacca 240
ggggagggga aagctgccag tcttccttgc ccacagtctg ctttgatttg attcagtc 300
ttgatgttaa agcagaattt tgggttctag ctctctacag agaaaactcc tgtttcctga 360
agtgatcaaa tgtgggtaaa atctggtgaa ggggggtttc tgattctcag aggactatac 420
cttttgaact cacagaacag tcacacgcag accacagaat gtccaagac acccgatcct 480
gtcctttatt cctggctcag cttgggagga ggaaggggct ccaggccagg gcagctggcc 540
aagctggcct tcctctaggg caccgcacgc cccttcccc tcgcccacgt ctacacagtc 600
accatcacia ggctcaagtg cccagtcact ggcttccaaa gaaggccaca gaacgtat 660
tcttcttgcc tctgaatgtc agcttcccc tggggtgcct ctcagtggct ctgccttctc 720
aggtccttct tggcatgctg agggcctgga gatgcacagg ggggtgttcaa tggcacctgc 780

```

48

cacctgaatt gcctcatagt ctcttgagaa acctcagagg ggaggggtggt gcaccagggc	840
tcagagagaa agaatctgtc ctgactttct gacccctcct ttaggtaggg agagaagatt	900
ggcagctggg cttggttgaa aggcattgtc gagaactctg agccagttgg ctgcagtttg	960
cgaggggagg ggaatagtcc agagatgagg gactggctga cacaatgcag aagaagctgg	1020
gttaaccagc ccagtgactc tcgggactgg tgtagaagca tgaagtgggtg gagaggcgca	1080
tattacctat gggcagaaga ggtgttcctg ttgagga	1117

<210> 70  
 <211> 1753  
 <212> DNA  
 <213> Homo sapien

<400> 70 gatcctgctt aaacaaggtc tcatggttct caccctaggg aattttgctc tccaagggac	60
atgagacaat gtctggaggc atttttggtt attacactgg gatgggggtg tgctgctggc	120
atctcaatag gttaggttca ggaacactgc tcaagattct gcaaggcaca ggacagcacc	180
cccacaataa tgaattattt gattcaagat gtcaataatg ccaaggttga gaaaccctag	240
ggtagctgta gtgttttctt ttaaccttag gggatttgag agccactgga aaccaagag	300
ccaaactgaa cctatgtggc tgcaactttt ttagtttctt attaaagaaa aagttctctg	360
gtttttcaac actaagttcc ctattttcga aaacaaccga aagagctcaa ttttgcaaaa	420
atggcacaac cacaacagag tcgagtgtga taacaataca gagtcaacta agattaaaaa	480
ttggtctact aagacttttag atataatacg ttttattcat ctagtggtag ttggtgctca	540
cagggcactg tacaacaaat tttaaaaata caatatgaaa aaaatcaaac agccagagat	600
caattccatt agagggcgat ggcccacaga aaaaccaaca aaggcccaca gaaaaacca	660
ccctgtctcc ttaagaacat ttctttgttt ggctttaaga aacacaaaaa gaaaatacaa	720
aagaaaaggt ctttgagaag ataggtaaaa cttcacatag cgtcttcac atatcaciaa	780
atgctttcct tatttaataa taagcacata aaataatcca aatatctgtg agcctctatt	840
tggtccaat gttttaggtc atagctttca ctacttcct cctctctatc ctcaaattat	900
ttgcatcagt aaaaaaagtt aattaagggtg taacagtctc ctttgtcca caatgccact	960
acaaagccta ttttcataa agaaccagag gccaagcaaa cgtaggctac taagtacttg	1020
aattgaaaat acaactaaaa tttcctgagt catttaacat caaattttg ctttgtaatc	1080
tatttgatt caattctcag tcattactga aggtcatttg acatcaacca tagagagcag	1140
tgagatttaa agttgcatgg aagtaccgct gaaaacttct aacaacagaa agatgagttt	1200
ggagtgttta attttactac atagtgcacat atattcagaa agttgtcata caagggaatga	1260

49

tgaggagtta caaatccaac ttggaaaccc ttaatgctca ctatcaattt gttgaaagtc	1320
aatttttttt tttttttttg agacggatct ctgctcgccc aggctggagt gtagcagcgc	1380
tatctcggct cactgcaagc tccgcctccc gggttcaagc cattctcctg cctcagcctc	1440
cctagtagct gggactacag gcgcccgccca ccacgcctgg ctaatttttt gtatttttag	1500
tagacgggac ttcaccgcgt tagccaggat ggtctcgatc tcttgacctc gtgatccgcc	1560
cgcctcagcc tcccaaagtg ctgggattac aggcattgagc caccacaccc ggccacaagc	1620
tgtttcttaa ctaagcttct gaagcaggaa ctccctaaagt gtcaataggc agttttactt	1680
acagtagtag ttatatacta atgctgcttg cagaattttt tttcccttta gagttcacag	1740
aagtactacc aca	1753

<210> 71  
 <211> 198  
 <212> DNA  
 <213> Homo sapien

<400> 71	
gatcaattgc attgatatag atagaaaatg atttgtatga tgttatgttc atttatcctc	60
tgaagtttga ggtccttata cacaagcttc cttagacctt tcccaccacc tcccaatttt	120
gtaatgtaat atttttttcc tttttatttg tggttattta aatgtctgta tataagaaat	180
taggaggctg ggtgcagt	198

<210> 72  
 <211> 7482  
 <212> DNA  
 <213> Homo sapien

<400> 72	
gcctgccgag ttccgagcga ccgatggaga tggcggctgc ggctgagtga cggacggtgg	60
aggcccagag cccgggctctg aaggggggga caaacctggg tgcccgcagg agcccggcag	120
ggtgtcttac aagtatcaag aacttactat atgtgggtga ataaacaatc aaggtaaaga	180
gcatcaagta aaaacttctg cttgttgata agtacttcag acattccccc agtggctgaa	240
gtggcatatg aattatgaag ttggatcatt tggaatgaat gtaagagaat tgccaagggc	300
tcctcctact ccagagagga aacctcatcc agggccatga agccacttcc tcaccatctg	360
tgtgctgctt aagctaagtc tgcgggaacc atggttcctt gggaggaatc aagctgactc	420
ttggcatgag attcctgcct tcctaggggt gagagcggca ctgccatggc ttctctggac	480
gaccagggg aagtgaaggga gggcttcctc tgccctctgt gcctgaagga tctgcagtct	540
ttctatcagc ttcactcaca ttacgaggaa gaacactcag gggaagaccg tgatgtcaaa	600
gggcaaatta aaagtcttgt ccagaaggct aaaaaagcaa aggacagggt gttgaaacga	660

gaaggggatg atcgagcaga gtcagggacc caaggatatg agtctttcag ctatggaggg	720
gttgatcctt acatgtggga accccaggag cttggtgctg tgagaagcca tctttccgac	780
ttcaaaaaac accgagctgc tagaattgac cactatgttg tggaagtcaa taaactaata	840
atcaggttag agaagctcac tgcatttgac agaacaata ctgagtctgc aaagattcga	900
gcaatagaaa agtctgtggg gccttgggtc aacgaccagg atgtcccttt ctgtccagac	960
tgtgggaata agttcagcat ccggaaccgc cgccaccact gccgcctctg cgggtctatt	1020
atgtgcaaga agtgatgga gctcatcagc cttcccttgg caaacaagct caccagtgcc	1080
agcaaggagt ccctgagcac ccacaccagc ccagccagt caccacaacag tgtccatggc	1140
tcccgcgag gcagcatcag cagcatgagc agtgctcagc cggctcctgga tgagaaggac	1200
gatgaccgga tccgctgctg tacacactgc aaggacacgc tgctcaagag agagcagcag	1260
attgatgaga aggagcacac acctgacatc gtgaagctct acgagaaatt acgactttgc	1320
atggagaaa ttgaccagaa agctccagaa tacatcagga tggcagcatc attaaatgct	1380
ggggagacaa cctacagtct ggaacatgcc agtgaccttc gagtggaaagt gcagaaagt	1440
tatgagctga tagacgcttt aagtaagaag atcttaacct tgggcttgaa ccaggaccct	1500
ccaccacatc caagcaatth gcggctgcag agaatgatca gatactcagc tacacttttt	1560
gtgcaggaaa agttgcttgg tttgatgtca ctgccaacca aagaacagtt tgaggaactg	1620
aaaaagaaaa ggaaggagga aatggagagg aagagggccg tggagagaca agctgccctg	1680
gagtgccagc gaaggcttga ggaaaggcag agtggcctgg cttctcgagc ggccaacggg	1740
gagggtggcat ctctccgagc gggccctgcc cccttgagaa aggctgaggg ctggctccca	1800
ctgtcaggag gtcaggggca gagtgaggac tcagaccgc tcctccagca gatccacaac	1860
atcacatcat tcatcaggca ggccaaggcc gcgggcccga tggatgaagt gcgcactctg	1920
caggagaacc tgcggcagct gcaggacgag tatgaccagc agcagacaga gaaggccatc	1980
gagctgtccc ggaggcaggc tgaggaggag gacctgcagc gggaacagct gcagatgttg	2040
cgtgaacggg agttggaacg agaaaggag cagtttcggg tggcatccct gcacacacgg	2100
actcggctcc tggacttcag agaaatcggc ccttttcagc tggagcccag cagagagcct	2160
cgcacccacc ttgcttatgc tttggatcta ggctcttccc cagttccaag cagcacagct	2220
cccaagacct cttcacttag ctcaactcaa ccaccagag tgtggtcttg gccccagcc	2280
gttgccaggc agcgcttacc ccagagcagc atgccacagc aacatgaggg gccctcctta	2340
aaccctttg atgaggaaga cctctccagc cccatggaag aggccactac tggctcctct	2400
gctgcagggg tttccttaga cccttcagcc cgcacctga aagagtacaa tcctttcgag	2460

51

gaagaggacg	aggaggagga	agcagtggca	gggaatccat	tcattcagcc	agacagccca	2520
gctcctaacc	ccttcagtga	ggaagacgaa	catccccagc	agaggctctc	aagccctctg	2580
gttcctggta	acccctttga	ggaaccacc	tgtatcaacc	cctttgagat	ggacagtgc	2640
agtgggcccag	aggctgagga	gcccatagag	gaagagctcc	tcctgcagca	gatcgataac	2700
atcaaggcat	acatctttga	tgccaagcag	tgcggccgcc	tggatgaggt	agagggtgctg	2760
acagagaatc	tgccgggagct	gaagcacacc	ctggccaagc	agaagggggg	cactgactga	2820
ccagcagtgg	agagggcacc	tttgggcca	ggggtctggc	aggagccagt	ggagcaggac	2880
agagggcagg	caggatggat	ggggaaggtg	gcagggtgag	aactcagatg	cacacagggtg	2940
aggggcaggga	atctgtctgt	ttgtgttgcg	cactttgagg	tatttccact	acagttgaat	3000
aataaaatag	aaactagaac	agggagaatc	agcattcagt	tgctgctttt	cctgtttatt	3060
attactatct	tttgtaatcg	gagggtttacc	ccttttgaag	ggactttaca	tttttactac	3120
cgagatataa	ctaaatgcag	ctctgttggg	cccagggcag	aaatggctgc	tgtgtacctc	3180
ttgggtccat	ttgctactgc	ctagtcttgg	ttccttatgc	agtattatag	ggcagccttt	3240
ttagagccct	tccttttagc	aagacagaga	agatagattc	cactgagctc	tattctgctc	3300
tgacagaagt	ccatccctag	taggctgtga	gttccatttc	acctggggcc	gcctctcccc	3360
tgctctgcac	ttcctgtctg	tacaatagaa	gggggaggtg	ctgctatgaa	ggggagagtt	3420
tagaccagg	agagcccagc	acctctcttt	aagggtgggt	gatgggaata	tttcaccagg	3480
gtctattttc	tcagtttaag	ttcttttttg	tctctttcag	gaagttaagc	tcccagtgca	3540
gggtatcaat	gtgaatctgg	tcctgagctt	tttagaaaat	aagagtgggt	gccgggcgcg	3600
ctggctcacg	cctgtaatcg	caacactttg	ggaggccgag	gcaggcagat	cacaagggtca	3660
ggagatcgag	accaccctgg	ctaacacagt	gaaatcccgt	ctctactaaa	aatacaaaaa	3720
attagccagg	cgtggtgggtg	ggtgcctgtg	gtcccggcta	ctttggaggc	tgaggcagga	3780
gaatgctgtg	aaccggggag	gcagagcttg	cagtgggccg	agatcgacc	actgcactcc	3840
agcctgggca	gtgagagtga	gactccgtct	caaaaaaaaa	taagagtgg	taactttttg	3900
gttgatatta	gtattatttg	tgagaagagt	ttccccaccc	ttcttctgat	agaacaattg	3960
tctgtcactg	gagaaatctc	cctccagagc	tttggcaaag	ttactctgat	ctgggtctgt	4020
ttaaaaggcc	gggtctctaa	tttaggaatc	ggtgatttgg	aagcttttgc	agaacatcac	4080
cagaagaagg	gaagcttccc	agagtcagaa	gctaaattaa	aataatttcc	aaggctatatt	4140
gatcagcctt	cttccttttt	ggttcattgt	gtcctgactt	ggggcactga	tgagattttt	4200
tatttttttt	gagacggagt	ttcactttgt	tgcccaggct	ggagtgtagt	ggcatgatct	4260
cggctcactg	caacctccac	ctccctgggt	caagtgatat	ttgtgcctca	gccccctgaa	4320

tagctgggat	tacaggcgtg	ggccaccacg	cctgggtaaat	ctctgtattt	ttggtagagg	4380
tagagtttca	ccattttggc	caggctgggt	tcgaactcct	ggcctcaagt	gatctgccac	4440
cttgccctcc	caaagtgtg	ggaatacagg	cgtgagccac	tgtgcccgcc	ctgatgagat	4500
atattattac	caatgttagt	attgagaaac	tgaatgttt	gaagaagcac	aaccaggat	4560
cgtgctggta	gcaccacagt	acttaaactg	ttgggtcaatt	aaggccagaa	agggaaattg	4620
ttaatttagc	tctggtgctt	tggtttacag	gaacataact	cttaactgac	atctgacatc	4680
atgatagcca	tatgtgtcga	gctctgggta	gagtttctgc	agttactcat	ctgaactaat	4740
gaacaataac	tgaccactag	tcactttatg	ccgtgtaact	agctctaggc	catactttca	4800
ctgggtactg	gtgtgaaagc	tgaaattcat	tttggttacat	tctgggtgaag	acccctcttg	4860
ataatgggaa	tgtttttaact	ctcttgatga	aaaaataatc	tgtattttgtg	ttgatgttca	4920
catttctgta	gcacatttct	tatccttttg	gttgaatgaa	aagatcttgt	ataggggtgt	4980
ggagatggg	agtgggtaga	agtgtgtgaa	ggacgctttg	catttgggat	ctgttcacaa	5040
acagccatat	gagtgtgtta	atgaatgtca	gccagttacc	aaccctgctg	gttggttatg	5100
gttggtttga	gaagttggca	accaggcatc	taagatgttg	cctggtacag	gcctcttttc	5160
ttccttgagg	cccatgacat	ttctctgtta	ctctagaggg	tttctcagat	ggccagtagg	5220
ctcctccctg	cttagggctt	catttctctg	aaaagaggat	gaactgaaaa	gcaggtagtt	5280
ccagaagcta	attgctgctt	tccatcataa	ttatttttct	tgtgagaaca	tttctctttt	5340
aattagctag	tgattttgat	taagactaat	tcactaaaca	tacccttccc	tcaaataacc	5400
tcaggtagca	atctgtaagt	aactaaaagc	attgaaaaac	acacaagaaa	cattttttaa	5460
aactattttt	aaaggcctgg	ccgggtgcag	tggtcactc	ctgtaatccc	agcactttgg	5520
gaggccgaga	cgggtggatc	acctgaggtc	aggaatttga	gactagcatg	gccaacatgg	5580
tgaaaccccg	tgtctactaa	aaatacaaaa	attagctggg	cgtggtggca	gacgcctgta	5640
atcccagcta	ctcagggagg	ctgaggcacg	agaatcgctt	gaacctggga	ggcggagggt	5700
ctcctgcctc	agcctcctga	gtagctggga	ttaccggcac	ctgccaccac	acccggctaa	5760
tttttgtatt	tttagtagag	atggggttcc	accatgttgg	ccaggctggg	ctcaaactct	5820
tgacctcaag	tgatctgccc	acctcggcct	cccaaagtgc	tgggattaca	ggcgtgagcc	5880
actgtgcctg	gccacgaagt	tcagaccgta	gagtttttca	taatgcaatt	gaaaccttat	5940
attcttatgt	ttcggacagg	ctgggtactt	aacttaaata	tttgaaaaaa	aaattgaatt	6000
caactctcag	aaagcttatg	gccttttgca	gaattataag	tttacaataa	cctgccatgc	6060
aacttagtga	tagatcagat	tagaaagggtg	cagcatgctt	cttgtttttag	cacgcctgaa	6120

53

```

ataaaactaa aagaaacaag agtccctagg ttttggtagg ctaaatttgt gtcttggtt 6180
ttgattctac tgtctccctt gtttttgact ctttttagtaa ccaagcaacc tctagcctca 6240
gtcttcattc tcagggatga actccttaga gtgaagtctt cactggtagt tcccagcatt 6300
ttgaaatctg agaattgctt ttaaagtaaa aaatgttggc tggcctccac acaatagtag 6360
ttttgaagtg tttgggaact gcatcatgat gaaaacaatc agatttgtat ttttaatcat 6420
tatagcagaa gctacaaaca ttttaagaat acaagtacac atgtggacaa aacattcttt 6480
attctataga caatgcttgg tatgcatatg ggtttgataa cccatttttg ataattctag 6540
gaccctgcc aatcatagaat tagagtcttc tttttttttt ttttttaatt tgagacaggg 6600
tcttggtctg ttgccaggc taaagcgagc tggcgagatc atagctcatt gcagcctcaa 6660
actcctgggc tcaaccaatc caccgcctc agcctcctga atagctagga ctactgatct 6720
gcaccaccac acgtagctga attataatca ttcttgggtc tacttggtgc aaagtgaagt 6780
gtagagacct taaataatth ggatctttga gccaaatgcc aacttcctcc ttctgacttg 6840
ccctcttttt ccctaagaaa tttggcagtg tagaccgaac tgtctgctta attctgttcc 6900
tggatctaca aagttaaagc gaggcccaag gattactcaa gcaagtaaca tcctttgagt 6960
tatctgaatc tgtgtctgtt ttctgactga ataagatgca gagacctggc taaatattca 7020
agtaagccaa gaatagaaca gaaagatcat ggtattctct ttaactata gtcaagattg 7080
aaaggaagat gaatctatgc cttcctcttg cttgggttagc cttttcctgt tttctactta 7140
taaaaatcaa agggtaagac agacaatagg ctagatttaa gataggccca tacaaggatc 7200
tcagcaagga tcagaatgtg ttatttctgt acccattgta gtgatgtcct tgctgtcaaa 7260
gctacagaag atcaagaata agtcttcaaa tgcaagtctg tactactgaa tgaacaactt 7320
taactaaga tgagggactt attttctttt tgacttgagc aaaaggctgt caccttggtg 7380
ttctgtttct gttgtaccct accaagtaag gaggataata atggcataaa catatctcct 7440
tgacactagt taatcatgtc caagctcttg gatgaatccc ac 7482

```

&lt;210&gt; 73

&lt;211&gt; 2512

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 73

```

cggcacgagg cagccctgct gaagccccag agctcagccc agtgctgggc acatagtagg 60
cgctcaggaa atgattgctg aatgtggaat gaaagtcccc agcaggcaaa aggctgtgac 120
ttctgttagt ggggtggtgg tcctctgggg cgagtgtatg gagaacttca aggcctcctc 180
ctggctgccc aggaagtaga gggcgccaaa ggcgacgtgc cggccgccag ctccaggccg 240

```



54

agccccgagc gcctgcagga acagggcccct tcaccgcggc cgggacgcag agctgcgaga	300
gaatcttgtt cagcgcggac tcaacgccag ggcgcgcgct agaggttggt ctctgtctcg	360
gcctcaccgc ccgggagacc acagagctgc ttccccagcc gcccgctgcc agaaattgga	420
aaaaaaaaa aatccagctg gggctctagga actcggcttc tggcacctct gaattctccg	480
agactgtctc ctccctcccc gcctgtaatg aacctgtga agggagacag gccaggaagt	540
cccagaaata ttatttcttg tgactctcac aaaatggaaa agggctctca tttttgtttc	600
tttaaggaa cttgtgttctg cgtctgtgtc tacactgcct cctctcacca accaaattgt	660
ctagcccccc tccagttacg ctagaactct gctttatctt caaggaagaa agggagtggg	720
gagaagttac ctctaaaccc tccagcatgg ccatcaattt tctgaataat ttggaggtca	780
acatgctttc ggaaaagtgt ttggaaaacg tttgggggtg aaaagaaatg tgcctaact	840
ggcctttact cacggagtga ccatcatctc agctagttag tgtatgagcg gcaccagcac	900
cccgccatg ggtgtctgtg ctgagcctct gaaagttagc ttatcctttg gggagccctc	960
ggaaagacac agctggtatc tatgggaatg gctttggggg gtctcttggc accatacaga	1020
taattttgtt tttttaattg gaatccatgg cctgggttct tgggatgggg gtagggggaa	1080
gccacaaagc ccctggaaat gtatgcaaaa catatgggtg tgcaggtgca tcatcctaag	1140
gctatggcct cttcagtttt tccaaagagt ctaagactat aaaaggtttc catctccttt	1200
tctcagccag ggagccacag agaccagggc cagcagtagg ctgggagcca gcacaccggc	1260
ccccaccagg tgcccggtag gggatgggta ataacactct tgaatggtct ggaaactgct	1320
ggccctcag tcctgccgtc ctcccagagg gaaatcctaa tagaagaagt gacagccagt	1380
agctgccatc tcagtatttt gaatgaaaat ataacatgat aaagagcaaa tgaggggaggc	1440
tggagggggc tccccatgca aatactggaa tatgaatgtt ggccagaaat aagatacttc	1500
ctgcctccca gctgttaaag agctcccaa ttcctccctt ttggtgctag gaaggggcca	1560
gagggcactg ccccagacc accaccacc tctggagagc tggggccgag tgggactgcc	1620
tgcagcagag ttaacccttc agaaaattca aaacctatac tgcctagtat tttccctgcc	1680
cgtttatttt ttaatcagat ttttaaaata tccagcagca ctttggtgcc ttttcttggg	1740
gttggggagt ggggttatct atgtgtgtat ctatgggaag gtgggtgcct tcagtgcact	1800
aaacccctc ttgggcctgc agctggacct cactcctgta cctgaacact ctgcctgagc	1860
ctgagcta at cttagccatc cattgtgtct caaaactgtt ttggaggtga ataactgtga	1920
ggcaggatgg agaacccttt gctctcccat ccagaagggc acctaaccag gccctggag	1980
cagacaaaag gagcaggaag tcaatcactt cgatccagc tctctgaagc ccaagaagaa	2040
aacggatttt cttcgtttt ggttcggagg cctagtagag aatttggatt ccaccaagtt	2100

```

ctcttttttc aaaaaaagta aacgggtccag agcagacaaa aactgtggaa acttgaggcc 2160
tgggtagtag tggttttgtt tgattttgag gctttaaaga gataaggaga cgggtggtgga 2220
gctccgccac gccgcgtggc tctcacttcc acgccgagga agaccgaccg gcccctaggt 2280
ttatcctctg ggagcccccg gcccaatcag ccccttcag gccttgggag tcaccccgag 2340
tcttatcttc tgtcccttc cagcaagtac ccggcaataa acgggcaggg ctgggcaaag 2400
gtctggccgc ggctggtcgg cctctgctct tcaaacctcg agctcactgt tggctgctct 2460
gggccccagt gtgggcagga gctgcgcttt ttccctgct tgctttctc ca 2512

```

```

<210> 74
<211> 954
<212> DNA
<213> Homo sapien

```

```

<400> 74
gcacgagctc cggccatctg ggcgctgctc ctccgcgcct ctggctcccc gcggcgcgcc 60
agggccatct cctcaccagc cgctctggga tccgacggcg ccgtgggtgg gggcagggtga 120
gacggccgag ccccgcccg cgatggcagg aagcgctcgc gcaatcccc tcccggaccc 180
tgtcctcgcc cgccactcac cggcgccagg ggaacgcagg agcgtgagcc ccttcgcgcc 240
cccagcgccg tcggcgctcg tgcccagac acagacactg cctcgagagg cctcacagag 300
gcggggggcag aaggcggcga cccagagccg ccacatcccc cgccttgggc gccgtcacag 360
tccccagacg ccctggactc ctgcagtcta cgaagacgcg cgggggacgg cgtggttccg 420
agagaggggc ccaaaggcga cgtgccggcc gccagctcca ggccgagccc cgagcgctg 480
caggaacagg ccccttcacc cggcgcggga cgcagagctg cgagagaatc ttgttcagcg 540
cggactcaac gccagggcg cgcctagagg ttggtctctg tctcggcctc acccgccggg 600
agaccacaga gctgcttccc cagccgcccc ccgccagaaa ttggaaaaaa aaaaaaaaaa 660
aaaaaaaaatt ccccgggggg cttagagaaa ccgcgggtgt ctggggccct ttagatttct 720
ccagaaaatg gtttcctcct ttccgaggtg ttataggggg acccccgtgt tgcaaggggg 780
aataaccggc cgaggaaagt ccccgagaa atttttcttc ctgggggacc tcctcacaat 840
ggggccacga gggctcccaa cttgtggtgc ctttacaggc gccccttgtt gttcccggcg 900
cctgtgtgtt caccgagggg ctctcttctt cccactcat tgttgtttgg ccc 954

```

```

<210> 75
<211> 949
<212> DNA
<213> Homo sapien

```

```

<400> 75

```

56

```

atcacttatg atggcaaaaa aaacacaatt acctttgcac caacctaaca ttaaactcag      60
gcgctttaa ttttactg aaatacgttg aaagctagct tagttgatct ctgtcattaa    120
cagaaacat ctctgttttt gttattttct tggcttgatt taacgttcgt tgctcgcaag    180
aaacagaaac cactcaagg tagttgaagg aaagggagg tttcattcaa gggagttgga    240
gaatcggaag gcaagaatga gcctcaggcc tctcatggga ctggaccg cgagtggaaa    300
gctgttgtct cacacctgc cccacctcac aatacatgtc tctttctgc ctcttccct    360
gcatgcttgt cattctcact cgctatgtat gccagcttct cctgcagctc catgcacgct    420
gcgtctgtgg cccttctctg ccttttgctt tccaggctaa aactagatag cttttgggtc    480
ttaattcaa atgcttagga gtgaatcgg tagctcagaa gtccaaccag ttcaaacc    540
tgtgtcaatc tagcacatta attctcaacc ttggctatta tttgatgtca ctgggagctt    600
taatagatac caaagcctgt gtcccattac cagaaattct ggtttttagtg gtctgggatg    660
ttactaaacc taatttggtg ggatatgttt aagttccag aggattctaa catagagctg    720
tgggtccatg ttaagaagca ctgatctagg agagaagagg gtcattctat aggcgtggaa    780
tgctcagata gtgggtctt ggctaggta gattattctc ccaaagatgt cctctaggg    840
gtccccattt ttggctttaa cctaccagtc ctcttcttta taggggtgtg ttggaataacc    900
tatggagctc tactttaagg aaaaaaaaaa aaaaaaaaaa ttggcggcc                949

```

```

<210> 76
<211> 2563
<212> DNA
<213> Homo sapien

```

```

<400> 76
ctgcttctgt tacotcaaag tggtaacagg actgatgccg aaatgtcacc aggtcctttc    60
aggtcttcac agtggagaac tcttgccaa aggttttttg ggggaggagg aggaaaccag    120
ctttctggtt aaggttaaca ccagatggtg cccctcattg gtgtcctttt aaaaaatatt    180
tactgtagtc caataagata gcagctgtac aaaatgacta aaatagattg taggatcata    240
tggcgtatat cttggttcat cttcaaaatc agagactgag ctttgaaact agtggttttt    300
aatcaaagt ttggctttatg gaggagtata atgtatgcac tactgtttta aaagaattag    360
tgtgagtgtg tttttgtatg aatgagccca ttcattgtaa gtcttaagct tgttggaat    420
aatgtacca tgtagactag caaaatagta tgtagatgtg atctcagttg taaatagaaa    480
aatctaattc aataaactct gtatcagccc ccaacatatt atttttcatt atttggggga    540
tatttcagtt ccagagcagc agtatcatgt tttctttgtt ggtgctgtct atagtctac    600
atgggttacg tgtgttttcg ttatagctgt tgccagattc taaagggtt gatattcaaa    660

```

57

aaaccacaga	tgctttcagt	ccagtatatc	ctagaaatat	agagctctac	tttgtgcaat	720
gcactgggga	tacagtggcg	atactgtcct	tgtcttcaag	gagttcggag	tcctagtata	780
ggagacatac	ataggagaag	ataattttca	cactgcagtg	gttgtagtaa	tagaatggga	840
gtccaaaggg	gagttccgga	gaggtcaggg	gtgacttcct	ggaggagatg	cccaagcttg	900
gaggctggat	aggctttgtt	gaaagatggt	acacaagagt	gtgaaacaaa	atttgtgtgtg	960
caggagagctt	aaaatacaag	gctggggaaa	gaagttggag	aagcaggaaa	gcccaggccc	1020
tctagtgtct	tacggaacat	cctgtggagg	tgagagctga	cttgtaggtg	gaagcagctc	1080
tttgagggtt	tgatttgga	ggtgaactga	gaagaagggtg	gtgatgcaag	ccggccgtgc	1140
tgaagccagg	atgaattggt	gtgactgggc	ttcagttagg	ctggcatagc	agttgagaga	1200
gcttagcagt	gggcagcagg	gcactgttgg	gggcggtggt	gagcggtgga	ttctggctgt	1260
ttggaggcag	gacagtgggtg	gaattcgatc	attgattgga	cgtgggacag	agaagggaga	1320
agagaagact	catctaggat	gagtcccagg	tttctggctc	agtcaactgg	ggaaacaaag	1380
tcacagagct	agggagtagt	tagagaacac	atctgggggt	gtgactcatg	gtcagttttg	1440
ggctcgtcag	ttttgagatg	cccaaatac	atgcagatct	gtcccacctg	aaaatggaga	1500
agacacggga	aaggagagga	gtaaaaacta	actccttttc	acaaagtgga	agttaccaga	1560
atgtgatttc	agaggccccc	ggggatttat	catgtgacta	ctgaccatc	ccacctcttg	1620
cccctgcctg	ttgcacagtg	ggcaagaatg	tttgtgacct	ttcactacca	ccacctcccc	1680
cgagcatggt	ccccccagtt	ttcaatatga	accatcctgt	gggtaccctg	tcacaggctg	1740
gccctgaggt	gagcaatatt	tggactgtga	tgttggttgt	tctccactct	ttctacagga	1800
cagaacaggg	cctctagagt	gggaaatggc	tttgggaaat	atgccaagca	gtagcctttg	1860
ttcttcaact	tgccaagagg	ataattctcc	acacccttcc	tgtactcagt	cctcagttgc	1920
ctggtgagag	agcagcctcc	tcccgtgtgc	tctgccagct	ggaccagac	tggccatatt	1980
accagtgaga	ccaaaaagat	ggagggtggg	aggtagctct	gaggctctgg	aaaccattcc	2040
agctcctgcc	agttttaact	tgtgtttaat	tcctggcaca	gttgctctgg	aaatgccttt	2100
ttctcttgcc	tgggaaccac	tagaagggga	tgttgtctgt	gttggccagg	gccatgcaaa	2160
ttcaacatct	tgtttctgcc	cttcccccg	gtagctgagg	ctaggtgttg	gcattaccca	2220
gtgcttggtc	ttcagagagc	aaaagcactg	ctcgtcatgt	ctgaaattta	gtgagtgagc	2280
tcaccacta	ggctggtgtt	tcctgcccgt	ggctgcacat	tggaagcacc	ggggcacttt	2340
gagaactaca	gatgcctggg	ttccagagca	tctaagggtgc	tctagggtgt	gtccaggaca	2400
cagccctggg	tgaggaccac	tgctatattg	tatggcctct	tttaaaaaag	ttaattttac	2460
ttggaaatga	tttcaaagct	acagaaaagt	tgcaagaata	aaaactgtac	aatgagggt	2520

caaaaaaaaa aaaaaaaaa aaaaaaaaa aaaatatgcg gtc 2563

<210> 77  
<211> 614  
<212> DNA  
<213> Homo sapien

<400> 77  
tgcaggtaaa tcatgaaagc attgttttat tcttttgtca tttttttcga aaacatcaaa 60  
cttttagagac cagtctagtt tatcttgctt tctcagtttt attcccatta aacttgatct 120  
tcttgcttat atttagtttt atgtcagctg tttttccagt aaatgtatag cattgttcaa 180  
ctaagttcag actcagtcctt tattcatact tgcagttaac tacttctggt atccttgacc 240  
atctcagtcg ggccaaaaac ccaaaagtaa atgaaaaaag acttctgaaa atggaggaaa 300  
ttagtcttca gaaagccctt tccttttttc tggaaactgcc actatcaagt cagatcctgc 360  
tgcttttaggt tgtaaatggt accagctaag tatctttttt tcccctataa cctcaagttc 420  
tttctctgct ttaacagggt aggagctatg gagtaggatt atgagggtggg tcgagagtac 480  
cttagaaaac ataatacata aagctaataa ccaaacaggg aggaaagaca acacaaaatc 540  
actaacatca acaatccacg gaagtctggc gttgtagtgt agggacaagc actcctccaa 600  
tgcatacaaga taag 614

<210> 78  
<211> 361  
<212> DNA  
<213> Homo sapien

<400> 78  
aagaagatc ttttgtgtgg aggctgggga ggaatgaaat ttgaaatga taaaaagtga 60  
ttgaagactt ctctaaatta aaggtagtat cgttcactct gcttaaagag tgagcttggt 120  
aattaattac agttaggaga tcaagaaact gagacattaa ttgatacaaa atcgcatcca 180  
acacgtagat ctagaagaaa atatctttat tttctttcta gcatcaagga atattaaatc 240  
taaagtgtcc ccaggatat gggttttcaat cctgtgctta aatatctcct gagaaggaga 300  
ttccataaat tccctctata actaaccaat cctcataatc agcaagttct tttctatctg 360  
a 361

<210> 79  
<211> 1321  
<212> DNA  
<213> Homo sapien

<400> 79  
gagaaaatag cataatatag gatggcagaa ataagtctag tagtcacaag cactgtaaat 60

59

```

gaattcagta cccctagtaa taacaaacac ttttaagatga gtttgaaaga aaatctagtc 120
atatgaagtt tcataaaaca gtgacataga aagattgaaa gacagctgat tgaaaaatat 180
gtaccaggca aatatcaaca ataagcaagt agcaatatta atgccatact gaatggaatt 240
caagggttta aatagcggtc agaagcacac aggcataatt tataaaagat aaaattcact 300
atgaagacgc catcaatttc tatgtaatat caatgtataa tgtcatctct cagcttcaaa 360
gtatgaagaa aatgcgatat tttctcatal ctgatgaaaa actttatcac actgctttta 420
gaagctgacg tattaagtag ataatataga tagagatgca aaggggattt ggaaaacagc 480
cttgatccaa aataaataga tattaacctt gtattcaata aaaagaaaag cactttcctt 540
ataaatataa atgggatatt tataaaaatt aacgatgact tgtgccctaa agctgtattt 600
tgccagtcac gttttctttt tgttgtaa atattctac tctagctggg ccccttttga 660
agacttgtaa ttttttaatt ggttgagaca tgccccaagt tactcctgtc acagaggtgg 720
tggtatggcc ctgggtctct gtgtttgtct tgtcattgaa gaatcaggca gcctgccagt 780
ccctttcctg ctgagggacc tagaggaagc atctctgttt ccagctctcc tcttgctccc 840
ctgtctttag gaatagagaa aattcagacc acttgatcag cattggctta gccttttgga 900
atccagaaga gaggaggcag atctaccaga cgtccctgcc aaccctggcc cccaaaatca 960
acagctctct ggtggccaag ttcttgccag tatctgctgc tttcccagcc ttgcttttag 1020
gcagcctggt gcagttctcc aggttaactt agcaaatcct cactctgga atctcctgtc 1080
caccaagatg tccaaaatc cttttaggcc ttaccagata cctgcctagg agaaactgga 1140
gctgacaatg gagatgatgg gagttatgtt caagttgcca tattccagca ttcgccacaa 1200
ctcctatcag ttttgccagg caacttacta ggtgtctttc atacctgctt ccttcacccc 1260
agtacctcta ttttcataac aagaagagtt catgaaaatt accctaccaa agggaaacttt 1320
g 1321

```

```

<210> 80
<211> 293
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (155)..(193)
<223> n=a, c, g or t

```

```

<400> 80
agctagtgtc agggagtttg gatgcccaga gctcccctga gggcagctta gatctgtttg 60
gtgtgcaagg ccctgtacac agttcagaaa agagaatgag gggcfaatct agttactttc 120

```

60

aactagtact ctctgttggt ctgtttctct gtctnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
 nnnnnnnnnn nnnatgaaaa agacttgact aaaagagaac agaagatttc agagagcaca 240  
 gaatgtagta ggagagtgat aagttgtgaa actctttatc tttgtctatc cac 293

<210> 81  
 <211> 549  
 <212> DNA  
 <213> Homo sapien

<400> 81  
 caggaaagaa aaatttatgg aaatgacata gaattcagaa agtattcccc acctaacagg 60  
 tgggagaaat tatgtggcct attttactct aatattatgc aaccaagaaa gtagaaaatt 120  
 ggaagatatt ctgaaaagca tgtataaaac acattgcaag gttacataaa atagtgacaa 180  
 aaatgagttc aatatatctg gatctgatct gattatttag tttaggagaa tcgctgttgt 240  
 caaagatggg gactctggaa atgctaaact caggcttcta gaatgagaag gggaaaatgg 300  
 gcaaggctcac gatggcttag ctgcttttta aaaatatgta ttaagggatt gaatatgttt 360  
 cctagcttca ctgtatatta ttagaaaatc tatctgtgaa attgggttgt cgagatttcg 420  
 taatctgtgc gtaagtggct gttcaggatg cttacatgct gtcttaatac cgaagatgcc 480  
 atcctttttt ccagggccct cttcttacat gggagatag tggatcctac tataaaatgc 540  
 ggatatagt 549

<210> 82  
 <211> 282  
 <212> DNA  
 <213> Homo sapien

<400> 82  
 aaataaaacc tatgtttttg agagtagcag gaaacatttt gtagaaaaac caaatgaata 60  
 caggagata tggctatcag gagctgagac tgatattata attttccaag tactagtatc 120  
 tgtgtattga tttttacagt aatttgact ttcccatcca gcttgtttgt gaccactgag 180  
 gcccttggtg aatatcttag aagtcactca aaatggataa agaatgaatg tgagtcaccc 240  
 atagcagtct tatgtgagat aatatatggg tgatcctcag ta 282

<210> 83  
 <211> 71  
 <212> DNA  
 <213> Homo sapien

<400> 83  
 ccaagataat gaacattcat aatcccagta gtttcctagt gtccctttgt aatcttgctt 60  
 ctcaaaacta t 71

<210> 84  
<211> 400  
<212> DNA  
<213> Homo sapien

<400> 84  
agcttccacc ctcccttggt cttgtacaaa taggaatata gtcctccaga agcccatagc 60  
tcacaggtc catgatgtat aaaagggtggg catttaatat cttgtcattt tattccttct 120  
gtttaaaaat cttcaattaa cacctaccac cagtcaaatg aagtctaaaa gtgccttcc 180  
ctcattagga gtcaaaacttc acaacttaat ttctgctgtc tctgctgcc tgtacttcag 240  
aaaaaaaaa caaactgttg ggtttccttg tgagagtgac ttttccttgt ctgcatattg 300  
tgcttctgcc tttccttggt tttctcatga ccttatggca tctctgactc caaattgtat 360  
gtatccagca caaatctcaa tccttcacaa ataatcattg 400

<210> 85  
<211> 165  
<212> DNA  
<213> Homo sapien

<400> 85  
ggaagctgat gtcattgaaa agatattgcc ttgctttgaa atcagcaagc gtgggtcaaag 60  
ttctccagta tatacacaca gaggaataat gtggctctga atcaccatgg gcagcttttt 120  
gataaacaga tattcaaaaa aaaagaaaaa aaaaccaccg taaaa 165

<210> 86  
<211> 406  
<212> DNA  
<213> Homo sapien

<400> 86  
aaagaaattc ttccacagtg acattttcac caggcaaact cagagttggt tgacatgaga 60  
aggtttaaaa aaggatagtt gtgaaagacc aggcaaagtt cacaaagtga agaagggaaa 120  
atattatttc agactgatat taaatgatgg cctagcctgc tgccatactg tctcacaggg 180  
aaaagtttta tttatgtctc ctttgatctt ttctcctttt tgtctctagg tttgatgtac 240  
aagcttttagc ttgggccttt gatttacagt gttctggaga aagagaccag ggatgacaaa 300  
gccaaaccagg ctgttaccta aaaacctgat atattgtcct agatctaggc tgtcttagag 360  
ctacacaaag aatttccagc agactgctca ggaagagcct gctggg 406

<210> 87  
<211> 416  
<212> DNA  
<213> Homo sapien



62

<400> 87  
 cagtaactct cttgagaact cagacaagga ttagtcctct cagctgggct actcctgatg 60  
 ttgatgggtga aacaccagcc actcaggcag tgtccatcaa tgtcaaccct aatctggaaa 120  
 tgaactgacc aggccaaggt agaagcctgt tggctctgtcc aactagtaac agatccgtaa 180  
 aagtgcacagc cactttttacc accatcatta tagctctgtac cactttccct gacttgattt 240  
 ggccaatgtg ttgtgtgagt ggtggatgga agaagctaata acagctatgg ctttcttcaa 300  
 taatgggtgag gtaccactat catttgcaaa tcagttcaaa aataggaggt cttcccagct 360  
 gggcactaag agctaattct cttgggcaat tttttttatt gcattcaacc atagaa 416

<210> 88  
 <211> 67  
 <212> DNA  
 <213> Homo sapien

<400> 88  
 gaaagattca ggaatatagg ccaataactg gttcccaact aggcagcttt cttgaatata 60  
 gaaccct 67

<210> 89  
 <211> 168  
 <212> DNA  
 <213> Homo sapien

<400> 89  
 ggccagtggg ggcaatcact gagcttggcc cggcgcctgt ctctcctttg tcagtttcct 60  
 tttgtgtgcc tccagctgct gggctgggag tgggtgcagag aatcaggggc acacagccct 120  
 gctctcaggg agattacact tgggggacag aactggggtg cttttcct 168

<210> 90  
 <211> 328  
 <212> DNA  
 <213> Homo sapien

<400> 90  
 attctttgat tttgatcact cttgacagga tttatcattt ttttctttaa aaaaaccctt 60  
 ttagtattgt ctaccacttt atatttaata tttctttggt ttgattaaat aataataatt 120  
 tttattttta tttcaagttt ggtttgtatc cctgctttac tttccaattc tgtgaagtgt 180  
 attaccagat cttaaattgt caggatttcc tcttttgcgt aaatggcatg aattttattt 240  
 tatgcccatg ttttgatgca tccacacaat ttctagtaat ttcagttaag tataattgat 300  
 ttaaaataaa ctgaaccact ttaacatt 328

<210> 91

<211> 2377  
<212> DNA  
<213> Homo sapien

<400> 91  
gttgtttgaa ttttgagcct ccagggttaga ggctccaagc agacaaagaa gaaagtttgt 60  
agacacaata ttctaacatt gcacaagttg atgagatata aagttttgaa tattattcag 120  
gaagcacttt ggagaatgtg ggagtcctac tgttttgac tagtctgtaa tttgttacct 180  
ctccccattc gataatatag taactcagaa ttttcatata aaattgaatt ctactcatta 240  
gagtactttt taaaagtaca gcagaaagaa aagaagtgga acataagcat tcaagattaa 300  
tatttgattc tctatctctt aactgtagat tttattggcc tgtttttttt ttctaaataa 360  
ttctttaaaa ctgactgga acatgcctct gcattttctga gtgtagaaat taaatgaagc 420  
cactcacagt cctttgattt cccactgaag ataccccaaa ggatgcaagt gcctacagta 480  
ttatcaggag gagaacatga aaatattaag acaaaaatcc tcagcagttg ttctccaccc 540  
cttctccacc tccaccagca aggagaagtc aatctacact tttttctcat gttctaaagt 600  
cttagaatac tgctggattg ttgagcatga gacagagcaa aggttagata cacaaggtag 660  
aagttcatag gagcacaatt cttgattca gggaaagtag cacagaatgc aatttgaaaa 720  
ctacaggctt aggactctgt gccaaaaatc tctattttta atgaaaatat ttatataaaa 780  
atacatttat tctgcttaac acaaattaaa actgacataa aattttatga taataacatg 840  
attcaagaaa tgtgatgtag atttttgaga atgccaataa tcaggtttca gaaaagctac 900  
agtatgaaat ctgaaaagca acagaaattg aaagtgcct taaagaataa atttcctaata 960  
ttttccagat ttcttatgtt tataactatt ataaagagtt taactttctg gaactgaagg 1020  
agaaaacatg aaaatgttta tattgcttct tgttaagcag gtagaccaa ttcgctttc 1080  
agtaattcat ccatacagaa ttggatgac tatgtataaa ggaaaactta aatcttaatt 1140  
attatcagtt taaatttttt ttgtttgttg aatgacaaag gcaataaaaa taaatttgac 1200  
tttagctttt tttctatact ttctctttt tgtaattctt aaattctagt cactagtcat 1260  
tatgagagta ttgactaaat attttcacaa tctaaatatt gtcacaatct aaatttctgt 1320  
agtagagaga gccgtagccc tttgtaaagg ctttcgttcg tccaaacaac acttgatcca 1380  
accaaagttc caatgtgact gtggatcttt gataggtctt tgggtgttgt tgtaacaaaa 1440  
tttgatttga actacctata aatgaaaagt cggggtttat tactttatat gtaatgctga 1500  
gaggagactg ttgggaacag ttatgtcaat gagcaaaacta gaaattggct tcaaagctg 1560  
atacttttaa aagcatgtgt tttgtgtata tgctcacaaa atgtctgtga agagatttct 1620  
ttcagctttt gctcagcttt atggtggggt gtactgtttt atctgggcgg tgagggtatt 1680

64

```

gatttacata aaaactgtag acaaacacag tacgagtctc agcacgtttt gcattttattg 1740
tactgcccaa attgttttta tgttaaaagt cacgtttcat aatctgcaat atttttgtca 1800
aagtgcacac tgtactttct tcttaaaaac gtgattaaag agatcacttt gtccggatga 1860
agcagctggt ggcatatcc gctgaggctt gaacaccacg tgctgattct ctcacatca 1920
tgaaaaataa cactcgtggc tcagaacaca caaggttaaa gtgtgtggcg cactgctact 1980
ttttatctca ctttttaacc aaccctttct tcaaccctct tctaaggaaa gcagaagtcc 2040
cctttgggta ccagctgtgt ggcataacca tggctccttg tccctgacag atgacacctt 2100
cctttagaat ccaccagcat catccactct gcgtctagct gacaccctca gacagggatc 2160
agccaccctg gggcgtgcag gtcaaatatg cagatgggga ctttgacagac cacttcagt 2220
tcacgtggc acatcatttt ttgactctt ttccttttta aacttcctgc accttttcag 2280
ataaaatcat attttactat gtatagctaa taaatcgtag ttttgttctc ttaatcgcat 2340
ggtcaggaaa tgagtttttc taggtgtaga gttaacc 2377

```

<210> 92  
<211> 182  
<212> DNA  
<213> Homo sapien

```

<400> 92
ggacgatgat cagaggtcac agtttgggag ttgccacaag ctaggcttac ttataatgct 60
ccaccctaca gaaatgggac cccaagtacc cgatcttccc tttaggagag gcaggcagg 120
gggtgagcag cagatgtagt ttccatttcc ctggggggtt aattttccaa actttgtctt 180
tt 182

```

<210> 93  
<211> 1783  
<212> DNA  
<213> Homo sapien

```

<400> 93
ccgccctgca ccctccaagc ctgcacctct tagtccagca ccaggaagag tggctctagg 60
agggagagga gccccaggac tgaccaaga tgccgttgac tccagagccg ccctctgggc 120
gcgtggaggg gccccccgca tgggaagcag ccccatggcc ctactgccc tgtgggccct 180
gcatcccat catgctggc ctggccaccc tggctgcgt cttcatctc accaccgctg 240
tgttggctga acgcctgttc cgccgtgctc tccgccaga cccagccac cgtgcaccca 300
ccctgggtgtg gcgcccagga ggagagctgt ggattgagcc catgggcacc gcccgagagc 360
gctctgagga ctggtatggc tctcggtcc ccctgctgac agatcgggcc cctgagcctc 420
ccaccaggt gggcactttg gagggccgag caacagcccc acctgcccc tcagcccca 480

```

65

```

attctgctcc cagcaacttg ggccccaga ccgtactgga ggtcccagcc cggagcacct 540
tctggggggc ccagccctgg gaggggaggc ccccgccaca ggcctggtga gctgggctga 600
acccgagcag aggccagagg ccagcgcca gtttgggagc cccagtgcc aggaggcagt 660
ggccaggagc ccggatcctg agtggggcct ccagccacgg gtcaccttgg agcagatctc 720
agctttcttg aagcgtgaag gccggaccag tgtgggggtc tgaatcccca gggttcccca 780
gagacccccg aggcaggcct tgcctcagtg ggaccgggga cccaggatc cagcattagg 840
attgagtctg cccagcgta gatgcccttc ccaggctcct tccacctggt agtccccctc 900
cccggtctg tgttgtgtgc ctggtctatg tggatctagg ggtaagccca tgcagtgcct 960
ctgctcagct acctgggctg tggctcagag tacctggggt tggagccaat gccaggccag 1020
aagccttcaa gatcgcatcc agatgaagaa ccctaggtat ctagatagtc aggaaatggc 1080
atcgaccagc cacctccacc ttctttcagt gtttaccgaa gccaccaata ccaaagagaa 1140
cgggtcctgc ggtgctgaac agcctcggtg tggcgatgac agctggcagg agatgacagg 1200
aatccagttt cccagagcca caaatcctgt tctccttggc cactcaccca ctgtgaggtc 1260
ctctaggaaa atacacaaag agaggaccag accaggcaga ggaacatttt gtttcatatg 1320
aactgtggct ttgaccccca aactgcaagg aggaacttgc tgggccaagc tgcagcggcg 1380
ctgtcttctg ggagtgggga cctagagtca gagaaaaccc acaggctcct ctgcccattc 1440
tcctccatct gcacacgtct cagcctcgga ccctcaccac tccatggtga ggaaggccat 1500
ggccagggga aactgagttt catccaatgt ggagaggagc gttgtcctag agcaggggcaa 1560
ctcccaaact gtgacctctg atcatcgtcc ctccagctt gctggagtgt ccagagagac 1620
agatttgcca caagctaggc ttacttataa tgctccaccc tacagaaatg ggacccaag 1680
tacccaatct tccttttagg agaggcaggc aggtgggtga gcagcagatg tagtttccat 1740
ttccctgggg gtttaatttt ccaaacttgt cttttttttt ttt 1783

```

```

<210> 94
<211> 612
<212> DNA
<213> Homo sapien

```

```

<400> 94
gtgtaaaata agtctcatga tatttgcttc tcatggtagt tataaagatt gagattctgt 60
gtgaaaggca cctggcacac aggtgctcac taaatgcagt tcctttcctc tgctgtactt 120
agacattttc taggaaggat aggtccaata ggactgaata ttttatttag aagagatggc 180
ttcctttaag ttgccaaca agaggtttgg aagaaaacca aatgcttacc agccacttca 240
tattaatacc agtcattttc tccttctagt atcaatgcct aggagccagg aagctgtgcc 300

```

```

aatgccagtg gttgtggaga tggcaaaaga agggaggcca gccacctggg acagctgaat 360
ccaagcctga ctctcagccc cagaagggtg gacaagatgc tgccaattca tcgaacccaa 420
agaaagctgc agagatcact gttatccagc agacatactt ctgaaaagtt ctgctctatc 480
tcaaagactg aatgatacta cacagtcctc tccctattaa tatgggcaca ttcttgccag 540
tttcacactt gtatcttcag cagggacatc aatcaaacac caattcctgg ttaatgccgg 600
gagagtgtgg gc 612

```

```

<210> 95
<211> 1839
<212> DNA
<213> Homo sapien

```

```

<400> 95
cttgggtcca gctgcgtgtg gtgaaagcaa ctagaggcag agctatcaag ggctgtgaca 60
gatgagcagt ggtctgtctg caatgagcat gtgctcaagc taacatggat accatcttgg 120
tcttcagcct aatcattgca tcctatgatg ccaacaagaa agacctcaga gatagcagtt 180
gccgactgga acagctgcct gggatcttcc caaaagacgt gagaagcatc agagaattgc 240
aaatgcaaga aactcacaca gaaacccaaa ggacaacatt cattcaaac cggactatag 300
ctaccctgca gtgccttggc tctgacagca aagtaaaagt caaccttgta tatttgagaa 360
gaaggccaaa ggtcaagcat attttgaaga acctgagaat cattgctgct ccccgagaa 420
acagctctgc ctccctcaagc tgtcacctaa tccccacatc caagtttcag actggatctc 480
ttctaaaagg caaagtatca atgcctagga gccaggaagc tgtgccaatg ccagtgggtg 540
tggagatggc aaaagaaggg aggccagcca cctgggacag ctgaatccaa gcctgactct 600
cagccccaga aggttgagca agatgctgcc aattcatcga acccaaagaa agctgcagag 660
atcactgtta tccagcagac atacttctga aaagtctctc tctatctcaa agactgaatg 720
atactacaca gtccctctcc tattaatatg ggacattctc tgccaatttc acactgtat 780
cttcagcagg gacattacaa tcaaacacca attcctgggt aatgaaggga gagtgtgggc 840
ttagcagagt taccctcatg cccctatctg agccacaacc ttctgtaatt cacttcatac 900
atccatctaa atggatacct ttccatcccc tcaaacgaga acaaaaagta tccctgcaa 960
gcactatgaa tggaccttac tactctcttt gacagaagac tcaaacacag cctctaagaa 1020
acaaggcagc tgttagtgtg acatagcttc cagctcctct gttatcttca cagctgactt 1080
cacactcact ggccctcaat agcttagagt gggactcctg atctccctgg ttgacgttta 1140
taagggtttg taatttagct tctggtacta catgtatcta tccacacact gctgaaggga 1200
acttgacctt acgcattcca aaagccttcc tcataagtta tccccaaggg gttcagggac 1260

```

```

tacagaccat tagtacccaa gtgaagtctt ctgacgatcc agaattccta aggtggctct 1320
gatattatat catactttaa tagagagttg catacctttt ggacaaagat tccagagcaa 1380
aataattatg ataatgctgt ttctcacagg agaatagcta tgagtcaaat ctaacctgct 1440
taaataagag tttggtgaga aagtgaaacc acctgatctt gaatcaatgt tgaggtgaaa 1500
aaggaaatgt caggagggat aagacagggg gaggccctgc ttcttttcct aagagtctga 1560
aaccattcca tttcattttg gtgaaatgtg tctgtttcta agaaattctg ttttcttagt 1620
tctctgggta aaaaaaaaaa tacataaact gtatccttct ttctttcact tcaagtgtgt 1680
tccaaaaagt gattatcaaa acaataccaa caggggaaaa tctcaccta aggctcgatt 1740
taatattcaa gtccagcctg aaagagaaca catataaagc atggataatg aggatatgtt 1800
tcaaagaagc tccaaagaac ctctagggcc aggcattggt 1839

```

```

<210> 96
<211> 5043
<212> DNA
<213> Homo sapien

```

```

<400> 96
atggcagaag gcaaggagaa gcaagtcaca tcttacatgg atggcagcag accttatgac 60
gtgagcatga cctacatcca caaagcagga gggcctgac agcaggaatt agtcatgctc 120
acctgcactg tgccccctga ctctgttgt catctgctc aggcccgaa gaattatcgc 180
aaatatttcc ggtcagaggc tgccttcacc ttggcagatt tcatctacaa gagcatgac 240
cgagtaaata gttccagatt ggttcgagtc acccaggtgg agaagagga gaaactgaag 300
gagctagagc agtttagtat ctggaacttt ttttctcct ttttaaaaga gaaattgaat 360
gacacctatg ttaacgtggg tctatacagc acaaaaacct gcctcaaagt tgagattata 420
gagaaggaca ccaagtacag tgtcattgtg atccggaggt cctgggatgt tatccgagta 480
aatagttcca gattgggttcg agtcacccag gtggagaatg aggagaaact gaaggagcta 540
gagcagttta gtatctggaa ctttttttcc tcctttttaa aagagaaatt gaatgacacc 600
tatgttaacg tgggtctata cagcacaaaa acctgcctca aagttgagat tatagagaag 660
gacaccaagt acagtgtcat tgtgatccgg aggtcctggg atgttatccg agtaaatagt 720
tccagattgg ttcgagtcac ccaggtggag aatgaggaga aactgaagga gctagagcag 780
tttagtatct ggaacttttt ttctccttt ttaaaagaga aattgaatga cacctatgtt 840
aacggcatac cgtggacaaa ggtggactac tttgataatg gcatcatttg taagctcatt 900
gagcataatc agcaggttat cctggccatg ttggatgagg agtgcctgcg gcctgggggtg 960
gtcagtgact ccactttcct agcaaagctg aaccagctct tctcaaagca tggccactac 1020

```

gagagcaaag	tcaccagaa	tgcccagcgt	cagtatgacc	acaccatggg	cctcagctgc	1080
ttccgcatct	gccactatgc	gggcaagggtg	acatacaacg	tgaccagctt	tattgacaag	1140
aataatgacc	tactcttccg	agacctgttg	caggccatgt	ggaaggccca	gcaccccctc	1200
cttcgggtcct	tgtttctga	gggcaatcct	aagcaggcat	ctctcaaacg	ccccccgact	1260
gctggggccc	agttcaagag	ttctgtggcc	atcctcatga	agaatctgta	ttccaagagc	1320
cccaactaca	tcagggtgcat	aaagcccaat	gagcatcagc	agcgagggtca	gttctcttca	1380
gacctggtgg	caaccaggc	tcggtacctg	ggactgctgg	agaacgtacg	ggtgcgacgg	1440
gcaggctatg	cccaccgcca	gggttatggg	cccttctctg	aaagggtaccg	attgctgagc	1500
cggagcacct	ggcctcactg	gaatggggga	gaccgggaag	gtgttgagaa	ggtcctgggg	1560
gagctgagca	tgctctcggg	ggagctggcc	tttggaaga	caaagatctt	cattagaagc	1620
ccaagactc	ttttctacct	cgaagaacag	aggcgctga	gactccagca	gctggccaca	1680
ctcatacaga	agatttaccg	aggctggcgc	tgccgcaccc	actaccaact	gatgcgaaag	1740
agtcagatcc	tcatctctc	ttggtttcgg	ggaaacatgg	cccgaagaa	ttatcgcaa	1800
tatttccggt	cagaggctgc	cctcaccttg	gcagatttca	tctacaagag	catggtacag	1860
aaattcctac	tggggctgaa	gaacaatttg	ccatccacaa	acgtcttaga	caagacatgg	1920
ccagccgccc	cctacaagtg	cctcagcaca	gcaaatacagg	agctgcagca	gctcttctac	1980
cagtgaaggg	caactcctgt	ccctccttcc	tcacagtgca	agaggttccg	ggatcagctg	2040
tccccgaagc	aggtagagat	cctgagggaa	aagctctgtg	ccagtgaact	gttcaagggc	2100
aagaaggctt	catatcccca	gagtgtcccc	attccattct	gtggtgacta	cattgggctg	2160
caagggaacc	ccaagctgca	gaagctgaaa	ggcggggagg	aggggcctgt	tctgatggca	2220
gaggccgtga	agaagggtcaa	tcgtggcaat	ggcaagactt	cttctcggat	tctcctctg	2280
accaagggcc	atgtgattct	cacagacacc	aagaagtccc	aggccaaaat	tgtcattggg	2340
ctagacaatg	tggttggggt	gtcagtcacc	agcctcaagg	atgggctctt	tagcttgcat	2400
ctgagtgaga	tgtcatcggg	gggctccaag	ggggacttcc	tgctggtcag	cgagcatgtg	2460
attgaactgc	tgacaaaaat	gtaccggggt	gtgctggatg	ccacgcagag	gcagcttaca	2520
gtcaccgtga	ctgagaagtt	ctcagtgagg	ttcaaggaga	acagtgtggc	tgtcaaggtc	2580
gtccagggcc	ctgcaggtgg	tgacaacagc	aagctacgct	acaaaaaaaa	ggggagtcac	2640
tgcttggagg	tgactgtgca	gcagctcagc	gccggctatc	atgctggcca	gggagaactg	2700
attaacttct	cttcctgcct	gcagattaat	ctgctgtctg	agcacaagcc	acgtgcttct	2760
ggcacaccct	gctttgagct	gagatagaac	ctggggaatc	atctgttttc	aggcgggtga	2820

ggggctagag cctgccttgt ttgggaggag ggtggctctg ttcagaatag gggtagctca	2880
ggctctggcc agccttctcc cgcccccaac agctcccccc atccttgact tctcagaatc	2940
aggccgagaa gagcctatct ggccgagagt ggggtgggtga cctgcgcctc atcgcccccg	3000
ctctccatct catctcctgc tcccagggcc caaattgtcg tcactttccc agtgaagtgt	3060
ctggtcattt tcagaagcaa tttcaggaga acatgcagct gccgctccct atcctgcatt	3120
tcccttcaca gggctgaagg cactgtcagc tccctgggct gggggtgatg ggagagggga	3180
agggctaggg cccctacccc tgtcctcact gtgcccatca tgtagatgga ctggagttca	3240
aggaagggca ggcactcccc tctccttta ctcttctgtc actctcttcc tectcttctt	3300
tctgtctctt gcctctcttt tctggagcct aggagtgtgt gttttcatcc cctgaaacaa	3360
atagggactc agtttcccca cctgtgttac agggttggaa ttggctccat cactgtggga	3420
gaagctggag ttctgctacc agtcctcccc tccccagccc tgcctcttct cctccagccc	3480
tctcccttca gccagttcag cgctctgaga gtctgggttg tttcagcctc tgaggggcac	3540
aagccatcct ggattcccct aaccccatga ggagccattc tagcatctca cagcttaaac	3600
cagctctagc tcagtcctcc tggcttagtc ctttttctt cctcaggtct tgagggcctc	3660
ttgttctctg ctctgtgggg ttttctccag ttgtctcctg gctgcaggac atggcaggac	3720
atagaatgct gtcaccttc cactcttcat tggcatctcc acccagtgtc acatatgacc	3780
ctagccgtgc tctcccttg ccagtacccc tctgggattt tgcgagagtc cacaagttgt	3840
gcatgtggtg gatataattca ggccatcttg tgtgtacaag ctagagggtc tgcttcacc	3900
tctggccctc agtgaattgc tgactaacct gtctcaacac agcacaactg tacacacctt	3960
ttcttggcct catccctaac ccatcatagc agcaaagagg ggaagttgca ggggaggagc	4020
tgctaaggac cctggactcc aagtaccctg ctcctctagg ccagggacat catctgagat	4080
gtggctcaaa taaaggggtg gtgttcaaga aaaaacactt ggggactcta tagctgcaac	4140
accacttta catgtcattt ccatatgatt tgtaggcaaa atgaagccca ggctgtccta	4200
gccctccaat acctccctct ctcatcacct ctccaacata gcctagcatt agctctttca	4260
agtctttgct aatcccagag atcaaggggt gatcaactct ccttgccatc cccttgttcc	4320
ccgcaccccc cgccccgggt cccccacat ccttggctcc tgccatcctc tttgagatgc	4380
tgcatcatca aaggacatta tttatggtgt acctttgctg aagccctgct tccctgggtc	4440
cagggcttgg gagcagggat ggggtgggtg gtgggggaga ggggtggatg cagagattgg	4500
accaggagg ctttttagtcc tcagctcttg gcttaacacc tctcctctt acacacccaa	4560
ctccctccag cctgcccagc ttgggccttc agctccagat tgggtgggtt aggagaggag	4620
gaggagggag atggatggaa ccaattagga acagcacctg ggctcctcac aggaatgaac	4680



```

cagtcacgcc atttgcacgt aaacagcttc ccacttctct cctcatccta ccaaagtctc 4740
ccaaccctgg gttctggccc atgttctttg cccacacagc cctgtaatta gctgggtaat 4800
gagaagcttt taatgagtc ccttagcatc tcgtgtaata aagaggcctt gagaccagc 4860
tgctgtcttc actttgggat gaacacgggt ccctgtgtag ccagtgactt ctgtcagtac 4920
agtctaagtt ctcggatggg gtgggagaca aacatttcag gacccagca gcacttgaga 4980
ggttccatgg tggatccatg tttttgactg tgatacaaga aacttggtc tggcttcctt 5040
ggt 5043

```

```

<210> 97
<211> 1171
<212> DNA
<213> Homo sapien

```

```

<400> 97
gggattgtca tctttagatc ctgactttcc aattccatct tggatgtgct acccgtggcc 60
agaagccact ggggtgcccc ttactttgac ctttcaccag tacattccat cttagggggc 120
gtttctctaa gttggcttca gactccctcc tgacccttta taccacccca aaaccaaagg 180
ccctggttta ggagctgaat tgtagcagcc gttcctcagt atctagatcg caggagagatt 240
tcactggagc tggctgaagc tggtggcgct ttgagcagcg ttgagccatc agtcctagtt 300
ctgcgtcttt gccccactgc agcttttggc cacttgcccc agtttagtgt caccaggccc 360
cgactataag ccacagtaat ttttatggct gcaggatatta gagggcagcc agtctacaga 420
ggtaggggct gcccatcctc cagctgtctt ttgcaatacg ggcatacact tcgagccaac 480
agcagctcca gccggccggt ccagctgtca aatgctttct gggctggcac ggctctttga 540
atccgtggta atggcttcct ctgttgaatg tcgtccaaa gcaattgctt gtcagcttaa 600
aagcgtgtgc catgttgta tgcccgcgct ctgagagggc aggcattccc gcacacttgc 660
agactgggat gctgtagcat cttctcatga gtcagggatt ggggtgaact ttgccaana 720
tttcctgcat tttccccacc ctctccaaca tgtctttgaa taccocatat cctttacatt 780
tgagatgaaa gtggaactct aaaaaccttg gaaagattct cttgtgaggt gacttctact 840
taagcttggc cacagcctcc tgctgtcttc aaagagtggg caggagattt cttcccttgg 900
acgctgccag tgctggaata tgaaacttac caagtgtcag cagttggggg ctgtccttca 960
cgttgaccca gccccctcat tgggtgtctg atgattgtgg acaccagtc agccccattt 1020
tctggccaca ccaagcatgg caatgacacc aggttggcac aaaacaactc tgcctggatt 1080
gattacttag cccatcatag cgtacacttt cttcatttta gtaagttgtg gttttatttt 1140
gaataagtct gtttcaacct attaatatta g 1171

```

<210> 98  
 <211> 660  
 <212> DNA  
 <213> Homo sapien

<400> 98  
 taacatgctg aatgggttg ctctcataga aggtattctt gaggggcag ttttccttac 60  
 aaaaacatagt atactaagac tgtggtattc agacagctct tcaatcttca agggaactgt 120  
 ggaagtaaac caggggtgac atggattatc aaatattgtg gatcaggtga gctctaggct 180  
 tctcaatgca aggtaattac cctgcacttt catctatttt ataatattgc ctttattttt 240  
 ttccatgaaa gagtaagggt tggaaaaaca agaaaaacac ggtaaaaatt atttctctag 300  
 tgaattgggt gtgtttataa atcttttagct tagcttgagt ccccttttgt gaaatgtata 360  
 aatccttttg atacattaac aaacacttgg aaaatgactt aacttattaa gttgaattct 420  
 ctaatataag ggttataagt gaaggcttaa ttattcagca ttactgaatt caatatatct 480  
 gccctttcag ttgacctagg gtgacaaata ctttcccat tacagcttgc caatgtaaca 540  
 cagccttatt tcatttttgt tgtaaataga atcacattct aatatgtttt agctgaaaac 600  
 agcaaagtat atattcaact acttcccaat agggaaaatt tttaaaaaaa gttatttctt 660

<210> 99  
 <211> 3002  
 <212> DNA  
 <213> Homo sapien

<400> 99  
 ggaatctggc ccctagaggc tgggtacttg gcccgaaacc cccatctccg gcggagagac 60  
 cgtccgaggt aattgtctgc cagcagtgca cattctgaaa acaggactgt ggaaactgaa 120  
 gtcattgcag agtttggatc tgtcattcaa tgggatattg caaatagggt ggtctgattt 180  
 tcacaactgc ctgcaactgg agaatctctg tttaaagagc aacaagatat tcaaaattcc 240  
 cccacaagcc ttcaaggacc tcaaaaaatt acaggtcata gaccttagca acaatgctct 300  
 gattaccatc ctaccaatga tgatcatagc tctagaattt ccccatctag tggttgactt 360  
 ggctgataat aactggcagt gtgatgatag tgtggcagtc tttcaaaatt ttatttctga 420  
 atcctggagg aaaaagtgga atgtcatttg caacaggctc atagggagtg aggaggccaa 480  
 cgggggcact cccagagca ggatttccag ggaaaccgc cttcctccca ttcattctgca 540  
 tcgcatgaaa agcctcataa ggagcaaagc agagaggccc cagggaggaa ggcacacggg 600  
 catttctact ctggggaaga aggcaaaggc cggctctggt ctcaggaaga agcagagacg 660  
 gctgccaagg agtgttagaa gcacccgcga tgtgcaggct gccggcaaaa aagaggacgc 720

72

tccccaggac	ctggctcttg	cggtgtgcct	gtcagtgttc	atcacattcc	ttgtcgcctt	780
cagcctgggg	gctttcacaa	ggccttatgt	tgacagactg	tggaacaaaa	agtgccagag	840
caaaagccct	ggcctggaca	acgcgtattc	aaacgagggc	ttctacgatg	acatggaagc	900
tgcggggcac	acaccacacc	cagagaccca	tctgcgcaa	gtatttcctc	atctaagcct	960
ctacgagaac	cagacccctt	tctgggtgac	acagccacac	ccacacgcca	ccgtaattcc	1020
tgatagaact	ctgggaagga	gcagaaagga	tcctggcagt	tcgcagagcc	caggacagtg	1080
cggggacaac	accggggcag	gaagtggaaa	tgatgggtgca	gtctattcca	ttctccagag	1140
acatccacat	gccggtaacc	gtgaactaat	gtcagcagcg	caggaccaca	tccataggaa	1200
tgatattctc	ggagaatgga	cttatgaaac	tgtggcccag	gaagagcctc	tcagtgcaca	1260
ttcagtgggc	gtctcttctg	tagctggcac	gtctcacgct	gtctctggct	caagccgtta	1320
tgattccaat	gaattagacc	ttccctctc	cggagaaata	acagcttccc	tctgtaaaat	1380
gctaacacat	gcagaagcac	agaggactgg	agatagtaag	gaaagagggg	gcactgaaca	1440
gtcacttttg	gactcgcaga	tggaattttc	taaggaaagg	caagtgagtt	catccattga	1500
tttgctgagc	atacagcagc	caaggctgtc	cggggcaagg	gctgaggaag	cgttttcagc	1560
ccactacagc	gaggttccat	acggtgaccc	aagagacaca	ggcccatcag	tctttcctcc	1620
aagatgggac	agtggcctgg	atgtcactcc	tgctaacaag	gaaccagtgc	agaaatccac	1680
tccttctgac	acttgctgtg	agttggagag	tgactgtgac	tctgatgagg	ggtctctgtt	1740
cactctgagc	tccataagtt	cagagagtgc	aaggagcaag	actgaagagg	cagtgcctga	1800
tgaggagtcc	ctgcaggacg	agagctcagg	ggcaagcaag	gacaatgtga	cggctgtaga	1860
cagtcttgag	gaaaaatgta	ccttccaaac	aattccaggg	aaatgcaaga	atcaagaaga	1920
tccctttgaa	aaacctctca	tttctgctcc	agactctggc	atgtacaaga	ctcatctgga	1980
aaatgcctct	gacactgata	gatctgaggg	cctgtcaccc	tgggccaggt	caccagggaa	2040
tagtccctta	ggggatgagt	ttccgggcat	gttcacttat	gattatgaca	cagctcttca	2100
atccaaggca	gcagaatggc	attgctcact	tagagactta	gaattttcaa	atgtggacgt	2160
tttacagcaa	acaccaccat	gttctgctga	agttccctca	gatcctgata	aggctgcctt	2220
ccatgaaaga	gactcagaca	ttttaaaata	agaatctttc	attaaggaaa	tattcacagc	2280
tctaacaat	attcttttaa	agatcatggc	aggggaaaac	taaagccttc	acaacaagat	2340
cctgaaggag	acaacatgaa	ttccaaccaa	gtggacactg	atgcaaatga	gggttttgtg	2400
ggcccaactg	agggcgatga	ttctagaagg	gttataagct	aaacacactt	gttaacatcc	2460
tatggggatg	aacctgctct	tcagtgtgaa	agagaaagag	gggaatatat	tgagatcatt	2520
ccaagaacca	tgcaccatta	ttacaagagc	tccaaacaaa	accagttcac	tgagaacaca	2580

73

```

ggagcacttc atcaataggt tggggtaaatt attcagaaga gaatctgttg cagtttagacg 2640
aagtgggttct aacttttcctt ctcaaataca gacctggagc aatctgatgg gatttggttc 2700
tctgaaaaga acagcttttag gatgacaaaag acaaggatgt tcaacttgat catcaaagag 2760
aattcaaatg acattttttc atacatattg aagcacttaa gtggaaatgc tggatagatt 2820
ttaatgaatt ctgaacacac actagcacia ctttttggag gctgatcgtg aaactgcaaa 2880
attggaaaag ttctgagtaa atataaatgt ttttaataa gttatgttaa aagagaagag 2940
gggccacttt ttagaataaa gtgtaaatta aaaatcaaaa aaaaaaaaaa aaaactgcgg 3000
cc 3002

```

```

<210> 100
<211> 312
<212> DNA
<213> Homo sapien

```

```

<400> 100
attcacagct ctaaacaata tttccttaat gaaagattct tattttaaaa tgtctgagtc 60
tcagatcctg ataaggctgc cttccatgaa agagactcag acattttaaa ataagaatct 120
ttcatggaag gcagccttat caggatctga ggggaacttca gcagaacatg gtggtgtttg 180
ctgtaaaaacg tccaccagga tctgagggaa cttcagcaga acatgggtgtg gtttgctgta 240
aaacgtccac atttgaaaat tctaagtctc taagttagca atgccattct gctgccttgg 300
attgaagagc tg 312

```

```

<210> 101
<211> 59
<212> PRT
<213> Homo sapien

```

```

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> x=any amino acid

```

```

<400> 101

```

```

Met His Ala Thr Pro Xaa Leu Thr Leu Pro Phe Leu Ser Tyr Ile Tyr
1           5           10          15

```

```

Met Val Leu Pro Phe Leu Pro Pro Tyr Ser Ser Ser Arg Asp Ser Ser
20           25           30

```

```

Tyr Leu Glu Cys Ser Ser Cys His Ile Cys Met Ile Lys Ser Cys Thr
35           40           45

```

74

Arg Leu Gln Thr His Leu Gly Tyr His Leu Val  
 50 55

<210> 102  
 <211> 64  
 <212> PRT  
 <213> Homo sapien

<400> 102

Met Ser Thr Tyr Asn Ile Phe Leu Ile Ile Met Pro Ile Ser Phe Ser  
 1 5 10 15

Lys Lys Asn Val His Asn Met Glu Tyr Ile Phe Pro Asp Leu Phe Asn  
 20 25 30

Ser Leu Met Asn Lys Thr Asp Ile Phe Tyr Lys Cys Asp His Ser Val  
 35 40 45

His Thr Trp Leu Lys Gln Leu Tyr Met Thr Phe Ile Ile Arg Lys Asn  
 50 55 60

<210> 103  
 <211> 49  
 <212> PRT  
 <213> Homo sapien

<400> 103

Met Val Thr Ala Thr Ile Tyr Pro Ile Met Asp Ala Ile Cys Phe Arg  
 1 5 10 15

Ala Arg Glu Asn Ala Lys Asp Lys Ser Arg Leu Asn Glu Gln Leu Ala  
 20 25 30

Gln Ile Pro Ile Ser Leu Met Pro Leu Ser Gln Leu Ile His Thr Val  
 35 40 45

Ser

<210> 104  
 <211> 40  
 <212> PRT  
 <213> Homo sapien

<400> 104

Met Lys Ile Pro Tyr Leu Lys Gly Lys Tyr Ser Leu Ile Leu Asn Cys  
 1 5 10 15

75

Asn Ala Gly Lys Pro Asn Cys Phe Gly Ile Cys Asn Leu Asn Val Leu  
                   20                  25                  30

Gln Asn Leu Val Leu Lys Phe Asp  
                   35                  40

<210> 105  
 <211> 51  
 <212> PRT  
 <213> Homo sapien

<400> 105

Met Ile Asn Asp Pro Lys Leu Leu Tyr Leu Ser Asn Pro Cys Val Pro  
 1                  5                  10                  15

Phe Leu Leu Phe Lys Lys Thr Ile Ser Pro Cys Arg Cys Leu Ser Leu  
                   20                  25                  30

Phe Cys Phe Cys Val Ser Val Leu Ser Tyr Ile Phe Ser Pro Pro Ile  
                   35                  40                  45

Cys Cys Phe  
                   50

<210> 106  
 <211> 45  
 <212> PRT  
 <213> Homo sapien

<400> 106

Met Gln Arg Tyr Thr Leu Ser Thr Ile Gln Tyr Val Phe Pro Ala Phe  
 1                  5                  10                  15

Leu Gly Ile Tyr Ile Ala Val Ala Ile Phe Leu Ala Lys Ile Gly Ser  
                   20                  25                  30

Tyr Tyr Ser Phe Pro Ile Leu Phe Phe Lys Val Asn Phe  
                   35                  40                  45

<210> 107  
 <211> 51  
 <212> PRT  
 <213> Homo sapien

<400> 107

Met His Asp Phe Leu Arg Met Ser Leu Pro Ser Asp Val Gly Ser Asp  
 1                  5                  10                  15

76

Glu Thr Tyr Ser His Lys Val Met Ser Ser Thr Met Leu Ser Leu Lys  
                   20                  25                  30

Ala Phe Glu Glu Leu Gly Gly Gln Val Cys Trp Gln Arg Pro Val Ile  
           35                  40                  45

Pro Ala Val  
       50

<210> 108  
 <211> 928  
 <212> PRT  
 <213> Homo sapien

<400> 108

Met Ala Glu Gly Lys Glu Lys Gln Val Thr Ser Tyr Met Asp Gly Ser  
   1                  5                  10                  15

Arg Pro Tyr Asp Val Ser Met Thr Tyr Ile His Lys Ala Gly Gly Pro  
           20                  25                  30

Asp Gln Gln Glu Leu Val Met Leu Thr Cys Thr Val Pro Leu Asp Ser  
           35                  40                  45

Cys Cys His Leu Pro Gln Ala Arg Thr Asn Tyr Arg Lys Tyr Phe Arg  
       50                  55                  60

Ser Glu Ala Ala Phe Thr Leu Ala Asp Phe Ile Tyr Lys Ser Met Ile  
   65                  70                  75                  80

Arg Val Asn Ser Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu  
           85                  90                  95

Glu Lys Leu Lys Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser  
           100                  105                  110

Ser Phe Leu Lys Glu Lys Leu Asn Asp Thr Tyr Val Asn Val Gly Leu  
       115                  120                  125

Tyr Ser Thr Lys Thr Cys Leu Lys Val Glu Ile Ile Glu Lys Asp Thr  
       130                  135                  140

Lys Tyr Ser Val Ile Val Ile Arg Arg Ser Trp Asp Val Ile Arg Val  
   145                  150                  155                  160

Asn Ser Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu Glu Lys

77

165

170

175

Leu Lys Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser Ser Phe  
 180 185 190

Leu Lys Glu Lys Leu Asn Asp Thr Tyr Val Asn Val Gly Leu Tyr Ser  
 195 200 205

Thr Lys Thr Cys Leu Lys Val Glu Ile Ile Glu Lys Asp Thr Lys Tyr  
 210 215 220

Ser Val Ile Val Ile Arg Arg Ser Trp Asp Val Ile Arg Val Asn Ser  
 225 230 235 240

Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu Glu Lys Leu Lys  
 245 250 255

Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser Ser Phe Leu Lys  
 260 265 270

Glu Lys Leu Asn Asp Thr Tyr Val Asn Gly Ile Pro Trp Thr Lys Val  
 275 280 285

Asp Tyr Phe Asp Asn Gly Ile Ile Cys Lys Leu Ile Glu His Asn Gln  
 290 295 300

Arg Gly Ile Leu Ala Met Leu Asp Glu Glu Cys Leu Arg Pro Gly Val  
 305 310 315 320

Val Ser Asp Ser Thr Phe Leu Ala Lys Leu Asn Gln Leu Phe Ser Lys  
 325 330 335

His Gly His Tyr Glu Ser Lys Val Thr Gln Asn Ala Gln Arg Gln Tyr  
 340 345 350

Asp His Thr Met Gly Leu Ser Cys Phe Arg Ile Cys His Tyr Ala Gly  
 355 360 365

Lys Val Thr Tyr Asn Val Thr Ser Phe Ile Asp Lys Asn Asn Asp Leu  
 370 375 380

Leu Phe Arg Asp Leu Leu Gln Ala Met Trp Lys Ala Gln His Pro Leu  
 385 390 395 400

Leu Arg Ser Leu Phe Pro Glu Gly Asn Pro Lys Gln Ala Ser Leu Lys  
 405 410 415



Arg Pro Pro Thr Ala Gly Ala Gln Phe Lys Ser Ser Val Ala Ile Leu  
 420 425 430  
 Met Lys Asn Leu Tyr Ser Lys Ser Pro Asn Tyr Ile Arg Cys Ile Lys  
 435 440 445  
 Pro Asn Glu His Gln Gln Arg Gly Gln Phe Ser Ser Asp Leu Val Ala  
 450 455 460  
 Thr Gln Ala Arg Tyr Leu Gly Leu Leu Glu Asn Val Arg Val Arg Arg  
 465 470 475 480  
 Ala Gly Tyr Ala His Arg Gln Gly Tyr Gly Pro Phe Leu Glu Arg Tyr  
 485 490 495  
 Arg Leu Leu Ser Arg Ser Thr Trp Pro His Trp Asn Gly Gly Asp Arg  
 500 505 510  
 Glu Gly Val Glu Lys Val Leu Gly Glu Leu Ser Met Ser Ser Gly Glu  
 515 520 525  
 Leu Ala Phe Gly Lys Thr Lys Ile Phe Ile Arg Ser Pro Lys Thr Leu  
 530 535 540  
 Phe Tyr Leu Glu Glu Gln Arg Arg Leu Arg Leu Gln Gln Leu Ala Thr  
 545 550 555 560  
 Leu Ile Gln Lys Ile Tyr Arg Gly Trp Arg Cys Arg Thr His Tyr Gln  
 565 570 575  
 Leu Met Arg Lys Ser Gln Ile Leu Ile Ser Ser Trp Phe Arg Gly Asn  
 580 585 590  
 Met Ala Arg Lys Asn Tyr Arg Lys Tyr Phe Arg Ser Glu Ala Ala Leu  
 595 600 605  
 Thr Leu Ala Asp Phe Ile Tyr Lys Ser Met Val Gln Lys Phe Leu Leu  
 610 615 620  
 Gly Leu Lys Asn Asn Leu Pro Ser Thr Asn Val Leu Asp Lys Thr Trp  
 625 630 635 640  
 Pro Ala Ala Pro Tyr Lys Cys Leu Ser Thr Ala Asn Gln Glu Leu Gln  
 645 650 655

79

Gln Leu Phe Tyr Gln Trp Lys Ala Thr Pro Val Pro Pro Ser Ser Gln  
 660 665 670

Cys Lys Arg Phe Arg Asp Gln Leu Ser Pro Lys Gln Val Glu Ile Leu  
 675 680 685

Arg Glu Lys Leu Cys Ala Ser Glu Leu Phe Lys Gly Lys Lys Ala Ser  
 690 695 700

Tyr Pro Gln Ser Val Pro Ile Pro Phe Cys Gly Asp Tyr Ile Gly Leu  
 705 710 715 720

Gln Gly Asn Pro Lys Leu Gln Lys Leu Lys Gly Gly Glu Glu Gly Pro  
 725 730 735

Val Leu Met Ala Glu Ala Val Lys Lys Val Asn Arg Gly Asn Gly Lys  
 740 745 750

Thr Ser Ser Arg Ile Leu Leu Leu Thr Lys Gly His Val Ile Leu Thr  
 755 760 765

Asp Thr Lys Lys Ser Gln Ala Lys Ile Val Ile Gly Leu Asp Asn Val  
 770 775 780

Ala Gly Val Ser Val Thr Ser Leu Lys Asp Gly Leu Phe Ser Leu His  
 785 790 795 800

Leu Ser Glu Met Ser Ser Val Gly Ser Lys Gly Asp Phe Leu Leu Val  
 805 810 815

Ser Glu His Val Ile Glu Leu Leu Thr Lys Met Tyr Arg Ala Val Leu  
 820 825 830

Asp Ala Thr Gln Arg Gln Leu Thr Val Thr Val Thr Glu Lys Phe Ser  
 835 840 845

Val Arg Phe Lys Glu Asn Ser Val Ala Val Lys Val Val Gln Gly Pro  
 850 855 860

Ala Gly Gly Asp Asn Ser Lys Leu Arg Tyr Lys Lys Lys Gly Ser His  
 865 870 875 880

Cys Leu Glu Val Thr Val Gln Gln Leu Thr Ala Gly Tyr His Ala Gly  
 885 890 895

80

Gln Gly Glu Leu Ile Asn Phe Ser Ser Cys Leu Gln Ile Asn Leu Leu  
                   900                  905                  910

Ser Glu His Lys Pro Arg Ala Ser Gly Thr Pro Cys Phe Glu Leu Arg  
           915                  920                  925

<210> 109  
 <211> 351  
 <212> PRT  
 <213> Homo sapien

<400> 109

Met Glu Pro Thr Glu Pro Met Glu Pro Thr Glu Pro Met Glu Pro Thr  
 1                  5                  10                  15

Glu Pro Met Glu Pro Thr Glu Pro Met Glu Pro Thr Glu Pro Met Glu  
           20                  25                  30

Pro Ala Arg Ser Ala His Arg Gly Gly Glu Ala Leu Leu Arg Glu Leu  
           35                  40                  45

Glu Val Leu Val Gln Asp Val Val Arg Thr Ser Ser Trp Trp Glu Arg  
           50                  55                  60

His Gly Val Asp Cys Ala Ile Leu Ala Leu Ser Leu Phe Ala Leu Pro  
 65                  70                  75                  80

Ala Gly Phe Leu Cys Leu Arg Trp Glu Asn Ala Leu Val Phe Ala Ser  
           85                  90                  95

Gly Ile Thr Ile Leu Gly Val Cys His Tyr Thr Leu Thr Val Lys Gly  
           100                  105                  110

Ser His Leu Ala Thr His Gly Ala Leu Thr Glu Ser Lys Arg Trp Ser  
           115                  120                  125

Lys Ile Trp Leu Leu Phe Phe Val Glu Val Cys Thr Ala Phe Thr Ala  
           130                  135                  140

Glu His Ala Thr His Gly His Val Lys Met His His Ala Tyr Thr Asn  
 145                  150                  155                  160

Val Val Gly Leu Gly Asp Ser Ser Thr Trp Arg Leu Pro Cys Leu Asn  
           165                  170                  175

Arg Tyr Val Tyr Met Phe Leu Ala Pro Phe Leu Leu Pro Ile Ala Thr  
           180                  185                  190



82

Asn Ile Gln Gln His Ser Val Arg Lys Arg Asp Leu Gln Thr Ser Thr  
 50 55 60

His Val Glu Thr Leu Leu Thr Phe Ser Ala Leu Lys Arg His Phe Lys  
 65 70 75 80

Leu Tyr Leu Thr Ser Ser Thr Glu Arg Phe Ser Gln Asn Phe Lys Val  
 85 90 95

Val Val Val Asp Gly Lys Asn Glu Ser Glu Tyr Thr Val Lys Trp Gln  
 100 105 110

Asp Phe Phe Thr Gly His Val Val Gly Glu Pro Asp Ser Arg Val Leu  
 115 120 125

Ala His Ile Arg Asp Asp Asp Val Ile Ile Arg Ile Asn Thr Asp Gly  
 130 135 140

Ala Glu Tyr Asn Ile Glu Pro Leu Trp Arg Phe Val Asn Asp Thr Lys  
 145 150 155 160

Asp Lys Arg Met Leu Val Tyr Lys Ser Glu Asp Ile Lys Asn Val Ser  
 165 170 175

Arg Leu Gln Ser Pro Lys Val Cys Gly Tyr Leu Lys Val Asp Asn Glu  
 180 185 190

Glu Leu Leu Pro Lys Gly Leu Val Asp Arg Glu Pro Pro Glu Glu Leu  
 195 200 205

Val His Arg Val Lys Arg Arg Ala Asp Pro Asp Pro Met Lys Asn Thr  
 210 215 220

Cys Lys Leu Leu Val Val Ala Asp His Arg Phe Tyr Arg Tyr Met Gly  
 225 230 235 240

Arg Gly Glu Glu Ser Thr Thr Thr Asn Tyr Leu Ile Glu Leu Ile Asp  
 245 250 255

Arg Val Asp Asp Ile Tyr Arg Asn Thr Ser Trp Asp Asn Ala Gly Phe  
 260 265 270

Lys Gly Tyr Gly Ile Gln Ile Glu Gln Ile Arg Ile Leu Lys Ser Pro  
 275 280 285

Gln Glu Val Lys Pro Gly Glu Lys His Tyr Asn Met Ala Lys Ser Tyr

83

290

295

300

Pro Asn Glu Glu Lys Asp Ala Trp Asp Val Lys Met Leu Leu Glu Gln  
 305 310 315 320

Phe Ser Phe Asp Ile Ala Glu Glu Ala Ser Lys Val Cys Leu Ala His  
 325 330 335

Leu Phe Thr Tyr Gln Asp Phe Asp Met Gly Thr Leu Gly Leu Ala Tyr  
 340 345 350

Val Gly Ser Pro Arg Ala Asn Ser His Gly Gly Val Cys Pro Lys Ala  
 355 360 365

Tyr Tyr Ser Pro Val Gly Lys Lys Asn Ile Tyr Leu Asn Ser Gly Leu  
 370 375 380

Thr Ser Thr Lys Asn Tyr Gly Lys Thr Ile Leu Thr Lys Glu Ala Asp  
 385 390 395 400

Leu Val Thr Thr His Glu Leu Gly His Asn Phe Gly Ala Glu His Asp  
 405 410 415

Pro Asp Gly Leu Ala Glu Cys Ala Pro Asn Glu Asp Gln Gly Gly Lys  
 420 425 430

Tyr Val Met Tyr Pro Ile Ala Val Ser Gly Asp His Glu Asn Asn Lys  
 435 440 445

Met Phe Ser Asn Cys Ser Lys Gln Ser Ile Tyr Lys Thr Ile Glu Ser  
 450 455 460

Lys Ala Gln Glu Cys Phe Gln Glu Arg Ser Asn Lys Val Cys Gly Asn  
 465 470 475 480

Ser Arg Val Asp Glu Gly Glu Glu Cys Asp Pro Gly Ile Met Tyr Leu  
 485 490 495

Asn Asn Asp Thr Cys Cys Asn Ser Asp Cys Thr Leu Lys Glu Gly Val  
 500 505 510

Gln Cys Ser Asp Arg Asn Ser Pro Cys Cys Lys Asn Cys Gln Phe Glu  
 515 520 525

Thr Ala Gln Lys Lys Cys Gln Glu Ala Ile Asn Ala Thr Cys Lys Gly  
 530 535 540

84

Val Ser Tyr Cys Thr Gly Asn Ser Ser Glu Cys Pro Pro Pro Gly Asn  
545 550 555 560

Ala Glu Asp Asp Thr Val Cys Leu Asp Leu Gly Lys Cys Lys Asp Gly  
565 570 575

Lys Cys Ile Pro Phe Cys Glu Arg Glu Gln Gln Leu Glu Ser Cys Ala  
580 585 590

Cys Asn Glu Thr Asp Asn Ser Cys Lys Val Cys Cys Arg Asp Leu Ser  
595 600 605

Gly Arg Cys Val Pro Tyr Val Asp Ala Glu Gln Lys Asn Leu Phe Leu  
610 615 620

Arg Lys Gly Lys Pro Cys Thr Val Gly Phe Cys Asp Met Asn Gly Lys  
625 630 635 640

Cys Glu Lys Arg Val Gln Asp Val Ile Glu Arg Phe Trp Asp Phe Ile  
645 650 655

Asp Gln Leu Ser Ile Asn Thr Phe Gly Lys Phe Leu Ala Asp Asn Ile  
660 665 670

Val Gly Ser Val Leu Val Phe Ser Leu Ile Phe Trp Ile Pro Phe Ser  
675 680 685

Ile Leu Val His Cys Val Ile Arg Asn Trp Ile Asn Ser Met Asn Leu  
690 695 700

Cys Leu Cys Phe Thr Pro Val Thr Ser Lys Cys  
705 710 715

<210> 111

<211> 65

<212> PRT

<213> Homo sapien

<400> 111

Met Ala Ser Gly Gly Val Leu His Val Met Ser Gly Arg Lys Ser Gly  
1 5 10 15

Val Phe Leu Arg Gln Cys Val Phe Met Trp Ser Lys Gln Ser Lys Pro  
20 25 30

85

Val Ser Glu Ser Asn Pro Ser Met Thr Met Phe Pro His Leu Cys His  
 35 40 45

Thr Leu Cys Glu Glu Leu Cys Pro His Phe Ser Leu Phe Asn Asn Leu  
 50 55 60

Met  
 65

<210> 112  
 <211> 22  
 <212> PRT  
 <213> Homo sapien

<400> 112

Met Asp His Tyr Ile Tyr Pro Val Asn Phe Pro Gly Ser Asn Cys Gly  
 1 5 10 15

Tyr Pro Asn Val Phe Glu  
 20

<210> 113  
 <211> 21  
 <212> PRT  
 <213> Homo sapien

<400> 113

Met Lys Phe Gln Leu Phe Ser Met His Lys Asn Arg Tyr Tyr Asp Ile  
 1 5 10 15

Val His Tyr Thr Met  
 20

<210> 114  
 <211> 41  
 <212> PRT  
 <213> Homo sapien

<400> 114

Met Ala Lys Leu Val Thr Thr Ala Arg Ser Gly Ser Glu Arg Asp Asp  
 1 5 10 15

Lys Glu Gly Glu Phe Lys Glu Pro Gln Thr Pro Gly Ile Phe Cys Ala  
 20 25 30

Arg Ala Asn Asp Thr Glu Ser Ile Pro  
 35 40



86

<210> 115  
 <211> 42  
 <212> PRT  
 <213> Homo sapien  
  
 <220>  
 <221> MISC\_FEATURE  
 <222> (42)..(42)  
 <223> x=any amino acid

&lt;400&gt; 115

Met Glu Lys Thr Leu Ala Trp Leu Ser Lys Asp Met Gly Ala Asn Ser  
 1 5 10 15

Arg Leu Ala Leu Pro Ile Thr Tyr Cys Ala Gly Leu Thr Gln Ser Leu  
 20 25 30

Pro Leu Thr Arg Ser Gln Phe Leu His Xaa  
 35 40

<210> 116  
 <211> 28  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 116

Met Glu Thr His Leu Leu Met Arg Lys Gln Phe Thr Thr Cys Ser Ile  
 1 5 10 15

Glu His Ser Tyr Leu Glu Phe Asn Thr His Leu Tyr  
 20 25

<210> 117  
 <211> 97  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 117

Met Pro Leu Ala Val Thr Gly Thr Cys His Ala Cys Ser Phe Ile Gly  
 1 5 10 15

His Cys Thr Cys Leu Leu Phe Ala Phe Lys Ala Leu Pro Leu Asp Ile  
 20 25 30

Arg Ile Ala Ser Phe Phe Ala Ser Phe Arg Phe Leu Thr Ile Cys His  
 35 40 45

Leu Leu Gly Glu Ala Phe Tyr Asp His Leu Thr Cys Asn Ser Ser Ser  
 50 55 60

87

Thr Pro Tyr Tyr Leu Ser Pro Ser Ser Val Leu Phe Phe Phe Thr Val  
 65 70 75 80

Tyr Phe Trp Leu Ile Val Ser Leu Pro Gln Asp Ile Val Ile Ser Gly  
 85 90 95

Gly

<210> 118  
 <211> 137  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 118

Met Cys Leu Gly Ser Gly Ile Thr Trp Leu Gly Pro Gln Ile Phe Ser  
 1 5 10 15

Ser Ala Trp Lys Arg Phe Thr Ser Ser Ala Ser Ser Arg Cys Gly Ser  
 20 25 30

Arg Gly Ile Asp Gly Leu Leu Thr Ser Thr Phe Ser Phe Pro Ala His  
 35 40 45

Leu Ala Leu Leu Leu Gly His Val Ser Pro Val His Leu Gln Glu Thr  
 50 55 60

Ser Val Asp Ala Pro Cys Leu Leu Thr Leu Ser Pro Ala His Thr Glu  
 65 70 75 80

Leu Val Leu Arg Gly Asn Leu Cys Leu Cys Cys Cys Leu Cys Leu Glu  
 85 90 95

Arg Pro Cys Pro Thr Pro Ser His Ser Cys Leu Ser Val Ile Phe Pro  
 100 105 110

Met Ser Val Leu Arg Glu Pro Phe Leu Ala Thr Pro Ser Lys Gly Val  
 115 120 125

Leu Gly Gln Val Trp Trp Pro Thr Pro  
 130 135

<210> 119  
 <211> 51  
 <212> PRT  
 <213> Homo sapien

88

&lt;400&gt; 119

Met Ser Val Leu Arg Glu Pro Phe Leu Ala Thr Pro Ser Lys Gly Val  
1 5 10 15

Leu Gly Gln Val Trp Trp Pro Thr Pro Val Ile Ser Glu Leu Trp Glu  
20 25 30

Thr Glu Val Gly Arg Ser Leu Glu Ala Arg Gly Ser Arg Pro Thr Trp  
35 40 45

Ala Thr Tyr  
50

&lt;210&gt; 120

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 120

Met Ser Leu Cys Leu Ala Cys Thr Leu Cys Leu Gly Cys Ser Leu His  
1 5 10 15

Pro Ala Leu Pro Gly Trp Ala Ser Asp Ser Asn Leu Leu Gly Leu Pro  
20 25 30

Pro His Leu Cys Asp Ser Gly Ile Ile Pro Lys Ala Val Val Arg Ile  
35 40 45

Leu Gln Glu Asn Ala Trp Lys Val Leu Gly Thr Met Leu Ser Pro Tyr  
50 55 60

Asp Thr His Ser Cys Val Leu Leu Ser Leu Thr Tyr Cys Phe Ser Thr  
65 70 75 80

Thr Thr Thr Ile Arg Ile Leu Lys Val  
85

&lt;210&gt; 121

&lt;211&gt; 64

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 121

Met Pro Ala Val Thr Ile Thr Ile Met Tyr Phe Cys Cys Cys His Thr  
1 5 10 15

89

Lys Met Asn Asn Asn Ile Leu Ser His Leu Lys Pro Lys Arg Arg Asn  
                   20                  25                  30

Gln Trp Glu Gly Cys Leu Gln Pro Ala His Gln His Arg Lys Gly Ser  
           35                  40                  45

Pro Ala Ser Tyr Pro Asn Ser Gln Arg Pro Asn Pro Arg Leu Leu His  
       50                  55                  60

<210> 122  
 <211> 34  
 <212> PRT  
 <213> Homo sapien

<400> 122

Met Arg Glu His Asn Asn His Asn Asp Asn Glu Cys Ser Val Val Lys  
   1                  5                  10                  15

Leu Thr Gly Thr Leu Leu Phe Leu Leu Ser Val Gln Pro Asn Ala Ser  
           20                  25                  30

Ala Asp

<210> 123  
 <211> 151  
 <212> PRT  
 <213> Homo sapien

<400> 123

Met Tyr Gly Cys Tyr Thr Pro Thr Ala Tyr Ser Thr Arg Ser Ala Pro  
   1                  5                  10                  15

Glu Glu Asp Trp Val Lys Leu Cys Lys Phe Gly Phe Pro Gly Asn Ala  
           20                  25                  30

Leu His Tyr Ser Ala Pro Asp Leu Pro Thr Thr Pro Val Gly Thr Arg  
           35                  40                  45

Ser Ser Thr His Leu Ala Glu Leu Met Thr Ala Trp Ala Gln Arg Ser  
       50                  55                  60

Ala His Cys Ala Asn Thr Arg Thr Gly Ile Ala Pro Leu Pro Glu Pro  
   65                  70                  75                  80

Pro His Arg Ala Pro Phe Lys Glu Leu Ala Thr Pro Leu Thr Cys Lys  
           85                  90                  95

90

Gln Pro Pro Thr Leu Lys Leu Ile Arg Thr Arg Val Phe His Pro Lys  
                   100                  105                  110

Gly Leu Cys Cys Gly Arg Cys Ser Asp Pro Arg Arg Gly Arg Glu Val  
           115                  120                  125

Pro Lys Ala Thr Ala Arg Gly Trp Gly Thr Pro Leu Leu Thr Leu Val  
       130                  135                  140

Leu Asp Phe Glu Gly Pro Asn  
   145                  150

<210> 124  
 <211> 59  
 <212> PRT  
 <213> Homo sapien

<400> 124

Met Asn Cys Leu Trp Ile Leu Leu Ser Ile Ser Leu Val Pro Phe Leu  
   1                  5                  10                  15

Gln Leu Tyr Gly Thr Leu Ser Ser Cys Thr Pro Glu Ala Pro Gln Leu  
           20                  25                  30

Gly Lys Val Ser Gln Arg Tyr Gln Glu Tyr Met Leu Arg Gly His Phe  
       35                  40                  45

Lys Val Phe His Arg Arg Leu Cys Leu Gly Lys  
       50                  55

<210> 125  
 <211> 83  
 <212> PRT  
 <213> Homo sapien

<400> 125

Met Asp Leu Cys Ile Ser Arg Ser Cys Ser Leu Leu Ser Val Gly Val  
   1                  5                  10                  15

Leu Thr Arg Lys Ser Leu Ala Val Gln His Arg Cys Thr Ala Thr Leu  
           20                  25                  30

Gly Ala Val Glu Trp Ser Ala Gly Ser Gln Ser Asn Cys Phe Pro Leu  
       35                  40                  45

Asp Leu Gly Leu Val Leu Phe Ser Lys Tyr Gln Ser Tyr Leu Lys Met  
       50                  55                  60

91

Lys Ala Cys Lys Pro Leu Leu Lys Ser Ile Glu Ser Glu Arg Glu Arg  
 65 70 75 80

Leu Phe Cys

<210> 126  
 <211> 34  
 <212> PRT  
 <213> Homo sapien

<400> 126

Met Lys Lys Ile Phe Lys Phe Asn Lys Ile Ile Ile Tyr Cys Pro Lys  
 1 5 10 15

Ile Ile Ile Lys Ser Leu Leu Val Glu Leu Ser Gln Asn Lys Gly Asn  
 20 25 30

Ser Phe

<210> 127  
 <211> 862  
 <212> PRT  
 <213> Homo sapien

<400> 127

Met Met Pro Trp Ala Leu Gln Lys Lys Arg Glu Ile His Met Ala Lys  
 1 5 10 15

Ala His Arg Arg Arg Ala Ala Arg Ser Ala Leu Pro Met Arg Leu Thr  
 20 25 30

Ser Cys Ile Phe Arg Arg Pro Val Thr Arg Ile Arg Ser His Pro Asp  
 35 40 45

Asn Gln Val Arg Arg Arg Lys Gly Asp Glu His Leu Glu Lys Pro Gln  
 50 55 60

Gln Leu Cys Ala Tyr Arg Arg Leu Gln Ala Leu Gln Pro Cys Ser Ser  
 65 70 75 80

Gln Gly Glu Gly Ser Ser Pro Leu His Leu Glu Ser Val Leu Ser Ile  
 85 90 95

Leu Ala Pro Gly Thr Ala Ser Glu Ser Leu Asp Arg Ala Gly Ala Glu

92

100	105	110
Arg Val Arg Ser Pro Leu Glu Pro Thr Pro Gly Arg Phe Pro Ala Val		
115	120	125
Ala Gly Gly Pro Thr Pro Gly Met Gly Cys Gln Leu Pro Pro Pro Leu		
130	135	140
Ser Gly Gln Leu Val Thr Pro Ala Asp Ile Arg Arg Gln Ala Arg Arg		
145	150	155
Val Lys Lys Ala Arg Glu Arg Leu Ala Lys Ala Leu Gln Ala Asp Arg		
165	170	175
Leu Ala Arg Arg Ala Glu Met Leu Thr Gly Arg Gln Thr Ile Pro Lys		
180	185	190
Tyr Asn Cys Gln Thr Gln Asn Lys Thr Val Ala Val Met Pro Gly Thr		
195	200	205
Thr Ser Val Ser Ser Thr Lys Ile Gly Ala Leu Leu Gly Cys Tyr Arg		
210	215	220
Ser Pro Arg Gly Ala Val Leu Arg Ala Leu Arg Asp Lys Gly Gly Ala		
225	230	235
Ser Cys Phe Pro Ala Ala Leu Leu Leu Ser Glu Ser Gln Asp Gly Gly		
245	250	255
Cys Arg Pro Ala Pro Asn Cys Arg Ala Met Leu Trp Phe Pro Trp Ile		
260	265	270
Ala Val Gly Trp Cys Leu Leu Gly Val Glu Val Asp Ala Leu Trp Val		
275	280	285
Thr Val Tyr Ala Trp Gly Pro Gly Arg Ser Gln Ala Ala Ser Gln Arg		
290	295	300
Glu Gly His Thr Glu Gly Gly Glu Leu Val Asn Glu Leu Leu Lys Ser		
305	310	315
Trp Leu Lys Gly Leu Val Thr Phe Glu Asp Val Ala Val Glu Phe Thr		
325	330	335
Gln Glu Glu Trp Ala Leu Leu Asp Pro Ala Gln Arg Thr Leu Tyr Arg		
340	345	350

Asp Val Met Leu Glu Asn Cys Arg Asn Leu Ala Ser Leu Gly Asn Gln  
 355 360 365  
 Val Asp Lys Pro Arg Leu Ile Ser Gln Leu Glu Gln Glu Asp Lys Val  
 370 375 380  
 Met Thr Glu Glu Arg Gly Ile Leu Ser Gly Thr Cys Pro Asp Val Glu  
 385 390 395 400  
 Asn Pro Phe Lys Ala Lys Gly Leu Thr Pro Lys Leu His Val Phe Arg  
 405 410 415  
 Lys Glu Gln Ser Arg Asn Met Lys Met Glu Arg Asn His Leu Gly Ala  
 420 425 430  
 Thr Leu Asn Glu Cys Asn Gln Cys Phe Lys Val Phe Ser Thr Lys Ser  
 435 440 445  
 Ser Leu Thr Arg His Arg Lys Ile His Thr Gly Glu Arg Pro Tyr Gly  
 450 455 460  
 Cys Ser Glu Cys Gly Lys Ser Tyr Ser Ser Arg Ser Tyr Leu Ala Val  
 465 470 475 480  
 His Lys Arg Ile His Asn Gly Glu Lys Pro Tyr Glu Cys Asn Asp Cys  
 485 490 495  
 Gly Lys Thr Phe Ser Ser Arg Ser Tyr Leu Thr Val His Lys Arg Ile  
 500 505 510  
 His Asn Gly Glu Lys Pro Tyr Glu Cys Ser Asp Cys Gly Lys Thr Phe  
 515 520 525  
 Ser Asn Ser Ser Tyr Leu Arg Pro His Leu Arg Ile His Thr Gly Glu  
 530 535 540  
 Lys Pro Tyr Lys Cys Asn Gln Cys Phe Arg Glu Phe Arg Thr Gln Ser  
 545 550 555 560  
 Ile Phe Thr Arg His Lys Arg Val His Thr Gly Glu Gly His Tyr Val  
 565 570 575  
 Cys Asn Gln Cys Gly Lys Ala Phe Gly Thr Arg Ser Ser Leu Ser Ser  
 580 585 590



His Tyr Ser Ile His Thr Gly Glu Tyr Pro Tyr Glu Cys His Asp Cys  
 595 600 605

Gly Arg Thr Phe Arg Arg Arg Ser Asn Leu Thr Gln His Ile Arg Thr  
 610 615 620

His Thr Gly Glu Lys Pro Tyr Thr Cys Asn Glu Cys Gly Lys Ser Phe  
 625 630 635 640

Thr Asn Ser Phe Ser Leu Thr Ile His Arg Arg Ile His Asn Gly Glu  
 645 650 655

Lys Ser Tyr Glu Cys Ser Asp Cys Gly Lys Ser Phe Asn Val Leu Ser  
 660 665 670

Ser Val Lys Lys His Met Arg Thr His Thr Gly Lys Lys Pro Tyr Glu  
 675 680 685

Cys Asn Tyr Cys Gly Lys Ser Phe Thr Thr Ser Thr Thr Ser Thr Thr  
 690 695 700

Ala Ser Ala Thr Ser Thr Thr Ala Ser Trp Ile His His Ser Asn His  
 705 710 715 720

His Ile His Tyr Ser Ile His Tyr Arg Ile His Tyr Ser Asp Ser Asn  
 725 730 735

Thr Val Ala Ser His Ser Trp Gly Tyr Ala Ser Gly Asn Gly Arg Val  
 740 745 750

Glu Glu Gly Gly Arg Asp Pro Arg Val Val Ala Ser Thr Gly Asn Asp  
 755 760 765

Pro Glu Ala Ser Asp Asn Asp Glu Asp Asn Asp Gly Asp Asp Lys Asn  
 770 775 780

Gly His Asp Gly Asp Asp Ser Asp Gly Asn Glu Gly Asp Gly Asp Glu  
 785 790 795 800

Met Val Met Met Met Met Ile Leu Thr Met Met Val Met Thr Val Ile  
 805 810 815

Met Met Met Val Met Leu Met Thr Val Met Glu Met Ala Asn Leu Thr  
 820 825 830

95

Thr Pro Tyr Cys Gly Thr Leu Gly Gln Ser Leu Glu Glu Cys Glu Glu  
835 840 845

Phe Arg Arg Asn Phe His Ala Ala Ser Gly Lys Leu Pro Gly  
850 855 860

&lt;210&gt; 128

&lt;211&gt; 187

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 128

Met Met Pro Trp Ala Leu Gln Lys Lys Arg Glu Ile His Met Ala Lys  
1 5 10 15

Ala His Arg Arg Arg Ala Ala Arg Ser Ala Leu Pro Met Arg Leu Thr  
20 25 30

Ser Cys Ile Phe Arg Arg Pro Val Thr Arg Ile Arg Ser His Pro Asp  
35 40 45

Asn Gln Val Arg Arg Arg Lys Gly Asp Glu His Leu Glu Lys Pro Gln  
50 55 60

Gln Leu Cys Ala Tyr Arg Arg Leu Gln Ala Leu Gln Pro Cys Ser Ser  
65 70 75 80

Gln Gly Glu Gly Ser Ser Pro Leu His Leu Glu Ser Val Leu Ser Ile  
85 90 95

Leu Ala Pro Gly Thr Ala Gly Glu Ser Leu Asp Arg Ala Gly Ala Glu  
100 105 110

Arg Val Arg Ser Pro Leu Glu Pro Thr Pro Gly Arg Phe Pro Ala Val  
115 120 125

Ala Gly Gly Pro Thr Pro Gly Met Gly Cys Gln Leu Pro Pro Pro Leu  
130 135 140

Ser Gly Gln Leu Val Thr Pro Ala Asp Ile Arg Arg Gln Ala Arg Arg  
145 150 155 160

Val Lys Lys Ala Arg Glu Arg Leu Ala Lys Ala Leu Gln Ala Asp Arg  
165 170 175

Leu Ala Arg Gln Ala Glu Met Leu Thr Cys Arg  
180 185

<210> 129  
 <211> 11  
 <212> PRT  
 <213> Homo sapien

<400> 129

Met Arg Lys Leu His Phe Glu Lys Tyr Arg Tyr  
 1 5 10

<210> 130  
 <211> 109  
 <212> PRT  
 <213> Homo sapien

<400> 130

Met Ala Gly Asn Leu Thr Gln Pro Ala Gly Gln His Thr Thr Pro Glu  
 1 5 10 15

Pro Ser His Ala Gly Gly Cys Pro Gln Val Pro Lys Gly Leu Glu Gln  
 20 25 30

Ala Thr Leu Gly Asp Cys Leu His Pro Ile Leu Gln Arg Ala Val Cys  
 35 40 45

Gln Arg Val Pro Ala Ala Ser Gln Thr Ala Ile Ile His Gly Glu Met  
 50 55 60

Leu Ala Thr Val Pro Ser Thr Lys Val Tyr Ser Gln Cys Ile Ser Leu  
 65 70 75 80

Arg Leu Tyr Gly Gln Arg Val Gly Tyr His Leu Lys Gly Gln Lys Ala  
 85 90 95

Glu Pro Leu Ser Cys Trp Gly Ser Gly His Gln Leu Val  
 100 105

<210> 131  
 <211> 127  
 <212> PRT  
 <213> Homo sapien

<400> 131

Met Leu Ile Ile Leu Ala Leu Trp Asp Ala Glu Val Glu Gly Pro Leu  
 1 5 10 15

Glu Ala Ser Leu Gln Ala Pro Glu Glu Thr Ser Ser Met Ile Pro Cys  
 20 25 30

97

Leu Arg Gly Arg Phe Leu Arg Thr Leu Pro Trp Gly Leu Lys Val Ala  
 35 40 45

Thr Pro Pro Gly Thr Tyr Ala Pro Gly Ala Glu Phe Gly Leu Pro Lys  
 50 55 60

Ser Val Cys Val Arg Leu Cys Leu Cys Ala Cys Leu His Val Cys Val  
 65 70 75 80

Phe Ala Cys Met Ser Val Cys Leu Cys Gly Leu Cys Val Cys Val Tyr  
 85 90 95

Thr Ser Val Cys Leu Ser Leu Cys Ile Phe Ala Cys Val Ser Met Cys  
 100 105 110

Leu Cys Ala Cys Leu Cys Val Tyr Met Ser Val Ser Leu Tyr Leu  
 115 120 125

<210> 132  
 <211> 78  
 <212> PRT  
 <213> Homo sapien

<400> 132

Met His Ile Tyr Val Ile Ser Thr Asn Ser Pro Phe Val Lys Thr Asn  
 1 5 10 15

His Met Ala Lys Pro Ile Val Arg Gly Lys Tyr Thr Val Phe Phe Arg  
 20 25 30

Ala Asn Tyr Arg Phe Thr Gln Gln Lys Ala Trp Ile Gln Glu Arg Val  
 35 40 45

Lys Gly Ser Ile Ile His Ser Thr Asn Arg Arg Ile Ser Arg Leu Arg  
 50 55 60

Pro Lys Asn Arg Cys Gln Gly His Val His His Thr Asp Ile  
 65 70 75

<210> 133  
 <211> 56  
 <212> PRT  
 <213> Homo sapien

<400> 133

Met Gly Gly Arg Glu Asp Arg Pro Gly Val Trp Asp Val Thr Ser Ala

98

1                      5                      10                      15

His Thr Gln Gly Arg Pro Ala Gln Gly Trp Gly Leu Leu Leu Cys Leu  
                          20                      25                      30

Met Cys Ala Gly Ser Asp Thr Gly Leu Val Trp Gly Arg Leu Arg Thr  
                  35                      40                      45

Val Lys Met Lys Asn Lys Arg Lys  
          50                      55

<210> 134  
 <211> 53  
 <212> PRT  
 <213> Homo sapien

<400> 134

Met Val Pro His Pro Gly Phe Ser Gly Met Thr Trp Gly Thr Val Lys  
 1                      5                      10                      15

Asn Thr Asp Ala Trp Val Pro Pro Pro Glu Ile Leu Ile Gly Leu Lys  
                  20                      25                      30

Gly Gln Val Gln Glu Ser Gly Val Leu Glu Val Pro Gln Val Ile Leu  
                  35                      40                      45

Ile Gly Ser Gln Gly  
          50

<210> 135  
 <211> 47  
 <212> PRT  
 <213> Homo sapien

<400> 135

Met Asn Pro Ile Ala Phe Phe Asp Ser Gln Asn Ser Leu Gln Asn Arg  
 1                      5                      10                      15

Leu Ser Ala Phe Gly Leu Ile Phe Thr Asn His Phe Pro Cys Ser Asn  
                  20                      25                      30

Met Tyr Leu Arg Val Leu Thr Leu Leu Ser Val Thr Met Phe Tyr  
                  35                      40                      45

<210> 136  
 <211> 162  
 <212> PRT  
 <213> Homo sapien

99

&lt;400&gt; 136

Met Val Arg Arg Phe Leu Val Thr Leu Arg Ile Arg Arg Ala Cys Gly  
 1 5 10 15

Pro Pro Arg Val Arg Val Phe Val Val His Ile Pro Arg Leu Thr Gly  
 20 25 30

Glu Trp Ala Ala Pro Gly Ala Pro Ala Ala Val Ala Leu Val Leu Met  
 35 40 45

Leu Leu Arg Ser Gln Arg Leu Gly Gln Gln Pro Leu Pro Arg Arg Pro  
 50 55 60

Gly Arg Lys Gly Pro Arg Lys Val Arg Gly Ala Phe Gly Thr Cys Phe  
 65 70 75 80

Val Cys Thr Val Glu Pro Gly Pro Pro Phe Thr Gln Pro Leu Asn Arg  
 85 90 95

Gly Lys Leu Arg Arg Thr Glu Leu Leu Asn Pro Pro Gln Lys Ser Glu  
 100 105 110

Ser Gly Gly Pro Val Arg Tyr Gly Ala Arg Arg Gln Arg Leu Pro Glu  
 115 120 125

Met Leu Thr Arg Ile Val Gly Ser Val Thr Ala Ala Arg Ser Lys His  
 130 135 140

Leu Leu Leu Gly Gly Val Leu Gln Pro Thr Gly Lys Trp Ala Phe Phe  
 145 150 155 160

Val Ser

&lt;210&gt; 137

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 137

Met Arg Ile Cys Leu Cys Phe His Leu Leu Ser Leu Cys Leu Cys Leu  
 1 5 10 15

Ser Asn Leu Pro Pro Gln Glu His Gln Gly Asn Gln Cys Cys Arg Pro  
 20 25 30

100

Arg Leu Asn Leu Arg Phe Leu Asn Gly Arg Asn Glu Ser Thr  
35 40 45

```
<210> 138
<211> 47
<212> PRT
<213> Homo sapien
```

<400> 138

Met Leu Phe Gln Gln Leu Leu Lys Leu Phe Cys Gln Met Leu Phe Leu  
1 5 10 15

Gln Cys Glu Gln Asn Ile Asn Arg Ile Lys Asn Ile Asn Arg Thr Glu  
20 25 30

Asn Lys Asn His Val Ile Ile Ser Ile Leu Ile Gly Leu His Met  
35 40 45

```
<210> 139
<211> 68
<212> PRT
<213> Homo sapien
```

**<400> 139**

Met Leu Ala Gly Ser Leu Leu Leu Ala Phe Glu Arg Gly Ala Ala Val  
1 5 10 15

Ser Ser Val Cys Arg Val Lys Lys Arg Gly Gln Ser Ser Glu Glu Met  
20 25 30

Asn Pro Ser Arg Lys Gly Cys Leu Thr Ser Arg Arg Glu Asp Asn Gln  
35 40 45

Glu Gly Leu Trp Val Ser Leu Leu Ser Tyr Thr Ser Phe Gln Val Thr  
50 55 60

Trp Asp His Gly  
65

```
<210> 140
<211> 13
<212> PRT
<213> Homo sapien
```

<400> 140

Met Trp Gln Val Glu Asp Gly Phe Leu Ser Ser Leu Thr  
1 5 10

101

<210> 141  
 <211> 108  
 <212> PRT  
 <213> Homo sapien

<400> 141

Met Gln Pro Arg Leu Phe Ser Cys Ala Tyr Val Ser Arg Met Pro Thr  
 1 5 10 15

Phe Leu Phe Asn Ala Met Gln Ile Ser Lys Lys Ser Leu Thr Met Lys  
 20 25 30

Ala Ala Cys Arg Gln Lys Ser Phe Gln Cys Ile His Val His Ile His  
 35 40 45

Thr Leu His Arg His Met Ser Ser Tyr Lys Glu Ile Thr Gln Asp Gln  
 50 55 60

Asn Phe Thr Tyr Cys Gln Phe Leu Lys Val Gln Pro His Phe Gln Lys  
 65 70 75 80

Pro Gln Thr Ser Ile Arg Ser Asn Glu Ile Tyr Ile Phe Leu Ile Leu  
 85 90 95

Gly Lys Cys Asn Ile Pro Val Leu Glu Gln Gly Glu  
 100 105

<210> 142  
 <211> 38  
 <212> PRT  
 <213> Homo sapien

<400> 142

Met Ser Leu Leu Ile Leu Thr Met Lys Leu Lys Lys Lys Lys His Leu  
 1 5 10 15

Lys Ser Thr Glu Ile Arg Val Lys Val Thr Val Ile Thr Tyr Leu Tyr  
 20 25 30

His Asn Ile Leu Val Asp  
 35

<210> 143  
 <211> 74  
 <212> PRT  
 <213> Homo sapien

<400> 143



102

Met His Thr His His Tyr Tyr Gly Val Ser Tyr Pro Gln Leu Ser Pro  
 1 5 10 15

Asp Gln Ala Leu Lys Ala Gly Arg Ala Arg Ser Gly Ile Pro Gly Lys  
 20 25 30

Gly Trp Glu Gly Leu Ala Leu Arg Lys Gly Cys Glu Thr Gly Met Arg  
 35 40 45

Trp Gly Glu Cys Ser Glu Gly Gly Gly Lys Gly Val Pro Ala Gly Gly  
 50 55 60

Val Cys Ser Ser Thr Ala Glu Ala Ala Glu  
 65 70

<210> 144

<211> 119

<212> PRT

<213> Homo sapien

<400> 144

Met Ile Ala Arg Gly Leu Ala Cys Cys Leu Leu Asp Ser Phe Leu Leu  
 1 5 10 15

Leu Phe Ser Leu Pro Val Gly Trp Thr Cys His Cys Cys Thr Cys Ala  
 20 25 30

Phe Ala Phe Ser Tyr Ser Phe Phe His Leu Leu Leu Ser Ile Cys Asp  
 35 40 45

Thr Ser Trp Cys Val Ser Tyr Arg Trp Pro Ser Ser Cys Cys Arg Ser  
 50 55 60

Leu Ala Leu Pro Gly Val Ser Ser Leu Ser Arg Val Pro Pro Leu Leu  
 65 70 75 80

Pro Ser Cys Arg Leu Arg Phe Gly Gly Pro Ser Val Arg Val Arg Phe  
 85 90 95

Pro Ile Val Pro Gly Tyr Pro Met Trp Ala Pro Leu Ala Arg Ser Pro  
 100 105 110

Pro Phe Gly Asn Arg Phe Arg  
 115

<210> 145

103

<211> 23  
 <212> PRT  
 <213> Homo sapien

<400> 145

Met Ile Lys Gly Ile Gly Lys Ser Thr Lys Thr Lys Ser Ser Asp Glu  
 1 5 10 15

Thr Gln Glu Ser Gly Arg Arg  
 20

<210> 146  
 <211> 33  
 <212> PRT  
 <213> Homo sapien

<400> 146

Met Leu Asn Leu Leu Ile Ile Ser Pro Leu Asp Cys Lys Ile Tyr Val  
 1 5 10 15

Gly Arg Asp Lys Ile Val Ser Val Leu Ile Val Ser Pro Lys Pro Leu  
 20 25 30

Glu

<210> 147  
 <211> 130  
 <212> PRT  
 <213> Homo sapien

<400> 147

Met Gln Leu Gln Ala Pro Trp Pro Gln Cys Ser Ser Lys His Gln Val  
 1 5 10 15

Cys Thr Cys Leu Gly Gln Ser Val Leu Gly Ile Pro Ser Ala Leu Asn  
 20 25 30

Val Val Leu Pro Glu Lys Cys Ile Val His Ser Tyr Ile Leu Lys Val  
 35 40 45

Ser Leu His Cys Tyr Leu Ser Arg Ser Ser Leu Asn Ile Tyr Ile Ser  
 50 55 60

Ile Pro Phe Pro Pro Cys Phe Met Tyr Val His Ser Thr His His Asp  
 65 70 75 80

Leu Thr Leu Leu Ser Ile Tyr Ser Phe Thr Val Cys Phe Pro Ile Pro

```
<210> 150
<211> 44
<212> PRT
<213> Homo sapien
```

105

&lt;400&gt; 150

Met Ser Glu Arg Ala Pro Lys Thr Phe Ser Cys Phe Phe Val Phe Phe  
 1 5 10 15

Tyr Pro Thr Trp His Thr Trp His Gln Pro Asn Cys Phe Ile Thr Glu  
 20 25 30

Asn Lys Tyr Phe Leu Pro Lys Tyr Leu Phe His Arg  
 35 40

&lt;210&gt; 151

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 151

Met Tyr Ile Phe Phe Gly Ser Ala Val Leu Leu Leu Arg Ile Phe His  
 1 5 10 15

Pro Thr Gly Tyr Lys Lys Met Phe Thr Ile Val Leu Phe Leu Leu Leu  
 20 25 30

Glu Ser Gly Thr Gln Tyr Lys Gln Gln Ser Leu Arg Asp Trp Ser His  
 35 40 45

Val Ser Thr Gln Glu His Arg Asp Gly Ile Gln Arg Leu Ile Ile Met  
 50 55 60

Trp Leu Ser Leu  
 65

&lt;210&gt; 152

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 152

Met Trp Ser Ile His Ser Leu Lys Leu Thr Leu Ser Glu Thr Thr Asp  
 1 5 10 15

Ser Arg Ser Ser Asn Asn Ala Thr Ala Phe Asn Met Val Ser Leu Ile  
 20 25 30

Thr Leu His Asp His Lys Glu Ala Ala Ile Tyr Ser Phe Cys Leu Arg  
 35 40 45

106

Leu Tyr Leu Gln Glu Pro Ile Asp Lys Val Asn Cys Phe Tyr Phe Lys  
 50 55 60

Leu Gln Ser Val Glu Tyr His His Ser Gln Ser Lys Leu His Glu Asn  
 65 70 75 80

Arg Ala Tyr Ile Phe Val Thr His Glu Gly Gly  
 85 90

&lt;210&gt; 153

&lt;211&gt; 156

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 153

Met His Arg Ser Gly His Leu Ser Trp Val Thr Ser Leu Val Ala Ile  
 1 5 10 15

Gly Leu Gly Ser Gly Ala Ala Cys Thr Glu Arg Arg Pro Trp Ala Gln  
 20 25 30

Arg Ala Ala Gly Ala Pro Gly Gly Ser Phe Thr Glu Ala Gly Leu Gly  
 35 40 45

Leu Ala Pro Glu Pro Val Arg Ser Gly Val Gly Ser Gly Ala Gly Asp  
 50 55 60

Ser Ala Met Ala Thr Ala Gly Ala Ala Cys Val Ser Ala Val Ala Pro  
 65 70 75 80

Ser Asp Pro Ile Gly Ala Arg Asp Leu Ser Gly Ala Ala Ala Gly  
 85 90 95

Pro Gly Arg Thr Gly Glu Gly Asp Ala Gly Arg His Gly Asp Leu Gly  
 100 105 110

Arg Arg Ala Gly Gly Gly Gly His Ala Gly Gly Ser Ala Gly Arg Gly  
 115 120 125

Arg Gly Gly His Arg Ala Ala Glu Lys Val Pro Met Ala Trp Gly Ser  
 130 135 140

Gly Ala Arg Val Gly Lys Thr Gln Asp Ile Ala Ser  
 145 150 155

&lt;210&gt; 154

&lt;211&gt; 22

107

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 154

Met Phe Arg Asp Leu Gly Tyr Phe Lys Glu Val Ser Ala Ala Val Val  
1 5 10 15

Thr Asp Val Glu Leu Leu  
20

&lt;210&gt; 155

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 155

Met Gly Glu Glu Leu Gly Arg Gln Glu Thr Ala Tyr Asn Leu Thr Asp  
1 5 10 15

Gln Glu Lys Gly Ser Gly Phe Tyr Ser Lys Cys Lys Gly Lys Leu Trp  
20 25 30

Glu Arg Phe Lys Gln Ile Ser Lys Thr Ile Phe Tyr Leu Gln  
35 40 45

&lt;210&gt; 156

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 156

Met Tyr Thr Ser Asn Gln Tyr Ile Tyr Leu Lys Leu Trp Leu Glu Leu  
1 5 10 15

Thr Ala Leu Met Asn Thr Met Cys Pro Gln Lys Leu Thr Ile Glu Gly  
20 25 30

Phe Lys Thr Lys Lys Leu His Thr Thr Thr Phe Leu His Thr Leu Asn  
35 40 45

Lys Lys Ile  
50

&lt;210&gt; 157

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 157

108

Met Ala Ser Leu Asn Ser Lys Ile Leu Pro Ser Ser Lys Leu Leu Leu  
 1 5 10 15

Gly Leu Met Val Lys Ile Leu Thr Asn Gly Ser Lys Ile Pro Tyr Leu  
 20 25 30

Pro His Pro Pro Ile Pro Thr Val Leu Arg Pro Leu Ser Pro Arg Ser  
 35 40 45

Trp Ile Leu Ser Ser Gln Val Val Ser Ala Cys His Gln Lys Glu Cys  
 50 55 60

Asn Ser Val Leu Asp Leu His Thr  
 65 70

<210> 158  
 <211> 32  
 <212> PRT  
 <213> Homo sapien

<400> 158

Met Lys Cys Arg Gln Met Ala Arg Cys Cys Glu Val Lys Trp Leu Trp  
 1 5 10 15

His Leu Val Ala Thr Glu Thr Thr Val Ile Lys Ile Met Ile Ile Thr  
 20 25 30

<210> 159  
 <211> 19  
 <212> PRT  
 <213> Homo sapien

<400> 159

Met Ser Leu Val Ser Gly Glu His Lys Ile Ile Asp Ser Ala Glu Val  
 1 5 10 15

Trp Ser Lys

<210> 160  
 <211> 46  
 <212> PRT  
 <213> Homo sapien

<400> 160

Met Tyr Thr Glu Ile Ser Lys Val Leu Gln Lys Tyr Pro Lys Ser Arg  
 1 5 10 15

109

Val Ser Ile Ser His Phe Thr Ser Ser Ala Cys Phe Thr Pro Ile Leu  
 20 25 30

Asp Cys Phe Ile Ser Glu Leu Asp Val Ile Pro Arg Val Arg  
 35 40 45

<210> 161  
 <211> 47  
 <212> PRT  
 <213> Homo sapien

<400> 161

Met Pro Gln Trp His Gln Pro Ser His Leu Glu Lys Lys Ser Leu Ser  
 1 5 10 15

Ser Val Met Cys Ser Ala Arg Pro Pro Met Val Gln Thr Tyr Cys Thr  
 20 25 30

Cys Leu Val Ser Pro Ala Leu Ala His Leu Pro Leu Tyr Ser Leu  
 35 40 45

<210> 162  
 <211> 137  
 <212> PRT  
 <213> Homo sapien

<400> 162

Met Ser Gln Asp Thr Arg Ser Cys Pro Leu Phe Leu Ala Gln Leu Gly  
 1 5 10 15

Arg Arg Lys Gly Leu Gln Ala Arg Ala Ala Gly Gln Ala Gly Leu Pro  
 20 25 30

Leu Gly His Arg Thr Pro Leu Pro Pro Arg Pro Arg Leu His Ser His  
 35 40 45

His His Lys Ala Gln Val Pro Ser His Trp Leu Pro Lys Lys Ala Thr  
 50 55 60

Glu Arg Ile Phe Phe Leu Pro Leu Asn Val Ser Phe Pro Leu Gly Cys  
 65 70 75 80

Leu Ser Val Ala Leu Pro Ser Gln Val Phe Leu Gly Met Leu Arg Ala  
 85 90 95

Trp Arg Cys Thr Gly Gly Val Gln Trp His Leu Pro Pro Glu Leu Pro  
 100 105 110



110

His Ser Leu Leu Arg Asn Leu Arg Gly Glu Gly Gly Ala Pro Gly Leu  
 115 120 125

Arg Glu Lys Glu Ser Val Leu Thr Phe  
 130 135

<210> 163  
 <211> 68  
 <212> PRT  
 <213> Homo sapien

<400> 163

Met Pro Val Ile Pro Ala Leu Trp Glu Ala Glu Ala Gly Gly Ser Arg  
 1 5 10 15

Gly Gln Glu Ile Glu Thr Ile Leu Ala Asn Ala Val Lys Ser Arg Leu  
 20 25 30

Leu Lys Ile Gln Lys Ile Ser Gln Ala Trp Trp Arg Ala Pro Val Val  
 35 40 45

Pro Ala Thr Arg Glu Ala Glu Ala Gly Glu Trp Leu Glu Pro Gly Arg  
 50 55 60

Arg Ser Leu Gln  
 65

<210> 164  
 <211> 17  
 <212> PRT  
 <213> Homo sapien

<400> 164

Met Asn Ile Thr Ser Tyr Lys Ser Phe Ser Ile Tyr Ile Asn Ala Ile  
 1 5 10 15

Asp

<210> 165  
 <211> 784  
 <212> PRT  
 <213> Homo sapien

<400> 165

Met Ala Ser Leu Asp Asp Pro Gly Glu Val Arg Glu Gly Phe Leu Cys  
 1 5 10 15

111

Pro Leu Cys Leu Lys Asp Leu Gln Ser Phe Tyr Gln Leu His Ser His  
                     20                    25                    30

Tyr Glu Glu Glu His Ser Gly Glu Asp Arg Asp Val Lys Gly Gln Ile  
           35                    40                    45

Lys Ser Leu Val Gln Lys Ala Lys Lys Ala Lys Asp Arg Leu Leu Lys  
           50                    55                    60

Arg Glu Gly Asp Asp Arg Ala Glu Ser Gly Thr Gln Gly Tyr Glu Ser  
   65                    70                    75                    80

Phe Ser Tyr Gly Gly Val Asp Pro Tyr Met Trp Glu Pro Gln Glu Leu  
                     85                    90                    95

Gly Ala Val Arg Ser His Leu Ser Asp Phe Lys Lys His Arg Ala Ala  
                     100                    105                    110

Arg Ile Asp His Tyr Val Val Glu Val Asn Lys Leu Ile Ile Arg Leu  
           115                    120                    125

Glu Lys Leu Thr Ala Phe Asp Arg Thr Asn Thr Glu Ser Ala Lys Ile  
           130                    135                    140

Arg Ala Ile Glu Lys Ser Val Val Pro Trp Val Asn Asp Gln Asp Val  
   145                    150                    155                    160

Pro Phe Cys Pro Asp Cys Gly Asn Lys Phe Ser Ile Arg Asn Arg Arg  
                     165                    170                    175

His His Cys Arg Leu Cys Gly Ser Ile Met Cys Lys Lys Cys Met Glu  
           180                    185                    190

Leu Ile Ser Leu Pro Leu Ala Asn Lys Leu Thr Ser Ala Ser Lys Glu  
           195                    200                    205

Ser Leu Ser Thr His Thr Ser Pro Ser Gln Ser Pro Asn Ser Val His  
           210                    215                    220

Gly Ser Arg Arg Gly Ser Ile Ser Ser Met Ser Ser Val Ser Ser Val  
   225                    230                    235                    240

Leu Asp Glu Lys Asp Asp Asp Arg Ile Arg Cys Cys Thr His Cys Lys  
                     245                    250                    255

112

Asp Thr Leu Leu Lys Arg Glu Gln Gln Ile Asp Glu Lys Glu His Thr  
 260 265 270

Pro Asp Ile Val Lys Leu Tyr Glu Lys Leu Arg Leu Cys Met Glu Lys  
 275 280 285

Val Asp Gln Lys Ala Pro Glu Tyr Ile Arg Met Ala Ala Ser Leu Asn  
 290 295 300

Ala Gly Glu Thr Thr Tyr Ser Leu Glu His Ala Ser Asp Leu Arg Val  
 305 310 315 320

Glu Val Gln Lys Val Tyr Glu Leu Ile Asp Ala Leu Ser Lys Lys Ile  
 325 330 335

Leu Thr Leu Gly Leu Asn Gln Asp Pro Pro Pro His Pro Ser Asn Leu  
 340 345 350

Arg Leu Gln Arg Met Ile Arg Tyr Ser Ala Thr Leu Phe Val Gln Glu  
 355 360 365

Lys Leu Leu Gly Leu Met Ser Leu Pro Thr Lys Glu Gln Phe Glu Glu  
 370 375 380

Leu Lys Lys Lys Arg Lys Glu Glu Met Glu Arg Lys Arg Ala Val Glu  
 385 390 395 400

Arg Gln Ala Ala Leu Glu Ser Gln Arg Arg Leu Glu Glu Arg Gln Ser  
 405 410 415

Gly Leu Ala Ser Arg Ala Ala Asn Gly Glu Val Ala Ser Leu Arg Arg  
 420 425 430

Gly Pro Ala Pro Leu Arg Lys Ala Glu Gly Trp Leu Pro Leu Ser Gly  
 435 440 445

Gly Gln Gly Gln Ser Glu Asp Ser Asp Pro Leu Leu Gln Gln Ile His  
 450 455 460

Asn Ile Thr Ser Phe Ile Arg Gln Ala Lys Ala Ala Gly Arg Met Asp  
 465 470 475 480

Glu Val Arg Thr Leu Gln Glu Asn Leu Arg Gln Leu Gln Asp Glu Tyr  
 485 490 495

113

Asp Gln Gln Gln Thr Glu Lys Ala Ile Glu Leu Ser Arg Arg Gln Ala  
 500 505 510

Glu Glu Glu Asp Leu Gln Arg Glu Gln Leu Gln Met Leu Arg Glu Arg  
 515 520 525

Glu Leu Glu Arg Glu Arg Glu Gln Phe Arg Val Ala Ser Leu His Thr  
 530 535 540

Arg Thr Arg Ser Leu Asp Phe Arg Glu Ile Gly Pro Phe Gln Leu Glu  
 545 550 555 560

Pro Ser Arg Glu Pro Arg Thr His Leu Ala Tyr Ala Leu Asp Leu Gly  
 565 570 575

Ser Ser Pro Val Pro Ser Ser Thr Ala Pro Lys Thr Pro Ser Leu Ser  
 580 585 590

Ser Thr Gln Pro Thr Arg Val Trp Ser Gly Pro Pro Ala Val Gly Gln  
 595 600 605

Glu Arg Leu Pro Gln Ser Ser Met Pro Gln Gln His Glu Gly Pro Ser  
 610 615 620

Leu Asn Pro Phe Asp Glu Glu Asp Leu Ser Ser Pro Met Glu Glu Ala  
 625 630 635 640

Thr Thr Gly Pro Pro Ala Ala Gly Val Ser Leu Asp Pro Ser Ala Arg  
 645 650 655

Ile Leu Lys Glu Tyr Asn Pro Phe Glu Glu Glu Asp Glu Glu Glu Glu  
 660 665 670

Ala Val Ala Gly Asn Pro Phe Ile Gln Pro Asp Ser Pro Ala Pro Asn  
 675 680 685

Pro Phe Ser Glu Glu Asp Glu His Pro Gln Gln Arg Leu Ser Ser Pro  
 690 695 700

Leu Val Pro Gly Asn Pro Phe Glu Glu Pro Thr Cys Ile Asn Pro Phe  
 705 710 715 720

Glu Met Asp Ser Asp Ser Gly Pro Glu Ala Glu Glu Pro Ile Glu Glu  
 725 730 735

Glu Leu Leu Leu Gln Gln Ile Asp Asn Ile Lys Ala Tyr Ile Phe Asp

114

740

745

750

Ala Lys Gln Cys Gly Arg Leu Asp Glu Val Glu Val Leu Thr Glu Asn  
 755 760 765

Leu Arg Glu Leu Lys His Thr Leu Ala Lys Gln Lys Gly Gly Thr Asp  
 770 775 780

<210> 166  
 <211> 96  
 <212> PRT  
 <213> Homo sapien

<400> 166

Met Ser Gly Thr Ser Thr Pro Ala Met Gly Val Cys Ala Glu Pro Leu  
 1 5 10 15

Lys Val Asp Leu Ser Phe Gly Glu Pro Ser Glu Arg His Ser Trp Tyr  
 20 25 30

Leu Trp Glu Trp Leu Trp Gly Val Leu Trp His His Thr Asp Asn Phe  
 35 40 45

Val Phe Leu Ile Gly Ile His Gly Leu Gly Ser Trp Asp Gly Gly Arg  
 50 55 60

Gly Lys Pro Gln Ser Pro Trp Lys Cys Met Gln Asn Ile Trp Val Cys  
 65 70 75 80

Arg Cys Ile Ile Leu Arg Leu Trp Pro Leu Gln Phe Phe Gln Arg Val  
 85 90 95

<210> 167  
 <211> 215  
 <212> PRT  
 <213> Homo sapien

<400> 167

Met Ser Gly Glu Lys Arg Ser Pro Ser Val Asn Thr Gln Ala Pro Gly  
 1 5 10 15

Thr Thr Arg Gly Ala Cys Lys Gly Thr Thr Ser Trp Glu Pro Ser Trp  
 20 25 30

Pro His Cys Glu Glu Val Pro Gln Glu Glu Lys Phe Leu Arg Gly Thr  
 35 40 45

115

Ser Ser Ala Gly Tyr Ser Pro Leu Gln His Gly Gly Pro Pro Ile Thr  
 50 55 60

Pro Arg Lys Gly Gly Asn His Phe Leu Glu Lys Ser Lys Gly Ala Gln  
 65 70 75 80

Thr Pro Ala Val Ser Leu Ser Pro Pro Gly Lys Phe Phe Phe Phe Phe  
 85 90 95

Phe Phe Phe Gln Phe Leu Ala Ala Gly Gly Trp Gly Ser Ser Ser Val  
 100 105 110

Val Ser Arg Arg Val Arg Pro Arg Gln Arg Pro Thr Ser Arg Arg Arg  
 115 120 125

Pro Gly Val Glu Ser Ala Leu Asn Lys Ile Leu Ser Gln Leu Cys Val  
 130 135 140

Pro Arg Arg Val Lys Gly Pro Val Pro Ala Gly Ala Arg Gly Ser Ala  
 145 150 155 160

Trp Ser Trp Arg Pro Ala Arg Arg Leu Trp Arg Pro Leu Ser Glu Pro  
 165 170 175

Arg Arg Pro Pro Arg Val Phe Val Asp Cys Arg Ser Pro Gly Arg Leu  
 180 185 190

Gly Thr Val Thr Ala Pro Lys Ala Gly Asp Val Ala Ala Leu Gly Arg  
 195 200 205

Arg Leu Leu Pro Pro Pro Leu  
 210 215

<210> 168  
 <211> 67  
 <212> PRT  
 <213> Homo sapien

<400> 168

Met Ser Leu Arg Pro Leu Met Gly Leu Asp Pro Ala Ser Gly Lys Leu  
 1 5 10 15

Leu Ser His Thr Leu Pro His Leu Thr Ile His Val Ser Phe Leu Pro  
 20 25 30

Leu Ser Leu His Ala Cys His Ser His Ser Leu Cys Met Pro Ala Phe  
 35 40 45

116

Pro Ala Ala Pro Cys Thr Leu Arg Leu Trp Pro Phe Pro Ala Phe Cys  
 50 55 60

Leu Pro Gly  
 65

<210> 169  
 <211> 102  
 <212> PRT  
 <213> Homo sapien

<400> 169

Met Pro Thr Pro Ser Leu Ser Tyr Thr Gly Glu Gly Gln Lys Gln Asp  
 1 5 10 15

Val Glu Phe Ala Trp Pro Trp Pro Thr Gln Thr Thr Ser Pro Ser Ser  
 20 25 30

Gly Ser Gln Ala Arg Glu Lys Gly Ile Ser Arg Thr Thr Val Pro Gly  
 35 40 45

Ile Lys His Lys Leu Lys Leu Ala Gly Ala Gly Met Val Ser Gln Thr  
 50 55 60

Ser Glu Leu Pro Pro His Leu His Leu Phe Gly Leu Thr Gly Asn Met  
 65 70 75 80

Ala Ser Leu Gly Pro Ala Gly Arg Ala His Gly Arg Arg Leu Leu Ser  
 85 90 95

His Gln Ala Thr Glu Asp  
 100

<210> 170  
 <211> 38  
 <212> PRT  
 <213> Homo sapien

<400> 170

Met Arg Trp Val Glu Ser Thr Leu Glu Asn Ile Ile His Lys Ala Asn  
 1 5 10 15

Asn Gln Thr Gly Arg Lys Asp Asn Thr Lys Ser Leu Thr Ser Thr Ile  
 20 25 30

His Gly Ser Leu Ala Leu

117

35

<210> 171  
 <211> 52  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 171

Met Ser Gln Phe Leu Asp Leu Leu Thr Val Ile Asn Ser Gln Ala His  
 1 5 10 15

Ser Leu Ser Arg Val Asn Asp Thr Thr Phe Asn Leu Glu Lys Ser Ser  
 20 25 30

Ile Thr Phe Tyr His Phe Gln Ile Ser Phe Leu Pro Ser Leu His Thr  
 35 40 45

Lys Asp Ser Ser  
 50

<210> 172  
 <211> 45  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 172

Met Lys Leu His Met Thr Arg Phe Ser Phe Lys Leu Ile Leu Lys Cys  
 1 5 10 15

Leu Leu Leu Leu Gly Val Leu Asn Ser Phe Thr Val Leu Val Thr Thr  
 20 25 30

Arg Leu Ile Ser Ala Ile Leu Tyr Tyr Ala Ile Phe Ser  
 35 40 45

<210> 173  
 <211> 34  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 173

Met Leu Thr Cys Cys Leu Asn Thr Glu Asp Ala Ile Leu Phe Ser Arg  
 1 5 10 15

Ala Leu Phe Leu His Gly Lys Ile Val Asp Pro Thr Ile Lys Cys Gly  
 20 25 30

Tyr Ser



118

<210> 174  
 <211> 29  
 <212> PRT  
 <213> Homo sapien

<400> 174

Met Phe Leu Arg Val Ala Gly Asn Ile Leu Leu Glu Asn Gln Met Asn  
 1 5 10 15

Thr Gly Arg Tyr Gly Tyr Gln Glu Leu Arg Leu Ile Leu  
 20 25

<210> 175  
 <211> 21  
 <212> PRT  
 <213> Homo sapien

<400> 175

Met Asn Ile His Asn Pro Ser Ser Phe Leu Val Ser Leu Cys Asn Leu  
 1 5 10 15

Ala Ser Gln Asn Tyr  
 20

<210> 176  
 <211> 78  
 <212> PRT  
 <213> Homo sapien

<400> 176

Met Lys Ser Lys Ser Ser Leu Pro Ser Leu Gly Val Lys Leu His Asn  
 1 5 10 15

Leu Ile Ser Ala Ser Ser Cys Cys Leu Tyr Phe Arg Lys Lys Lys Gln  
 20 25 30

Thr Val Gly Phe Pro Cys Glu Ser Asp Phe Ser Leu Ser Ala Tyr Cys  
 35 40 45

Ala Ser Ala Phe Pro Cys Val Ser His Asp Leu Met Ala Ser Leu Thr  
 50 55 60

Pro Asn Cys Met Tyr Pro Ala Gln Ile Ser Ile Leu Pro Gln  
 65 70 75

<210> 177

119

<211> 37  
<212> PRT  
<213> Homo sapien

&lt;400&gt; 177

Met Ser Leu Lys Arg Tyr Cys Leu Ala Leu Lys Ser Ala Ser Val Val  
1 5 10 15

Lys Val Leu Gln Tyr Ile His Thr Glu Glu Lys Cys Gly Ser Glu Ser  
20 25 30

Pro Trp Ala Ala Phe  
35

<210> 178  
<211> 21  
<212> PRT  
<213> Homo sapien

&lt;400&gt; 178

Met Thr Lys Pro Thr Arg Leu Leu Pro Lys Asn Leu Ile Tyr Cys Pro  
1 5 10 15

Arg Ser Arg Leu Ser  
20

<210> 179  
<211> 57  
<212> PRT  
<213> Homo sapien

&lt;400&gt; 179

Met Cys Cys Val Ser Gly Gly Trp Lys Lys Leu Ile Gln Leu Trp Pro  
1 5 10 15

Ser Ser Ile Met Val Arg Tyr His Tyr His Leu Gln Ile Ser Ser Lys  
20 25 30

Ile Gly Gly Leu Pro Ser Trp Ala Leu Arg Ala Asn Ser Leu Gly Gln  
35 40 45

Phe Phe Leu Leu His Ser Thr Ile Glu  
50 55

<210> 180  
<211> 23  
<212> PRT  
<213> Homo sapien

120

&lt;400&gt; 180

Met Asn Phe Ile Leu Cys Pro Cys Phe Asp Ala Ser Thr Gln Phe Leu  
1 5 10 15

Val Ile Ser Val Lys Tyr Asn  
20

&lt;210&gt; 181

&lt;211&gt; 92

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 181

Met Arg Lys Lys Cys Arg Leu Thr Ser Pro Cys Trp Trp Arg Trp Arg  
1 5 10 15

Arg Gly Gly Glu Gln Leu Leu Arg Ile Phe Val Leu Ile Phe Ser Cys  
20 25 30

Ser Pro Pro Asp Asn Thr Val Gly Thr Cys Ile Leu Trp Gly Ile Phe  
35 40 45

Ser Gly Lys Ser Lys Asp Cys Glu Trp Leu His Leu Ile Ser Thr Leu  
50 55 60

Arg Asn Ala Glu Ala Cys Ser Ser Gln Val Leu Lys Asn Tyr Leu Glu  
65 70 75 80

Lys Lys Asn Arg Pro Ile Lys Ser Thr Val Lys Arg  
85 90

&lt;210&gt; 182

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 182

Met Leu His Pro Thr Glu Met Gly Pro Gln Val Pro Asp Leu Pro Phe  
1 5 10 15

Arg Arg Gly Arg Gln Val Gly Glu Gln Met  
20 25

&lt;210&gt; 183

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

121

&lt;400&gt; 183

Met Pro Leu Thr Pro Glu Pro Pro Ser Gly Arg Val Glu Gly Pro Pro  
 1 5 10 15

Ala Trp Glu Ala Ala Pro Trp Pro Ser Leu Pro Cys Gly Pro Cys Ile  
 20 25 30

Pro Ile Met Leu Val Leu Ala Thr Leu Ala Ala Leu Phe Ile Leu Thr  
 35 40 45

Thr Ala Val Leu Ala Glu Arg Leu Phe Arg Arg Ala Leu Arg Pro Asp  
 50 55 60

Pro Ser His Arg Ala Pro Thr Leu Val Trp Arg Pro Gly Gly Glu Leu  
 65 70 75 80

Trp Ile Glu Pro Met Gly Thr Ala Arg Glu Arg Ser Glu Asp Trp Tyr  
 85 90 95

Gly Ser Ala Val Pro Leu Leu Thr Asp Arg Ala Pro Glu Pro Pro Thr  
 100 105 110

Gln Val Gly Thr Leu Glu Ala Arg Ala Thr Ala Pro Pro Ala Pro Ser  
 115 120 125

Ala Pro Asn Ser Ala Pro Ser Asn Leu Gly Pro Gln Thr Val Leu Glu  
 130 135 140

Val Pro Ala Arg Ser Thr Phe Trp Gly Pro Gln Pro Trp Glu Gly Arg  
 145 150 155 160

Pro Pro Pro Gln Ala Trp  
 165

&lt;210&gt; 184

&lt;211&gt; 80

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 184

Met Leu Thr Ser His Phe Ile Leu Ile Pro Val Ile Phe Ser Leu Gln  
 1 5 10 15

Tyr Gln Cys Leu Gly Ala Arg Lys Leu Cys Gln Cys Gln Trp Leu Trp  
 20 25 30

122

Arg Trp Gln Lys Lys Gly Gly Gln Pro Pro Gly Thr Ala Glu Ser Lys  
 35 40 45

Pro Asp Ser Gln Pro Gln Lys Val Gly Gln Asp Ala Ala Asn Ser Ser  
 50 55 60

Asn Pro Lys Lys Ala Ala Glu Ile Thr Val Ile Gln Gln Thr Tyr Phe  
 65 70 75 80

&lt;210&gt; 185

&lt;211&gt; 159

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 185

Met Asp Thr Ile Leu Val Phe Ser Leu Ile Ile Ala Ser Tyr Asp Ala  
 1 5 10 15

Asn Lys Lys Asp Leu Arg Asp Ser Ser Cys Arg Leu Glu Gln Leu Pro  
 20 25 30

Gly Ile Phe Pro Lys Asp Val Arg Ser Ile Arg Glu Leu Gln Met Gln  
 35 40 45

Glu Thr His Thr Glu Thr Lys Arg Thr Thr Phe Ile Gln Asn Arg Thr  
 50 55 60

Ile Ala Thr Leu Gln Cys Leu Gly Ser Asp Ser Lys Val Lys Val Asn  
 65 70 75 80

Leu Val Tyr Leu Glu Arg Arg Pro Lys Val Lys His Ile Leu Lys Asn  
 85 90 95

Leu Arg Ile Ile Ala Ala Pro Arg Arg Asn Ser Ser Ala Ser Ser Ser  
 100 105 110

Cys His Leu Ile Pro Thr Ser Lys Phe Gln Thr Gly Ser Leu Leu Lys  
 115 120 125

Gly Lys Val Ser Met Pro Arg Ser Gln Glu Ala Val Pro Met Pro Val  
 130 135 140

Val Val Glu Met Ala Lys Glu Gly Arg Pro Ala Thr Trp Asp Ser  
 145 150 155

&lt;210&gt; 186

&lt;211&gt; 928

123

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 186

```

Met Ala Glu Gly Lys Glu Lys Gln Val Thr Ser Tyr Met Asp Gly Ser
 1              5              10              15

Arg Pro Tyr Asp Val Ser Met Thr Tyr Ile His Lys Ala Gly Gly Pro
      20              25              30

Asp Gln Gln Glu Leu Val Met Leu Thr Cys Thr Val Pro Leu Asp Ser
      35              40              45

Cys Cys His Leu Pro Gln Ala Arg Thr Asn Tyr Arg Lys Tyr Phe Arg
 50              55              60

Ser Glu Ala Ala Phe Thr Leu Ala Asp Phe Ile Tyr Lys Ser Met Ile
 65              70              75              80

Arg Val Asn Ser Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu
      85              90              95

Glu Lys Leu Lys Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser
      100              105              110

Ser Phe Leu Lys Glu Lys Leu Asn Asp Thr Tyr Val Asn Val Gly Leu
      115              120              125

Tyr Ser Thr Lys Thr Cys Leu Lys Val Glu Ile Ile Glu Lys Asp Thr
      130              135              140

Lys Tyr Ser Val Ile Val Ile Arg Arg Ser Trp Asp Val Ile Arg Val
      145              150              155              160

Asn Ser Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu Glu Lys
      165              170              175

Leu Lys Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser Ser Phe
      180              185              190

Leu Lys Glu Lys Leu Asn Asp Thr Tyr Val Asn Val Gly Leu Tyr Ser
      195              200              205

Thr Lys Thr Cys Leu Lys Val Glu Ile Ile Glu Lys Asp Thr Lys Tyr
      210              215              220

```

124

Ser Val Ile Val Ile Arg Arg Ser Trp Asp Val Ile Arg Val Asn Ser  
 225 230 235 240

Ser Arg Leu Val Arg Val Thr Gln Val Glu Asn Glu Glu Lys Leu Lys  
 245 250 255

Glu Leu Glu Gln Phe Ser Ile Trp Asn Phe Phe Ser Ser Phe Leu Lys  
 260 265 270

Glu Lys Leu Asn Asp Thr Tyr Val Asn Gly Ile Pro Trp Thr Lys Val  
 275 280 285

Asp Tyr Phe Asp Asn Gly Ile Ile Cys Lys Leu Ile Glu His Asn Gln  
 290 295 300

Arg Gly Ile Leu Ala Met Leu Asp Glu Glu Cys Leu Arg Pro Gly Val  
 305 310 315 320

Val Ser Asp Ser Thr Phe Leu Ala Lys Leu Asn Gln Leu Phe Ser Lys  
 325 330 335

His Gly His Tyr Glu Ser Lys Val Thr Gln Asn Ala Gln Arg Gln Tyr  
 340 345 350

Asp His Thr Met Gly Leu Ser Cys Phe Arg Ile Cys His Tyr Ala Gly  
 355 360 365

Lys Val Thr Tyr Asn Val Thr Ser Phe Ile Asp Lys Asn Asn Asp Leu  
 370 375 380

Leu Phe Arg Asp Leu Leu Gln Ala Met Trp Lys Ala Gln His Pro Leu  
 385 390 395 400

Leu Arg Ser Leu Phe Pro Glu Gly Asn Pro Lys Gln Ala Ser Leu Lys  
 405 410 415

Arg Pro Pro Thr Ala Gly Ala Gln Phe Lys Ser Ser Val Ala Ile Leu  
 420 425 430

Met Lys Asn Leu Tyr Ser Lys Ser Pro Asn Tyr Ile Arg Cys Ile Lys  
 435 440 445

Pro Asn Glu His Gln Gln Arg Gly Gln Phe Ser Ser Asp Leu Val Ala  
 450 455 460

Thr Gln Ala Arg Tyr Leu Gly Leu Leu Glu Asn Val Arg Val Arg Arg

125

465		470		475		480
Ala Gly Tyr	Ala His	Arg Gln Gly Tyr	Gly Pro Phe Leu	Glu Arg Tyr		
	485		490		495	
Arg Leu Leu	Ser Arg	Ser Thr Trp	Pro His Trp Asn	Gly Gly Asp Arg		
	500		505		510	
Glu Gly Val	Glu Lys Val	Leu Gly Glu Leu	Ser Met Ser Ser	Gly Glu		
	515		520		525	
Leu Ala Phe	Gly Lys Thr	Lys Ile Phe Ile	Arg Ser Pro Lys	Thr Leu		
	530		535		540	
Phe Tyr Leu	Glu Glu Gln Arg	Arg Leu Arg Leu	Gln Gln Leu Ala	Thr		
	545		550		555	
Leu Ile Gln	Lys Ile Tyr Arg	Gly Trp Arg Cys	Arg Thr His Tyr	Gln		
	565		570		575	
Leu Met Arg	Lys Ser Gln Ile	Leu Ile Ser Ser	Trp Phe Arg Gly	Asn		
	580		585		590	
Met Ala Arg	Lys Asn Tyr Arg	Lys Tyr Phe Arg	Ser Glu Ala Ala	Leu		
	595		600		605	
Thr Leu Ala	Asp Phe Ile Tyr	Lys Ser Met Val	Gln Lys Phe Leu	Leu		
	610		615		620	
Gly Leu Lys	Asn Asn Leu Pro	Ser Thr Asn Val	Leu Asp Lys Thr	Trp		
	625		630		635	
Pro Ala Ala	Pro Tyr Lys Cys	Leu Ser Thr Ala	Asn Gln Glu Leu	Gln		
	645		650		655	
Gln Leu Phe	Tyr Gln Trp Lys	Ala Thr Pro Val	Pro Pro Ser Ser	Gln		
	660		665		670	
Cys Lys Arg	Phe Arg Asp Gln	Leu Ser Pro Lys	Gln Val Glu Ile	Leu		
	675		680		685	
Arg Glu Lys	Leu Cys Ala Ser	Glu Leu Phe Lys	Gly Lys Lys Ala	Ser		
	690		695		700	
Tyr Pro Gln	Ser Val Pro Ile	Pro Phe Cys Gly	Asp Tyr Ile Gly	Leu		
	705		710		715	
					720	



126

Gln Gly Asn Pro Lys Leu Gln Lys Leu Lys Gly Gly Glu Glu Gly Pro  
 725 730 735

Val Leu Met Ala Glu Ala Val Lys Lys Val Asn Arg Gly Asn Gly Lys  
 740 745 750

Thr Ser Ser Arg Ile Leu Leu Leu Thr Lys Gly His Val Ile Leu Thr  
 755 760 765

Asp Thr Lys Lys Ser Gln Ala Lys Ile Val Ile Gly Leu Asp Asn Val  
 770 775 780

Ala Gly Val Ser Val Thr Ser Leu Lys Asp Gly Leu Phe Ser Leu His  
 785 790 795 800

Leu Ser Glu Met Ser Ser Val Gly Ser Lys Gly Asp Phe Leu Leu Val  
 805 810 815

Ser Glu His Val Ile Glu Leu Leu Thr Lys Met Tyr Arg Ala Val Leu  
 820 825 830

Asp Ala Thr Gln Arg Gln Leu Thr Val Thr Val Thr Glu Lys Phe Ser  
 835 840 845

Val Arg Phe Lys Glu Asn Ser Val Ala Val Lys Val Val Gln Gly Pro  
 850 855 860

Ala Gly Gly Asp Asn Ser Lys Leu Arg Tyr Lys Lys Lys Gly Ser His  
 865 870 875 880

Cys Leu Glu Val Thr Val Gln Gln Leu Thr Ala Gly Tyr His Ala Gly  
 885 890 895

Gln Gly Glu Leu Ile Asn Phe Ser Ser Cys Leu Gln Ile Asn Leu Leu  
 900 905 910

Ser Glu His Lys Pro Arg Ala Ser Gly Thr Pro Cys Phe Glu Leu Arg  
 915 920 925

<210> 187

<211> 96

<212> PRT

<213> Homo sapien

<400> 187

127

Met Arg Arg Cys Tyr Ser Ile Pro Val Cys Lys Cys Ala Gly Met Pro  
 1 5 10 15

Ala Leu Ser Asp Gly Gly His Asp Asn Met Ala His Ala Phe Lys Leu  
 20 25 30

Thr Ser Asn Cys Phe Trp Thr Thr Phe Asn Arg Gly Ser His Tyr His  
 35 40 45

Gly Phe Lys Glu Pro Cys Gln Pro Arg Lys His Leu Thr Ala Gly Thr  
 50 55 60

Ala Gly Trp Ser Cys Cys Trp Leu Glu Val Tyr Ala Arg Ile Ala Lys  
 65 70 75 80

Asp Ser Trp Arg Met Gly Ser Pro Tyr Leu Cys Arg Leu Ala Ala Leu  
 85 90 95

<210> 188  
 <211> 47  
 <212> PRT  
 <213> Homo sapien

<400> 188

Met Tyr Gln Lys Asp Leu Tyr Ile Ser Gln Arg Gly Thr Gln Ala Lys  
 1 5 10 15

Leu Lys Ile Tyr Lys His Asn Gln Phe Thr Arg Glu Ile Ile Leu Thr  
 20 25 30

Val Phe Phe Leu Phe Phe Gln Thr Leu Leu Phe His Gly Lys Lys  
 35 40 45

<210> 189  
 <211> 644  
 <212> PRT  
 <213> Homo sapien

<400> 189

Met Met Ile Ile Ala Leu Glu Phe Pro His Leu Val Val Asp Leu Ala  
 1 5 10 15

Asp Asn Asn Trp Gln Cys Asp Asp Ser Val Ala Val Phe Gln Asn Phe  
 20 25 30

Ile Ser Glu Ser Trp Arg Lys Lys Trp Asn Val Ile Cys Asn Arg Ser  
 35 40 45

128

Ile Gly Ser Glu Glu Ala Asn Gly Gly Thr Pro Gln Ser Arg Ile Ser  
 50 55 60

Arg Glu Thr Arg Leu Pro Pro Ile His Leu His Arg Met Lys Ser Leu  
 65 70 75 80

Ile Arg Ser Lys Ala Glu Arg Pro Gln Gly Gly Arg His Thr Gly Ile  
 85 90 95

Ser Thr Leu Gly Lys Lys Ala Lys Ala Gly Ser Gly Leu Arg Lys Lys  
 100 105 110

Gln Arg Arg Leu Pro Arg Ser Val Arg Ser Thr Arg Asp Val Gln Ala  
 115 120 125

Ala Gly Lys Lys Glu Asp Ala Pro Gln Asp Leu Ala Leu Ala Val Cys  
 130 135 140

Leu Ser Val Phe Ile Thr Phe Leu Val Ala Phe Ser Leu Gly Ala Phe  
 145 150 155 160

Thr Arg Pro Tyr Val Asp Arg Leu Trp Gln Lys Lys Cys Gln Ser Lys  
 165 170 175

Ser Pro Gly Leu Asp Asn Ala Tyr Ser Asn Glu Gly Phe Tyr Asp Asp  
 180 185 190

Met Glu Ala Ala Gly His Thr Pro His Pro Glu Thr His Leu Arg Gln  
 195 200 205

Val Phe Pro His Leu Ser Leu Tyr Glu Asn Gln Thr Pro Phe Trp Val  
 210 215 220

Thr Gln Pro His Pro His Ala Thr Val Ile Pro Asp Arg Thr Leu Gly  
 225 230 235 240

Arg Ser Arg Lys Asp Pro Gly Ser Ser Gln Ser Pro Gly Gln Cys Gly  
 245 250 255

Asp Asn Thr Gly Ala Gly Ser Gly Asn Asp Gly Ala Val Tyr Ser Ile  
 260 265 270

Leu Gln Arg His Pro His Ala Gly Asn Arg Glu Leu Met Ser Ala Ala  
 275 280 285

129

Gln Asp His Ile His Arg Asn Asp Ile Leu Gly Glu Trp Thr Tyr Glu  
 290 295 300

Thr Val Ala Gln Glu Glu Pro Leu Ser Ala His Ser Val Gly Val Ser  
 305 310 315 320

Ser Val Ala Gly Thr Ser His Ala Val Ser Gly Ser Ser Arg Tyr Asp  
 325 330 335

Ser Asn Glu Leu Asp Leu Pro Leu Ser Gly Glu Ile Thr Ala Ser Leu  
 340 345 350

Cys Lys Met Leu Thr His Ala Glu Ala Gln Arg Thr Gly Asp Ser Lys  
 355 360 365

Glu Arg Gly Gly Thr Glu Gln Ser Leu Trp Asp Ser Gln Met Glu Phe  
 370 375 380

Ser Lys Glu Arg Gln Val Ser Ser Ser Ile Asp Leu Leu Ser Ile Gln  
 385 390 395 400

Gln Pro Arg Leu Ser Gly Ala Arg Ala Glu Glu Ala Leu Ser Ala His  
 405 410 415

Tyr Ser Glu Val Pro Tyr Gly Asp Pro Arg Asp Thr Gly Pro Ser Val  
 420 425 430

Phe Pro Pro Arg Trp Asp Ser Gly Leu Asp Val Thr Pro Ala Asn Lys  
 435 440 445

Glu Pro Val Gln Lys Ser Thr Pro Ser Asp Thr Cys Cys Glu Leu Glu  
 450 455 460

Ser Asp Cys Asp Ser Asp Glu Gly Ser Leu Phe Thr Leu Ser Ser Ile  
 465 470 475 480

Ser Ser Glu Ser Ala Arg Ser Lys Thr Glu Glu Ala Val Pro Asp Glu  
 485 490 495

Glu Ser Leu Gln Asp Glu Ser Ser Gly Ala Ser Lys Asp Asn Val Thr  
 500 505 510

Ala Val Asp Ser Leu Glu Glu Asn Val Thr Phe Gln Thr Ile Pro Gly  
 515 520 525

Lys Cys Lys Asn Gln Glu Asp Pro Phe Glu Lys Pro Leu Ile Ser Ala

130

530

535

540

Pro Asp Ser Gly Met Tyr Lys Thr His Leu Glu Asn Ala Ser Asp Thr  
 545 550 555 560

Asp Arg Ser Glu Gly Leu Ser Pro Trp Pro Arg Ser Pro Gly Asn Ser  
 565 570 575

Pro Leu Gly Asp Glu Phe Pro Gly Met Phe Thr Tyr Asp Tyr Asp Thr  
 580 585 590

Ala Leu Gln Ser Lys Ala Ala Glu Trp His Cys Ser Leu Arg Asp Leu  
 595 600 605

Glu Phe Ser Asn Val Asp Val Leu Gln Gln Thr Pro Pro Cys Ser Ala  
 610 615 620

Glu Val Pro Ser Asp Pro Asp Lys Ala Ala Phe His Glu Arg Asp Ser  
 625 630 635 640

Asp Ile Leu Lys

<210> 190

<211> 48

<212> PRT

<213> Homo sapien

<400> 190

Met Trp Thr Phe Tyr Ser Lys His His Val Leu Leu Lys Phe Pro  
 1 5 10 15

Gln Ile Leu Val Asp Val Leu Gln Gln Thr Pro Pro Cys Ser Ala Glu  
 20 25 30

Val Pro Ser Asp Pro Asp Lys Ala Ala Phe His Glu Arg Phe Leu Phe  
 35 40 45

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number  
**WO 2003/020953 A3**

- (51) International Patent Classification<sup>7</sup>: **C07H 21/00**,  
C12P 21/06, C12Q 1/68
- (74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number:  
PCT/US2002/027728
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 29 August 2002 (29.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/316,259 31 August 2001 (31.08.2001) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).
- (63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 60/316,259 (CIP)  
Filed on 31 August 2001 (31.08.2001)
- (71) Applicant (*for all designated States except US*): DI-  
ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard,  
South San Francisco, CA 94080 (US).
- Published:  
— with international search report
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SUN, Yongming  
[CN/US]; 551 Shoal Drive, Redwood City, CA 94065  
(US). LIU, Chenghua [CN/US]; 1125 Ranchero Way  
#14, San Jose, CA 95117 (US). GHOSH, Malavika, G.  
[IN/US]; 1733 Via Lugano, San Jose, CA 95120 (US).
- (88) Date of publication of the international search report:  
29 January 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic colon cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon, identifying colon tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered colon tissue for treatment and research.

WO 2003/020953 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27728

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C07H 21/00; C12P 21/06; C12Q 1/68  
US CL : 536/23.1, 25.3; 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 25.3; 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Genbank on NCBI, Accession Number AC024725. WATERSON, R.H. 'The sequence of Homo sapiens clone'. 01 September 2000 (01.09.00), see entire document for stretches of matching nucleotides.	1, 2, 4, 5, 7
X	US 6,117,654 A (PAN) 12 September 2000 (12.09.00), see sequence identification number 17.	1, 2, 4, 5, 7, 8
X	Database Genbank on NCBI, Accession Number BG696484 from Homo sapien. STRAUSBERG, R. 'National Institutes of Health, Mammalian Genes Collection'. 07 May 2001 (07.05.01), see entire document, especially nucleotides 475-1019.	1, 2, 4, 5, 7, 8

☐ Further documents are listed in the continuation of Box C.

See patent family annex.

**\* Special categories of cited documents:**

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

09 April 2003 (09.04.2003)

Date of mailing of the international search report

05 AUG 2003

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer  
Lori A. Gallow

Telephone No. 703-308-0916

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/27728

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-9 and SEQ ID NO:10

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

PCT/US02/27728

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Groups 1-32 (claims 1-9), drawn to an isolated nucleic acids, methods of detecting nucleic acids, and a method for producing a polypeptide encoded by a polynucleotide wherein the polynucleotides are SEQ ID NO. X. X is anyone of SEQ ID NOs:10-190. For example, if Group 1 is elected, this correlates to SEQ ID NO. 10.

Groups 33-65 (claims 10 and 11), drawn to a polypeptide encoded by SEQ ID NO. X, wherein X is anyone of SEQ ID NOs:10-190.

Group 66 (claim 12), drawn to an antibody.

Groups 67-89 (claim 13), drawn to a method for determining the presence of a colon specific protein by contacting sample with a reagent such that the reagent will interact with the colon specific protein comprising a sequence of SEQ ID NO. X, wherein X is encoded by anyone of SEQ ID NOs:108-190.

Groups 90-122 (claim 14), drawn to a method for diagnosing metastases by determining a nucleic acid molecule of SEQ ID NO. X, where in X is anyone of SEQ ID NOs: 10-190.

Groups 123-155 (claim 14), drawn to a method for diagnosing metastases by determining amount of polypeptide encoded by SEQ ID NO. X, wherein X is selected from anyone of SEQ ID NOs: 10-190.

Groups 156-188 (claim 15), drawn to a kit for detecting cancer using nucleic acids of SEQ ID NO. X, wherein X is anyone of SEQ ID NOs:10-190.

Groups 189-221 (claim 15), drawn to a kit for detecting cancer using a polypeptide encoded by SEQ ID NO. X, wherein X is anyone of SEQ ID NOs:10-190.

Groups 222-254 (claim 16), drawn to a method for treating a patient with colon cancer, comprising administering a composition (polypeptide) if SEQ ID NO. X, wherein X is anyone of SEQ ID NOs:10-190.

Groups 255-287 (claim 16), drawn to a method for treating colon cancer by administering a composition (antibody)of SEQ ID NO. X, wherein X is anyone of SEQ ID NOs:10-190.

Groups 288-310 (claim 17), drawn to a vaccine comprising polypeptides encoded by SEQ ID NO. x, wherein X is anyone of SEQ ID NOs:10-190.

The inventions listed as Groups 1-310 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups 1-32 have as their special technical feature nucleic acids, which are chemically distinct from the polypeptides of Groups 33-65, the antibodies of Group 66. Polynucleotides, polypeptides, and antibodies are separately characterized in the biochemical literature.

The methods and kit of the other groupings (90-122, 123-155, 156-188, 189-221, 222-254, 255-287, and 288-310) are have special technical features in that they propose to do different things, such as treat patients, detect risks, diagnose conditions.

Each of the sequences listed above does not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of the sequences are separate and distinct polynucleotides and have separate chemical structures, sequences, and biochemical activities. As such, no single sequence is a shared special technical feature across all of the Groups.

**INTERNATIONAL SEARCH REPORT**

PCT/US02/27728

**Continuation of B. FIELDS SEARCHED Item 3:**

WEST, Medline, CAPLUS, Biosis, Scirus, BLAST Alignment Database, Patent Database.  
Colon Cancer, colon specific nucleic acids (CSNA).